Drug;Gene;Allele;Genotype;Outcome;Effect_direction;Effect;Effect_subcat;Population_Affected;Entity_Affected;Therapeutic_Outcome
SITAGLIPTIN;DPP4;TT;DPP4_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SITAGLIPTIN;KCNJ11;GG;KCNJ11_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;KCNQ1;GG;KCNQ1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN;DPP4;GG;DPP4_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;CYP2C9;TT;CYP2C9_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AG;GLP1R_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR/LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AA;GLP1R_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE, LIRAGLUTIDE;GLP1R;GG;GLP1R_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1_RECEPTOR_AGONISTS;GLP1R;A;GLP1R_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;TCF7L2;CT + TT;TCF7L2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HISTORY_OF_GASTRIC_BYPASS_SURGERY;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1_RECEPTOR_AGONISTS;ARRB1;A;ARRB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIAC_RHYTHM_DISEASE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIAC_RHYTHM_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1_RECEPTOR_AGONISTS;ARRB1;A;ARRB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LURBINECTEDIN;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1_RECEPTOR_AGONISTS;ARRB1;T;ARRB1_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;CAUTION_DRUG_ACCUMULATION
ALBIGLUTIDE, DULAGLUTIDE, GLP-1_RECEPTOR_AGONISTS;ARRB1;C;ARRB1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE-6'-GLUCURONIDE, RALOXIFENE-4'-GLUCURONIDE;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OSTEOPOROSIS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LURBINECTEDIN;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LURBINECTEDIN;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;PON1;GG;PON1_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
DABIGATRAN;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;SCN1A;C;SCN1A_CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;SCN1A;T;SCN1A_AA;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*11;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;GENE_NOT_SPECIFIED;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TELMISARTAN;UGT1A3;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTM3;TCCTC/TCCTC;GSTM3_TC/TC + TC/TCCTC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTM3;TCCTC/TCCTC;GSTM3_TC/TC + TC/TCCTC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LIRAGLUTIDE;CNR1;CT + TT;CNR1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2, OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLONIDINE;ADRA2C;GGGGAGCTTTCCCAGAGACCC/del + del/del;ADRA2C_GGGGAGCTTTCCCAGAGACCC/del + del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN_ACID;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:DYSLIPIDAEMIA;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN_ACID;SLCO1B1;AG + GG;SLCO1B1_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:DYSLIPIDAEMIA;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ASPIRIN;P2RY1;T;P2RY1_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COLONIC_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RIBAVIRIN, SOFOSBUVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;SLCO1B1;TT;SLCO1B1_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
MODAFINIL;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:METHAMPHETAMINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;GENE_NOT_SPECIFIED;AA;AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
VALSARTAN;AGT;GG;AGT_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
MELOXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;G;OPRM1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
REMIFENTANIL;ADRA2A;CG + GG;ADRA2A_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
REMIFENTANIL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
POSACONAZOLE, TACROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;*4/*4 + *4/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
MOXIFLOXACIN;UGT1A1;*1/*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*46/*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;SLC39A10;C;SLC39A10_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
SIMVASTATIN, WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT, OTHER:ATRIAL_FIBRILLATION,OTHER:STROKE, OTHER:PULMONARY_EMBOLISM, OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT, OTHER:ATRIAL_FIBRILLATION,OTHER:STROKE, OTHER:PULMONARY_EMBOLISM, OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIVAROXABAN;ABCB1;CC;ABCB1_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;TYMS;GG;TYMS_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
METHOTREXATE;ATIC;TT;ATIC_C;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1A;GG;HTR1A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;*6/*60 + *6/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DIHYDROPYRIDINE_DERIVATIVES;NUMA1;AA + AG;NUMA1_GG;OTHER;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CC;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES, UREA_DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;NR3C1;GG;NR3C1_GG;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT1A6;TT;UGT1A6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*46/*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;SYT1;AA + AG;SYT1_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;CBR3;AA + AG;CBR3_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;ABCC2;AA + AG;ABCC2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*11 + *2/*11;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SEPTIN3;AG;SEPTIN3_AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*1/*10 + *10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SREBF2;AC;SREBF2_AC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
N-DESMETHYLTAMOXIFEN;TCF20;GG;TCF20_GG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;SREBF2;TT;SREBF2_TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PIROXICAM;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SREBF2;TT;SREBF2_TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;AG;CENPM, SMIM45_AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RIBAVIRIN, SOFOSBUVIR;IFNL4;GG;IFNL4_TT/TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
VARENICLINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;GENE_NOT_SPECIFIED;AA;AA;OTHER;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS, OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MELOXICAM;CYP2C9;*1/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OPIOIDS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR, LUMACAFTOR;CFTR;del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;EGFR;GG;EGFR_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
3-AMINOISOBUTYRATE;DPYD;TT;DPYD_CT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
MEXILETINE;CYP2D6;*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MYOTONIC_DYSTROPHY, OTHER:NONDYSTROPHIC_MYOTONIA;LIKELIHOOD_THERAPEUTIC_FAILURE
3-AMINOISOBUTYRATE;UPB1;AA;UPB1_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
3-AMINOISOBUTYRATE;AGXT2;TT;AGXT2_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3 + *2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;PD, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;TT;DPYD_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
2-AMINOHEPTANOATE, 2-AMINOOCTANOIC_ACID, 2-HYDROXYLAURATE;ACAD11;AA;ACAD11_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CYSTEINE-S-SULFATE, L-ORNITHINE;NPC2;TT;NPC2_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
5, 6-DIHYDROTHYMINE;UPB1;AA;UPB1_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
10-MONOHYDROXY_OXCARBAZEPINE;ABCC2;G;ABCC2_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A5;TT;CYP3A5_CC;TOXICITY;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHISTOSOMIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHISTOSOMIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;AA + AG;CYP2D6_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:TIC_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CT + TT;CYP2D6_CT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:TIC_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUINAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CT + TT;CYP2D6_CT + TT;EFFICACY;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:TIC_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;CYP3A4_TT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY, TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;UGT1A4;TT;UGT1A4_GG + GT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;GG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS, OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ALOGLIPTIN;PNPLA3;CG + GG;PNPLA3_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2, OTHER:FATTY_LIVER_DISEASE,OTHER:BODY_WEIGHT_CHANGES;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, LUMACAFTOR;CFTR;CTT/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
SERTRALINE;DRD3;AG;DRD3_AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;DRD3;AG;DRD3_AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ILOPERIDONE, ILOPERIDONE_METABOLITE_P88;CYP2D6;AA;CYP2D6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
VALPROIC_ACID;CACNA1H;T;CACNA1H_T;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PENICILLIN_G;IFNG;CC;IFNG_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYPHILIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PENICILLIN_G;IFNG;TT;IFNG_AA + AT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYPHILIS;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AVATROMBOPAG;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AVATROMBOPAG;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENETOCLAX;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;NFIB;CT;NFIB_CT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;TT;CYP3A4_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SLC6A2;GG;SLC6A2_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_NEPHRITIS;CAUTION_DRUG_ACCUMULATION
LITHIUM;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
VARENICLINE;HYKK;CT + TT;HYKK_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ENALAPRIL, LOSARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;GG;CYP2B6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:NEPHROTIC_SYNDROME;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MESALAZINE, THIOGUANINE;NAT1;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ULCERATIVE_COLITIS, DISEASE:CROHN_DISEASE,DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
CETUXIMAB;VEGFA;del/del;VEGFA_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS, DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LORNOXICAM;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LORNOXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ADRB1;C;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*6;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LETROZOLE;GENE_NOT_SPECIFIED;C;C;OUTCOME_NOT_SPECIFIED;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
PROPOFOL;CYP2C9;*1/*1 + *1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NOROXYCODONE, OXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DISULFIRAM;SLC6A3;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;SLC6A3_GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
BENAZEPRIL, PERINDOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MALARIA;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ARTEMETHER;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;CYP2B6_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
QUINAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TESTOSTERONE;UGT1A4;*3a;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT1A4;*2 + *3a;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CURCUMIN, IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE;CYP2A6;*1/*12;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
CAPTOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;HLA-G;del/del;HLA-G_ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EOSINOPHILIC_ESOPHAGITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IVACAFTOR, TEZACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CHIGLITAZAR;PPARA;CC + CT;PPARA_CC + CT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*1b;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;*5 + *10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*3 + *4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE, MERCAPTOPURINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;T/T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SULFASALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A4;T/T;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;G;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;CYP3A4_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;CYP3A4;T/T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C/C;CYP3A4_CT + TT;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
BETA_BLOCKING_AGENTS;GRK5;T;GRK5_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON_BETA-1A;HLA-B;*15:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RUBELLA_VACCINES;HLA-B;*35:03;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;HLA-B;*38:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY_ACTIVE_ANTIRETROVIRAL_THERAPY_(HAART);OPRM1;GG;OPRM1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;*18/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;*18/*18;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
RUBELLA_VACCINES;HLA-C;*15:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES_VACCINES;HLA-DQA1;*01:04;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEASLES_VACCINES;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
INTERFERON_BETA-1A;HLA-DRB1;*04:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1;*04:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEPATITIS_VACCINES;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLUENZA_VACCINES;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES_VACCINES;HLA-DRB1;*08:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
INFLUENZA_VACCINES;HLA-DRB1;*13:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;CYP2C8;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;GGH;AA + AG;GGH_A;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C8;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2B6;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*6 + *9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*2 + *3 + *4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*9/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*1/*15;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN, WARFARIN;CYP2C9;*2 + *3 + *11;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN, PRAVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;*14;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;*31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*20;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CONJUGATED_ESTROGENS;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C18;GG;CYP2C18_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
3, 4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CEREBRAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA_BLOCKING_AGENTS;ADRA2C;del;ADRA2C_GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:CARDIOMYOPATHY, DILATED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYBUPROPION;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;SULT1C4;G;SULT1C4_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
BREXPIPRAZOLE;CYP2D6;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;TOXICITY;DECREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;C;ERCC1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP3A4;*22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LIRAGLUTIDE;GLP1R;TT;GLP1R_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GLICLAZIDE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCL8;AA + AT;CXCL8_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP3A4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROPYRIDINE_DERIVATIVES;CYP3A5;TT;CYP3A5_CC;OTHER;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
N-DESMETHYLCLOZAPINE;CYP1A2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;ALDH2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COUMARIN, NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*46 + *46/*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15/*15 + *15/*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;VKORC1_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PITAVASTATIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXALIPLATIN;MTHFR;GG + GT;MTHFR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C/C;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/C;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/T + T/T;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C/C;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS_AND_DRUG-ELUTING_STENTS;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:SCOLIOSIS;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*4/*4 + *4/*7;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LYMPHOMA,OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
SOMATROPIN_RECOMBINANT;COL1A1;AA;COL1A1_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GROWTH_HORMONE_DEFICIENCY;CAUTION_DOSE_ADJUST
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VITAMIN_B-COMPLEX, INCL._COMBINATIONS;MTHFR;A;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SLCO1B1;GG;SLCO1B1_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VITAMIN_B-COMPLEX, INCL._COMBINATIONS;MTHFR;G;MTHFR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;SLC6A2;A;SLC6A2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, TACROLIMUS;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;CC;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIZATRIPTAN;DRD2;AA + AG;DRD2_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;G;G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SULFONAMIDES, UREA_DERIVATIVES;CYP2C9;CC;CYP2C9_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD3;CC + CT;DRD3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;FOXA3;T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYSTEAMINE;CFTR;CTT/del + del/del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROPROPOXYPHENE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FELODIPINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PANTOPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TOLPERISONE;CYP2D6;*4 + *5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MIANSERIN;CYP2D6;*1/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SALVIANOLIC_ACID_B;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPHENYTOIN;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT1A6;*1a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;UGT1A6;*1a;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8/*8;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS, TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LOW_BACK_PAIN, DISEASE:OSTEOARTHRITIS;CAUTION_DRUG_ACCUMULATION
RASAGILINE;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;NR1I2;del/del;NR1I2_GAGAAG/del + del/del;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;GG;IFNL4_TT/TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SIPOGLITAZAR;UGT2B15;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;del/del;SLC22A1_del/del;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC22A1;GAT/del + del/del;SLC22A1_del/del;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;GSTT1;null/null;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;HSD3B1;AA + AC;HSD3B1_AC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MORPHINE;SLC22A1;del/del;SLC22A1_del/del;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MOOD_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*28/*28 + *1/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*6/*6 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;RXRA;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOBAZAM;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*4;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GLATIRAMER_ACETATE;CCR5;del;CCR5_del;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;CAUTION_DRUG_ACCUMULATION
GLIPIZIDE;TCF7L2;T;TCF7L2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CAROTID_ARTERY_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;SLC14A2;T;SLC14A2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL;TPMT;*3C;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAVOSONSTAT;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10 + *5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;NR1I2_GAGAAG/del + del/del;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IVACAFTOR/LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A1;*6 + *28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TELMISARTAN;UGT1A3;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
IVACAFTOR/LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
HALOPERIDOL;CYP2D6;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DRUG_ACCUMULATION
MEASLES_VACCINES;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUCINDOLOL;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;ADRA2C_GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
MEASLES_VACCINES;HLA-B;*07:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEASLES_VACCINES;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES_VACCINES;HLA-B;*08:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCB11;G;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
INFLUENZA_VACCINES;HLA-DQB1;*03:03;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES_VACCINES;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES_VACCINES;HLA-DRB1;*03:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*20;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:GASTROINTESTINAL_NEOPLASMS,DISEASE:RECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL;TPMT;*3B;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCB11;G;ABCB11_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIROLIMUS, TEMSIROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GRANISETRON;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*40;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;CYP1A1;*2A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROCURONIUM;SLCO1A2;CC;SLCO1A2_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCC2;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
CAPECITABINE, FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3/*3 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLC10A1;T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN_K1;CYP4F2;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUMETANIDE, FUROSEMIDE, TORASEMIDE;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MORPHINE;SLC22A1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VARENICLINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RALOXIFENE;UGT1A8;*1a/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*5 + *6 + *11;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;NR1I2;T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DIMETHYL_FUMARATE;GSTP1;GG;GSTP1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
O-DESMETHYLTRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LOW_BACK_PAIN, DISEASE:OSTEOARTHRITIS;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;TYMP;AA + AG;TYMP_AA + AG;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
USTEKINUMAB;HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC_ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""RIBAVIRIN""";HLA-B;*44:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON, TROPISETRON;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE, TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-HYPERCHOLESTEROLAEMIC_PATIENTS_SCHEDULED_FOR_ANGIOPLASTY;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FLUOXETINE, SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_CT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;ADRA2C;del;ADRA2C_GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;AT;DPYD_A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;CG;DPYD_C;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
SIROLIMUS, TEMSIROLIMUS;NR1I2;GG;NR1I2_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;GENE_NOT_SPECIFIED;G;G;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ROCURONIUM;IAPP, SLCO1A2;CC;IAPP, SLCO1A2_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MEASLES_VACCINES;HLA-B;*44:02;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;del/del;CYP2D6_A/DELA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMOXICILLIN, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ESTRONE_SULFATE;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;CXCL5;CC;CXCL5_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMOXICILLIN, OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATAZANAVIR/RITONAVIR;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN, DEXTRORPHAN;TCF20;C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*4 + *6 + *8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CSMD1;CT + TT;CSMD1_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR/RITONAVIR;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ESTRONE;SLCO1B1;*5/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NT5C2;AA + AG;NT5C2_AA + AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL;UGT1A1;*60;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*8 + *8/*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C18;GG;CYP2C18_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP2D6;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL;CYP2A6;*4 + *7 + *9;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;*1/*2 + *1/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BURNS;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVONORGESTREL;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN, DEXTRORPHAN;IP6K2;AG;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEBRISOQUINE;CYP2D6;*29/*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE, METOPROLOL;CYP2D6;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVONORGESTREL;CYP2B6;CT;CYP2B6_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CODEINE, DEBRISOQUINE, DEXTROMETHORPHAN, METOPROLOL;CYP2D6;*5/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SORAFENIB;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*29/*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:GASTROESOPHAGEAL_REFLUX;CAUTION_DRUG_ACCUMULATION
ATENOLOL, ENALAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A4;*22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOBAZAM;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*4/*9 + *9/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;C;ABCB1_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, FLUOXETINE;SERPINE1;G;SERPINE1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;GT/del + del/del;CYP2C9_del;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;SLC25A31;TTA/del;SLC25A31_TTA/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;CNNM2;CC + CT;CNNM2_CC + CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEMATOLOGIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;UGT1A3;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;TTAAAGTTA/del;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SERTRALINE;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MALARIA;CAUTION_DRUG_ACCUMULATION
CILOSTAZOL;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RASAGILINE;SLC22A1;CT;SLC22A1_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A7;*1A/*1A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
COTININE, NICOTINE;CYP2A6;*2 + *4 + *9 + *12;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
KETAMINE;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCC2;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLURBIPROFEN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;ABCC2;T;ABCC2_CT + TT;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;SLC6A3;del;SLC6A3_GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;DRD2;A;DRD2_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VARDENAFIL;CYP3A5;TT;CYP3A5_CC;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SIPOGLITAZAR;UGT2B15;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETHANOL;SLC6A3;del;SLC6A3_GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;TOXICITY;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;CC;SLC22A1_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A6;*2a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:ATRIAL_FLUTTER,DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT1A6;*2a/*2a + *1a/*2a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT2B15;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRK1;TT;OPRK1_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
DEBRISOQUINE;CYP2D6;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;CT;TPMT_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TOLTERODINE;CYP2D6;*3 + *4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;*1xN + *2xN;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MOOD_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;SIN3A;GG;SIN3A_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;TT;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, RALTITREXED;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL4;G/TT + TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
RASAGILINE;SLC22A1;AG;SLC22A1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
LOVASTATIN_ACID;SLCO1B1;*5/*15 + *15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLURBIPROFEN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:B-CELL_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTTRAUMATIC_STRESS_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASAGILINE;ABCC2;AA;ABCC2_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;HTR2A;CC;HTR2A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;HLA-G_ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DONEPEZIL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;ABCB1;A;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DIPYRONE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE, SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NILOTINIB;UGT1A1;*6/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DOSE_ADJUST
COTININE, NICOTINE;CYP2B6;*1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
BUPROPION;DBH;CC;DBH_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS, DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
PACLITAXEL, PLATINUM_COMPOUNDS;GSTM1;non-null;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;non-null/non-null;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HODGKIN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ENALAPRIL, LISINOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;SLC18A2;CC;SLC18A2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALTEGRAVIR;UGT1A9;*3a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C18;TT;CYP2C18_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATIC_HEART_DISEASE;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;CC;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYAMITRIPTYLINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETYLCYSTEINE;EPHX1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SLC18A2;GG;SLC18A2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GSTM3;CCT/CCT;GSTM3_CCT/CCT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVODOPA, METHYLPHENIDATE;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;SLC6A3_CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;SLC6A3_CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
BUPROPION;FKBP5;TT;FKBP5_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;CYP3A5;*3 + *6 + *7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
INTERFERON_BETA-1A;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;EPHX1;CG;EPHX1_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESOPHAGITIS, DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ERYTHEMA_NODOSUM, DISEASE:LEPROSY;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANGINA_PECTORIS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:PULMONARY_EMBOLISM,OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IMATINIB;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;SLCO1B1;*5 + *15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;CC;UGT2B7_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;UGT2B7;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AG;ABCB1_A;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NELFINAVIR;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDROXYBUPROPION;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NELFINAVIR;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*1/*6 + *1/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, TEZACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*6/*6 + *6/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, TEZACAFTOR;CFTR;CTT/del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;A;CDA_A;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;NR1I2;TT;NR1I2_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;A;ABCB1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;CC;FKBP5_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GNB3;CC + CT;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;AC + CC;FKBP5_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;OPRK1;CC;OPRK1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;ABCB1_A;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
IMATINIB;ABCG2;T;ABCG2_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;PPARA;G;PPARA_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;SLCO1C1;G;SLCO1C1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;T;POR_CT + TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DALCETRAPIB;ADCY9;AA;ADCY9_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;BDNF;CT;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS, FLECAINIDE;ADRB1;G;ADRB1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TACHYCARDIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;T;ABCC2_CT + TT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;FCGR3A;AA;FCGR3A_AC + CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEUROMYELITIS_OPTICA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DRUGS_USED_IN_ALCOHOL_DEPENDENCE;GATA4;CC;GATA4_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHORIONIC_GONADOTROPIN;FSHR;CC;FSHR_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BEPRIDIL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIAC_RHYTHM_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;GG;CYP3A4_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NICARDIPINE, NIMODIPINE;CACNA1B;AG + GG;CACNA1B_AG + GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM;GLDC;G;GLDC_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTISONE_ACETATE;CYP3A7;*1C;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ADRENAL_HYPERPLASIA, CONGENITAL;CAUTION_DOSE_ADJUST
DAUNORUBICIN;G6PD;A-202A_376G;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;*2;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
METFORMIN;HNF1B;AA + AG;HNF1B_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;CYP3A4;C/C;CYP3A4_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GLATIRAMER_ACETATE;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE;NAT2;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;C/C;CYP3A4_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIAZEPAM;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON_ALFA-2A"", ""PEGINTERFERON_ALFA-2B"", ""RIBAVIRIN""";IL18;T;IL18_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, PAROXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;SLC6A4_(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;POR;CC;POR_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANOSINE_DIPHOSPHATE, THIOGUANOSINE_MONOPHOSPHATE, THIOGUANOSINE_TRIPHOSPHATE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;CYP2A6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TOCILIZUMAB;IL6R;CT + TT;IL6R_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;T/T;CYP3A4_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MIRTAZAPINE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAPYRIDINE;NAT2;*7/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;CT;SLC19A1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON_ALFA-2A"", ""PEGINTERFERON_ALFA-2B"", ""RIBAVIRIN""";IL18;C;IL18_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HUMAN_LIVER_MICROSOMES;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LOSARTAN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLMESARTAN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ONDANSETRON;CYP2D6;*1xN + *2xN;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NATEGLINIDE;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCC2;T;ABCC2_C;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*1/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;CC;CYP2D6_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;EFFICACY:ALCOHOL_ABUSE, EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METFORMIN;GENE_NOT_SPECIFIED;CG;CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CC;ATIC_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LORNOXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;CYP2D6;*10 + *5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BENZBROMARONE;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LABETALOL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;CYP2C8;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;HLA-A;*01:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CA/CA;CYP2B6_CA/CA;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;*40:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
BOCEPREVIR, PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT;IFNL4_TT/TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL, PRASUGREL, TICAGRELOR;CYP2C19;A;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*11;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;POR;CT + TT;POR_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;DRD2;AA + AG;DRD2_AG + GG;OUTCOME_NOT_SPECIFIED;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TREATMENT_FOR_HEROIN_ADDICTION;CAUTION_DOSE_ADJUST
CARBOPLATIN, PACLITAXEL;GSTP1;G;GSTP1_GG;TOXICITY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CISPLATIN;MIR335;AA + AG;MIR335_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;ALDH1A1_CTGGTGAGGAGAGAACC/del;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE, METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SIROLIMUS, TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NIMODIPINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BURNS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SIMVASTATIN;F3;CT;F3_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR/LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETYLCHOLINE, NITROPRUSSIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;CTT/del;CFTR_del/del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ARTERIOSCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;C;CYP3A5_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SEDATION;CAUTION_DOSE_ADJUST
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SEDATION;CAUTION_DOSE_ADJUST
FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SEDATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;C;CYP3A4_CT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FULVESTRANT;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ABATACEPT;HLA-DRB1;*04:05;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;SLCO1C1;G;SLCO1C1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DULOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;A;VDR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;A;VDR_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;A;CYP2D6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION, NALTREXONE;ANKK1, DRD2;AA + AG;DRD2_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;CYP2D6_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:AUTISM_SPECTRUM_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DAPOXETINE;CYP2D6;*10/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;PPARD;G;PPARD_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
O-DESMETHYLTRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN,OTHER:CONSTIPATION;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;PPARD;G;PPARD_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;NEDD4;G;NEDD4_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;DDHD1;G;DDHD1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE_5, 6-ORTHOQUINONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;UGT1A1;AA;UGT1A1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESVENLAFAXINE, VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;VKORC1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:SCHISTOSOMIASIS;CAUTION_DRUG_ACCUMULATION
PALIPERIDONE, RISPERIDONE;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;C;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;PK:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSION,DISEASE:PSYCHOTIC_DISORDER, DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;GENE_NOT_SPECIFIED;A;PRKG1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFINPYRAZONE;UGT1A9;T;UGT1A9_C;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE;NAT2;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ICOTINIB;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MICA;AA;MICA_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:PULMONARY_EMBOLISM,OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*1/*4 + *1/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
LITHIUM;GSK3B;GG;GSK3B_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;ABCB1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LITHIUM;NR1D1, THRA;TT;NR1D1, THRA_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAPYRIDINE;NAT2;*5/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DQA1;*05;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENZYME_INHIBITORS;CYP19A1;CC;CYP19A1_C;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;FCER2;G;FCER2_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE, OLMESARTAN;SLC22A1;AG;SLC22A1_A;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:HYPERTENSION, OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;G;SLCO1B3_G;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;A;SLCO1B3_AA;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;G;SLCO1B3_G;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;VDR;C;VDR_TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;KLRC4;GG;KLRC4_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIAZEPAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;EFFICACY:MAJOR_DEPRESSIVE_DISORDER, EFFICACY:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RESISTANT_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIPYRONE;NAT2;*16 + *6 + *7 + *14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*1xN/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_T;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
MARAVIROC;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1/*2xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*2xN/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;DRD2;C;DRD2_CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MARAVIROC;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, ESCITALOPRAM;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDROCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TACHYCARDIA;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CITALOPRAM, ESCITALOPRAM;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSYCHOTIC_DISORDER, OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
DESIPRAMINE, IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TRANS_4-HYDROXYPRAZIQUANTEL;CYP2J2;AA + AC;CYP2J2_AA + AC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:SCHISTOSOMIASIS;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PERPHENAZINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORTIOXETINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENTANYL;GENE_NOT_SPECIFIED;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;G;OPRM1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTON_PUMP_INHIBITORS;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;T;OPRM1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;T;KCNQ1_CT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;G/del + del/del;DRD2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LINAGLIPTIN;TCF7L2;CC + CT;TCF7L2_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;T;OPRM1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYBUPROPION;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;COMT;AG + GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;A;OPRM1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;T;OPRM1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;VDR;T;VDR_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYMORPHONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYMORPHONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PHANTOM_LIMB_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYMORPHONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PHANTOM_LIMB_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LOW_BACK_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;FKBP5;AC + CC;FKBP5_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OPIOIDS;COMT;GG;COMT_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ATENOLOL, METOPROLOL;ADRB2;CC;ADRB2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TACHYCARDIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;C;KCNQ1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SOLANIDINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEPRESSION;CAUTION_DRUG_ACCUMULATION
FLECAINIDE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TACHYCARDIA, SUPRAVENTRICULAR;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PRIDOPIDINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PREGNANCY;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE, (S)-METHADONE;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARSENIC_COMPOUNDS;CBS;AA + AG;CBS_AA + AG;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
(R)-METHADONE, (S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;FOXP3;G;FOXP3_GT + TT;OTHER;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL, METOPROLOL;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TACHYCARDIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C2;TT;NT5C2_CC + CT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;TT;CDA_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;CTRB1, CTRB2;GG + GT;CTRB1, CTRB2_GG + GT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2B6;*6/*6 + *6/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ARSENIC_COMPOUNDS;CBS;CT + TT;CBS_CT + TT;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
3-HYDROXYCOTININE, 3-HYDROXYCOTININE_GLUCURONIDE;CYP2A6;*1 + *2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;VDR;C;VDR_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;VDR;C;VDR_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;CT + TT;CYP2C19_TT;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEMATOLOGIC_DISORDER, DISEASE:INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARISOPRODOL;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;GLP1R;AA + AG;GLP1R_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GLICLAZIDE;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NORQUETIAPINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*2xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
INDOMETHACIN;CYP2C9;G;CYP2C9_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;CDA_AA;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;SLC6A4;TT;SLC6A4_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NIMODIPINE;CACNA1C;CC;CACNA1C_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NIMODIPINE;CACNA1C;CG;CACNA1C_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MARAVIROC;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;GABRQ;AA + AT;GABRQ_AA + AT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, IDARUBICIN;DCK;G;DCK_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:SURGERY;CAUTION_DOSE_ADJUST
2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN;UGT1A3;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IBOGAINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN, ATORVASTATIN_LACTONE;CYP3A4;*2 + *22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS, VENLAFAXINE;GRIA3;CC;GRIA3_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*39;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;HLA-DQA1;*05;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:INFLAMMATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
1-HYDROXYMIDAZOLAM, MIDAZOLAM;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS, VENLAFAXINE;GRIA3;TT;GRIA3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CALU;G;CALU_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MALARIA_FALCIPARUM;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL_LUMEFANTRINE;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MALARIA_FALCIPARUM;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2D6;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SUBSTANCE-RELATED_DISORDERS, OTHER:MAJOR_DEPRESSIVE_DISORDER,OTHER:ANXIETY_DISORDERS, OTHER:BORDERLINE_PERSONALITY_DISORDER;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SUBSTANCE-RELATED_DISORDERS, OTHER:MAJOR_DEPRESSIVE_DISORDER,OTHER:ANXIETY_DISORDERS, OTHER:BORDERLINE_PERSONALITY_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCC2;TT;ABCC2_C;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
LEVONORGESTREL;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS, VENLAFAXINE;GRIA3;TT;GRIA3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NKX2-6;AG + GG;NKX2-6_AG + GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CYTARABINE, IDARUBICIN;DCK;T;DCK_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;HTR2A;AG + GG;HTR2A_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:THERAPEUTIC_DRUG_MONITORING_ANALYSES;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;GENE_NOT_SPECIFIED;CC + CT;CC + CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
FOLLITROPIN_BETA, UROFOLLITROPIN;FSHR;CC + CT;FSHR_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER, OTHER:ANXIETY_DISORDERS,OTHER:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;UBE2I;CG;UBE2I_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;FRAS1;AA + AG;FRAS1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;FAM201A;AG + GG;FAM201A_AG + GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;SCN1A;T;SCN1A_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;DPYD;CC + CT;DPYD_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;A;DRD2_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:THROMBOEMBOLISM;CAUTION_DRUG_ACCUMULATION
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*5 + *5/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;A;OPRM1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FAMOTIDINE, OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MALARIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA7;CC;CHRNA7_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;DRD2;GG;DRD2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
WARFARIN;EPHX1;A;EPHX1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FAMOTIDINE, OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC2A2;C;SLC2A2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;G;CYP2C9_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CONNECTIVE_TISSUE_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DULOXETINE;CYP2D6;CC;CYP2D6_TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;del;CYP2C9_del;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDROXYUREA;BCL11A;A;BCL11A_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;A;CYP2C9_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BETA_BLOCKING_AGENTS;KL;A/del + del/del;KL_A/del + del/del;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;RRM1;AC;RRM1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, SERTRALINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;SLC6A4_(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;ACE;TT;ACE_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM, VALPROIC_ACID;UGT2B7;A;UGT2B7_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM, VALPROIC_ACID;UGT2B7;T;UGT2B7_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDROXYCHLOROQUINE;CYP3A4;CC;CYP3A4_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC1;CC;XRCC1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;CT;RRM1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;HNF4A;C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCC2;A;ABCC2_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;DOSAGE, EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;A;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_WITH_DECREASED_CONCENTRATIONS_OF_VORICONAZOLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;PPARD;T;PPARD_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;OR10P1;G;OR10P1_G;PD;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PIOGLITAZONE;CYP2C8;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;RRM1;AC;RRM1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FAMOTIDINE, LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE, LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GENE_NOT_SPECIFIED;AG + GG;AG + GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CALU;G;CALU_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ATENOLOL, METOPROLOL;SNX9;A;SNX9_A;PD;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;GENE_NOT_SPECIFIED;GT + TT;GT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;STX4;T;C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SIROLIMUS, TEMSIROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
URACIL;DPYD;c.295_298delTCAT (*7);GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.2846A>T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1679T>G (*13);GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1905+1G>A (*2A);GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;CC;ABCB1_CC;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BCR-ABL_TYROSINE_KINASE_INHIBITORS;HLA-A;*03:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL_TYROSINE_KINASE_INHIBITORS;HLA-A;*23:17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL_TYROSINE_KINASE_INHIBITORS;HLA-B;*57:03;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;*6 + *18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*3b;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;PPARD;C;PPARD_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DQA1;*05;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;CHST3;A;CHST3_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BRAIN_INJURY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TILDRAKIZUMAB;PDE4D;CT/CT;PDE4D_CT/CT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;ABCB1;A;ABCB1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;PPARD;C;PPARD_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;UGT1A6;*2a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A1;*1/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;CHST3;A;CHST3_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI, IRINOTECAN;UGT1A1;*28 + *60;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
MIRABEGRON;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PEPTIC_ULCER_DISEASE, OTHER:GASTROESOPHAGEAL_REFLUX,OTHER:ESOPHAGITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *8;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:CAESARIAN_SECTION, OTHER:PAIN;CAUTION_DOSE_ADJUST
DULOXETINE;DRD3;GG;DRD3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;C11orf65;C;ATM_AC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ, NEVIRAPINE;NR1I3;AA + AG;NR1I3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HEMATOLOGIC_NEOPLASMS, OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PIMOZIDE;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;CHST3;C;CHST3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, THALIDOMIDE;CHST3;C;CHST3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCB11;G;ABCB11_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1B3;AA + AG;SLCO1B3_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLCO1B3;GG + GT;SLCO1B3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:SCHISTOSOMIASIS;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FESOTERODINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LYMPHOMA,OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;CHST13;C;CHST13_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACOSAMIDE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSIGLITAZONE;CYP2C8;C;CYP2C8_C;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LACOSAMIDE;ABCC2;T;ABCC2_CT + TT;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;CYP3A4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE_DIPHOSPHATE, THIOGUANOSINE_MONOPHOSPHATE, THIOGUANOSINE_TRIPHOSPHATE;TPMT;*3A + *3B + *3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ITIH3;AA;ITIH3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;ADORA1;CC;ADORA1_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;OTHER:APNEA_OF_PREMATURITY;LIKELIHOOD_THERAPEUTIC_FAILURE
NORQUETIAPINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMLODIPINE;CACNA1D;GG;CACNA1D_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;ZHX2;C;ZHX2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BERBERINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;EFFICACY, OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
RANIBIZUMAB;VEGFA;CC + CT;VEGFA_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ONDANSETRON;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
IMATINIB;ABCA3;GG + GT;ABCA3_GG + GT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CBARP, STK11;TT;STK11_C;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A3;T;SLC22A3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;PRKAA1;A;PRKAA1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC29A4;A;SLC29A4_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAG2;T;PRKAG2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;SLC47A1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;STK11;C;STK11_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;C;SLC47A2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
ALECTINIB;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
METFORMIN;TCF7L2;T;TCF7L2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRK1;CC;OPRK1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;AG;SLC22A1_AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
N, N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:IMMUNOGLOBULIN_A_VASCULITIS;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;AG + GG;IL6R_AG + GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;CT;ABCC2_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;CG + GG;IL6R_CG + GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;IL6R;AA + AG;IL6R_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;GENE_NOT_SPECIFIED;AA;AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;CLEC2D;GG;CLEC2D_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;KCNMB1;AA + AG;KCNMB1_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ELDERLY_ADULT, OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
MORPHINE;CCL11;AA;CCL11_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;IL16;TT;IL16_TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;CT;SLC22A1_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;SLC16A1;GG;SLC16A1_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;C;SLC22A1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;CC;SLC22A1_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;AC + CC;ABCC4_AC + CC;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;FKBP5;CT + TT;FKBP5_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN_SULFATE;CYP2E1;*1/*5B;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;OTHER:PATENT_DUCTUS_ARTERIOSUS, OTHER:PREMATURE_BIRTH;CAUTION_DRUG_ACCUMULATION
FENTANYL;ABCC1;(A)14;ABCC1_(A)14;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:PAIN, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2 + *17;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;T;CBR1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SUNITINIB;KDR;AG;KDR_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;CC;FKBP5_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;KCNQ1;GT + TT;KCNQ1_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
RAMIPRIL;SLCO1B1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RAMIPRIL;ABCG2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;DRD3;CC + CT;DRD3_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, DAUNORUBICIN;RAD50;AA + AC;RAD50_AA + AC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;TT;ABCC4_TT;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DULOXETINE;DRD3;CT;DRD3_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ, NEVIRAPINE;NR1I2;AA + AC;NR1I2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EZETIMIBE;ABCG8;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EZETIMIBE;ABCG5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DULOXETINE;DRD3;AG;DRD3_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER,DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;*10 + *41;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PROSTATIC_HYPERPLASIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;HBG2;AA + AG;HBG2_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;HBG2;AA;HBG2_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;BCL11A;C;BCL11A_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;A;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;SCN1A;AA + AT;SCN1A_AA + AT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ENG;G;ENG_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;PKD1L2;A;PKD1L2_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
PREGABALIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;FKBP5;TT;FKBP5_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITAVASTATIN;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ, NEVIRAPINE;NR1I3;AG + GG;NR1I3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;FKBP5;AA;FKBP5_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2D6;C;CYP2D6_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;G;CYP2D6_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DRD4;C;DRD4_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD4;del;DRD4_del;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;SORCS1;GG;SORCS1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;KCNJ11;GG;KCNJ11_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;PRKD1;G;PRKD1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;NR1I2;CC;NR1I2_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RESPIRATORY_FAILURE_REQUIRING_ASSISTED_VENTILATION;CAUTION_DRUG_ACCUMULATION
METHADONE, R-EDDP, S-EDDP;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;G;MTHFR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT + TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:CROHN_DISEASE,DISEASE:AUTOIMMUNE_HEPATITIS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;APOE_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:PULMONARY_EMBOLISM,OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;CC;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A2;CC;SLC22A2_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHACHOLINE;ADRB2;AA;ADRB2_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TEMSIROLIMUS;NR1I2;TT;NR1I2_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TEMSIROLIMUS;ABCB1;CC;ABCB1_C;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;GENE_NOT_SPECIFIED;C;C;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;G;CYP3A5_AA + AG;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;A;CYP3A4_A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATIC_HEART_DISEASE;CAUTION_DOSE_ADJUST
ATENOLOL, METOPROLOL;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;SLC4A1;CC + CT;SLC4A1_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;SLCO1C1;G;SLCO1C1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_T;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
DICHLOROACETIC_ACID;GSTZ1, POMT2;G;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC_ACID;GSTZ1, POMT2;C;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC_ACID;GSTZ1, POMT2;G;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA;ABCB1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;AG + GG;DPYD_AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;GENE_NOT_SPECIFIED;AA + AG;AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AA;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;T;OPRM1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;A;OPRM1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;HINT1;CT + TT;HINT1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG;OPRM1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;CT;CYP2D6_TT;EFFICACY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;EFFICACY:ALCOHOL_ABUSE, EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;DBH;CT + TT;DBH_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;CYP1A2;AA;CYP1A2_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;OR2B11;A;OR2B11_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
SULFONAMIDES, UREA_DERIVATIVES;KCNJ11;CT;KCNJ11_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFONAMIDES, UREA_DERIVATIVES;ABCC8;AA + CC;ABCC8, KCNJ11_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIRACIL_HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;CT + TT;SLC29A1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;UGT1A10, UGT1A8, UGT1A9;del;UGT1A9_T/del + del/del;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
AXITINIB;UGT1A7;G;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_G;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
RISPERIDONE;HTR2C;A;HTR2C_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTRR;CT + TT;MTRR_CT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HTR2A;CT + TT;HTR2A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;ABCB1;A;ABCB1_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
BUTORPHANOL;COMT;GG;COMT_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;ABCG2;T;ABCG2_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
AXITINIB;ABCB1;T;ABCB1_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;AA + AG;CYP2C19_AA;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;EGFR;GT + TT;EGFR_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;SLC29A1;A;SLC29A1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUTORPHANOL;COMT;CC;COMT_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC + TT;SLC19A1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A9;TT;UGT1A9_T/del + del/del;DOSAGE;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC + CT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;CYP2B6_CC + CT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;CRHR1;T;CRHR1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;ERICH3;C;ERICH3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;SLCO1B1;CC + CT;SLCO1B1_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
SALMETEROL;ADRB2;AA;ADRB2_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP3A4;CT;CYP3A4_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;AA + AG;CYP2C19_A;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;GRIN2B;CC;GRIN2B_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BURNS;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL, SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;CRHR2;T;CRHR2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;T;ABCA1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL, SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;CRHR2;T;CRHR2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;CYP2D6;T;CYP2D6_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICARDIPINE, NIMODIPINE;CACNA1B;AG + GG;CACNA1B_AG + GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;TT;MTHFR_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;C;CYP3A5_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CG + GG;SLC22A1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;APOA5;AA;APOA5_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;AG;APOB_G;EFFICACY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
IRBESARTAN;APOB;GG;APOB_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ATORVASTATIN;APOA5;AA;APOA5_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2A6;C;CYP2A6_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;PRCP;GG + GT;PRCP_GG + GT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;UGT2B7;GG;UGT2B7_G;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY, OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;CYP2B6;AG + GG;CYP2B6_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;MTHFR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;G;ABCB1_A;EFFICACY, OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
MIDAZOLAM;VDR;CT + TT;VDR_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLDOPA;ARG2;G;ARG2_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:PREGNANCY, OTHER:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA + AG;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;CYP2C8;C;CYP2C8_C;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
REPAGLINIDE;CYP2C8;T;CYP2C8_TT;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;TT;CYP2C19_TT;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;TT;CYP2C19_TT;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;TT;CYP2C19_CT + TT;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;TT;CYP2C19_CT + TT;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;TT;CYP2B6_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE, METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
GEMCITABINE;CMPK1;CC;CMPK1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;CG + GG;ADRA2A_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUDESONIDE, FLUTICASONE/SALMETEROL, FORMOTEROL, OMALIZUMAB;IL10;CC + CT;IL10_CC + CT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;ADRA2A_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;ADRA2A_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;GG;CMPK1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DCTD;CC;DCTD_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;APOA5;AA;APOA5_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;TENT4A;GG;TENT4A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;CT + TT;FPGS_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDC5L;CT + TT;CDC5L_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;AA;TYMS_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;APOA5;AA;APOA5_AG + GG;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DYSLIPIDAEMIA;CAUTION_DOSE_ADJUST
BUDESONIDE, FLUTICASONE/SALMETEROL, FORMOTEROL, OMALIZUMAB;IL17A;AG + GG;IL17A_AG + GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SH2D5;GT + TT;SH2D5_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CETP;A;CETP_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;AA;SLCO1B1_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;DOSAGE, TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;CT;TPMT_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;ITPA;AC;ITPA_AC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPRENORPHINE;CYP3A4;TT;CYP3A4_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ISCHEMIA, DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERINDOPRIL;AGTR1;AA;AGTR1_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
NITRENDIPINE;AGTR1;AA;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE;OPRM1;AG + GG;OPRM1_AA;PD;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HNF4A;AA;HNF4A_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;ABCG2;CC + CT;ABCG2_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;TSPYL1;AG + GG;TSPYL1_AA;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;CC;CMPK1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
GEMCITABINE;ESR2;TT;ESR2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;TT;DRD2_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC2;AA + AG;ABCC2_GG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;T;DRD2_CT;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCC2;CT + TT;ABCC2_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOSE;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GENE_NOT_SPECIFIED;A;A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;AA + AG;SLCO1B1_AA + AG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CONJUGATED_ESTROGENS;SLCO1B1;CT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;A;ERCC1_AC + CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;GG;ABCB1_A;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;ABCB1_C;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
DIAZEPAM;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;CT + TT;CYP2C19_TT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;POR;CT + TT;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;IGF2R;AG;IGF2R_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;SLC24A4;AG;SLC24A4_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;AG;CYP3A4_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;AG;IL1B_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;AA;IL1B_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;ERCC1;AG + GG;ERCC1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OVARIAN_NEOPLASMS, OTHER:NEOPLASM_OF_ESOPHAGUS,OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ULINASTATIN;MMP2;T;MMP2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PANCREATITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;G;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ULINASTATIN;MMP9;T;MMP9_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PANCREATITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AA + AG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;NR1I2;CT + TT;NR1I2_T;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;G;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;NR1I2;AA;NR1I2_AA;TOXICITY, METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL10;CC;IL10_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD3;C;DRD3_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;ADH1A;A;ADH1A_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES_VACCINES;TLR3;CT;TLR3_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;ADH1A;T;ADH1A_T;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;ABCC2;CT;ABCC2_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;CT;CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;A;TNF_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
SALBUTAMOL;PAPPA2;CT;PAPPA2_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORBUPRENORPHINE;OPRD1;GG;OPRD1_A;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;CT;CYP3A4_TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SALMETEROL;ADRB2;G;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;AG;AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;NCOA3;CT;NCOA3_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;AG;AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;CT;CRHR2_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP3A4;C;CYP3A4_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SALBUTAMOL;ADCY9;AG;ADCY9_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERPHENAZINE;MCPH1;A;MCPH1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;CDH13;G;CDH13_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;SKOR2;G;SKOR2_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA;SLC47A2_AA;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;KCNMA1;G;KCNMA1_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;MAML3;A;MAML3_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT2B7;CC + CT;UGT2B7_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
METHACHOLINE;RUNX1;AA;RUNX1_AG + GG;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;LRP1B;G;LRP1B_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
BEVACIZUMAB;HTRA1;AA;HTRA1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;PSMD14;A;PSMD14_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
RISPERIDONE;AGAP1;C;AGAP1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
BEVACIZUMAB;ARMS2;TT;ARMS2_GT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;APEH;CC;APEH_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NPAS3;G;NPAS3_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
RISPERIDONE;TMEFF2;G;TMEFF2_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
METFORMIN;PCK1;CT + TT;PCK1_CT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIPRASIDONE;CDH4;A;CDH4_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ZIPRASIDONE;LYN;G;LYN_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
BEVACIZUMAB;CFH;GG;CFH_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CT;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ZIPRASIDONE;NALCN;C;NALCN_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ZIPRASIDONE;CNTN4;A;CNTN4_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;GG;COMT_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DOSE_ADJUST
IMATINIB;SLCO1A2;CT + TT;SLCO1A2_CC;TOXICITY, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
IMATINIB;SLCO1B3;GG;SLCO1B3_GG;TOXICITY, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;ADD1_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CALU;AA;CALU_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:SURGERY;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOB;AA;APOB_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHACHOLINE;RUNX1;AG + GG;RUNX1_AG + GG;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE;SERPINE1;G;SERPINE1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTR;G;MTR_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS, VENLAFAXINE;FKBP5;A;FKBP5_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MOOD_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CSMD1;A;CSMD1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OLANZAPINE;PLAGL1;C;PLAGL1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;AA;CYP3A5_AA + AG;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;PLAGL1;A;PLAGL1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;PTPRN2;C;PTPRN2_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;AA + AG;SLC22A1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;AA + AG;NQO1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PERPHENAZINE;PRKCE;C;PRKCE_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;GENE_NOT_SPECIFIED;C;C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;DOT1L;CT + TT;DOT1L_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ADM;CC;ADM_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TILDRAKIZUMAB;ATG5;CT;ATG5_CC + CT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TILDRAKIZUMAB;IL17RC;CC;IL17RC_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;BDNF;TT;BDNF_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;OXT;T;OXT_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DIAZEPAM;CYP3A4;GG;CYP3A4_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;MTHFR_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;C;DHFR_TT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NOS1AP;T;NOS1AP_GG;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CITALOPRAM;BDNF;TT;BDNF_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY_ACTIVE_ANTIRETROVIRAL_THERAPY_(HAART);ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;BDNF;CC;BDNF, BDNF-AS_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;ABCC1;CC + CT;ABCC1_CC + CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;BDNF;CT;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TILDRAKIZUMAB;TNFAIP3;GG;TNFAIP3_GG + GT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ERICH3;CC;ERICH3_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT;CYP2C19_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;DRD3;CC + CT;DRD3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENTACAPONE;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2D6;AA;CYP2D6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELMISARTAN;SLCO1B3;C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2D6;GG;CYP2D6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN, SIMVASTATIN;ABCG8;CC + CG;ABCG8_CG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;CFTR_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ULK3;GG;ULK3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD1;GT;DRD1_GT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS;STAT3;GG;STAT3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;SLCO2B1;AA + AG;SLCO2B1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AG;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RISPERIDONE;HRH3;TT;HRH3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GENE_NOT_SPECIFIED;AA + AG;A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AC + CC;VKORC1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RISPERIDONE;HRH3;TT;HRH3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;TAAR6;AA + AG;TAAR6_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;IL6;G;IL6_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFASALAZINE;ABCG2;TT;ABCG2_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A;IL6;G;IL6_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A;IL6;G;IL6_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;AA + AG;ABCG2_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ILOPERIDONE;CNTF, ZFP91-CNTF;GG;CNTF, ZFP91-CNTF_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DISULFIRAM;OPRD1;CC;OPRD1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROPOIETIN;STIM1;AG + GG;RRM1_GG;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_DISORDER, OTHER:ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
LATANOPROST;PTGFR;CC;PTGFR_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;VEGFA;AC + CC;VEGFA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ABCC4;T;ABCC4_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;CC;SLC22A1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GENETIC_VARIATION_AT_RS2289669;CAUTION_DOSE_ADJUST
MORPHINE;COMT;T;COMT_T;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;COMT;G;COMT_G;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;CYP1A1;AA;CYP1A1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;COMT_A;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;COMT, TXNRD2;C;COMT, TXNRD2_C;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;COMT_AG + GG;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A4;TT;CYP3A4_TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;COMT_A;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;ABCC3;T;ABCC3_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;POR;T;POR_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;CYP2D6;DELT/T;CYP2D6_DELT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL, TRAMADOL;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AG;CYP2C19_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCC2;CC;ABCC2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;SORCS2;A;SORCS2_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;ZNF816;CC;ZNF816_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;UGT2B7;AA;UGT2B7_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;NR1I2;T;NR1I2_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;PGLYRP4;CC + CT;PGLYRP4_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES, UREA_DERIVATIVES;CYP2C9;TT;CYP2C9_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;GNB3;CT;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CLUSTER_HEADACHE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL12B;AG + GG;IL12B_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYL_HYDROXYCHLOROQUINE;CYP2D6;G;CYP2D6_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABINOIDS;TRPV1;CC;TRPV1_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABINOIDS;UGT2B7;AA;UGT2B7_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CTNNA2;AA;CTNNA2_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;GT;ABCG2_T;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DESETHYL_HYDROXYCHLOROQUINE;CYP2D6;AA;CYP2D6_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;KCNJ11;T;KCNJ11_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;TCF7L2;TT;TCF7L2_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;A;COMT_AA;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;TT;EPHX1_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
MORPHINE;COMT;C;COMT_CG + GG;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ERYTHROPOIETIN;ORAI1;GG + GT;ORAI1_GG + GT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_DISORDER, OTHER:ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;COMT_A;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;CT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
MORPHINE;ARVCF, COMT;T;ARVCF, COMT_T;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCB1;AG;ABCB1_G;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;TT;ABCB1_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
MORPHINE;ARVCF, COMT;T;ARVCF, COMT_T;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;del;DRD2_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;CETP;AA;CETP_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CDKAL1;CT + TT;CDKAL1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCC2;AA + AG;ABCC2_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SIK3;AA;SIK3_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;HLA-C;CT + TT;HLA-C_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITODRINE;KCNMB2;TT;KCNMB2_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCC2;AA + AG;ABCC2_AA + AG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA + AC;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCC2;CT + TT;ABCC2_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MAP3K1;AG + GG;MAP3K1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITODRINE;KCNMB2;CC;KCNMB2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;G;GGCX_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;G;NR1I2_GG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;METTL21A;CC;CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;T;NR1I2_T;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABINOIDS;ABCB1;AG + GG;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;C;NR1I2_AA;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;AA;ADRB1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;VKORC1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;SRP19;G;SRP19_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;G;REEP5_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;GG;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;A;REEP5_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;ABCB1;AA + AG;ABCB1_A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ATAZANAVIR;SLCO1B1;TT;SLCO1B1_TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;DPYD_CT;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;NR1I2;TT;NR1I2_T;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AC;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:WARFARIN_MAINTENANCE_TREATMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM_COMPOUNDS, VINORELBINE;CASP7;CG + GG;CASP7_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM_COMPOUNDS, VINORELBINE;CASP7;CC + CT;CASP7_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM_COMPOUNDS, VINORELBINE;CASP7;AA + AC;CASP7_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM_COMPOUNDS, VINORELBINE;CASP7;CT;CASP7_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;SLC26A9;A;SLC26A9_A;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
SOLANIDINE;NFIB;CC + CT;NFIB_CT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ZIPRASIDONE;EHF;A;EHF_A;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CLOZAPINE;SLC6A3;A;SLC6A3_A;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OLANZAPINE;IL1A;C;IL1A_C;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CYCLOSPORINE;POR;TT;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;C;EPHX1_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FESOTERODINE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AA;UGT1A1_AG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;PTPRD;CC;PTPRD_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;CC + CT;VKORC1_CT + TT;EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
ACAMPROSATE;GRIN2B;A;GRIN2B_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ATP1A2;T;ATP1A2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TNFRSF11A;A;TNFRSF11A_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;PPA2;G;PPA2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;OPRM1;AA;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:SURGERY;CAUTION_DOSE_ADJUST
RISPERIDONE;PPA2;A;PPA2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;GT + TT;IGF2BP2_G;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
RASAGILINE;COMT;AA;COMT_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;AC + CC;IGF2BP2_AC + CC;DOSAGE, EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
DISULFIRAM;MTHFR;AA + AG;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR2A;AG + GG;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS,  DISEASE:CROHN_DISEASE,DISEASE:PSORIASIS, DISEASE:SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;AT;NAT2_A;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
PLATINUM_COMPOUNDS;ERCC1;AA;ERCC1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;AA;NAT2_AA;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;BEST3;AA + AG;BEST3_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;AA;UGT1A6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR3A;C;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS,  DISEASE:CROHN_DISEASE,DISEASE:PSORIASIS, DISEASE:SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;ADRA1A;AA + AG;ADRA1A_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;AA;UGT1A6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;GG;UGT1A6_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;PPARG;CG;PPARG_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL, PLATINUM_COMPOUNDS;CASP7;CC + CT;CASP7_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TNF;GG;TNF_AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CT;SCN1A_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PACLITAXEL, PLATINUM_COMPOUNDS;CASP7;CG + GG;CASP7_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TJP1;T;TJP1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;A;IL6_AG + GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;ADGRL3;CC + CT;ADGRL3_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL, PLATINUM_COMPOUNDS;CASP7;AA + AG;CASP7_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE_PROPIONATE, MONTELUKAST;CA10;CC + CT;CA10_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;CT;EPHX1_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;CC;EPHX1_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
GEMCITABINE, PLATINUM_COMPOUNDS;CASP7;AA + AG;CASP7_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE_PROPIONATE, MONTELUKAST;GENE_NOT_SPECIFIED;AA + AG;AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;ADGRL3;AG + GG;ADGRL3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADGRL3;CC + CG;ADGRL3_CC + CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;CFH;TT;CFH_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;SPOPL;C;SPOPL_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;PDE4D;T;PDE4D_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;VKORC1_CT + TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
QUETIAPINE;PDE4D;G;PDE4D_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;PDE4D;A;PDE4D_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
PERINDOPRIL;AGTR1;CC + CT;AGTR1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TJP1;T;TJP1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TJP1;A;TJP1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR_ALAFENAMIDE;ABCB1;CT;ABCB1_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;SLC6A4;T;SLC6A4_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
RALOXIFENE;UGT1A8;CC;UGT1A8_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MENOPAUSE, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;STAT6;CC + CT;STAT6_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EOSINOPHILIC_ESOPHAGITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;WBP2NL;A;WBP2NL_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PACLITAXEL, PLATINUM_COMPOUNDS;CASP7;AA + AC;CASP7_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;CD40LG;T;CD40LG_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;ESR1;CC;ESR1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MENOPAUSE, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PERINDOPRIL;AGTR1;AA + AT;AGTR1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;MYO1H;C;MYO1H_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;FCGR2A;G;FCGR2A_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;EPHX2;T;EPHX2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN, LOSARTAN_E-3174;FBXW12;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LITHIUM;GRAMD1B;A;GRAMD1B_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2D6;AA + AG;CYP2D6_AA + AG;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;GT + TT;CYP2B6_GT;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CATECHOLAMINES;ADRB1;CC;ADRB1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;APOE;CC;APOE_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
LOSARTAN, LOSARTAN_E-3174;ZNF703;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PERINDOPRIL;BDKRB1;AA + AG;BDKRB1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN, LOSARTAN_E-3174;SLC17A4;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DRUGS_USED_IN_NICOTINE_DEPENDENCE;CHRNA5;C;CHRNA5_C;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;NFATC2;CC + CT;NFATC2_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS_USED_IN_NICOTINE_DEPENDENCE;CHRNA3, CHRNA5;G;CHRNA3, CHRNA5_A;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_USED_IN_NICOTINE_DEPENDENCE;CHRNA5;T;CHRNA5_C;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GOUT;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;FAM177A1;T;FAM177A1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;GENE_NOT_SPECIFIED;A;ABCA1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CHUK;G;CHUK_CC + CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LITHIUM;ADCY1;A;ADCY1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
REPAGLINIDE;KCNQ1;CT + TT;KCNQ1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;FAM178B;A;FAM178B_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA_BLOCKING_AGENTS;GRK5;AT + TT;GRK5_AT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZILEUTON;PRORP;AA;PRORP_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN, LOSARTAN_E-3174;CYP2C9;GT;CYP2C9_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LITHIUM;ZNF804A;T;ZNF804A_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;KCNQ1;AC + CC;KCNQ1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;XRCC1;AA + AG;XRCC1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLATIRAMER_ACETATE;TGFB1;A;TGFB1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCC2;CT + TT;ABCC2_C;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GLUCOCORTICOIDS;GLCCI1;G;GLCCI1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ABCC2;CT + TT;ABCC2_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;CYP3A4;AG + GG;CYP3A4_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENELIGLIPTIN;FMO3;AG + GG;FMO3_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUGS_USED_IN_NICOTINE_DEPENDENCE;CHRNA3, CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;COMT;C;COMT_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;GPR83;GG;GPR83_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;COMT;T;COMT_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TENELIGLIPTIN;FMO3;CT + TT;FMO3_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MENOTROPINS;FSHR;CT;FSHR_T;OUTCOME_NOT_SPECIFIED;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
QUETIAPINE;COMT;A;COMT_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;GPR83;GG;GPR83_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;IL6_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TENELIGLIPTIN;FMO3;AG + GG;FMO3_AG + GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;ABCB1;CT;ABCB1_C;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;HSD3B1;CC + CT;HSD3B1_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;TTC6;CC + CT;TTC6_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENELIGLIPTIN;CYP3A4;CT + TT;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER_ACETATE;IFNAR1;G;IFNAR1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
5-HYDROXYOMEPRAZOLE, OMEPRAZOLE;GENE_NOT_SPECIFIED;A;A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;CC;CYP3A4_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
6-HYDROXY_S-WARFARIN;GENE_NOT_SPECIFIED;A;A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;CYP3A5_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;BDNF;CC;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
6-HYDROXY_S-WARFARIN;PARP14;A;PARP14_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
METOPROLOL;ADRB1;C;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;ADRB2;AA;ADRB2_AA;PD;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;NR1I3;GG;NR1I3_GG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;G;ABCG2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;GG + GT;ABCG2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA + AC;CYP19A1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
6-HYDROXY_R-WARFARIN, 6-HYDROXY_S-WARFARIN;GRID2;G;GRID2_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;CC + CT;ABCG2_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CT + TT;SLCO1B1_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;AC + CC;ABCG2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACIDIPINE, NIFEDIPINE, NITRENDIPINE;CACNA1C;TT;CACNA1C_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMEFANTRINE;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MALARIA, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;HTR1A;TT;HTR1A_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;BDNF;CT + TT;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;EPM2A;C;EPM2A_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE, FELODIPINE;CACNA1C;GG;CACNA1C_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C18;A;CYP2C18_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;TT;CYP3A4_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, FLUOXETINE;GSK3B;GG;GSK3B_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SRPRB;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;CYP2C9_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ETHANOL;ALDH2;AG;ALDH2_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LUMEFANTRINE;CYP3A5;T;CYP3A5_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MALARIA, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;CAUTION_DRUG_ACCUMULATION
ETHANOL;PGM1;CC;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;FPGS;G;FPGS_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACETALDEHYDE;ADH1A;CT;ADH1A_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;FPGS;G;FPGS_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LUMEFANTRINE;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MALARIA, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
ACETALDEHYDE;ALDH2;AG;ALDH2_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;FCGR3A;A;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;FCGR3A;A;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETALDEHYDE;PGM1;CC;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VERAPAMIL;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETALDEHYDE;ADH1B;CT;ADH1B_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE, FELODIPINE;CACNA1C;C;CACNA1C_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A5;T;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
N-DESMETHYLCLOZAPINE;UGT2B10;GT;UGT2B10_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMEFANTRINE;CYP3A4;T;CYP3A4_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MALARIA, DISEASE:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;N6AMT1;G;N6AMT1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT1A6;TT;UGT1A6_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
FENTANYL;ASTN2;CT + TT;ASTN2_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
BENAZEPRIL, IMIDAPRIL;CYP11B2;AA + AG;CYP11B2_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ASTN2;CC + CT;ASTN2_CC + CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT1A6;AA;UGT1A6_AC + CC;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;UGT1A6;AA;UGT1A6_AG + GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;AA + AG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VERAPAMIL;ABCB1;CC;ABCB1_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC + CT;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETIDRONIC_ACID;COL1A1;AA + AC;COL1A1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METABOLIC_BONE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;ABCG2;CC;ABCG2_CT + TT;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MORPHINE, NORTRIPTYLINE;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR1A;CG + GG;HTR1A_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;UGT1A6;GG;UGT1A6_GG;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;T;ZNF385D_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;BDNF;CC;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC_ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;SLC19A1;T;SLC19A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;T;ZNF385D_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC_ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;MTR;A;MTR_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;SULT1A1;TT;SULT1A1_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;G;ZNF385D_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TERBUTALINE;ADRB2;CT;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;T;SLC19A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;NRXN1;T;NRXN1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;G;ZNF385D_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;CC;VEGFA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROPOIETIN;HFE;A;HFE_A;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEMODIALYSIS_TREATMENT;CAUTION_DOSE_ADJUST
DULOXETINE;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;ADRB2;CG + GG;ADRB2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, ENALAPRIL;ADRB2;CG + GG;ADRB2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;TT;VEGFA_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROPOIETIN;HFE;G;HFE_G;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEMODIALYSIS_TREATMENT;CAUTION_DOSE_ADJUST
DULOXETINE;TEX10;C;TEX10_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;AA;CYP3A5_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DULOXETINE;TEX10;A;TEX10_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;TEX10;T;TEX10_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ATP10A;G;ATP10A_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;TEX10;G;TEX10_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;CC;ABCB1_C;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DULOXETINE;TEX10;G;TEX10_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;INVS;G;INVS_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;A;ABCB1_A;DOSAGE, TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
AMLODIPINE;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;C;ZNF385D_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;GENE_NOT_SPECIFIED;CC + CT;CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;CYP2C9;CC + CT;CYP2C9_C;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;CYP2C19;AA + AG;CYP2C19_AA;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;C;ZNF385D_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;A;ZNF385D_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;ABAT;GG;ABAT_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;T;ZNF385D_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;G;ZNF385D_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;C;ZNF385D_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;G;ZNF385D_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE;CDA;CC;CDA_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDRALAZINE/ISOSORBIDE_DINITRATE;NOS3;GG;NOS3_GG + GT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;CRP;AG + GG;CRP_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A43;AA;CYP3A43_AA;DOSAGE, EFFICACY, TOXICITY, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
GLATIRAMER_ACETATE;EOMES;T;EOMES_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT1A1;A;UGT1A1_AA;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANGINA_PECTORIS;CAUTION_DRUG_ACCUMULATION
ETOPOSIDE;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;ATG5;CC + CT;ATG5_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;MIEF2;G;MIEF2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;MIEF2;G;MIEF2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;ATG5;CT + TT;ATG5_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;MIEF2;G;MIEF2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;AOX1;G;AOX1_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;AOX1;AG + GG;AOX1_AG + GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
HYDRALAZINE/ISOSORBIDE_DINITRATE;CYP11B2;AA;CYP11B2_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C;CYP3A4_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;LPL;GG;LPL_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;FCN2;T;FCN2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOA1;CG;APOA1_CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;FCN2;A;FCN2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER_ACETATE;CLEC16A;A;CLEC16A_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DULOXETINE;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;SKIC3;G;SKIC3_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHOSUXIMIDE;CACNA1H;T;CACNA1H_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;SKIC3;G;SKIC3_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHOSUXIMIDE;CACNA1I;T;CACNA1I_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;TREML4;A;TREML4_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;MOCOS;AA + AC;MOCOS_AA + AC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;TREML4;G;TREML4_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCB1;A;ABCB1_C;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CALM1;T;CALM1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;GG;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;T;SLC19A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;AA + AG;GGH_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;AA + AC;CDA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;CACNA1H;A;CACNA1H_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ADRA2A;GG;ADRA2A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;CC;APOB_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;CC;ABCB1_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;CYP2B6_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CHLORPROMAZINE;DRD2;GG;DRD2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;AA + AG;AMPD1_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;TT;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:GASTROESOPHAGEAL_REFLUX;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;AA;OPRM1_AA;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
NELFINAVIR;CYP2C19;AA;CYP2C19_AA;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;C;CYP2C9_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOLBUTAMIDE;CYP2C9;T;CYP2C9_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;A;SLC22A1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;C;CYP2C9_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;F7;AA + AG;F7_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE;HTR1A;GG;HTR1A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPHENYTOIN;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES, UREA_DERIVATIVES;TCF7L2;TT;TCF7L2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;AGT;G;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;AGT;A;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, OXALIPLATIN;GSTP1;AG + GG;GSTP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BENAZEPRIL;AGT;T;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOA5;CG + GG;APOA5_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN, SIMVASTATIN;RHOA;A;RHOA_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AG;CYP2B6_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM;GENE_NOT_SPECIFIED;CT;CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GGCX;CG + GG;GGCX_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GENE_NOT_SPECIFIED;A;A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;A;CYP2C9_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ISONIAZID;CYP2E1;A;CYP2E1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;CYP2B6_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GATA4;TT;GATA4_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;CYP2C9_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;GATA4;TT;GATA4_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MYCOPHENOLIC_ACID_ACYL_GLUCURONIDE;UGT2B7;GG;UGT2B7_GG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;UGT2B7;CC;UGT2B7_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC_ACID_ACYL_GLUCURONIDE;UGT2B7;CC;UGT2B7_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;AA;SLC19A1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SILDENAFIL;VEGFA;AA;VEGFA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SILDENAFIL;VEGFA;AA + AC;VEGFA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE2;GG;ACE2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;FCGR2A;AA;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR3A;CC;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;UGT2B7;GG;UGT2B7_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ECULIZUMAB;CR1;AG + GG;CR1_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAROXYSMAL_NOCTURNAL_HEMOGLOBINURIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRABEGRON;UGT1A4;GT;UGT1A4_GG + GT;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;CT;CYP3A4_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLIC_ACID;UGT1A1;AG;UGT1A1_AA;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;UGT1A3;AA;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;SLC6A2;CC;SLC6A2_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOZAPINE;DRD1;G;DRD1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID_ACYL_GLUCURONIDE;UGT2B7;AA;UGT2B7_AA;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;CC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;SLC19A1;TT;SLC19A1_TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD3;TT;DRD3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;G;TPMT_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
TICAGRELOR;CYP3A4;CC;CYP3A4_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;AGTR1;AA;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGTR1;AC;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;G;CYP2C9_G;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, PACLITAXEL;CYP3A5;CC;CYP3A5_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, TEGAFUR/GIMERACIL/OTERACIL;DPYD;CC + CT;DPYD_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;AGTR1;AC;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;SLCO1B1;C;SLCO1B1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;SLCO1B1;T;SLCO1B1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE, PACLITAXEL;SLC29A1;A;SLC29A1_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;BDNF;CC;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;CES1;CT;CES1_CT;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
TICAGRELOR;UGT2B7;TT;UGT2B7_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;HTR1A;GG;HTR1A_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A43;G;CYP3A43_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL, WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
SIMVASTATIN;LEPR;GG;LEPR_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCG2;T;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;CC;SULT1A1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL2;AA;IL2_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
OPIOIDS;BDNF;CC;BDNF, BDNF-AS_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;IL6;CC;IL6_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
ATENOLOL, IRBESARTAN;AGT;AG;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC4;AA + AG;ABCC4_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A1;T;CYP1A1_T;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;GG;VEGFA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;IL1B;AA + AG;IL1B_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;SCARB1;CT + TT;SCARB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;SLC22A6;TT;SLC22A6_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRD1;CC;OPRD1_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL, WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
IRBESARTAN;AGT;AG + GG;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;CXCL10;CT + TT;CXCL10_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;T;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;T;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;ERCC2;AA + AG;ERCC2_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;APOA5;CC + CG;APOA5_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INSULIN_RECOMBINANT, ZINC_ACETATE;SLC30A8;CT + TT;SLC30A8_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD1;CT + TT;DRD1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;T;SLC22A1_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCB1;GG;ABCB1_A;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FOLIC_ACID, METHOTREXATE;ATIC;CC;ATIC_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS, SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;ADAM33;AA;ADAM33_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LITHIUM;GADL1;T;GADL1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CC;POR_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FOLIC_ACID, METHOTREXATE;ITPA;CC;ITPA_AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;C;ATIC_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;C;GGCX_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;ADA;C;ADA_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ADORA2A;T;ADORA2A_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC_ACID, METHOTREXATE;AMPD1;A;AMPD1_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RITUXIMAB;FCGR3A;CC;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;EGFR;CC;EGFR_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;TGFBR3;TT;TGFBR3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;C;VKORC1_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;ABCG2_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;VKORC1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIFAMPIN;AADAC;GG;AADAC_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;SLCO2B1;AA + AG;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CETUXIMAB, PANITUMUMAB;AREG;AA;AREG_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, PANITUMUMAB;AREG;GG;AREG_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
RIFAMPIN;ABCB1;CC;ABCB1_CC;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
FENTANYL;P2RX7;CT + TT;P2RX7_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;DRD1;CC + CT;DRD1_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD3;TT;DRD3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD4;AA;DRD4_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;XRCC1;CT + TT;XRCC1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;CC;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;COMT;AA + AG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE_SULFATE;SLCO1B1;C;SLCO1B1_C;EFFICACY;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOBUTAMINE;GNAS;CC + CT;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE_SULFATE;SLCO1B1;C;SLCO1B1_C;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;TT;GGCX_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CETUXIMAB, PANITUMUMAB;AREG;GG;AREG_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, PANITUMUMAB;AREG;AA;AREG_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CRHR1;AA + AG;CRHR1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9_GG + GT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;POR;T;POR_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;SLC29A1;GG;SLC29A1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIRACIL_HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;AG + GG;SLC29A1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;A;ADH1B_A;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;C;ADH1B_C;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;G;ADH1B_G;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;PPARA;A;PPARA_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;ADH1A;A;ADH1A_A;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHADONE;KCNJ6;TT;KCNJ6_TT;OUTCOME_NOT_SPECIFIED;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
ETHANOL;ADH1C;A;ADH1C_A;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;PPARG;CG;PPARG_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1C;A;ADH1C_A;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;ADH1C;C;ADH1C_C;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;SUMO4;AA;SUMO4_AA;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;TT;VKORC1_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;LPA;G;LPA_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA + AG;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;ABCG2;G;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA + AC;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM;NEDD4L;A;NEDD4L_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;TOMM40;G;TOMM40_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;PEBP4;T;PEBP4_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
VERAPAMIL;ITGAL;C;ITGAL_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
PAZOPANIB;KDR;AG;KDR_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH7;C;ADH7_C;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HEPATITIS_VACCINES;IL4R;C;IL4R_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;ADH1A_C;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;ADH1A_C;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL, IMIDAPRIL;AGT;CC;AGT_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;ADH1A_C;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
URSODEOXYCHOLIC_ACID;MGAT5;TT;MGAT5_TT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHOLANGITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL_THIOL_METABOLITE_H4;CYP2C19;A;CYP2C19_AA;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HEPATITIS_VACCINES;IL13;T;IL13_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;CT + TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;CYP27B1;GT + TT;CYP27B1, METTL1_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN;CES1;AA + AG;CES1_GG;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;VDR;TT;VDR_TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADGRL3;AA;ADGRL3_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SNAP25;GG + GT;SNAP25_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A3;CC + CT;SLC6A3_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
INTERFERONS, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;AA + AG;SLC22A1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;ADRA2A;G;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;XRCC1;CT + TT;XRCC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;PLCB1;A;PLCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;LRP1;TT;LRP1_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;LRP1;CC;LRP1_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;T;CYP2A6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS, RIBAVIRIN;IFNL3;GG;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;AA + AG;VKORC1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;XRCC1;G;XRCC1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC22A1;TT;SLC22A1_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;LGR5;CC + CT;LGR5_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;AA;SLC22A1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;A;UGT2B15_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;AA;SLC22A1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;KIF6;AA + AC;KIF6_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;MTHFR;AA + AG;MTHFR_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
PITAVASTATIN, PITAVASTATIN_LACTONE;SLCO1B1;A;SLCO1B1_CC + CT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCG2;AG + GG;ABCG2_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOMATROPIN_RECOMBINANT;CDK4;CC;CDK4_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TURNER_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;FMO5;A;PRKAB2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;USP24;CC + CT;USP24_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN, PITAVASTATIN_LACTONE;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;GG;SLC6A2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_BETA-1A;RORA;TT;RORA_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A2;AT + TT;SLC6A2_AT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIMAZOLAM;CES1;CT + TT;CES1_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NICOTINE;GENE_NOT_SPECIFIED;T;T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;APOE;CC + CT;APOE_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADRA2A;GG;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GENE_NOT_SPECIFIED;A;A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;APOE;CT + TT;APOE_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;CG + GG;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;NCF4;AA;NCF4_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCC2;CT + TT;ABCC2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;RAC2;AT;RAC2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYELOPROLIFERATIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;LPA;AG + GG;LPA_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;UGT1A1_CT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;BDNF;CC;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG + GT;CYP2B6_GT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATORVASTATIN;CYP3A7;G;CYP3A7_G;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATALUREN;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;CYP2B6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;CYP2B6_CC + CT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SOMATROPIN_RECOMBINANT;CDK4;TT;CDK4_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:GROWTH_HORMONE_DEFICIENCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;G;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METFORMIN;PRPF31;C;PRPF31_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
GABAPENTIN;SLC7A5;AG;SLC7A5_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEUROPATHIC_PAIN;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METFORMIN;NBEA;C;NBEA_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SUMATRIPTAN;SLC22A1;T;SLC22A1_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;AA + AG;SLC22A1_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FENOTEROL;SLC22A1;T;SLC22A1_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FENOTEROL;SLC22A1;C;SLC22A1_C;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SUMATRIPTAN;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;CYP2B6_GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUGS_USED_IN_DIABETES;IRS1;CT + TT;IRS1_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SUMATRIPTAN;SLC22A1;C;SLC22A1_C;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;CC;XRCC1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;A;FASTKD3, MTRR_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;GG;ERCC1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;NEDD4L;A;NEDD4L_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;SLC22A1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYELOPROLIFERATIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EMTRICITABINE;ABCC2;TT;ABCC2_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOGUANIL;SLC22A1;T;SLC22A1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATALUREN;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
CYCLOGUANIL;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GABAPENTIN, PREGABALIN;SLC7A5;AG;SLC7A5_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEUROPATHIC_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT + TT;SLC19A1_TT;TOXICITY;DECREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA;COMT_AA;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METFORMIN;CPA6;T;CPA6_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;DUSP1;G;DUSP1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AC;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;A;SLC22A1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;SLCO1B3;GG + GT;SLCO1B3_GG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;IL11;CT + TT;IL11_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CES1;CT + TT;CES1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;SLC2A2;CC;SLC2A2_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ABIRATERONE;YBX1;AC + CC;YBX1_AC + CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NFATC4;CC + CT;NFATC4_CC + CT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
GRAZOPREVIR;SLCO1B1;C;SLCO1B1_TT;PD;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;CYP2D6;CC;CYP2D6_CC + CG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
GRAZOPREVIR;SLCO1B1;A;SLCO1B1_CC;PD;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;VKORC1_CT + TT;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;VKORC1_CT + TT;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GENE_NOT_SPECIFIED;AA + AG;A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;BDNF, BDNF-AS;C;BDNF, BDNF-AS_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;T;SLC22A1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ENALAPRIL;NOS3;CC + CT;NOS3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;BDNF, BDNF-AS;G;BDNF, BDNF-AS_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AG + GG;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;CYP2C9_AT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;BDNF, BDNF-AS;C;BDNF, BDNF-AS_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CG + GG;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BISOPROLOL;CYP2D6;G;CYP2D6_CC + CG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;BDNF;G;BDNF_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
BISOPROLOL;CYP2D6;CT + TT;CYP2D6_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTA1;AA;GSTA1_AA + AG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;BDKRB2;TT;BDKRB2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;BDNF;C;BDNF_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;C;SLC22A1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;C;SLC22A1_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;CC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;BDNF;G;BDNF_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TRAMADOL;SLC22A1;T;SLC22A1_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T;CYP3A4_CT + TT;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;CC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;A;SLC22A1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1A;AA;TNFRSF1A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR4;AA + AG;TLR4_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;CT + TT;SLC47A1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GLUCOSE_INTOLERANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR2;TT;TLR2_AT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IFNG;AA + AT;IFNG_AA + AT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR9;TT;ALAS1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1L1;AA;VKORC1L1_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR2;CC + CT;TLR2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR2;CT + TT;TLR2_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;OPRM1;G;OPRM1_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PAIN;CAUTION_DOSE_ADJUST
OPIOIDS;ENPP2;AA;ENPP2_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;APOE;CC + CT;APOE_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;PAX4;AA + AG;PAX4_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PAX4;AA + AG;PAX4_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;APOE;CT;APOE_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;AA;ABCB1_A;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL6;CC + CT;IL6_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL17A;AA + AG;GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
LATANOPROST;ABCC4;AC;ABCC4_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPEN-ANGLE_GLAUCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;TNFRSF1B;GG + GT;TNFRSF1B_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CNPY4;CC + CT;CNPY4_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
BOTULINUM_TOXIN_TYPE_A;CALCA;G;CALCA_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CD14;AA + AG;CD14, TMCO6_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR2;AA + AC;TLR2_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
BOTULINUM_TOXIN_TYPE_A;TRPV1;A;TRPV1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ENPP2;AA;ENPP2_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL1B;AA + AG;IL1B_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL1RN;CC + CT;IL1RN_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFAIP3;CG + GG;TNFAIP3_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;APOE;CC;APOE_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;FOLR3;CT + TT;FOLR3_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;AC + CC;IFNL3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;GRK4;CT;GRK4_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY_ACTIVE_ANTIRETROVIRAL_THERAPY_(HAART);IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG;HTR2A_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT_ACTING_ANTIVIRALS, ELBASVIR/GRAZOPREVIR, LEDIPASVIR/SOFOSBUVIR;IFNL3, IFNL4;GG + GT;IFNL3_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;GRK4;GT + TT;GRK4_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCC2;CT + TT;ABCC2_C;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCC2;CT + TT;ABCC2_C;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCC2;CT + TT;ABCC2_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METOPROLOL;GRK4;CC;GRK4_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;CC;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GAD1;G;GAD1_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
INFLIXIMAB;IL1B;GG;IL1B_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;GAD1;TT;GAD1_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ROCURONIUM;SLCO1A2;T/del + TT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP1A2;AA + AC;CYP1A2_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;GG;CYP2D6_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;AA;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP4F2;AA;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;VKORC1;GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AT;DPYD_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
CLOZAPINE;UGT1A4;C;UGT1A4_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;DPYD;CT;DPYD_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
URIC_ACID;VEGFC;C;VEGFC_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
LETERMOVIR;SLCO1B1;TT;SLCO1B1_CC;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;T;UGT1A1_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CAPN10;G;CAPN10_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
LETERMOVIR;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LETERMOVIR;UGT1A1;AA + AG;UGT1A1_AA;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
INTERFERON_BETA-1A, INTERFERON_BETA-1B;FHIT;C;FHIT_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GLYBURIDE;FMO2;T;FMO2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;AG + GG;FASTKD3, MTRR_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;ADRB2;GG;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;G;ABCB1_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC16A7;A;SLC16A7_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IFNL3, IFNL4;C;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC16A7;T;SLC16A7_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ARID5B;CC;ARID5B_CC + CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;UGT1A1;A;UGT1A1_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;APOE;CT + TT;APOE_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IFNL3, IFNL4;T;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GAD1;G;GAD1_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA;MTHFR_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;GAD1;G;GAD1_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;NAT2;AG + GG;AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CC;CYP2D6_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN, VILDAGLIPTIN;KCNQ1;GG + GT;KCNQ1_G;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
IGURATIMOD;ABCG2;GT + TT;ABCG2_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GAPVD1;G;GAPVD1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRD1;GG;OPRD1_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;AA;OPRD1_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRD1;GG;OPRD1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;ZNF804A;AA;ZNF804A_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;XRCC1;CC + CT;XRCC1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GAPVD1;T;GAPVD1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, DOCETAXEL;CYP1A1;AG + GG;CYP1A1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GLYBURIDE;CYP51A1;G;CYP51A1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;FMO2;T;FMO2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;ABCB1;AA;ABCB1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR1A;TT;HTR1A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
URIC_ACID;BRINP3;T;BRINP3_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;UGT2B15;G;UGT2B15_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GAPVD1;C;GAPVD1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
URIC_ACID;PADI4;G;PADI4_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
INTERFERON_BETA-1A, INTERFERON_BETA-1B;ZNF697;A;ZNF697_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCC5;TT;ABCC5_TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;XRCC3;AA + AG;KLC1, XRCC3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;MAPK1;A;MAPK1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCC5;A;ABCC5_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;GG;CYP2D6_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;SPINK5;T;SPINK5_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;BDKRB2;A;BDKRB2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;MAPK1;G;MAPK1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;ABCB1;CT + TT;ABCB1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;KLB;A;KLB_A;TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;XRCC1;AA + AG;XRCC1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ESR1;T;ESR1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;G;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:AUTOIMMUNE_DISEASES,OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;BDNF;C;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUNISOLIDE;TBXT;TT;TBXT_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GRANISETRON, PALONOSETRON;ERCC1;AC + CC;ERCC1_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;IL6_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;CYP2D6;CT + TT;CYP2D6_TT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1B;T;TNFRSF1B_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;IL6_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;C;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RASAGILINE;DRD2;CC;DRD2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RASAGILINE;DRD2;CC;DRD2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CTLA4;AG + GG;CTLA4_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;BDNF-AS;T;BDNF-AS_CC + CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;IL3;AA;IL3_AA;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;CC;UGT1A4_AC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;CYP2C9_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TELAPREVIR;CYP24A1;C;CYP24A1_CT + TT;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CTLA4;AA;CTLA4_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VARENICLINE;CHRNA4;GG;CHRNA4_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;T;CYP1A2_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;G;CYP1A2_G;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;C;CYP1A2_TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;HSPA5;TT;HSPA5_TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR2A;A;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR3A;C;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;CYP2B6_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;AA + AG;P2RY12_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;P2RY12;AA + AC;MED12L, P2RY12_AC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AG;CYP2B6_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;G;TNF_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE_PROPIONATE;ORMDL3;AA + AG;ORMDL3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RITUXIMAB;FCGR3A;AC + CC;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR2A;AG + GG;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CALU;G;CALU_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATAZANAVIR/RITONAVIR;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;ABCG2;CT + TT;ABCG2_CT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR/RITONAVIR;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;CYP2C9_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;VDR;AA + AC;VDR_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN_II;AGTR1;AA;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;NR3C1;GG;NR3C1_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;ABCC2;AG;ABCC2_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUVASTATIN;APOE;CT;APOE_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;SLC47A1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
TALINOLOL;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;TT;UGT2B7_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC + CT;CYP3A4_TT;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
RITODRINE;PDE4B;AA;PDE4B_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;G;CYP3A4_AG;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DESIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PLATINUM_COMPOUNDS;XPA;CC;XPA_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;CC;ABCB1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;IL10;AA;IL10_AG + GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;MMP9;CT;MMP9_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GESTATIONAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATIC_HEART_DISEASE, OTHER:ATRIAL_FIBRILLATION,OTHER:HEART_VALVE_DISEASES, OTHER:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
DACLATASVIR;VDR;TT;VDR_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;AG + GG;COMT_AA;EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLDOPA;MMP9;CT + TT;MMP9_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GESTATIONAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
DACLATASVIR;CYP24A1;CT + TT;CYP24A1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;TT;SCN1A_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB1;AA;ADRB1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM_CHANNEL_BLOCKERS;NUMA1;GG;NUMA1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;TT;SCN1A_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CALCIUM_CHANNEL_BLOCKERS;TANC2;GG;TANC2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIBUTRAMINE;GNB3;CC;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, OXCARBAZEPINE;ABCC2;AG;ABCC2_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
BUSULFAN;GSTA1;T;GSTA1_CT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
S-EDDP;CYP2B6;CT;CYP2B6_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTA1;A;GSTA1_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;UGT1A9;T;UGT1A9_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;UGT1A9;A;UGT1A9_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC4;TT;ERCC4_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;ERCC1;AA + AG;ERCC1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;TT;CYP2D6_TT;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;ERCC3;AG + GG;ERCC3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEGAFUR;CYP2A6;AA + AG;CYP2A6_AA + AG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;MTHFR;AG;MTHFR_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;UGT2B7;TT;UGT2B7_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TERBUTALINE;ADRB2;GG;ADRB2_GG;METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HRH4;TT;HRH4_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GRK4;T;GRK4_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GRK4;T;GRK4_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM_CHANNEL_BLOCKERS;PICALM;GG;PICALM_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DELEOBUVIR, FALDAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PROPOFOL;GABRA2;CC;GABRA2_G;OTHER;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;HNF4A;T;HNF4A_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CODEINE, TRAMADOL;CYP1B1;C;CYP1B1_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB, GEFITINIB;EGFR;G;EGFR_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NR1I3;TT;NR1I3_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VERAPAMIL;PCDHB8;G;PCDHB8_G;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;POR;TT;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VERAPAMIL;PCDHB6;A;PCDHB6_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, CETUXIMAB, OXALIPLATIN;KRAS;AC;KRAS_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN_ACID;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;AGTR1;AC;AGTR1_AA + AC;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;BDKRB2;CT;BDKRB2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LOSARTAN;AGTR1;AA;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
HEROIN;OPRM1;AG;OPRM1_AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
5-HYDROXYINDOLE-3-ACETIC_ACID, SEROTONIN;MAOB;T;MAOB_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;GRIK4;CC;GRIK4_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;CT;ABCB1_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
5-HYDROXYINDOLE-3-ACETIC_ACID, SEROTONIN;MAOB;TT;MAOB_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
APIXABAN;POR;T;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;UGT1A9;CC;UGT1A9_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SEIZURES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE, TRAMADOL;CYP1B1;A;CYP1B1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;CYP11B2;GG;CYP11B2_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-HYDROXYCOTININE;GENE_NOT_SPECIFIED;CC + CT;CC + CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
HYDROCODONE, OXYCODONE;CYP2D6;DELT;CYP2D6_DELT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-HYDROXYCOTININE;EGLN2;AA + AG;EGLN2_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE, OXYCODONE;MACROD2;G;MACROD2_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLONIDINE;GNB3;CT + TT;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP1A1;AC + CC;CYP1A1_A;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PITRAKINRA;IL4R;GG;IL4R_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
RADIOTHERAPY;CACNA2D3;AG + GG;CACNA2D3_AG + GG;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;MAP3K5;CC;MAP3K5_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;CLNK;G;CLNK_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;MAP3K5;CC;MAP3K5_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCC2;CT + TT;ABCC2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LENALIDOMIDE, THALIDOMIDE;FGF2;CG + GG;FGF2_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;MAOA;AA;MAOA_AA;METABOLISM/PK;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;GRIK4;C;GRIK4_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ALDH2;AG;ALDH2_AA + AG;OTHER;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;NEDD4L;CC + CG;NEDD4L_CC + CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;GG;IL4R_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PITRAKINRA;IL4R;AA;IL4R_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;AA;IL4R_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;AA;IL4R_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
BENAZEPRIL;MTR;AG + GG;MTR_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PITRAKINRA;IL4R;AA;IL4R_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCC2;CT + TT;ABCC2_CT + TT;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;GG;VKORC1_AA + AG;DOSAGE, TOXICITY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SULINDAC;FMO3;AA;FMO3_AG + GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLATE_MOFETIL;SLCO1B3;A;SLCO1B3_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SULINDAC;FMO3;GG;FMO3_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCC3;CC;ABCC3_C;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;C;IFNL3_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;C;IFNL3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEMANTINE;NR1I2;CT + TT;NR1I2_TT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEMENTIA;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;ADRB2;AG + GG;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;G;IFNL3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;A;IFNL3_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;ANKS1B;CC;ANKS1B_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;C;IFNL3_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;C;IFNL3_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ESCITALOPRAM;GENE_NOT_SPECIFIED;A;A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SCARB1;CC;SCARB1_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;ABCC2;GG;ABCC2_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;SV2C;TT;SV2C_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;TBX21;CG;TBX21_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC1;GG;ABCC1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AG + GG;HTR2A_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC_ACID;CYP2D6;A;CYP2D6_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC_ACID;CYP2C9;C;CYP2C9_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC_ACID;CYP2D6;C;CYP2D6_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC_ACID;CYP3A4;C;CYP3A4_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC_ACID;CYP3A4;C;CYP3A4_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;ANO2;C;ANO2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;ANO2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;ANO2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;ANO2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;ANO2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;ANO2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;ANO2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;ARG1;A;ARG1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;ANO2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;ANO2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;ANO2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;ANO2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DULOXETINE;ANO2;A;ANO2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;C;ABCB1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;ANO2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;ANO2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DOBUTAMINE;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ANO2;C;ANO2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER_ACETATE;PVT1;A;MIR1206_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;ANO2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CT;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;A;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;ANO2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;ANO2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;UGT2B7;CT;UGT2B7_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEMETREXED, PLATINUM_COMPOUNDS;CCND1;A;CCND1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LIRAGLUTIDE;GLP1R;CT + TT;GLP1R_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OBESITY, DISEASE:POLYCYSTIC_OVARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;CACNA1H;A;CACNA1H_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;DPYD_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC + CT;DPYD_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ASPIRIN;GP1BA;CT + TT;GP1BA_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;DPYD_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;GG;DPYD_AG + GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;ABCC2;CC;ABCC2_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;GENE_NOT_SPECIFIED;G;G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LACOSAMIDE;ABCC2;A;ABCC2_GG;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
LACOSAMIDE;ABCC2;T;ABCC2_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;GENE_NOT_SPECIFIED;T;T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TRAZODONE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
DOBUTAMINE;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN_ACID;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ARID5B;A;ARID5B_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
OXYCODONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;A;CYP2C19_AA;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DRUG_ACCUMULATION
FENOFIBRATE;PPARA;GG;PPARA_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC22A11;AT + TT;SLC22A11_AT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;ABCC1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;AA;HMGCR_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;ABCC1_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;AG + GG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;CC + CT;CYP3A5_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;C;CYP2B6_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;A;APOC1, APOE_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;LPA;G;LPA_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;IL6;CC + CG;IL6_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_WITH_A_HIGH_RISK_OF_CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;NRP1;T;NRP1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CETP;GG;CETP_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;MICB;CC;MICB_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;CC;ABCG2_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DBH;GG;DBH_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC + CT;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
NICOTINE;MAOA;TT;MAOA_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
OMEPRAZOLE, PANTOPRAZOLE;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;AA;VDR_AA;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DOSE_ADJUST
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;TT;HTR1A_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;G;VDR_AA + AG;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GRM3;AA;GRM3_AG + GG;TOXICITY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;AA;SLC47A1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CC + CT;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;AA;SLC47A1_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;G;NR1I3_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;AG;NR1I3_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ANTIHYPERTENSIVES;ATP2B1;CT + TT;ATP2B1_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;EPHX1;CT;EPHX1_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA;IFNL3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;AA;NAT2_AA;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;T;NUDT15_GT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
WARFARIN;PRSS53, VKORC1;CT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NR1I2;TT;NR1I2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
AMLODIPINE, FELODIPINE;CACNA1C;TT;CACNA1C_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;SLCO1B1;CC;SLCO1B1_CC;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM_CHANNEL_BLOCKERS;CACNA1C;C;CACNA1C_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;A;SLCO1B1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM_CHANNEL_BLOCKERS;CACNA1C;GG;CACNA1C_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;CELSR2;C;CELSR2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;UGT2B7;GG;UGT2B7_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;T;CYP2A6_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CALCIUM_CHANNEL_BLOCKERS;CACNA1C;TT;CACNA1C_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
PHENPROCOUMON, WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GG;CYP2B6_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;CYP2C9_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;AG;CYP2B6_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;UGT2B7;CT;UGT2B7_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;G;CYP2C9_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;APOC1, APOE;T;APOE_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HAPLOTYPE_EPSILON2;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT2B7;TT;UGT2B7_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;APOC1, APOE;T;APOE_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HAPLOTYPE_EPSILON2;CAUTION_DOSE_ADJUST
INFLIXIMAB;GENE_NOT_SPECIFIED;CC + CT;CC + CT;EFFICACY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHOTODYNAMIC_THERAPY;CFH;TT;CFH_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT2B7;TT;UGT2B7_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
RISPERIDONE;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;CC + TT;HTR1B_CC + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CC;CYP2B6_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;OUTCOME_NOT_SPECIFIED;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ASPIRIN, PRASUGREL;PEAR1;AC + CC;PEAR1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;AC + CC;ABCB1_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL, PRASUGREL;PEAR1;AA + AG;PEAR1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;AG + GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE/ISOSORBIDE_DINITRATE;GNB3;TT;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
LOVASTATIN_ACID;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;T;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
LOVASTATIN;PPARA;AG + GG;PPARA_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP1A2;CC;CYP1A2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;AA;CYP19A1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
SEROTONIN;ERICH3;T;ERICH3_T;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG + GG;ABCB1_A;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;AG + GG;CYP3A4_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;AA;CYP19A1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC2;CT + TT;ERCC2_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SEROTONIN;TSPAN5;G;TSPAN5_G;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TRAF1;G;TRAF1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;CTNNB1;AA;CTNNB1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:CARDIOMYOPATHIES,DISEASE:HEART_VALVE_REPLACEMENT, DISEASE:PERIPHERAL_VASCULAR_DISEASES, DISEASE:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:PAIN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;CTNNB1;AA;CTNNB1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL17A;A;GG;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;CYP1A1;CC + CT;CYP1A1_C;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;C;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AC + CC;ABCB1_C;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;ERICH3;C;ERICH3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;OPRM1_AA;OTHER;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AC + CC;ABCB1_C;DOSAGE;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A7;TT;CYP3A7_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NULL;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;VKORC1_CT + TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACETAMINOPHEN, TRAMADOL;OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEUROPATHIC_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR2A;AA;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
COTININE;UGT2B10;CC;UGT2B10_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
FENTANYL;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;AC + CC;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;AG + GG;ALDH1A1_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CC;POR_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHADONE;ABCB1;CC;ABCB1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;FCGR3A;AA;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB2;GG;ADRB2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A5;CC;CYP3A5_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ARTERIOSCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;UGT2B10;CC;UGT2B10_CC;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;A;ERCC1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;C;VKORC1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;PRSS53, VKORC1;TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENOBARBITAL;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;FMO3;CC;FMO3_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
FENOFIBRATE;CRP;TT;CRP_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A3;G;SLC22A3_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;CC + TT;HTR1B_CC + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;UGT2B10;T;UGT2B10_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;GG;NQO1_GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENOFIBRATE;CRP;AG + GG;CRP_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;MMP3;A/del + AA;MMP3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;UGT1A4;G;UGT1A4_GG + GT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;CRP;GG + GT;CRP_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C18;T;CYP2C18_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;C;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DESLORATADINE, MIZOLASTINE;FCER1A;AA;FCER1A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URTICARIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;TT;CYP3A5_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;G;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;SELE;CC;SELE_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;CC;CYP3A5_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;PCSK9;T;PCSK9_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;AG;CYP3A4_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;CC;ABCB1_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;AA;MTHFR_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;ERCC5;GG;ERCC5_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR, IVACAFTOR/TEZACAFTOR;CFTR;AG + GG;CFTR_AG + GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT2B7;T;UGT2B7_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;AA + AG;CHRNA5_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;AA + AG;CHRNA3, CHRNA5_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT2B7;G;UGT2B7_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;FMO3;CC;FMO3_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AA + AT;ABCB1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;NR1I2;CT + TT;NR1I2_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LUMACAFTOR;CFTR;AA;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;CDH2;AA;CDH2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERTUSSIS_VACCINES;TLR4;AA;TLR4_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CT + TT;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CDH2;CC;CDH2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SORAFENIB;ABCG2;CT;ABCG2_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;CT + TT;CYP2A6_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SORAFENIB;ABCG2;GT;ABCG2_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;CC;SLC22A1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BILIRUBIN;UGT1A1;TT;UGT1A1_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;CT;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;AA + AG;GGH_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;A;NUDT15_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
IMIQUIMOD;TLR7;A;TLR7_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BASAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;T;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;CC + CT;GGH_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE, OTHER;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLONIDINE;GNB3;CT + TT;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
CLOZAPINE;UGT2B10;T;UGT2B10_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
OPIOIDS;TAOK3;AG + GG;TAOK3_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;TT;TAOK3_TT;DOSAGE;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;OPRM1;GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;CT + TT;TAOK3_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;AC + CC;ABCC4_AC + CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VITAMIN_B12_AND_FOLIC_ACID;MTHFR;A;MTHFR_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERHOMOCYSTEINEMIA, OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY, METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPTOPRIL;AGTR1;AC + CC;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;GSTP1;A;GSTP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;CBR1;CC;CBR1_CC;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
SILIBININ;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;CC;TPMT_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;C;SLCO1B1, SLCO1B3, SLCO1B7_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;AG;CYP2C19_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE, OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;CC;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;PSORS1C1;C;PSORS1C1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;POR;CT + TT;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;ABCC4;AA;ABCC4_AC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;TPH2;AA + AT;TPH2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;AA;GNB3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;NR3C2;TT;NR3C2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;GG;GNB3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;CC;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;AA;GNB3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;T;CYP2C9_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;AA;GNB3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;STAT4;T;STAT4_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GNB3;GG;GNB3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;AC + CC;GGH_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AG;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;ABCG2;T;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;SLCO1B1_AG;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;CC;ABCB1_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, TEZACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATORVASTATIN, HMG_COA_REDUCTASE_INHIBITORS, PRAVASTATIN, SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;ABCA1;CT;ABCA1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;HTR2A;AA + AG;HTR2A_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_DOSE_ADJUST
FENOFIBRATE;ABCA1;CC;ABCA1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;NUP107;C;NUP107_C;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;ABCA1;TT;ABCA1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;COMT;AA + AG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;NQO1;AA;NQO1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
KETOPROFEN;CYP2C9;CC;CYP2C9_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TNF;AG + GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CHL1;TT;CHL1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSIVE_DISORDER,DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TANK;CC;TANK_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;AA;CYP3A5_AA + AG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;VEGFA;T;VEGFA_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;GG;ADRB1_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;GG;CYP3A5_A;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNF;GG;TNF_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;VASP;AG + GG;VASP_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNFAIP3;T;TNFAIP3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;AA + AG;SLC19A1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN, SIMVASTATIN_ACID;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;AG + GG;SLC19A1_AG + GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
LITHIUM;NR1D1, THRA;T;NR1D1, THRA_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;GG;GNB3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC2;GG;ERCC2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;APOE;C;APOE_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATAZANAVIR;SORCS2;A;SORCS2_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC1;GG;ERCC1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;MTHFR;AA;MTHFR_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CNR1;CT + TT;CNR1_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;TPH2;GG;TPH2_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;GG;NPPA_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;UGT2B7_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, SIMVASTATIN;KIF6;GG;KIF6_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;CYP2B6_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;CT;CYP2B6_CT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;OPRL1;CT;OPRL1_CT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ROSUVASTATIN;KIF6;GG;KIF6_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADRENERGICS, INHALANTS;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TOPIRAMATE;GRIK1;AA + AC;GRIK1_AA + AC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALCOHOL-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
BUMETANIDE, FUROSEMIDE, TORASEMIDE;ADD1;TT;ADD1_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, GEMCITABINE;CDA;AA;CDA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;GRIK1;AA + AC;GRIK1_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;GG;KIF6_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;ERCC1;AA;ERCC1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;CC;SLC12A3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;ABCB1;AA;ABCB1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;CT + TT;KCNQ1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F11;G;CYP4F11_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBOPLATIN, TAXANES;VEGFA;CC + CT;VEGFA_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEBRISOQUINE;CYP2D6;C;CYP2D6_CC + CG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;AA + AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;AC;CYP2A6_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CETP;GG;CETP_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;CC + CT;ABCB1_TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTRR;AG + GG;FASTKD3, MTRR_AG + GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TENOFOVIR;IFNL3, IFNL4;C;IFNL3_TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A1;A;SLC22A1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;EFFICACY:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOCORTICOIDS;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;BCL11A;T;BCL11A_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;BCL11A;C;BCL11A_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;A;CYP2C9_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENTANYL;UGT2B7;TT;UGT2B7_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TIOTROPIUM;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMEFANTRINE;ABCC2;AA;ABCC2_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:MALARIA;CAUTION_DRUG_ACCUMULATION
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR;CFTR;G;CFTR_CG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;APOE;CT;APOE_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;GG;NPPA_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
BUMETANIDE, FUROSEMIDE, TORASEMIDE;GNB3;TT;GNB3_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;UGT2B7_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;TT;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT1A6;AG + GG;UGT1A6_AG + GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT1A6;AC + CC;UGT1A6_AC + CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR2A;AA + AG;HTR2A_AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;ACE;CG + GG;ACE_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LPL;GG;LPL_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;CETP;AG;CETP_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENTANYL;UGT2B7;CC;UGT2B7_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;MTHFR_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNA3;A;CHRNA3_A;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUVASTATIN;LIPC;CC + CT;LIPC_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A1;T;CYP1A1_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;CES1;CG;CES1_CG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
SIMVASTATIN;LIPC;CT;LIPC_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, OXALIPLATIN;VEGFA;CT + TT;VEGFA_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;CC;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;AC + CC;SLCO1B1_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;CC + CT;CYP3A5_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERTUSSIS_VACCINES;TLR4;GG;TLR4_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;CC + TT;CC + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + TT;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;SLCO1B1;GT + TT;SLCO1B1_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CATECHOLAMINES, METFORMIN;SLC22A3;T;SLC22A3_T;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LOVASTATIN;LDLR;TT;LDLR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CACNA1C;GG;CACNA1C_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;CYP3A4;AG;CYP3A4_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ADH1C;C;ADH1C_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ADH1B;A;ADH1B_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;LDLR;CC;LDLR_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;TT;GALNT14_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG;HTR2A_GG;EFFICACY;DECREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NALTREXONE;ALDH2;G;ALDH2_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CYP2B6;AG + GG;CYP2B6_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;CYP2C9_AT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA;P2RY12_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NULL;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AA;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;C;CYP2C19_T;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;ABCB1_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;CYP2C9_C;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A7;CG + GG;CYP3A7_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NULL;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;GG;P2RY12_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIBIOTICS, ESOMEPRAZOLE;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;VEGFA;CT + TT;VEGFA_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;DRD3;TT;DRD3_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL;GALNT14;GG;GALNT14_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;CT + TT;KDR_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;AT + TT;KDR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_CANCER, OTHER:PAIN;CAUTION_DOSE_ADJUST
SORAFENIB;GALNT14;GG;GALNT14_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION, OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;ABCC2;A;ABCC2_GG;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MYCOPHENOLIC_ACID;ABCC2;T;ABCC2_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FENTANYL;ATF2;A;ATF2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;ABCC2;T;ABCC2_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;NR1I2;CT + TT;NR1I2_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
AFLIBERCEPT, RANIBIZUMAB;ANO2;TT;ANO2_TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NR1I2;CT + TT;NR1I2_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;SLC6A2;CC;SLC6A2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;ABCC2;A;ABCC2_GG;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BOCEPREVIR, PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;C;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;TT;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHRNA7;T;CHRNA7_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;FCGR2A;A;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ENOSF1;CC;ENOSF1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN_ACID;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DOBUTAMINE;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACLATASVIR, SOFOSBUVIR;HINT1;CT + TT;HINT1_CT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;IL6;G;IL6_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CC;OPRD1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC_ACID;SCN2A;A;SCN2A_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LITHIUM;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;CYP3A4, TMEM130;C;CYP3A4, TMEM130_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;CYP3A4;A;CYP3A4_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;MYLIP;AA;MYLIP_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;PDE4D;T;PDE4D_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADRA2A;CG + GG;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SCAP;TT;SCAP_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA + AG;CYP1A2_GG;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
APREMILAST;CDKN2B, CDKN2B-AS1;G;CDKN2B, CDKN2B-AS1_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LIPC;CT + TT;LIPC_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CT;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LOSARTAN;AGTR1;AC + CC;AGTR1_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
(R)-METHADONE;NR1I3;GG;NR1I3_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2A;GG;HTR2A_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT;NUDT15_CT;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
(R)-METHADONE;NR1I3;GG;NR1I3_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;CFH;CT;CFH_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;CC;OPRD1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
BEVACIZUMAB;ARMS2;GT + TT;ARMS2_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;ABCB1;CC;ABCB1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;AA + AG;NQO1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;ABCC2;AG;ABCC2_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
BUDESONIDE;GENE_NOT_SPECIFIED;AG + GG;AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIORIDAZINE;CYP2D6;CC + CG;CYP2D6_CC + CG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;G;SLCO1B1_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;CYP1A2;CC + CT;CYP1A2_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP1A2;AC + CC;CYP1A2_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCC2;AG;ABCC2_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;DRD2;AA + AC;DRD2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP1A1;AC + CC;CYP1A1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;UGT1A1;TT;UGT1A1_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLC10A1;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR2A;GG;FCGR2A_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;GG;MTHFR_AA;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DACLATASVIR, SOFOSBUVIR;IFNL3;CC;IFNL3_TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;CYP2D6_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ALCOHOLIC_PSYCHOSIS, DISEASE:ALCOHOL_ABUSE,DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A1;GG;SLC22A1_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
BUPRENORPHINE;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR3A;AA;FCGR3A_AC + CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;IL10;CC;IL10_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;ADAMTSL2;A;ADAMTSL2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
(R)-METHADONE;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TGFB1;CG;TGFB1_CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;AG + GG;SLCO1B1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ, NON-NUCLEOSIDE_REVERSE_TRANSCRIPTASE_INHIBITORS;CYP2B6;T;CYP2B6_GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC + CT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
XK469;AOX1;G;AOX1_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;PON1;CC;PON1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;T;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ETANERCEPT;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;CT;TPMT_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUCINDOLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CT;CYP3A4_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;AG + GG;CYP4F2_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PHENPROCOUMON;EPHX1;CC;EPHX1_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;TNF;A;TNF_AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;PROC;CC;PROC_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B7;CT + TT;UGT2B7_CC;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A4;TT;SLC22A4_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
ATORVASTATIN;TNF;AA + AG;TNF_AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A5;CG + GG;SLC22A5_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A5;CG + GG;SLC22A5_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SP1;G;SP1_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TNF;CT + TT;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;EPHX1;CG;EPHX1_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;APOE_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;CYP2B6_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP3A4;AA;CYP3A4_AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP1A2;GG;CYP1A2_GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
IMATINIB;ABCC4;AG;ABCC4_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;DRD3;TT;DRD3_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;SLC15A2;TT;SLC15A2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;MTHFR;AA + AG;MTHFR_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;GG + GT;UGT1A4_GG + GT;METABOLISM/PK;DECREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;EPHX1;CC;EPHX1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
RITONAVIR;NR1I2;CC + CT;NR1I2_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
L-TRYPTOPHAN;SLC22A2;CC;SLC22A2_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RITONAVIR;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RITONAVIR;ABCB1;AC + CC;ABCB1_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;A;RAMP1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, INFLIXIMAB;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;CYP1A2;AA + AG;CYP1A2_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;POR;CT + TT;POR_CT + TT;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
OLANZAPINE;BDNF;CC;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;NR1I2;AA + AG;NR1I2_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;G;RAMP1_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;SLC22A12;CC + CT;SLC22A12_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION, DISEASE:HYPERURICEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;G;RAMP1_G;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;SLC22A12;CT + TT;SLC22A12_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION, DISEASE:HYPERURICEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;OPRM1_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;IL10;CC;IL10_C;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;ABCB1;CT;ABCB1_TT;TOXICITY, METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLADRIBINE, CYTARABINE;RRM1;AT;RRM1_AT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, CYTARABINE;RRM2B;AA;RRM2B_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AA;DPYD_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM1;AC + CC;RRM1_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;AA;CYP2B6_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM1;GG;RRM1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;PSMA4;A;PSMA4_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;GG;ATIC_GG;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;TT;ABCC1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CHRNA5;A;CHRNA3, CHRNA5_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNFRSF10A;CC;TNFRSF10A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM2;GT + TT;RRM2_GT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";FTO;AA + AT;FTO_AA + AT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;GENE_NOT_SPECIFIED;G;G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DTNBP1;CT + TT;DTNBP1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM2;CG + GG;RRM2_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CHRNB4;A;CHRNB4_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;SLCO1B3;AA;SLCO1B3_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;SLC15A2;AA;SLC15A2_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;SLCO1B3;GG;SLCO1B3_GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETANERCEPT;TNF;GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CHRNA3;A;CHRNA3_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
SUNITINIB;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;CYP4F2_TT;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
"""INTERFERON_ALFA-2A, RECOMBINANT"", ""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUPENTHIXOL;NFKB1;CT + TT;NFKB1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;SLCO2B1;AG;SLCO2B1_GG;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;CYP24A1;CT + TT;CYP24A1_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP24A1;CT + TT;CYP24A1_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
FLUPENTHIXOL;NFKB1;AG;NFKB1_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;TPH2;C;TPH2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE_POLYGLUTAMATE;IMPDH1;GG;IMPDH1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN, CISPLATIN;EIF3A;AA + AG;EIF3A_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE_POLYGLUTAMATE;CEP72;TT;CEP72_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL10;TT;IL10_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MIRTAZAPINE, VENLAFAXINE;TPH2;C;TPH2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
BILIRUBIN;UGT1A1;GG + GT;UGT1A1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN, CISPLATIN;EIF3A;AA + AG;EIF3A_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP24A1;CT + TT;CYP24A1_TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
FLUPENTHIXOL;NFKB1;AT;NFKB1_AT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE_POLYGLUTAMATE;SLCO1B3;AA + AG;SLCO1B3_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
NICOTINE;FMO3;AA;FMO3_GG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;VEGFA;A;VEGFA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE_POLYGLUTAMATE;FSTL5;AA + AC;FSTL5_AA + AC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE_POLYGLUTAMATE;ATG16L1;AG + GG;ATG16L1_AG + GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC;DPYD_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;AA + AG;CYP1A2_GG;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNFRSF10A;CC;TNFRSF10A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;TT;TNFRSF1A_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;G;VEGFA_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF10A;CC;TNFRSF10A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;TT;TNFRSF1A_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;VEGFA;T;VEGFA_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;PTTG1;CC + CT;PTTG1_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;CMPK1;CC;CMPK1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;A;CHRNA5_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;NR1I2;GG;NR1I2_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;HLA-B;TT;HLA-B_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;MAP3K1;AG + GG;MAP3K1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR1A;GG;HTR1A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;GBP6;AG + GG;GBP6_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELIPROLOL;ABCB1;G;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELIPROLOL;SLCO1A2;G;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;IL12B;AG + GG;IL12B_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TEMOZOLOMIDE;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GLIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;SLC26A9;CC + CT;SLC26A9_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DCK;AG + GG;DCK_AG + GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;CC;NR1I2_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;ADRA2A;CC + CG;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;GG;IGF2, IGF2-AS, INS-IGF2_GG;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;FMO3;AA;FMO3_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;GG;SLCO1B1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;FGF2;CC + CT;FGF2_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;POR;GG;POR_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PLATINUM_COMPOUNDS;INS-IGF2;GG;INS-IGF2_GG;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;HTR1A;CC + CG;HTR1A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;SCN2A;AA + AG;SCN2A_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;SCN1A;TT;SCN1A_CT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;NR1I2;AA;NR1I2_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;GG;NR1I2_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC2;TT;ABCC2_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;RRM1;TT;RRM1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;AA;NR1I2_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;AA;SLCO1B1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, GEMCITABINE;RRM1;AA;RRM1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;CMPK1;CC;CMPK1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;GG;SLCO1B1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, GEMCITABINE;RRM1;TT;RRM1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;GGCX;G;GGCX_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;NR1I2;G;NR1I2_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;TGFB1;AG;TGFB1_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;TGFB1;CG;TGFB1_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;A;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;T;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CYP3A4;A;CYP3A4_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;ADIPOQ;GT;ADIPOQ_GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CYP3A5;C;CYP3A5_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;GSK3B_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
NALOXONE;OPRM1;AG + GG;OPRM1_AA;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIFARNIB;ABCB1;AA;ABCB1_A;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;ZNF816;CC;ZNF816_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;T;ABCG2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRM1;G;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRG1;G;NRG1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1A2;CC + CT;SLCO1A2_CC + CT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;ADCY2;C;ADCY2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRG1;A;NRG1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA5;GG;CHRNA3, CHRNA5_A;OTHER;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
METHADONE;DAO;TT;DAO_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CCL2;G;CCL2_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CCL2;T;CCL2_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;DAO;TT;DAO_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;HTR2A;GG + GT;HTR2A_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE, OTHER:MALARIA;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;DRD1;TT;DRD1_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;CYP2D6;GG;CYP2D6_GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;SLCO1B1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;CYP2D6;CG;CYP2D6_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;GG;SLCO1B1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AA;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;VKORC1_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;GLP1R;A;GLP1R_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RENAL_CELL_CARCINOMA, OTHER:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;CC;CYP2D6_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS;GRK5;A;GRK5_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IFNG;G;IFNG_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;MLLT3;AA;MLLT3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS;GRK5;A;GRK5_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA_BLOCKING_AGENTS;GRK5;A;GRK5_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;CYP27B1;AG + GG;CYP27B1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;ST13;G;ST13_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;VDR;TT;VDR_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;GG + GT;CYP2B6_GT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
DOCETAXEL;CYP3A5;T;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RAMIPRIL;ADRB2;AA + AG;ADRB2_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;GG;COMT_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METHADONE;NGF;AA;NGF_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
NICOTINE;CYP1A2;T/del + del/del;CYP1A2_T;EFFICACY;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;AA + AG;CYP2B6_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
GEMCITABINE;NT5C3A;AA;NT5C3A_GG;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C2;TT;NT5C2_CC + CT;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FENTANYL, REMIFENTANIL;PGAP6;T;PGAP6_T;EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT1A4;GT;UGT1A4_GG + GT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ADCY9;CC;ADCY9_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN;CES1;GG + GT;CES1_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;PI4KA;AG + GG;PI4KA_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GRM3;AA + AT;GRM3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE/SALMETEROL, FLUTICASONE_PROPIONATE;ZNF432;TT;ZNF432_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AA + AC;ITPA_AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB2;G;ERBB2_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;SLC1A3;AA + AG;SLC1A3_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GRM3;CC;GRM3_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;RNF8;A;RNF8_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;GRM3;AG + GG;GRM3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;BARD1;A;BARD1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;CC;CDA_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;C;ERBB3_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ST13;G;ST13_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;A;ERBB3_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;SLC1A4;AA;SLC1A4_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;GRM3;CC + CT;GRM3_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;COMT;AA;COMT_AA;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUINDIONE;VKORC1;TT;VKORC1_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
APREMILAST;LEPR, LEPROT;AA + AG;LEPR, LEPROT_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;ABCB1_A;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN;AKT1;AG;AKT1_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINAPRIL;AGT;GG;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KCNJ6;CC;KCNJ6_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LOW_BACK_PAIN;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;T/del;CYP1A2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL, TEGAFUR;TYMS;C;TYMS_C;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2C9;AC;CYP2C9_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;SLC22A1_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA;CYP1A2_AA;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;SLC22A1_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNFRSF1B;GT;TNFRSF1B_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL, REMIFENTANIL;SLC9A9;GG;SLC9A9_GG;EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;EFFICACY;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;PDE4B;T;PDE4B_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SCARB1;AA;SCARB1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;TSPAN16;C;TSPAN16_C;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;FCAR;AA + AG;FCAR_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;AA + AG;GSTP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;APOA1;G;APOA5_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;SCN1A;CT;SCN1A_CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;DOCK6;G;DOCK6_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPTOMYCIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NALTREXONE;DBH;CT + TT;DBH_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLC28A2;CC;SLC28A2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC_AGENTS;ABCG2;GG;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SLC28A2;CC;SLC28A2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;G;EIF3G, P2RY11, PPAN-P2RY11_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1A;TT;TNFRSF1A_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;METTL3;GG;METTL3_G;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;OPRM1;AG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
APREMILAST;ILF3;T;ILF3_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GSTP1;A;GSTP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;ABCG2;GT + TT;ABCG2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;T;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG + GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;PRSS53, VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;T;IFNL3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;VDR;A;VDR_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;NOS3;TT;NOS3_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA, OTHER:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;GREM2;T;GREM2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;NAT1;AG + GG;NAT1_AG + GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;GREM2;G;GREM2_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;CC;ABCB1_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ALLOPURINOL;ABCG2;C;ABCG2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EXENATIDE;GLP1R;T;GLP1R_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
TOPIRAMATE;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA, OTHER:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT2B7;TT;UGT2B7_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BENAZEPRIL;AGT;GG;AGT_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT2B7;GG;UGT2B7_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC4;GG;ABCC4_AG + GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;AGTR1;GG;AGTR1_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ALENDRONATE;MVK;GG;MVK_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BONE_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;A;ITPA_AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;CC;IL6R_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;LDLR;GG;LDLR_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;SPTA1;G;SPTA1_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
IMATINIB;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;TT;IL6R_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;AT + TT;CYP2C9_AT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;C;ABCB1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CC;OPRD1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;NCR3;AT + TT;NCR3_AT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SALBUTAMOL;COL2A1;GT + TT;COL2A1_GT + TT;PD;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1C;CC;CACNA1C_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";PRKCA;T;PRKCA_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1B;CC;CACNA1B_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;STX4;T;C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GENE_NOT_SPECIFIED;AA + AG;A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CORTICOSTEROIDS;GLCCI1;GG;GLCCI1_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHINITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;GC;AA;GC_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP4F2;CC + CT;CYP4F2_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;CES1;T;CES1_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
INTERFERON_BETA-1A, INTERFERON_BETA-1B;CD58;CC;CD58_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFAIP3;GG + GT;TNFAIP3_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIATIC_ARTHRITIS,  OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFAIP3;AA;TNFAIP3_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSORIATIC_ARTHRITIS,  OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC + CT;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNB2;TT;CACNB2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A7;C;CYP3A7_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A1;CC;UGT1A1_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNG3;TT;CACNG3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;TT;UGT1A3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP27B1;GG;CYP27B1, METTL1_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;CYP3A4_AA + AG;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
ADALIMUMAB;ATG16L1;CT + TT;ATG16L1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;CC;CACNB2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;CYP3A4_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;VDR;GG;VDR_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;TT;VDR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;CYP3A5_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLC19A1;CC;SLC19A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLCO1B1;AA + AG;SLCO1B1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;CYP3A5_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN_ACID;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CG;CYP2C9_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNB2;TT;CACNB2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;TT;UGT1A1_CT;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA2D3;AA;CACNA2D3_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C9;AC;CYP2C9_AC + CC;EFFICACY;DECREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;OTHER:PATENT_DUCTUS_ARTERIOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1E;TT;CACNA1E_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;TAAR6;GG;TAAR6_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;VEGFA;CT + TT;VEGFA_CC;PD;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, RANIBIZUMAB;CFH;CC;CFH_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;TT;TAOK3_TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;G;NR3C1_G;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;AA;UGT1A1_AA;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;GENE_NOT_SPECIFIED;G;G;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;HTR2A;CC;HTR2A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;SLCO1C1;AG + GG;SLCO1C1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;A;NR3C1_A;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A9;del/del;UGT1A9_T/del + del/del;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;G;CYP2C9_G;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;CT + TT;ABCG2_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;A;NR3C1_A;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP1A2;CC;CYP1A2_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;A;CYP2C9_A;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
LURASIDONE;HTR1A;CG + GG;HTR1A_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;T;CYP2C9_CT;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;PK:NO_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;del;CYP2C9_del;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;PK:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;RXRA;A;RXRA_A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNFRSF1B;G;TNFRSF1B_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;TT;SLC22A1_T;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;OPRM1;AA;OPRM1_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;UGT2B7;TT;UGT2B7_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;CC;CACNB2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;CYP3A4_TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB4;AA + AC;CACNB4_AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;CYP3A4_AA + AG;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNA2D3;CC;CACNA2D3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;TT;CACNB2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;CES1;A;CES1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;SCN9A;AA + AG;SCN9A_AA + AG;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
SALBUTAMOL;PRKG1;A;PRKG1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TOCILIZUMAB;IL6R;AA;IL6R_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;AG + GG;BDNF_AG + GG;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DRUG_ACCUMULATION
PROPOFOL;HTR2A;AA;HTR2A_GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;BDNF-AS;CC + CT;BDNF-AS_CC + CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;GABRA1;GG;GABRA1_G;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OPIOIDS;COMT;AA + AG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AG;COMT_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
"""METFORMIN"", ""SULFONAMIDES, UREA_DERIVATIVES""";ABCC8, KCNJ11;CT + TT;KCNJ11_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALIPERIDONE, RISPERIDONE;NFIB;CT;NFIB_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
REMIFENTANIL, SEVOFLURANE;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:TONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TAOK3;GG;TAOK3_GG;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;CT;ABCB1_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;KLF4;C;KLF4_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SICKLE_CELL_ANEMIA,  OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRM1;GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CT + TT;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;SLCO1B1_A;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SLC6A2;AT + TT;SLC6A2_AT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BILIRUBIN;UGT1A;AG + GG;UGT1A_AG + GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A3;CT + TT;UGT1A3_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CERS6;A;CERS6_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;CT + TT;SLC22A1_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;CC + CT;SLC22A1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION, DRUGS_USED_IN_NICOTINE_DEPENDENCE;CYP2A6;T;CYP2A6_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SRR;CC + CT;SRR_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A2;AG + GG;SLC6A2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROMYCIN;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;T;CYP2A6_CC + CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ABCB1;G;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA + AC;CYP1A2_AA;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GENE_NOT_SPECIFIED;AA + AC;AA + AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;GENE_NOT_SPECIFIED;AA + AC;AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GENE_NOT_SPECIFIED;AA + AG;AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;AA + AG;SLC22A1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATENOLOL;GENE_NOT_SPECIFIED;GG + GT;GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;A;ABCB1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A3;CC;UGT1A3_CC;EFFICACY, METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRANDOLAPRIL, VERAPAMIL;PTPRD;T;PTPRD_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
DEFERASIROX;ABCG2;CC;ABCG2_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
"""METFORMIN"", ""SULFONAMIDES, UREA_DERIVATIVES""";SLC47A1;A;SLC47A1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VDR;GG;VDR_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;AA;SULT1A2_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A3;AA;SLC28A3_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VDR;GG;VDR_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VDR;TT;VDR_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;ALPL;T;ALPL_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;SLIT1;AA;AA;METABOLISM/PK;DECREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;C;SLCO1B1_TT;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;SLCO1B1_AA + AG;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;TT;SULT1A2_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;SLCO1B1_AA;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;EYA4;C;EYA4_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;C;SLCO1B1_T;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYLEPHRINE;ADRB2;AA;ADRB2_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
ANASTROZOLE;CSMD1;G;CSMD1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;AA;ABCC2_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;C;CYP2A6_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCB1;AA + AC;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_T;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACAMPROSATE;CHDH, IL17RB;A;CHDH, IL17RB_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;GG;CYP2B6_GT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AG;ABCB1_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
COUMARIN;CYP2A6;C;CYP2A6_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IL21R;C;IL21R_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, IRINOTECAN;VEGFA;GG;VEGFA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;CARD16;C;CARD16_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;CC;CYP2C19_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA + AC;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;ABCC2;TT;ABCC2_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CT + TT;GGCX_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;AA;SLCO1B1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCC3;C;ABCC3_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:PAIN, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;CARD16;A;CARD16_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;CASP1;T;CASP1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;CFAP44;G;CFAP44_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP7A1;TT;CYP7A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;CASP1;A;CASP1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNB2;AG;CHRNB2_AG;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DAILY_SMOKING;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;SLC22A1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;UGT1A8;CC;UGT1A_CG + GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC + CT;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC + CT;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;C;CHRNA4_CC;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DAILY_SMOKING;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;TUT7;C;TUT7_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLCYSTEINE;TOLLIP;TT;TOLLIP_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;ABCB1;A;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;UGT2B7;C;UGT2B7_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CDA;AG + GG;CDA_AG + GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;RRM1;CT + TT;RRM1_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP3A5;CC + CT;CYP3A5_CC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;CTPS1;AG;CTPS1_AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CTPS1;AA + AG;CTPS1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;CT + TT;CTPS1_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;UGT1A8;CC;UGT1A_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;UGT1A8;CC;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A1;TT;SLC28A1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCTD;GG;DCTD_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;ABCG2;GT + TT;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;SLC22A1;C;SLC22A1_C;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PARKINSON_DISEASE;CAUTION_DOSE_ADJUST
ARA-CTP;DCK;CC + CT;DCK_CT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;ABCC3;CC;ABCC3_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:SCOLIOSIS, DISEASE:TONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE-3-GLUCURONIDE;ABCC3;TT;ABCC3_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
GLUCOSE;CRTC2;AA + AG;CRTC2_AA + AG;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;SLCO1C1;AG + GG;SLCO1C1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SERTRALINE;GNB3;GG;GNB3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;TT;CYP3A4_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;OPRM1_AG + GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AG;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;A;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;ABCB1;AA + AC;ABCB1_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
HDL_CHOLESTEROL;CRTC2;AA;CRTC2_AA + AG;TOXICITY;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
O-DESMETHYLTRAMADOL;SLC22A1;GG;SLC22A1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC_ACID;ABCC2;TT;ABCC2_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;COMT;GG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;TT;SLC22A1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;AA + AG;CYP2C9_A;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENTANYL;ABCC3;T;ABCC3_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:PAIN, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;COMT;G;COMT_AA;EFFICACY;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;CYP2C9_CT;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;XRCC1;CC;XRCC1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP1A2;T/del + del/del;CYP1A2_T;EFFICACY;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;ERCC1;CC;ERCC1_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;UGT2B7;G;UGT2B7_GG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;TH;GG;TH_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;CC + CG;IL18_CC + CG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A4;CC + CT;CYP3A4_TT;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CETUXIMAB;FCGR2A;AA;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A4;CC;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HTR2C;CC;HTR2C_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;AA;GLP1R_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;C;CYP2C8_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;EPHX1;CG;EPHX1_CG;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;CT;CYP2C9_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN_ACID;SLCO1B1;CC;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C19;AG;CYP2C19_AA;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR2C;C;HTR2C_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;AG + GG;EPHX1_G;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
SULFONAMIDES, UREA_DERIVATIVES;TCF7L2;TT;TCF7L2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, FLUOROURACIL;XRCC1;T;XRCC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;ABCB1;AA;ABCB1_C;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRAMADOL;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN, CISPLATIN, FLUOROURACIL;SLC19A1;A;SLC19A1_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;AA;IL6R_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;ADORA1;CC;ADORA1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;OTHER:APNEA_OF_PREMATURITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;CC + CT;IL6R_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2C;CC;HTR2C_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;TT;HTR2C_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";PRKCA;A;PRKCA_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;RGS17;A;RGS17_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AT;CYP2C9_AT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AT;CYP2C9_AT + TT;DOSAGE;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VORICONAZOLE;SLCO1B3;GT + TT;SLCO1B3_GG;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;TP53;CG + GG;TP53_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;NBEA;T;NBEA_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CRH;C;CRH_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FHIT;C;FHIT_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;PARP11;G;PARP11_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SILDENAFIL;GNB3;TT;GNB3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;MTRF1L;G;MTRF1L_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;POR;CT + TT;POR_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;HSD11B1;AA;HSD11B1_AA;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;CC;IL6R_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
SALVIANOLIC_ACID_B;NOS3;GG;NOS3_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;COMT;AA + AG;COMT_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;COMT;AA;COMT_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;CRHR2;G;CRHR2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;T;CYP2C8_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
SALMETEROL;ADRB2;AA;ADRB2_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;STX1B;AG + GG;STX1B_AG + GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ADALIMUMAB;HFE;CC + CT;HFE_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;LPIN1;G;LPIN1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;HSD11B1;AA;HSD11B1_AA;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2D6;AA;CYP2D6_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;HSD11B1;AA;HSD11B1_AA;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;GATA4;AG + GG;GATA4_AG + GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
"""BETA_BLOCKING_AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;AG + GG;NEDD4L_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CTNNA3;C;CTNNA3_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ALDOSTERONE_ANTAGONISTS, AMILORIDE;NEDD4L;G;NEDD4L_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AG + GG;HTR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;A;CRHR2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;HTR2A;GG;HTR2A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CACNA1A;A;CACNA1A_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;G;CRHR2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;ORM1;AG + GG;ORM1_AG + GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;CC;UGT2B7_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;VKORC1_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;RAPGEF5;C;RAPGEF5_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;PON2;G;PON2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CISPLATIN;GALNT18;GG;GALNT18_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;AG + GG;CYP2B6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:VASCULITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;CYP3A43;CG;CYP3A43_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;HDAC1;CC;HDAC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;MTNR1B_AG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_DRUG_ACCUMULATION
MORPHINE;TLR2;CC + CT;TLR2_CC + CT;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;CHST3;T;CHST3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL1B;A;IL1B_AA;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;MLLT3;AA + AC;MLLT3_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;T;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MORPHINE;IL1B;A;IL1B_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CT;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;CHST3;A;CHST3_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATORVASTATIN;MTTP;TT;MTTP_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;LIKELIHOOD_THERAPEUTIC_SUCCESS
NITROGLYCERIN;ALDH2;AA + AG;ALDH2_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CONGENITAL_HEART_DEFECTS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;GALNT18;CC;GALNT18_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;RARS1;TT;RARS1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ABCB1;AG + GG;ABCB1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NITROGLYCERIN;ALDH2;AA + AG;ALDH2_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CONGENITAL_HEART_DEFECTS, DISEASE:PULMONARY_HYPERTENSION;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AT;ABCB1_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TOCILIZUMAB;CD69;A;CD69_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;CC + CT;CYP2C19_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;SNU13;G;SNU13_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_DRUG_ACCUMULATION
ATENOLOL;GENE_NOT_SPECIFIED;A;GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;XIRP2;C;XIRP2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A7;TT;CYP3A7_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A7;CC;CYP3A7_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;JAK2;CC;JAK2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;GSTP1;A;GSTP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;GENE_NOT_SPECIFIED;C;C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL12B;GG;IL12B_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;ADRB1;G;ADRB1_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;CC + CT;ABCB1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;CYP1A1;CT + TT;CYP1A1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;NLRP3;CG + GG;NLRP3_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GENE_NOT_SPECIFIED;GG;GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;GG;SLCO1B1_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL18;GT + TT;IL18_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;C;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;AKT1;CT;AKT1_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;AKT1;TT;AKT1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IFNGR1;AG;IFNGR1_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP2B6;GG + TT;CYP2B6_GT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;AA + AG;CYP2C19_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C19;CT + TT;CYP2C19_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CANNABIDIOL;AOC1;CT + TT;AOC1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT + TT;CYP2B6_T;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TBX21;CC;TBX21_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;RAB7A;CT;RAB7A_CT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;CHST3;C;CHST3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IFNGR2;CC;IFNGR2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABIDIOL;SLC15A1;TT;SLC15A1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GENE_NOT_SPECIFIED;T;T;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;SLCO1B1;C;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL12B;CG + GG;IL12B_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS_FOR_SYSTEMIC_USE;HDAC1;CC;HDAC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;COMT;G;COMT_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GRM3;G;GRM3_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR5;AG;TLR5_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;KCNJ6;CC;KCNJ6_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;POR_CT + TT;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE, REMIFENTANIL;KCNJ6;TT;KCNJ6_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LOW_DENSITY_LIPOPROTEIN;SH2B1;CC;SH2B1_CC;OTHER;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSIVE_DISORDER,DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;T;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ENALAPRIL;VEGFA;AA + AC;VEGFA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LITHIUM;CACNG2;TT;CACNG2_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOCETAXEL;ORM2;AA;ORM2_AA;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ETANERCEPT, INFLIXIMAB;CARD8;TT;CARD8_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IFNGR1;AG;IFNGR1_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT, INFLIXIMAB;NLRP3;TT;NLRP3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANASTROZOLE;DLG2;T;DLG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NEPHROTIC_SYNDROME;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GG;CYP2B6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NEPHROTIC_SYNDROME;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AA;ABCB1_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;MTHFR_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B;HLA-DPA1;GG;HLA-DPA1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;BCHE;CC;BCHE_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CC;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;A;TNF_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABIDIOL;ABCC5;AA + AG;ABCC5_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;CC;IFNL3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;CC + CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AA + AG;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;CT + TT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;NFKBIA;TT;NFKBIA_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA;IFNL3_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOSE;RABEP1;AG + GG;RABEP1_AG + GG;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSIVE_DISORDER,DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PAROXETINE;BDNF;TT;BDNF, BDNF-AS_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
REMIFENTANIL;COMT;AA;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;GG;COMT_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE, REMIFENTANIL;COMT;AA + AG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;CC;ABCB1_C;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ADALIMUMAB, INFLIXIMAB;TLR2;T;TLR2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON_ALFA-N1, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;G;COMT_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE, EFFICACY:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
INTERFERON_ALFA-N1, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HSCT;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;CC;IFNL3_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;GT;ABCG2_T;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;AA;AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CHRM1;CC;CHRM1_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP1B1;CC;CYP1B1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;G;IFNL3_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_ALFA-N1, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_ALFA-N1, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA, OTHER:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDROXYUREA;ASS1;T;ASS1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA,  DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;CSMD1;T;CSMD1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;ASS1;T;ASS1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA,  DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;T;IFNL3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EPIRUBICIN;NQO1;AA;NQO1_A;EFFICACY, TOXICITY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:BREAST_CANCER_CELL_LINES;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, EPIRUBICIN;MDM4;AA;MDM4_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;C;CDA_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;NEDD4L_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNJ11;TT;KCNJ11_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GENE_NOT_SPECIFIED;AA + AG;A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;GG;DRD2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, RADIOTHERAPY;AREG;AA + AC;AREG_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
CAPECITABINE, RADIOTHERAPY;ERCC1;AG + GG;ERCC1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, OXALIPLATIN;VEGFA;CG;VEGFA_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT2B15;AA;UGT2B15_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ANKK1;AA + AG;DRD2_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;C;COMT_CC + CT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE, EFFICACY:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;TRPV1;AA + AG;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR3A;G;HTR3A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GRM7;CC;GRM7_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR3A;A;HTR3A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOSE;COMT;AA + AG;COMT_AA;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR3A;C;HTR3A_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;PTPRC;G;PTPRC_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;GRID2;GG;GRID2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ABCB1;CC;ABCB1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;NR1I2;CC;NR1I2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE, OXALIPLATIN;VEGFA;AC;VEGFA_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;PRSS53, VKORC1;A;PRSS53, VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN_LACTONE;SLCO2B1;AG;SLCO2B1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_DISEASE;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;ABCB1;AA + AT;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AG + GG;IFNL3_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN_LACTONE, 4-HYDROXYATORVASTATIN_LACTONE, ATORVASTATIN_LACTONE;UGT1A1;CC;UGT1A1_CT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;TT;RGS5_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;AA;UGT1A1_AA;DOSAGE;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;CC + CT;IFNL3_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AG + GG;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;GABRA1;AA + AG;GABRA1_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CT + TT;IFNL3_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CHRM1;GG;CHRM1_GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SCAP;C;SCAP_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;CT;IFNL3_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RALBP1;GG;RALBP1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ROCURONIUM;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC_ACID;UGT1A9;AA + AT;UGT1A9_A;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ROCURONIUM;SLCO1B1;AA;SLCO1B1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;G;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A5, ZSCAN25;C;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;AA + AG;UGT2B7_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GT;IFNL3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA + AG;IFNL3_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;GG;CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;CG + GG;CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IMATINIB;ABCG2;C;ABCG2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:MAINTENANCE_DOSAGE_BY_1.5_MG/WEEK;CAUTION_DOSE_ADJUST
ATENOLOL, IRBESARTAN;EDN1;GT;EDN1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR2A;CC;HTR2A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;T;CYP2C9_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:MAINTENANCE_DOSAGE_BY_2.2_MG/WEEK;CAUTION_DOSE_ADJUST
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;APOE;C;APOE_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;C;ABCG2_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;NR1I2;CT;NR1I2_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;SLCO1B1_AG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN;CYP3A5;CC + CT;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;G;ABCG2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIACIN;HCAR2;CT + TT;HCAR2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;ABCA1;C;ABCA1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFTRIAXONE;ABCG2;TT;ABCG2_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_INFECTIOUS_DISORDER;CAUTION_DOSE_ADJUST
RIBAVIRIN;ITPA;CC;ITPA_AC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;SLCO1B1_AG;METABOLISM/PK;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;LIKELIHOOD_THERAPEUTIC_SUCCESS
CREATINE;MOBP;AA + AG;MOBP_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:AMYOTROPHIC_LATERAL_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;EXO1;AA + AG;EXO1_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;STX4;T;C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:MAINTENANCE_DOSAGE_BY_4.8_MG/WEEK;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;GT + TT;CYP2B6_GT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR9;CT + TT;ALAS1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;CYP2C19;AA + AG;CYP2C19_AA;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;CAUTION_DOSE_ADJUST
APIXABAN;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;TT;SLC6A2_TT;OTHER;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;AGT;AG + GG;AGT_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;GG;SLC6A2_GG;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;AA;SLC6A2_AA;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;AGT;CT + TT;AGT_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;HLA-E;AA;HLA-E_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLC30A8;CT + TT;SLC30A8_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DISULFIRAM;ADRA1A;AA + AG;ADRA1A_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;ATP5F1E;GG;ATP5F1E_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
FELODIPINE;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;CYP2A6;C;CYP2A6_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;CT;CYP2C9_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CALCA;GG;CALCA_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
NITRIC_OXIDE;NAMPT;TT;NAMPT_CC + CT;EFFICACY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;GALNT18;CC + CT;GALNT18_CC + CT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;AA;OPRD1_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;GENE_NOT_SPECIFIED;C;C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
WARFARIN;GGCX;AA + AG;GGCX_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ARSENIC_COMPOUNDS;AS3MT;C;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;HTR7;TT;HTR7_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;HTR7;TT;HTR7_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS, VENLAFAXINE;HTR7;TT;HTR7_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRBESARTAN;CYP2C9;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6;CC;IL6_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;HTR7;TT;HTR7_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRBESARTAN;CYP2C9;CT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;MTHFR;G;MTHFR_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE, PAROXETINE;HTR7;TT;HTR7_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;MTHFR;G;MTHFR_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_DRUG_ACCUMULATION
PAROXETINE;HTR7;TT;HTR7_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CALCA;AG + GG;CALCA_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN, OTHER:CAESARIAN_SECTION;CAUTION_DOSE_ADJUST
PEMETREXED;CAMKK2;GT;CAMKK2_GT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;SRD5A2;CC;SRD5A2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;AA + AG;OPRD1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, LONAFARNIB, PACLITAXEL;FNTB;GG;FNTB_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCG2;GG;ABCG2_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;BMP5;A;BMP5_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;CES1;CT;CES1_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCG2;GT + TT;ABCG2_GT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCG2;CC;ABCG2_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;CYP3A4;CT + TT;CYP3A4_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;GG + GT;IL18_GG + GT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL10;TT;IL10_C;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RIVASTIGMINE;BCHE;CT + TT;BCHE_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;G;CYP2B6_G;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
VALPROIC_ACID;CYP2C9;C;CYP2C9_AC + CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AG + GG;MTHFR_AA;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;NUDT15;TT;NUDT15_CT;TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LEUKOPENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;PTGS2;CC;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;NFIB;CT;NFIB_CT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;AA + AG;SLC22A1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;TDP1;GG;TDP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;AA;CYP2C9_AT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;GG;SLC47A1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;CC + CG;IL18_CC + CG;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;CYP2D6;GG;CYP2D6_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;CYP3A4;T;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE, TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9_GG + GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;C;ABCB1_CC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CYCLOSPORINE, TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;WBP2NL;AG + GG;WBP2NL_AA;TOXICITY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
MEMANTINE, RIVASTIGMINE;BCHE;CT + TT;BCHE_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CC;GGCX_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;GT;MTHFR_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;POR;CT + TT;POR_CT + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIVASTIGMINE;BCHE;CT;BCHE_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LEWY_BODY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CALCA;GG;CALCA_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
APIXABAN;ABCG2;G;ABCG2_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1B;GG;TNFRSF1B_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1B;CC;TNFRSF1B_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;ABCB1;GG;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LATANOPROST;PTGFR;CC;PTGFR_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GLAUCOMA, DISEASE:OCULAR_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1B;AA;TNFRSF1B_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AG;MTHFR_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNFRSF1B;C;TNFRSF1B_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;ABCB1;CC;ABCB1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;NECTIN4;AA;NECTIN4_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOID_ANESTHETICS, OTHER_GENERAL_ANESTHETICS, VOLATILE_ANESTHETICS;OPRM1;GG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOID_ANESTHETICS, OTHER_GENERAL_ANESTHETICS, VOLATILE_ANESTHETICS;ABCG2;TT;ABCG2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;NECTIN4;AA;NECTIN4_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;KCNMA1;AA + AG;KCNMA1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;CES1_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCG8;CC + CG;ABCG8_CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;GG;ADRA2A_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;GG + GT;UGT1A4_GG + GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMATINIB;CYP2B6;GG + GT;CYP2B6_GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;ATIC_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;GG;AGT_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;GG;CYP2C9_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CANNABIDIOL;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AG + GG;MTHFR_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;TT;CYP2C9_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;TXNDC11;G;TXNDC11_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP1A2;A;CYP1A2_AA;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;TT;CYP2C9_CT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;KCNMA1;AA + AG;KCNMA1_AA + AG;TOXICITY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
TOPOTECAN;ABCG2;AA + AG;ABCG2_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:BRAIN_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A4;G;CYP3A4_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
DULOXETINE;KMT2E;GG;KMT2E_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;ACHE;TT;ACHE_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
DULOXETINE;NCAM1;TT;NCAM1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A5;T;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;TT;ZNF385D_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;AG + GG;CYP2B6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;GG;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;GENE_NOT_SPECIFIED;CC;CC;TOXICITY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
AMPHETAMINE;CDH13;AG + GG;CDH13_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;CT;SLCO1B1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_STENOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;KCNMB1;CC + CT;KCNIP1, KCNMB1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;CC + CT;UGT2B7_CC + CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A7P1, CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
DABIGATRAN;CES1;GG;CES1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;CLCN6, MTHFR;AA;MTHFR_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;C1orf167, CLCN6, MTHFR;TT;MTHFR_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTR;AA;MTR_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;CXCL8;AA;CXCL8_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AA;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AA + AG;COMT_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
METHOTREXATE;BIRC5;CG;BIRC5_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;GG;VKORC1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;CHRNA3_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
ABIRATERONE, PREDNISOLONE;TSPYL1;A;TSPYL1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;RICTOR;GG;RICTOR_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DRD2;T;DRD2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AA + AG;FASTKD3, MTRR_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;KDR;AA + AG;KDR_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG;OPRM1_AA;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;GSTA1;CT;GSTA1_CT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CT + TT;ATIC_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR3A;T;HTR3A_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CT + TT;ATIC_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;ATIC;CC + CG;ATIC_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;CT + TT;ATIC_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;KCNK3;C;KCNK3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;NR1I2;CC;NR1I2_TT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSION,DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;ABCB1;GG;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ADALIMUMAB;IL17F;TT;IL17F_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMMUNOGLOBULINS;CASP3, PRIMPOL;CT + TT;CASP3, PRIMPOL_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;COMT;AA;COMT_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;VKORC1_T;DOSAGE;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
IMMUNOGLOBULINS;COQ8B, ITPKC;CC + CG;COQ8B, ITPKC_CC + CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL17F;TT;IL17F_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AA;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
INFLIXIMAB;IL17F;CT;IL17F_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;CSK;C;CSK_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD3;CT + TT;DRD3_CT + TT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MOOD_DISORDER, OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;PDE3A;C;PDE3A_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANDESARTAN;SULT1C3;T;SULT1C3_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;STN1;A;STN1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;GENE_NOT_SPECIFIED;TT;TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;IL1B;GG;IL1B_CG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;VKORC1_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, PACLITAXEL;TP53;CG + GG;TP53_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAPENTINE;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;CC;VEGFA_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHOROIDAL_NEOVASCULARIZATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;NQO1;AA + AG;NQO1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METASTATIC_NEOPLASM, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT;VKORC1_CT + TT;EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;PON1;CC;PON1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:METASTATIC_NEOPLASM, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;NR1I2;CC;NR1I2_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSION,DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT;VKORC1_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;FCGR3A;C;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:AUTOIMMUNE_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3, CHRNA5;AA + AG;CHRNA3, CHRNA5_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR3A;G;HTR3A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AT + TT;ABCB1_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;T;ABCG2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
TELMISARTAN;GNB3;TT;GNB3_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LITHIUM, VALPROIC_ACID;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL;GNAS;CC;GNAS_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;ZMAT4;T;ZMAT4_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;LRRC15;del;LRRC15_del;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LITHIUM, OLANZAPINE;DRD2;GG;DRD2_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOCEPREVIR, PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRC1;CC;KLRC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;PRKAG2;A;PRKAG2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AGOMELATINE, MELATONIN_RECEPTOR_AGONISTS, SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS, VENLAFAXINE;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, CERTOLIZUMAB_PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRD1;TT;KLRD1_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;PLCE1;A;PLCE1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;RRP1B;T;RRP1B_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;TBX2;C;TBX2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
AMISULPRIDE;DRD2;C;DRD2_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;NFKBIA;CC;NFKBIA_CC + CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;ADO;C;ADO_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;XBP1;CC;XBP1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANDESARTAN;DOT1L, PLEKHJ1;A;DOT1L, PLEKHJ1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;ADAM33;CC;ADAM33_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;NUCB2;C;NUCB2_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;GENE_NOT_SPECIFIED;AG + GG;AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXENATIDE;KCNQ1;G;KCNQ1_G;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
USTEKINUMAB;AGBL4;CC + CT;AGBL4_CC + CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;SLC39A14;C;SLC39A14_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
USTEKINUMAB;CHUK;CC + CG;CHUK_CC + CG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;HTR2A;CT + TT;HTR2A_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC + CT;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;C5orf56;G;C5orf56_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CANDESARTAN;SH2B3;T;SH2B3_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
2-HYDROXYATORVASTATIN, 2-HYDROXYATORVASTATIN_LACTONE, 4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN_LACTONE, ATORVASTATIN, ATORVASTATIN_LACTONE;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;AA;CYP3A5_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;COMT;A;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, PACLITAXEL;TP53;GG;TP53_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;CYP3A4;CC;CYP3A4_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TRIGLYCERIDES;CYP19A1;A;CYP19A1_A;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL_CHOLESTEROL;CYP19A1;G;CYP19A1_G;OTHER;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AA;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_DISEASES;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;PPM1A;AA;PPM1A_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
AMILORIDE, SPIRONOLACTONE;CYP4A11;GG;CYP4A11_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;CC;UGT1A3_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;AA + AG;CYP2B6_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SPIRONOLACTONE;CYP4A11;CC;CYP4A11_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ATAZANAVIR;NR1I2;TT;NR1I2_T;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;AADAC;AA;AADAC_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
APATINIB, APATINIB_METABOLITE_M1-1;CYP2C9;GG;CYP2C9_GG;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;FTO;AT + TT;FTO_AT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPRENAVIR;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACAMPROSATE;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;CYP3A5;CC + CT;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NALTREXONE;GENE_NOT_SPECIFIED;A;A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;ABCG2;CC;ABCG2_CT + TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RITONAVIR;ABCB1;AA;ABCB1_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;APOE;CC;APOE_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CC;CBR1_TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEHYDROARIPIPRAZOLE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AA;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PREDNISOLONE;GATA3;AA;GATA3_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;GSTM3;TT;GSTM3_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MICA;AG;MICA_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;CC;TNF_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MICA;GG;MICA_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;AA + TT;HTR1B_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;TNF_AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;APOE;TT;APOE_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;TNF_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC6A4;CC;SLC6A4_AA;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
FLUOXETINE;TPH2;TT;TPH2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A-AS1;CT + TT;ADORA2A-AS1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;AA;ABCB1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, HYDROCHLOROTHIAZIDE;ALDH1A2;T;ALDH1A2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;REV3L;AG + GG;REV3L_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;REV1;CT + TT;REV1_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;SCN1A;CC + CT;SCN1A_CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
AZITHROMYCIN;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AZITHROMYCIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;OPRM1;AA;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FENTANYL;KCNJ6;TT;KCNJ6_TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ABIRATERONE;HSD3B1;AC;HSD3B1_AC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;GENE_NOT_SPECIFIED;CC;CC;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FENTANYL;GENE_NOT_SPECIFIED;AA;AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTA1;CT;GSTA1_CT;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;SOD2;GG;SOD2_AA + AG;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;OPRM1_AA;OTHER;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;GG;SLC6A2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CT + TT;POR_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;UGT1A3;T;UGT1A3_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;ABCC9;T;ABCC9_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, DOXORUBICIN;AKR1C3;GG;AKR1C3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GRIK4;TT;GRIK4_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GRIK4;C;GRIK4_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:AN_INTERNATIONAL_NORMALIZED_RATIO_(INR)_OF_2.0-3.0;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPRENORPHINE;OPRM1;CC + CG;OPRM1_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
SELECTIVE_SEROTONIN_(5HT1)_AGONISTS;PRDM16;C;PRDM16_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;NR1I2;AA + AG;NR1I2_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
RIVAROXABAN;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;COMT;CC + CT;COMT_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AG;UGT1A6_AG + GG;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ATAZANAVIR;ABCB1;AC + CC;ABCB1_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;GT + TT;MTHFR_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;GRIN2B;AC;GRIN2B_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
VALPROIC_ACID;GRIN2B;CC;GRIN2B_CC;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;CT + TT;SLC19A1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC_ACID;SCN1A;C;SCN1A_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOPINAVIR;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VALPROIC_ACID;UGT1A6;AC;UGT1A6_AC + CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:KIDNEY_NEOPLASMS,OTHER:NEUROENDOCRINE_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;C;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
AMISULPRIDE;SNAP25;CT;SNAP25_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCA1;A;ABCA1_A;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;N6AMT1;G;N6AMT1_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TENOFOVIR;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;A;ABCB1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;NRXN1;AA;NRXN1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRXN1;TT;NRXN1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;CYP2C19_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CES1;GG;CES1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;ABCB1_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB_PEGOL, GOLIMUMAB, INFLIXIMAB;TNF;GG;TNF_AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BEHCET_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;OTHER, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CFH;CC;CFH_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;UGT1A6_AG + GG;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL;DPYD;CT;DPYD_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOCETAXEL, IRINOTECAN;XRCC3;AA;KLC1, XRCC3_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;UGT1A6_GG;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GT;UGT1A6_GG;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;UGT1A6;CC;UGT1A6_AC + CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
10-MONOHYDROXY_OXCARBAZEPINE;INSR;C;INSR_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR1A;GG;HTR1A_GG;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
FENTANYL;CACNA1E;CC + CT;CACNA1E_CC + CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FENTANYL;LAMB3;G;LAMB3_G;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CETUXIMAB;VEGFA;TT;VEGFA_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;VEGFA;GG;VEGFA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;A;MECP2_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;A;MECP2_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;A;MECP2_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP3A4;CT;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;T;T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
PROCHLORPERAZINE;ANKK1, DRD2;AA + AG;DRD2_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NAUSEA;LIKELIHOOD_THERAPEUTIC_FAILURE
PROCHLORPERAZINE;DRD2;CT + TT;DRD2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NAUSEA;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;ATM;AC;ATM_AC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRK1;A;OPRK1_A;DOSAGE, EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;G;GALNT14_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;GALNT14_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
ATORVASTATIN;HMGCR;CT + TT;HMGCR_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;TPH1;GT + TT;TPH1_GT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;GALNT14_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
TENOFOVIR_ALAFENAMIDE;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;GALNT14_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG;CES1_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;A;GALNT14_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;TT;CYP3A4_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
APATINIB, APATINIB_METABOLITE_M1-1;CYP2C9;TT;CYP2C9_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;T;T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;GALNT14_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
ALLOPURINOL, FEBUXOSTAT;AOX1;G;AOX1_G;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
PAZOPANIB;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;IL2;GG;IL2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL2;GG;IL2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, FEBUXOSTAT;AOX1;T;AOX1_T;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;GG;MTHFR_TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIAZEPAM;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL, FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
ALLOPURINOL, FEBUXOSTAT;XDH;G;XDH_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
ALLOPURINOL, FEBUXOSTAT;AOX1;T;AOX1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;AC;SLC22A1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL, REMIFENTANIL;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC3;TT;ABCC3_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;TT;CYP3A4_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;CG;SLC19A1_CG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;BCHE;T;BCHE_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFD1;AA + AG;MTHFD1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;TT;GALNT14_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;GDNF;CT + TT;GDNF_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;GDNF;AA + AG;GDNF_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL17RA;AA;IL17RA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;SLC6A2;T;SLC6A2_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;BDNF;CC + CT;BDNF, BDNF-AS_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR3A;AC + CC;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CETP;G;CETP_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;GT;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;C;CYP2D6_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;DBH;CC;DBH_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;A;CYP2D6_GG;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;CYP3A5;TT;CYP3A5_CC;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;GG;COMT_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;C6;CC + TT;C6_CC + TT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;C6;CC + CT;C6_CC + CT;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOXORUBICIN, METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;RGS4;C;RGS4_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;SLC22A1;AA + AG;SLC22A1_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ANKK1;A;DRD2_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;CT;CYP3A4_TT;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;AG + GG;GSTP1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PHENYTOIN;SCN1A;T;SCN1A_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;T;ABCB1_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;CYP2D6_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;GG;HTR1A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;ABCB1;G;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;CC;HTR1A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;ABCB1;T;ABCB1_CT + TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;AT + TT;CYP2C9_AT + TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:HEART_VALVE_REPLACEMENT,DISEASE:PULMONARY_HYPERTENSION, DISEASE:PULMONARY_EMBOLISM, DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;APOC1;G;APOC1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE, DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:HEART_VALVE_REPLACEMENT,DISEASE:PULMONARY_HYPERTENSION, DISEASE:PULMONARY_EMBOLISM, DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
PHOTODYNAMIC_THERAPY;F13A1;AA + AC;F13A1_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHOROIDAL_NEOVASCULARIZATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:HEART_VALVE_REPLACEMENT,DISEASE:PULMONARY_HYPERTENSION, DISEASE:PULMONARY_EMBOLISM, DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
CITALOPRAM;TPH1;GT + TT;TPH1_GT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;NPC1L1;G;NPC1L1_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE, DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SORT1;T;SORT1_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE, DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC_ACID;UGT1A9;del;UGT1A9_T/del + del/del;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;ACY3;T;ACY3_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;SLCO1B1;AA + AG;SLCO1B1_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IMATINIB;BCL2L11;T;BCL2L11_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;DPYD_CT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ITOPRIDE;FMO3;AA;FMO3_AG + GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METOPROLOL;SEPTIN3;G;SEPTIN3_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ITOPRIDE;FMO3;GG;FMO3_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;CXCL12;CT + TT;CXCL12_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC_ACID;ABCC2;CT;ABCC2_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AA;RRM1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CXCL8;AA;CXCL8_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AC;RRM1_AC;EFFICACY, TOXICITY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;NEDD4L_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;AA;UGT1A1_AA;DOSAGE;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
COTININE_GLUCURONIDE;UGT1A9;CT;UGT1A9_CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;GT;CYP2A6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB, RANIBIZUMAB;VEGFA;CT + TT;VEGFA_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CC + CT;CYP3A5_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEART_FAILURE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CC + CT;SCN1A_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, RANIBIZUMAB;VEGFA;CT + TT;VEGFA_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ETANERCEPT;CD84;AG;CD84_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOPINAVIR;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;SCN1A;TT;SCN1A_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;GABRA1;AA + AG;GABRA1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
USTEKINUMAB;IL12B;CT;IL12B_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;CDA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;CC;IL6R_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;AA;IL6R_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AA;ABCB1_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALFENTANIL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CETUXIMAB;FCGR3A;AA;FCGR3A_AC + CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;FCGR2A;GG;FCGR2A_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HNF4A;CC;HNF4A_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHADONE;ALDH5A1;CT + TT;ALDH5A1_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;UGT1A1;TT;UGT1A1_CT;TOXICITY;INCREASED;DISCONTINUATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;XRCC1;CT + TT;XRCC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;CHAT;A;CHAT_G;DOSAGE, EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PRAVASTATIN;ABCC2;CG;ABCC2_CG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RAMIPRIL;ACE;CC + TT;ACE_CC + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RAMIPRIL;ACE;AA + GG;ACE_AA + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:GLOMERULONEPHRITIS, MEMBRANOUS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRD1;AA + AG;OPRD1_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;KLRK1;GG;KLRK1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CRHR2;CC + CG;CRHR2_CC + CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;NR1I2;AA + AG;NR1I2_AA + AG;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT + TT;SLC19A1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;GENE_NOT_SPECIFIED;CT;CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;ATP7B;G;ATP7B_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;NR3C1;CC;NR3C1_CC;EFFICACY;INCREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;HTR2A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ATP7B;A;ATP7B_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;NR3C1;AA;NR3C1_AA;EFFICACY;INCREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CCL2;AA + AG;CCL2_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CCL2;CC + CT;CCL2_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;TT;FPGS_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;FPGS;TT;FPGS_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
DEXAMETHASONE;NR3C1;TT;NR3C1_T;EFFICACY;INCREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;AAAA;ABCA1_AAAA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS, SELECTIVE_BETA-2-ADRENORECEPTOR_AGONISTS;ADRB2;A;ADRB2_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CCL2;GG;CCL2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT1A4;TT;UGT1A4_GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;A;ITPA_AC;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT1A4;TT;UGT1A4_GG + GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;SLC22A1;AG;SLC22A1_A;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;CC;CYP2B6_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNB3;G;CHRNB3_G;EFFICACY, OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PLATINUM_COMPOUNDS;HMGB1;CC;HMGB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR9;CT + TT;ALAS1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB3;G;CHRNB3_G;EFFICACY, OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DEXAMETHASONE;CYP3A4;AG;CYP3A4_AA + AG;EFFICACY;INCREASED;TIME_RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ABCB1;T;ABCB1_CC;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;HMGB1;GG;HMGB1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;G;CYP2B6_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CISPLATIN, RADIOTHERAPY;XRCC1;TT;XRCC1_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS, DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;ACE;AT + TT;ACE_AT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VEGF/VEGFR_(VASCULAR_ENDOTHELIAL_GROWTH_FACTOR)_INHIBITORS;VEGFA;AC + CC;VEGFA_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;COMT;AA + AG;COMT_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, INFLIXIMAB;IL12B;AA + AG;IL12B_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;CYP3A4_TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, INFLIXIMAB;IVL;CT + TT;IVL_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AA + AG;COMT_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
USTEKINUMAB;TIRAP;CT + TT;TIRAP_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG + GG;OPRM1_AA;OTHER;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
USTEKINUMAB;TLR5;AG + GG;TLR5_AG + GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR2;AA + AC;TLR2_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;LY96;CG + GG;LY96_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;BRD3;AA;GENOTYPE_NOT_SPECIFIED;PD;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TLR2;AT + TT;TLR2_AT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS, USTEKINUMAB;IL1B;CG + GG;IL1B_CG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;ABCB1;A;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC + CT;APOE_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS, USTEKINUMAB;IL1B;AG + GG;IL1B_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;GG;NR1I2_GG;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;T;OPRM1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;C;COMT_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;CC;NR1I2_C;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATEZOLIZUMAB, BEVACIZUMAB;IL7;AA;IL7_AA + AG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;OPRM1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;C;COMT_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;OPRM1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;ABCB1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RISPERIDONE;COMT;C;COMT_C;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;OPRM1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;OPRM1_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRD1;AA + AC;OPRD1_AA + AC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;A;OPRM1_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;T;OPRM1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
PREDNISONE;EDNRA;CC + CT;EDNRA_CC + CT;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;CC;NR1I2_C;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;TLR4;CC;TLR4_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PAZOPANIB;NR1I2;T;NR1I2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;T;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ADALIMUMAB, INFLIXIMAB;ZNF816;CC + CT;ZNF816_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CALU;G;CALU_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL18;GG + GT;IL18_GG + GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, INFLIXIMAB;NFKBIA;CC + CG;NFKBIA_CC + CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, INFLIXIMAB;TNFRSF1B;AG + GG;TNFRSF1B_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;GG;NR1I2_GG;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, INFLIXIMAB;SLC9A8;GG;SLC9A8_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, PLATINUM_COMPOUNDS, RADIOTHERAPY;XRCC4;G;XRCC4_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, PLATINUM_COMPOUNDS, RADIOTHERAPY;XRCC4;T;XRCC4_T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC_ACID;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, PLATINUM_COMPOUNDS, RADIOTHERAPY;ERCC1;A;ERCC1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;T;OPRM1_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;OPRM1_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;G;OPRM1_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;OPRM1_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;OPRM1_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;OPRM1_G;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;T;OPRM1_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;NR1I2;T;NR1I2_CC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;AA + AG;SLCO1B1_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC3;C;ABCC3_C;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;NR1I2;G;NR1I2_G;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;C;ABCB1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCG2;T;ABCG2_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
GLUCOCORTICOIDS;GENE_NOT_SPECIFIED;AA;AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN_GLUCURONIDE;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;NTRK2;CC;NTRK2_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;G;CYP2C9_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA + AC;MED12L, P2RY12_AC;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;CBR1;CC;CBR1_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;ADRA2A;CG;ADRA2A_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;ABCB1;AA;ABCB1_A;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;ABCB1_A;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC1;GG;ABCC1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;NR1I2;TT;NR1I2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;ABCB1_C;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LOSARTAN;AGTR1;CC;AGTR1_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;KDR;T;KDR_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;CT + TT;UGT2B7_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;T;NUDT15_GT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
METFORMIN;ARFGEF3;AC;ARFGEF3_AC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERBB2;G;ERBB2_AG + GG;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOXORUBICIN;CBR1;GG;CBR1_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAB2;A;PRKAB2_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;CT + TT;NUDT15_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES, DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;POR_CT + TT;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOXORUBICIN;CBR1;GG;CBR1_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;GG;CBR1_GG;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAMIPEXOLE;DRD3;T;DRD3_CT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, BENZODIAZEPINE_DERIVATIVES, MIRTAZAPINE, SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;GAL;C;GAL_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PREGNANCY;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;A;CYP3A5_A;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GG;SLC22A1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;CYP3A5_T;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;VKORC1_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;C;CYP3A5_CC;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MYCOPHENOLIC_ACID;ABCC2;CC;ABCC2_CT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;PRSS53, VKORC1;A;VKORC1_A;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA;CYP1A2_AA;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CC;CBR1_TT;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG;GGCX_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA;CYP1A2_AA;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEAVY_COFFEE_CONSUMPTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;PEAR1;GT + TT;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;GG;ATIC_G;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;AA + AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;PEAR1;TT;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C;CYP3A4_TT;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;A;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;PEAR1;AA;PEAR1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TICAGRELOR;PEAR1;AA;PEAR1_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;PRSS53, VKORC1;T;VKORC1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL9;AA + AG;IL9_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;AA;FCGR3A_AC + CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NEUROMYELITIS_OPTICA;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISOLONE;CD40;CC;CD40_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A1;AA;SLC47A1_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB;CALCRL;G;CALCRL_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + TT;ABCB1_C;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;VKORC1_T;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HALOTHANE;RYR1;T;RYR1_CT;OTHER;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;VKORC1_G;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;VKORC1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
2-HYDROXYATORVASTATIN;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL5;AA + AG;IL5_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS, SELECTIVE;BST1;A;BST1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA;CYP19A1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
BISPHOSPHONATES;FDPS;T;FDPS_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CETP;A;CETP_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;APOE;TT;APOE_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GG;ABCG2_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;C;TNF_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES,DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;UMOD;GT + TT;UMOD_GT + TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MODAFINIL;ABCB1;AC + CT;ABCB1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NARCOLEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MODAFINIL;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NARCOLEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;MYC;CT;MYC_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;MYC;CT + TT;MYC_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;EPHX1_G;DOSAGE, METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
MODAFINIL;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:NARCOLEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;G;TNF_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES,DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISPHOSPHONATES;FDPS;A;FDPS_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;MYC;CC;MYC_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TNF;G;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES,DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;ABCC2;T;ABCC2_CT + TT;EFFICACY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;DHODH;CC;DHODH_CC;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;G;DRD2_GG;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MOOD_DISORDER, OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;SLC22A4_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2A;AA + AG;HTR2A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HTR2A;AG;HTR2A_AA;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MOOD_DISORDER, OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;TT;CYP2B6_GT;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;HTR2A;AG + GG;HTR2A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR2A;AA + AG;HTR2A_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;CC;EPHX1_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;CYP2B6_GT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;GG;EPHX1_G;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;ITPA;AC + CC;ITPA_AA;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES, DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;SLC22A4_CT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;CC + CT;OPRM1_C;OUTCOME_NOT_SPECIFIED;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;COMT;AG;COMT_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCC2;CT;ABCC2_CT + TT;TOXICITY;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;AA;COMT_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CT + TT;OPRD1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AC;ABCB1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;AG + GG;OPRM1_AA;OTHER;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TNIK;CC;TNIK_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;CG;COMT_CG + GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
SUNITINIB;ABCB1;AA + AT;ABCB1_C;DOSAGE, TOXICITY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_DOSE_ADJUST
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;AG + GG;TNF_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA;ABCB1_A;DOSAGE, TOXICITY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
METHADONE;POR;CT + TT;POR_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;AA;CYP2B6_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
DOLUTEGRAVIR;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;GG;CYP2B6_GT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
PREDNISOLONE;TLR4;T;TLR4_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A4;CG;CYP3A4_CG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TELBIVUDINE;TK2;CC + CT;TK2_CC + CT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;CAUTION_DRUG_ACCUMULATION
WARFARIN;EPHX1;TT;EPHX1_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;TT;CYP2B6_GT;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;CC + CT;OPRM1_C;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTP1;AA;GSTP1_GG;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFOTAXIME;SLC22A8;AT;SLC22A8_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C18;G;CYP2C18_G;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;PRKCE;T;PRKCE_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C18;T;CYP2C18_T;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_CC + CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PERAMPANEL;CYP3A4;CT + TT;CYP3A4_CT + TT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;GENE_NOT_SPECIFIED;T;T;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PREDNISOLONE;TLR4;G;TLR4_G;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;CC;ABCB1_C;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA;ABCB1_A;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;ABCB1;AC + CC;ABCB1_AC + CC;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GABRB1;T;GABRB1_T;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GABRB1;A;GABRB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;VKORC1_CT + TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;ABCC1;CT + TT;ABCC1_CT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;ABCB1;AA;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DOSE_ADJUST
LITHIUM;ASIC2;CC;ASIC2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;ABCC1;AT + TT;ABCC1_AT + TT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CAPECITABINE, FLUOROURACIL;HLA-G;GG;HLA-G_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;MAPK1;AG;MAPK1_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;HLA-G;CT;HLA-G_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;VKORC1_CT + TT;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;G;CHAT_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;COMT;GG;COMT_AA;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN;PPARA;AA + AG;PPARA_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;OR52E2;TT;OR52E2_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;OR52J3;GG;OR52J3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CREB1;GG;CREB1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;C;TPMT_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:LEUKEMIA;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;A;CHAT_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;GG;ATIC_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT2B7;G;UGT2B7_G;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;CT;ABCG2_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOLESTEROL;APOE;TT;APOE_C;TOXICITY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;DRD2;AA;DRD2_AG + GG;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA + AG;SLC47A2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;ADRB1;CG + GG;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;DRD2;CC;DRD2_CT;DOSAGE, METABOLISM/PK;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A2;AA + AC;SLC22A2_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AA + AC;ABCB1_C;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROMYCIN;ABCC2;TT;ABCC2_CT + TT;OTHER, METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG + GG;GGCX_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE, DUTASTERIDE;HSD3B1;AC;HSD3B1_AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;PACSIN2;CT + TT;PACSIN2_CT + TT;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:IRRITABLE_BOWEL_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO2B1;AA + AG;SLCO2B1_GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;NOS3;CC + CT;NOS3_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;TT;CYP2B6_GT;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ABIRATERONE;SRD5A2;CC;SRD5A2_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP2C9;AC;CYP2C9_AC + CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TRIGLYCERIDES;CYP19A1;A;CYP19A1_G;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;CYP19A1_C;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL_CHOLESTEROL;CYP19A1;G;CYP19A1_GG;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TRIGLYCERIDES;CYP19A1;C;CYP19A1_T;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;AC + CC;SLC19A1_AC + CC;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL_CHOLESTEROL;CYP19A1;G;CYP19A1_G;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T;CYP3A4_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
HDL_CHOLESTEROL;CYP19A1;T;CYP19A1_T;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;ESR1;TT;ESR1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;GT;CYP2B6_GT;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LEFLUNOMIDE;ESR1;AA;ESR1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN, ATORVASTATIN_LACTONE;LPP;A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;C9orf72;CC + CT;C9orf72_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;GG;GGH_AA;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL_CHOLESTEROL;CYP19A1;A;CYP19A1_A;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL13;AA + AC;IL13_AA + AC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;CYP19A1_C;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;ZNF816;CC + CT;ZNF816_CC + CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIGLYCERIDES;CYP19A1;C;CYP19A1_C;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG + GG;GGCX_G;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
USTEKINUMAB;STAT4;GT + TT;STAT4_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;SLC22A4;CT;SLC22A4_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;GG;CHRNA3, CHRNA5_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;STX1B;AA + AG;STX1B_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP1A1;CC;CYP1A1_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VARENICLINE;CHRNA5;AA + AG;CHRNA3, CHRNA5_A;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;DNMT3A;TT;DNMT3A_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;NQO1;AA;NQO1_GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
RALOXIFENE;ESR1;TT;ESR1_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENTANYL;DRD1;AG + GG;DRD1_AG + GG;EFFICACY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE/SALMETEROL;CHRM2;A;CHRM2_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE, RISPERIDONE;DRD2;CC;DRD2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PSYCHOTIC_DISORDER, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCG2;GT + TT;ABCG2_T;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LEUKEMIA_OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;CAUTION_DRUG_ACCUMULATION
WARFARIN;STX1B;AG + GG;STX1B_AG + GG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;CC;UGT1A1_CT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC + CT;CYP4F2_TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;ITPA;AA + AC;ITPA_AC;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;A;SHMT1_AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL6;G;IL6_CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;GENE_NOT_SPECIFIED;GG + GT;GG + GT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;CYP2C9;G;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A2;TT;SLC22A2_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;DOSAGE, EFFICACY;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;T;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PLATINUM_COMPOUNDS;MALAT1;AG + GG;MALAT1_AG + GG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;HOTAIR;CC + CG;HOTAIR_CC + CG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;H19;AA + AG;H19_AA + AG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG;CYP3A4_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;C;EPHX1_CC;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUTICASONE/SALMETEROL;CHRM2;A;CHRM2_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AG + GG;OPRM1_AA;OTHER;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BETA_BLOCKING_AGENTS;ADRB1;C;ADRB1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:CARDIOMYOPATHY, DILATED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN_ACID;SLCO1B1;CC;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BETA_BLOCKING_AGENTS;ADRB2;A;ADRB2_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:CARDIOMYOPATHY, DILATED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE/SALMETEROL;CHRM2;A;CHRM2_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;EPHX1_G;DOSAGE, METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FLUTICASONE_PROPIONATE;CRHR1;T;CRHR1_T;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TNIK;AA;TNIK_AA;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE_PROPIONATE;CRHR1;T;CRHR1_TT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CSMD1;AC + CC;CSMD1_AC + CC;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE_PROPIONATE;CRHR1;C;CRHR1_C;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE_PROPIONATE;CRHR1;G;CRHR1_G;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;CYP2B6_GT;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NICOTINE;POR;CT + TT;POR_CT + TT;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PK:CYP2A6_NORMAL_METABOLIZERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;CYP4F2_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C18;T;CYP2C18_T;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LEUKEMIA_OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;G;CYP2C18_G;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LEUKEMIA_OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIFENTANIL;ABCB1;GG;ABCB1_A;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CT + TT;GGCX_CT + TT;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
REMIFENTANIL;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC + CT;DPYD_CC;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;VKORC1_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CES1;CT + TT;CES1_CT;METABOLISM/PK;INCREASED;EXPOSURE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;CT + TT;CES1_CT;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;METABOLISM/PK;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
NALTREXONE;OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;P2RY1;T;P2RY1_T;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;TT;CMPK1_CC;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;CC;NUDT15_CC;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;ABCC2;AA;ABCC2_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEOXY-THIOGUANOSINE_TRIPHOSPHATE, THIOGUANOSINE_TRIPHOSPHATE;TPMT;CT;TPMT_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;PACSIN2;CC + CT;PACSIN2_CT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL_CARBOXYLIC_ACID;ABCB1;AA + AG;ABCB1_A;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MALARIA_VIVAX;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CT;CYP3A5_CC;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;ABCB1;CC;ABCB1_C;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;GLP1R;GG;GLP1R_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ARTEMETHER, LUMEFANTRINE;CYP2B6;GT;CYP2B6_GT;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
4-ENE_VALPROIC_ACID;CPT1A;GG;CPT1A_GG;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CC + CT;ATIC_CC + CT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CT + TT;ATIC_C;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;GT + TT;ADA_GT + TT;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC + CG;ATIC_G;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;CG + GG;ADA_CG + GG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;AA;ADA_AA;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;GG;GLP1R_AA + AG;EFFICACY;INCREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:HYPERTENSION, OTHER:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;ADRB2;AA;ADRB2_AA;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;ADRB2;GG;ADRB2_GG;EFFICACY;DECREASED;CLINICAL_BENEFIT;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
PERPHENAZINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;CDKAL1;CC;CDKAL1_CC;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;CDKAL1;GG;CDKAL1_GG;EFFICACY;INCREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;AA;GLP1R_AA + AG;EFFICACY;DECREASED;RESPONSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:MENTAL_DISORDERS,OTHER:NEUROTIC_DISORDER, OTHER:PERSONALITY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:MENTAL_DISORDERS,OTHER:NEUROTIC_DISORDER, OTHER:PERSONALITY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2;*30;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RESISTANCE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:MENTAL_DISORDERS,OTHER:NEUROTIC_DISORDER, OTHER:PERSONALITY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;AG;CYP3A4_AA + AG;DOSAGE;DECREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC + CT;CYP3A4_TT;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC22A3;AG + GG;SLC22A3_AG + GG;DOSAGE;INCREASED;DOSE;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;OTHER:DEPRESSION;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANITIDINE;SLC22A1;del;SLC22A1_del/del;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*32;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*30;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*54;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*44;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*42;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*40;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*52;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*43;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*45;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*39;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*55;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*38;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*48;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*53;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*47;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*50;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*60;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*60;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*60;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2B6;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2E1;*7B;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2E1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ACE;del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OUTCOME_NOT_SPECIFIED;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ACE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*32;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;C;CES1_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CES1;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;A;UGT1A1_A;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ESTRONE_SULFATE, ROSUVASTATIN;SLCO2B1;T;SLCO2B1_T;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO2B1;CAUTION_DRUG_ACCUMULATION
ESTRONE_SULFATE, ROSUVASTATIN;SLCO2B1;C;SLCO2B1_C;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO2B1;CAUTION_DRUG_ACCUMULATION
ESTRONE_SULFATE, ROSUVASTATIN;SLCO2B1;T;SLCO2B1_T;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO2B1;CAUTION_DRUG_ACCUMULATION
ESTRONE_SULFATE;SLCO2B1;T;SLCO2B1_T;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO2B1;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2B6;CA/CA;CYP2B6_CA/CA;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;AGTR1;A;AGTR1_A;OTHER;DECREASED;AFFINITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;DPYD_CT;OTHER;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;NAMPT;CC + CT;NAMPT_CC + CT;OTHER;INCREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NAMPT;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2E1;*7A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2E1;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
RALOXIFENE;UGT1A8;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE-6'-GLUCURONIDE;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*22 + *48;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;T;RYR1_T;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*169;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;G;CYP2D6_G;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2D6;*169;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2D6;G;CYP2D6_G;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
RANITIDINE;SLC22A1;A;SLC22A1_A;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
RANITIDINE;SLC22A1;T;SLC22A1_T;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TYMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC2;CG;ABCC2_CG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;A;UGT1A1_AA;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;NR1I2;G;NR1I2_G;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;NR1I2;G;NR1I2_G;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CDA;del/del;CDA_C/del + CC;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;del;CYP2C9_del;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP3A4;*8;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP3A4;*12;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A4;*11;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A9;C;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_CT + TT;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2A6;*46;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A9;G;UGT1A1_G;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
COUMARIN, NICOTINE, TEGAFUR;CYP2A6;*7 + *19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2A6;*4;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;*4/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2A6;*4/*9;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN, TEGAFUR;CYP2A6;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;G;UGT1A9_G;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
NIMESULIDE;PTGS2;G;PTGS2_G;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PTGS2;LIKELIHOOD_THERAPEUTIC_FAILURE
NIMESULIDE;PTGS2;C;PTGS2_C;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PTGS2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2A6;*46;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2A6;*46;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
VANDETANIB;CYP3A4;*6 + *30;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*17 + *24;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*14 + *15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*20;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;ERCC2;TT;ERCC2_CT + TT;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ERCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ERCC2;GG;ERCC2_TT;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ERCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;GGH;A;GGH_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;ERCC1;GG;ERCC1_AA;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ERCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CDA;C/del + del/del;CDA_C/del + CC;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;del;RYR1_del;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;del/del;CFTR_del/del;OTHER;INCREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*27;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*54;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*53;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*56;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*55;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EBASTINE;CYP2J2;(CTC)1;CYP2J2_(CTC)1;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*30;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T/T;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CYTARABINE;CDA;AA + AG;CDA_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;CAUTION_DRUG_ACCUMULATION
CISPLATIN;ERCC2;GG;ERCC2_TT;TOXICITY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;GG;ERCC1_AA;TOXICITY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AG;GSTP1_GG;TOXICITY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATRASENTAN;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CD38;T;CD38_T;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CD38;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;AFFINITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;CG;DPYD_C;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;TPMT;*1/*2 + *1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
CELECOXIB, FLUCONAZOLE;CYP2C19;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, SERTRALINE;CYP2C19;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2C19;*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOXSALEN;CYP2A6;*15 + *21 + *22;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;SLCO1B1;*37;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLCO1B1;*20;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLCO1B1;*14;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANINE;TPMT;*16;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*3B/*3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;CT;DPYD_CT;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, TRANYLCYPROMINE;CYP2C19;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;*16;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;*11;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *28 + *35;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;ABCB1;AC + CC;ABCB1_C;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;POOR_METABOLIZER;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;IFNL4;TT/TT;IFNL4_TT/TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IFNAR1;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*49 + *55;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*54;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2C19;*16;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*47;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;TPMT;*3A + *3C + *24;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*50;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*51;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;UPTAKE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;UPTAKE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP, S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*53;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;C;C;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP, S-EDDP;CYP2B6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEBRISOQUINE;CYP2D6;*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A6;*2a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A6;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*16;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*9 + *10 + *16;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*17 + *24;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*14 + *15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2D6;*92 + *96;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;UGT1A4;*3a;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;ABCB1;AG + GG;ABCB1_A;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE, COPTISINE;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE, COPTISINE;CYP2D6;*1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO1B1;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;A;CYP2D6_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2B6;*27;GENOTYPE_NOT_SPECIFIED;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;T;CYP2D6_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;del/del;CFTR_del/del;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;AKR1C3;T;AKR1C3_T;METABOLISM/PK;DECREASED;AFFINITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;AKR1C4;A;AKR1C4_A;METABOLISM/PK;DECREASED;AFFINITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*24;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;AC;DPYD_AC;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ABCC10;TT;ABCC10_CT;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*75;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*2C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*11;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;TPMT;*3A + *3C;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*17 + *35;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ABCC4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DEFICIENCY;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DEFICIENCY;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*92 + *96;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*32;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*92 + *96;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CISPLATIN;TPMT;*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TLR4;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MKI67;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADEFOVIR_DIPIVOXIL;SLC22A6;T;SLC22A6_T;OTHER;DECREASED;UPTAKE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SCAP;TT;SCAP_CC + CT;OTHER;DECREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SCAP;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NAMPT;CC + CT;NAMPT_CC + CT;OTHER;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NAMPT;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;FKBP5;CT;FKBP5_CT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;FKBP5;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE_5-N-GLUCURONIDE, DESMETHYLCLOZAPINE_GLUCURONIDE;UGT1A4;G;UGT1A4_GG + GT;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28 + *1/*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*62;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*47;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*49;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*43;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*45;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*39;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*42;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*13;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*16;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*14;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*50;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*52;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*51;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del;CFTR_del/del;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DRUG_NOT_SPECIFIED;CYP2C9;AT + TT;CYP2C9_AT + TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*72;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*75;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*74;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN;CYP2C9;*73;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;MIR27A;C;MIR27A_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2D6;G;CYP2D6_C;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP2C19;*3 + *35;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*20;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*29;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE;NAT2;*4/*4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NAT2_RAPID_ACETYLATOR;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOLITHROMYCIN;NAT2;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NAT2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ALDH1A2;AA + AG;ALDH1A2_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ALDH1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;BCL2L11;CC;BCL2L11_CC;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DEXAMETHASONE;BCL2L11;AA;BCL2L11_AA;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
THIOXANTHINE;XDH;T;XDH_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;XDH;CAUTION_DRUG_ACCUMULATION
THIOXANTHINE;XDH;T;XDH_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;XDH;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;HLA-G;C;HLA-G_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HLA-G;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;HLA-G;GG;HLA-G_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HLA-G;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*47;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*47;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*46;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;PD;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HDAC2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;PD;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;FKBP5;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;PD;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;GLCCI1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;PD;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NR3C1;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CDA;GG;CDA_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;TPH2;T;TPH2_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPH2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CDA;TT;CDA_TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;C;RYR1_C;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;A;RYR1_A;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;C;HTR1B_C;PD;INCREASED;AFFINITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HTR1B;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETANSERIN;HTR1B;C;HTR1B_C;PD;DECREASED;AFFINITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HTR1B;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CDA;TT;CDA_CT + TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;TPH2;AA;TPH2_GG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPH2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CDA;CC;CDA_AA;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;T;DPYD_T;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;G;DPYD_G;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;AA;AA;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;WNT5B;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;GG;GG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL1B;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;PROTEIN_STABILITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;CC + CT;CYP2A6_T;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;TT;CYP2A6_TT;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;AA + AG;CYP2A6_AA + AG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;CC + CG;CYP2A6_GG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*12;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*11 + *18 + *33;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;C;C;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCG2;C;ABCG2_C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCG2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;A;A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;G;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCA12;A;ABCA12_A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA12;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCA12;C;ABCA12_C;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA12;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICINOL;AKR1A1;C;AKR1A1_C;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICINOL;AKR1A1;C;AKR1A1_C;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCA8;T;ABCA8_T;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA8;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;G;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;PITPNM2;C;PITPNM2_C;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB9;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICINOL;AKR1A1;G;AKR1A1_G;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;PSMB8, TAP1, TAP2;T;PSMB8, TAP1, TAP2_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TAP2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;PSMB8, TAP2;A;PSMB8, TAP2_A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TAP2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCB9;T;ABCB9_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB9;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICINOL;AKR1A1;G;AKR1A1_G;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCA1;G;ABCA1_G;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCA1;G;ABCA1_G;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;T;T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCA1;C;ABCA1_C;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;F3;T;F3_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD3;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCD2;C;ABCD2_C;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;REDIC1;T;REDIC1_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;G;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC10;A;ABCC10_A;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC4;T;ABCC4_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCC10;A;ABCC10_A;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;G;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCD1, BCAP31;C;ABCD1, BCAP31_C;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCC10;G;ABCC10_G;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;PLXNB3;A;PLXNB3_A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;C;C;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCD1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;TMPRSS11E;T;TMPRSS11E_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT2B4;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;CC;CC;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT2B17;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;AG + GG;CYP2A6_AG + GG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;UGT2B4;T;UGT2B4_T;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT2B15;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;GG;CYP2A6_GG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;G;NT5C1A_G;OTHER;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;A;NT5C1A_A;OTHER;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;T;NT5C1A_T;OTHER;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;CC + CT;CYP2A6_CC + CT;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;GG;OPRM1_AA;EFFICACY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;RARG;A;RARG_AA;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUG_NOT_SPECIFIED;IL18;GG + GT;IL18_GG + GT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL18;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;IL18;CC + CG;IL18_CC + CG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL18;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;*11 + *32 + *34;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;T;CES1_CT;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CES1;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;C;CES1_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CES1;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;T;CES1_T;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CES1;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIMAZOLAM;CES1;G;CES1_G;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CES1;CAUTION_DRUG_ACCUMULATION
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR, IVACAFTOR/TEZACAFTOR;CFTR;A;CFTR_A;PD;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;DPP4;CC;DPP4_CC;PD;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPP4;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;DPP4;TT;DPP4_TT;PD;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPP4;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN;AKR1C4;G;AKR1C4_G;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AKR1C4;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR;CFTR;CT;CFTR_CT;PD;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;AKR7A2;T;AKR7A2_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AKR7A2;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN, DOXORUBICIN;AKR1C3;T;AKR1C3_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AKR1C3;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN, DOXORUBICIN;AKR1C3;T;AKR1C3_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AKR1C3;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN;AKR1C3;A;AKR1C3_A;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AKR1C3;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DRUG_NOT_SPECIFIED;DPYD;C;DPYD_CC;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DRUG_NOT_SPECIFIED;EPO;AA;EPO_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;EPO;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
DOXORUBICIN;AKR1C3;T;AKR1C3_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;A;AKR1C3_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;T;AKR1C3_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP4F2;A;CYP4F2_GG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP4F11;A;CYP4F11_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP4F2;T;CYP4F2_TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F11;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP4F2;T;CYP4F2_TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP4F2;A;CYP4F2_GG;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F12;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;CFTR_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;CFTR_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;CFTR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
ADALIMUMAB;TNF;AG;TNF_AG;METABOLISM/PK;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TNF;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;TNF;AA + AG;TNF_AG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TNF;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;VKORC1;C;VKORC1_C;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;VKORC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;NFATC2;T;NFATC2_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NFATC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLC22A3;G;SLC22A3_G;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC22A3;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP4F2;CT;CYP4F2_TT;OTHER;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;CAUTION_DRUG_ACCUMULATION
BUPROPION;POR;AG + GG;POR_AG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN_K_AND_ANALOGUES;CYP4F2;CT + TT;CYP4F2_TT;OTHER, METABOLISM/PK;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;WBP2NL;AG + GG;WBP2NL_AA;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP2D6;AA + AG;CYP2D6_GG;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;A;CYP2C9_A;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;RALGAPA2;GG;RALGAPA2_GG;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DISP1;TT;DISP1_TT;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SPAG16;CC;SPAG16_CC;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DISP1;GG;DISP1_GG;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;TXLNB;CC;TXLNB_CC;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ZNF890P;AA;ZNF890P_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;NAF1;AA;NAF1_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ECHDC1;AA;ECHDC1_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ZBED5;GG;ZBED5_GG;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DHRS4L1;GG;DHRS4L1_GG;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;KCNQ3;AA;KCNQ3_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;AMPH;CC;AMPH_CC;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;STXBP4;AA;STXBP4_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ADCYAP1;AA;ADCYAP1_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CHD2;TT;CHD2_TT;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;RGMA;GG;RGMA_GG;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;UGT1A1;AG;UGT1A1_AA;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;AG;UGT1A1_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;T;SLCO2B1_T;METABOLISM/PK;DECREASED;UPTAKE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2C19;A;CYP2C19_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOCISTEINE;PAH;G;PAH_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_CT;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;DPYD_CC;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC_ACID;UGT1A6;C;UGT1A6_AC + CC;METABOLISM/PK;INCREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;UGT1A1;GG + GT;UGT1A1_GG;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;GG + GT;UGT1A1_GG;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
CALCIUM;RYR1;AG;RYR1_AG;OTHER;INCREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;XRCC4;T;XRCC4_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;XRCC4;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UGT1A9;T/del + TT;UGT1A9_T/del + del/del;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;AG;CYP3A4_AA + AG;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;XRCC4;G;XRCC4_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ERCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;TCL1A_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ERCC1;A;ERCC1_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ERCC1;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;TCL1A;A;TCL1A_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;TCL1A_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;T;T;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CETP;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;TCL1A;G;TCL1A_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;G;TCL1A_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;TCL1A_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;G;TCL1A_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;TCL1A_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;TCL1A_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;A;G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;A;G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;A;G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLC22A3;AA;SLC22A3_AA;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC22A3;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;G;G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;PROM1;CC;PROM1_CC;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PROM1;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;GENE_NOT_SPECIFIED;G;G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;C;C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;C;C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;G;C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;C;C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;G;C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;MTHFR;GG + GT;MTHFR_TT;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESTRADIOL;TCL1A;G;TCL1A_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;RARG;A;RARG_AA;OTHER;DECREASED;PROTEIN_STABILITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;RARG;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A9;T/del + TT;UGT1A9_T/del + del/del;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NRP2;C;NRP2_C;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;UGT1A9;T/del + TT;UGT1A9_T/del + del/del;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A9;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;AG;RYR1_AG;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIMAZOLAM;CES1;T;CES1_CT;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;T;RYR1_CT;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;CT;CES1_CT;EFFICACY;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CES1;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
L-PHENYLALANINE;PAH;T;PAH_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
CARBOCISTEINE;PAH;T;PAH_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;OPRM1;G;OPRM1_AA;EFFICACY;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;OPRM1;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
CARBOCISTEINE;PAH;C;PAH_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;C;PAH_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTM1;C;GSTM5_C;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOCISTEINE;PAH;A;PAH_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;A;PAH_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;A;SLCO2B1_A;METABOLISM/PK;DECREASED;UPTAKE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;A;SLCO2B1_A;METABOLISM/PK;DECREASED;UPTAKE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SOD2;G;SOD2_AA + AG;TOXICITY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT2B10;GT + TT;UGT2B10_T;METABOLISM/PK;DECREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;NOS3;GT + TT;NOS3_GG + GT;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NOS3;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;IL7;AA + AG;IL7_AA + AG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL7;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOCISTEINE;PAH;T;PAH_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;T;PAH_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PAH;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;UGT2B7;A;UGT2B7_AA;METABOLISM/PK;INCREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A5;CC;CYP3A5_CC;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;A;DPYD_AT + TT;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUG_NOT_SPECIFIED;DPYD;T;DPYD_AT + TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;CYP3A4;C;CYP3A4_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;PACSIN2;CT + TT;PACSIN2_CT + TT;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;UGT1A4;CC;UGT1A_CG + GG;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A4;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;AG;CYP19A1_AA;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP19A1;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;CT;CYP19A1_TT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP19A1;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;G;CYP2C19_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UGT1A1;CG;UGT1A1_CG;METABOLISM/PK;DECREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;UGT1A9;TT;UGT1A9_CT + TT;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;DCTD;C;DCTD_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DCTD;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;CT + TT;UGT1A9_CT + TT;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;UGT1A9;CT + TT;UGT1A9_CT + TT;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A9;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;AA;UGT1A9_AA;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;CYP2C19_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;C;CDA_AA;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ABCC4;TT;ABCC4_CT + TT;TOXICITY, METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUG_NOT_SPECIFIED;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;G;DPYD_AG + GG;METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;C;DPYD_CC;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;NT5E;A;NT5E_A;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NT5E;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ARNT;GG;ARNT_GG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;GENE_NOT_SPECIFIED;CC;CC;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;E2F7;CC;E2F7_CC;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;CC;CC;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;USP7;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;PPARA;AA;PPARA_AA + AG;METABOLISM/PK;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C9;C;CYP2C9_C;OTHER;DECREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C9;C;CYP2C9_C;OTHER;DECREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;UGT1A1;A;UGT1A1_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP3A4;TT;CYP3A4_CT + TT;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2B6;TT;CYP2B6_GT;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;YEATS4;CC;YEATS4_C;METABOLISM/PK;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;YEATS4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;YEATS4;CC;YEATS4_C;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;YEATS4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NQO1;A;NQO1_A;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NQO1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NQO1;AA;NQO1_A;OUTCOME_NOT_SPECIFIED;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NQO1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;T;DPYD_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;A;DPYD_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;G;DPYD_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;T;DPYD_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;A;SLCO1B3_AA;OTHER;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;ABCC11;AA + AG;ABCC11_AA + AG;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC11;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, HALOTHANE;RYR1;CT;RYR1_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;GT;RYR1_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;CT;RYR1_CT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;AG;RYR1_A;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;CT;RYR1_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DRUG_NOT_SPECIFIED;VDR;T;VDR_T;OTHER;INCREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;T;DPYD_CT + TT;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;T;DPYD_T;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;G;DPYD_AG + GG;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;del;DPYD_del;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
CEFOTAXIME;SLC22A8;A;SLC22A8_A;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;NCOA1;T;NCOA1_CT;OUTCOME_NOT_SPECIFIED;INCREASED;HALF-LIFE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NCOA1;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;NCOA1;T;NCOA1_CT;OUTCOME_NOT_SPECIFIED;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NCOA1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;A2M;T;A2M_TT;METABOLISM/PK;INCREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;A2M;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUG_NOT_SPECIFIED;F12;G;F12_GG;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;F12;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;C;C;TOXICITY, OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MIRLET7I;CAUTION_SIDE_EFFECT
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;C;C;TOXICITY, OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TRAF1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;CT;DPYD_CT + TT;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC9;T;ABCC9_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC9;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLCO1B1;C;SLCO1B1_TT;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO1B1;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;UGT1A3;T;UGT1A3_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A3;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;CYP3A5;A;CYP3A5_A;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;IMPDH2;A;IMPDH2_A;OTHER;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IMPDH2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ORMDL3;AG + GG;ORMDL3_AG + GG;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ORMDL3;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC2;T;ABCC2_CT + TT;OUTCOME_NOT_SPECIFIED;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;RYR1_T;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CYP3A5;C;CYP3A5_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;A;RYR1_A;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;RYR1_A;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;RYR1_A;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;RYR1_T;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;G;RYR1_AG;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE;SLC17A3;A;SLC17A3_A;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC17A3;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;A;SLC17A3_A;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC17A3;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;A;SLC17A3_A;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC17A3;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;T;SLC17A3_T;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC17A3;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;C;CES1_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;G;CES1_G;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;A;CES1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;T;CES1_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;C;CES1_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;A;CES1_A;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CYTARABINE;NT5C2;G;NT5C2_G;EFFICACY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NT5C2;G;NT5C2_G;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NT5C2;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;NT5C2;GG;NT5C2_GG;EFFICACY;DECREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NT5C2;GG;NT5C2_GG;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NT5C2;LIKELIHOOD_THERAPEUTIC_FAILURE
AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;T;ABCB1_CT + TT;METABOLISM/PK;DECREASED;TRANSPORT;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A;CC;UGT1A_CT + TT;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A;CAUTION_DRUG_ACCUMULATION
CHLOROCRESOL;RYR1;T;RYR1_T;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;RYR1;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARACHIDONIC_ACID;CYP4F2;G;CYP4F2_G;PD;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
ARACHIDONIC_ACID;CYP4F2;T;CYP4F2_TT;PD;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
ARACHIDONIC_ACID;CYP4F2;A;CYP4F2_A;PD;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, HALOTHANE;RYR1;CT;RYR1_CT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT1A;CC;UGT1A_CG + GG;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;CT;DPYD_CT;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC;DPYD_CC;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A;CC;UGT1A_CG + GG;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;CT;DPYD_CT;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, CHLOROCRESOL;RYR1;T;RYR1_G;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLCO1A2;T;SLCO1A2_T;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLCO1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
ALDOSTERONE, INSULIN_RECOMBINANT;SCNN1B;A;SCNN1B_A;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SCNN1B;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;BCL2L11;T;BCL2L11_CC;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;BCL2L11;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;IL11;CT + TT;IL11_CT + TT;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IL11;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;C;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UMPS;C;UMPS_CC;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UMPS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROMOMYCIN;MT-RNR1;G;MT-RNR1_G;PD;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MT-RNR1;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A4;G;UGT1A4_GG + GT;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A4;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, CHLOROCRESOL;RYR1;G;RYR1_G;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP1A2;AA + AC;CYP1A2_AA;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;EGFR;TT;EGFR_GT + TT;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;EGFR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;GENE_NOT_SPECIFIED;GG;GG;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;GG;GG;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;TT;TT;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;SEPTIN3, WBP2NL;G;SEPTIN3, WBP2NL_G;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;PHETA2, SMDT1;G;PHETA2, SMDT1_G;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;GENE_NOT_SPECIFIED;TT;TT;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;G;SEPTIN3, WBP2NL_G;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
TERFENADINE;CYP2J2;A;CYP2J2_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;C;CES1_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;A;CES1_A;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
17BETA-ESTRADIOL_GLUCURONIDE;ABCC4;T;ABCC4_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;ABCC4;C;ABCC4_C;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL_GLUCURONIDE;ABCC4;T;ABCC4_T;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL_GLUCURONIDE;ABCC4;T;ABCC4_T;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL_GLUCURONIDE;ABCC4;A;ABCC4_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;TBXAS1;AA;TBXAS1_AA;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TBXAS1;LIKELIHOOD_THERAPEUTIC_FAILURE
EBASTINE, TERFENADINE;CYP2J2;A;CYP2J2_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;G;RYR1_G;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;TBXAS1;AA;TBXAS1_AA;OTHER;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TBX2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;PHETA2, SMDT1;G;PHETA2, SMDT1_G;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC4;A;ABCC4_AA;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CCND1;AA + AG;CCND1_AA;OTHER;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CCND1;LIKELIHOOD_THERAPEUTIC_SUCCESS
EBASTINE, TERFENADINE;CYP2J2;A;CYP2J2_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;AT;DPYD_A;OTHER;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GSK3B;A;GSK3B_AA;OUTCOME_NOT_SPECIFIED;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;GSK3B;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;FCER2;GG;FCER2_G;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;FCER2;LIKELIHOOD_THERAPEUTIC_FAILURE
GENTAMICIN;MT-RNR1;T;MT-RNR1_T;PD;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MT-RNR1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;MIR27A;CC;MIR27A_C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MIR27A;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ADRB2;G;ADRB2_AA;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ADRB2;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLOROCRESOL;RYR1;T;RYR1_T;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;T;RYR1_T;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROMOMYCIN;MT-RNR1;T;MT-RNR1_T;PD;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
CISPLATIN, IRINOTECAN;UBE2I;CG;UBE2I_CG;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SAE1;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;CYP2B6_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;A;CYP2B6_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, CHLOROCRESOL;RYR1;A;RYR1_A;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;ABCB1;AA;ABCB1_C;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCB1;AA;ABCB1_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCB1;AA;ABCB1_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;CYP2B6_G;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;CYP2B6_G;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TNFRSF11B;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;PLG;G;PLG_G;METABOLISM/PK;DECREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PRSS55;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;PLG;G;PLG_G;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PLG;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;C;C;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;VKORC1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GCLC;CC;GCLC_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;GCLC;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A4;A;CYP3A4_A;OUTCOME_NOT_SPECIFIED;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;AA;AA;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AGPAT2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SQSTM1;C;SQSTM1_C;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SQSTM1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;SLC22A3;C;SLC22A3_C;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC22A3;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;MGMT;G;MGMT_G;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MGMT;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;KDR;G;KDR_G;OTHER;DECREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;KDR;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GSTT1;T;GSTT1_T;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;GSTT1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;AG;AG;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCC11;C;ABCC11_C;METABOLISM/PK;INCREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCC11;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;NAT2;A;NAT2_A;OTHER;DECREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NAT2;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;C;CYP2A6_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;T;CYP2C9_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;CAUTION_DRUG_ACCUMULATION
PAROMOMYCIN;MT-RNR1;G;MT-RNR1_G;PD;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MT-RNR1;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE_ANALOGUES;TPMT;CT;TPMT_C;OTHER, METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;SLC28A3;AA;SLC28A3_AA;TOXICITY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PURINE_ANALOGUES;PACSIN2;C;PACSIN2_CT + TT;OTHER, METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;G;CYP2B6_G;METABOLISM/PK;INCREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;T;CYP2A6_T;METABOLISM/PK;DECREASED;METABOLISM;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
QUINIDINE;KCNH2;T;KCNH2_C;EFFICACY;DECREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;A;CYP2C19_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
IVACAFTOR/LUMACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR, NPPB;CFTR;A;CFTR_A;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESLICARBAZEPINE_ACETATE;AADAC;G;AADAC_G;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
ESLICARBAZEPINE_ACETATE;AADAC;A;AADAC_A;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;A;RYR1_A;DOSAGE;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ESLICARBAZEPINE_ACETATE;AADAC;A;AADAC_A;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
ESLICARBAZEPINE_ACETATE;AADAC;G;AADAC_G;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;A;RYR1_A;DOSAGE;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE;RYR1;A;RYR1_A;DOSAGE;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DISOPYRAMIDE;KCNH2;T;KCNH2_C;EFFICACY;DECREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
DISOPYRAMIDE;KCNH2;C;KCNH2_C;EFFICACY;DECREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINIDINE;KCNH2;C;KCNH2_C;EFFICACY;DECREASED;INHIBITION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR;CFTR;CG;CFTR_CG;PD;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;RYR1_T;DOSAGE;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE;RYR1;T;RYR1_T;DOSAGE;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ESLICARBAZEPINE_ACETATE;AADAC;T;AADAC_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AADAC;CAUTION_DRUG_ACCUMULATION
ESLICARBAZEPINE_ACETATE;AADAC;C;AADAC_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;AADAC;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_AC;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CBR3;A;CBR3_G;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CBR3;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CBR3;A;CBR3_A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CBR3;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;DPYD_A;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;VKORC1;T;VKORC1_CT + TT;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;VKORC1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;DPYD;CT + TT;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;SLC29A1;G;SLC29A1_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC29A1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;SLC29A1;A;SLC29A1_A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SLC29A1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;CT + TT;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;DPYD;CC + CT;DPYD_CC;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;MIR6076;G;MIR6076_GG + GT;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;P2RY12;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;UGT2B17;C;UGT2B17_C;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT2B17;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DPYD;CT;DPYD_CT;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;POR;AA;POR_AG;OTHER, METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;POR;AA;POR_AG;OTHER, METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ABCB1;GG;ABCB1_A;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;CYP2E1;T;CYP2E1_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2E1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP2E1;T;CYP2E1_T;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2E1;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;DPYD_C;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
BUPROPION;POR;GG;POR_AG;OTHER, METABOLISM/PK;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;T;DPYD_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
HALOTHANE, ISOFLURANE;CACNA1S;A;CACNA1S_A;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CACNA1S;T;CACNA1S_T;OTHER;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CACNA1S;T;CACNA1S_T;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CACNA1S;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;A;CYP2D6_A;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;FKBP5;CT;FKBP5_CT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;NR3C1;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;T;CYP2D6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;G;CYP2D6_G;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;T;CYP2D6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;HSPA5;TT;HSPA5_TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HSPA5;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;T;CYP2D6_T;METABOLISM/PK;DECREASED;CLEARANCE;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;POR;AG;POR_AG;EFFICACY;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE_TRIPHOSPHATE;SLC28A3;CC;SLC28A3_CC;METABOLISM/PK;INCREASED;FORMATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;AT;TPMT_AT;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;CT;TPMT_C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TPMT;CAUTION_DRUG_ACCUMULATION
VITAMIN_E;CYP4F2;T;CYP4F2_TT;METABOLISM/PK;INCREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
VITAMIN_E;CYP4F2;T;CYP4F2_TT;METABOLISM/PK;INCREASED;STEADY-STATE_LEVEL;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;HPR;G;HPR_G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HP;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;G;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;HP;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;DCK;T;DCK_T;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DCK;LIKELIHOOD_THERAPEUTIC_SUCCESS
XENOBIOTICS;AHR;A;AHR_AA + AG;METABOLISM/PK;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE, XENOBIOTICS;AHR;G;AHR_G;METABOLISM/PK;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1A1;CAUTION_DRUG_ACCUMULATION
VITAMIN_E;CYP4F2;C;CYP4F2_C;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;NHLH1;T;NHLH1_CT + TT;OTHER;INCREASED;LUCIFERASE_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VITAMIN_E;CYP4F2;T;CYP4F2_TT;OTHER;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;CYP2B6_C;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;SEMA6A;A;SEMA6A_A;OTHER;INCREASED;LUCIFERASE_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;CYP2B6_A;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;CYP2B6_T;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2B6;CAUTION_DRUG_ACCUMULATION
ETHANOL;ADH1B;CT + TT;ADH1B_TT;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ADH1B;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;GT;MTHFR_TT;OUTCOME_NOT_SPECIFIED;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TYMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SHMT1;AA;SHMT1_AG;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TYMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FASTKD3, MTRR;AG + GG;FASTKD3, MTRR_AG + GG;OUTCOME_NOT_SPECIFIED;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;TYMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;G;DPYD_G;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP1A2;A;CYP1A2_GG;OUTCOME_NOT_SPECIFIED;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP1A2;A;CYP1A2_AA;OUTCOME_NOT_SPECIFIED;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1A2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP3A4;A;CYP3A4_AA + AG;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP1A2;del;CYP1A2_T;OUTCOME_NOT_SPECIFIED;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
GLYBURIDE;KCNJ11;T;KCNJ11_T;METABOLISM/PK;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;KCNJ11;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;CBR1;GG;CBR1_GG;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CBR1;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;GG;CBR1_GG;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CBR1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;ATP2B1;CT + TT;ATP2B1_CT + TT;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ATP2B1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;IFNL3;C;IFNL3_CC;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;IFNL3;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CETP;GG;CETP_A;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CETP;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;SULT1A1;A;SULT1A1_A;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;C;SULT1A1_C;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;A;SULT1A1_A;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PALBOCICLIB;CDKN2A;C;CDKN2A_C;EFFICACY;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;SULT1A1;T;SULT1A1_T;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;C;SULT1A1_C;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;SULT1A1_T;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;SULT1A1_T;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;A;SULT1A1_A;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;G;SULT1A1_G;METABOLISM/PK;INCREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DESMETHYLNAPROXEN;SULT1A1;G;SULT1A1_G;METABOLISM/PK;INCREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;SULT1A1;T;SULT1A1_T;METABOLISM/PK;INCREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;SULT1A1;G;SULT1A1_G;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;T;SULT1A1_T;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;T;SULT1A1_CT + TT;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UGT1A1;G;UGT1A1_GG;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;T;SULT1A1_T;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;A;SULT1A1_A;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;C;SULT1A1_C;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UGT1A1;T;UGT1A1_CT;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
OXAZEPAM;UGT2B15;A;UGT2B15_AA;OTHER;DECREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;A;SULT1A1_A;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;T;SULT1A1_T;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;G;SULT1A1_G;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;SULT1A1_CT + TT;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;A;SULT1A1_A;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;UGT1A1;A;UGT1A1_AG;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;G;SULT1A1_G;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;G;SULT1A1_G;METABOLISM/PK;INCREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;T;SULT1A1_CT + TT;METABOLISM/PK;DECREASED;SULFATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;G;SULT2B1_G;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;T;SULT2B1_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SULT2B1;CAUTION_DRUG_ACCUMULATION
ESTRADIOL;GENE_NOT_SPECIFIED;GG;GG;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MIR2052;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;GENE_NOT_SPECIFIED;CC;CC;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;MIR2052;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREGNENOLONE;SULT2B1;T;SULT2B1_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;A;SULT2B1_A;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;T;SULT2B1_T;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;A;SULT2B1_A;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;SULT2B1;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2C19;A;CYP2C19_A;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C19;T;CYP2C19_T;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C19;T;CYP2C19_T;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C9;C;CYP2C9_C;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C9;C;CYP2C9_C;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP2C9;T;CYP2C9_T;OTHER;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CYP3A5;TT;CYP3A5_CC;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP3A5;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;HTR1B;C;HTR1B_C;PD;INCREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;cAMP;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;CYP2A6;AA + AG;CYP2A6_AA + AG;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP2A6;AG + GG;CYP2A6_AG + GG;OUTCOME_NOT_SPECIFIED;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CYP2A6;AC + CC;CYP2A6_C;OUTCOME_NOT_SPECIFIED;DECREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;TT;DPYD_CT + TT;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;GG;DPYD_AG + GG;OTHER;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CC;DPYD_AC;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
OXAZEPAM;UGT1A1;A;UGT1A1_AG;OTHER;DECREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXAZEPAM;UGT1A1;G;UGT1A1_GG;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXAZEPAM;GENE_NOT_SPECIFIED;G;UGT1A1_AG;OTHER;DECREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
OXAZEPAM;UGT1A1;T;UGT1A1_CT;OTHER;DECREASED;GLUCURONIDATION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DRUG_ACCUMULATION
DRUG_NOT_SPECIFIED;GENE_NOT_SPECIFIED;G;UGT1A1_AG;OTHER;DECREASED;CONCENTRATIONS;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;PKNOX1;A;PKNOX1_AA;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PKNOX1;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;PKNOX1;A;PKNOX1_AA;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CBS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CBS;C;CBS_TT;OTHER;INCREASED;EXPRESSION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;PKNOX1;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, CHLOROCRESOL;RYR1;T;RYR1_T;METABOLISM/PK;INCREASED;SENSITIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUG_NOT_SPECIFIED;CDA;CC;CDA_TT;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CDA;AA;CDA_G;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;CDA;AA;CDA_AA;OTHER;DECREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CDA;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUG_NOT_SPECIFIED;YAP1;C;YAP1_C;OUTCOME_NOT_SPECIFIED;DECREASED;TRANSCRIPTION;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;YAP1;LIKELIHOOD_THERAPEUTIC_FAILURE
ELEXACAFTOR, TEZACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;A;CFTR_A;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;T;CFTR_T;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;T;CFTR_T;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;T;CFTR_T;EFFICACY;INCREASED;ACTIVITY;EFFECT_SUBCAT_NOT_SPECIFIED;POPULATION_AFFECTED_NOT_SPECIFIED;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;AA + AT;CYP2A6_AT + TT;TOXICITY;DECREASED;RISK;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SACITUZUMAB_GOVITECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;T;CYP3A4_TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:BIPOLAR_DISORDER, OTHER:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;NAT2;A;NAT2_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_REACTIONS;CHILDREN;DISEASE:PNEUMONIA;CAUTION_SIDE_EFFECT
ATORVASTATIN, FLUVASTATIN, HMG_COA_REDUCTASE_INHIBITORS, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HLA-DRB1;*04:06;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA5;T;CHRNA5_T;TOXICITY, OTHER;DECREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;AT + TT;GLP1R_AT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;T;NAT2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;A;NAT2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_AUC24;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
GEFITINIB;ABCG2;GG;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;GLP1R_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR3B;G;HTR3B_G;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ACHIEVING_OPTIMAL_TROUGH_LEVEL;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;UST;A;UST_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_OF_DEPRESSION_SYMPTOMS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;G;CYP3A4_G;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OSIMERTINIB;IL6;CG + GG;IL6_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCLOXACILLIN;HLA-DQB1;*03:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;CT + TT;HTR2A_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*6/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;OTHER:INTERSTITIAL_INFLAMMATORY_CELL_INFILTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;AA + AG;HTR2A_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OXAZEPAM;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:S-OXAZEPAM_GLUCURONIDATION_IN_HUMAN_LIVER_MICROSOMES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
OXAZEPAM;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:OXAZEPAM_ORAL_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ, ISONIAZID;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERCHOLESTEROLEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;PPARA;GG;PPARA_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY, DISEASE:INFECTIOUS_DISEASE, DISEASE:STOMATITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NITROUS_OXIDE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STROKE, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:DEATH;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD3;G;DRD3_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-A;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, PACLITAXEL;GGT1;CC;GGT1_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYROID_PREPARATIONS;HLA-B;*27:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:UTERINE_DISORDER, SIDE_EFFECT:LEIOMYOMA, SIDE_EFFECT:ENDOMETRIAL_HYPERPLASIA, SIDE_EFFECT:POLYPS;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;ABCC11;AA + AG;ABCC11_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:DIFFERENCES_IN_THE_FLUVOXAMINE_PLASMA_LEVEL_AT_50_MG/DAY;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;HLA-DQA1;*05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IDO1;CC;IDO1_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DEPRESSION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;GENE_NOT_SPECIFIED;AA + AG;AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;HLA-DQB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
NITROUS_OXIDE;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;TT;CYP2C19_CT + TT;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;C;CYP3A4_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;ABCB1;AA;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPARAGINASE;ATL2;T;ATL2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;*2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MAXIMAL_PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HIGH_RISK_PATIENTS_(ACUTE_MYOCARIDAL_INFARCTION, DIABETES_E.G.);CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS_(ST)_AFTER_1_YEAR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;A;CYP2C19_A;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;RETN;GG;RETN_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
PRIMAQUINE;MAOA;CC + CT;MAOA_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;TT;CYP2C19_TT;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;GGAGTC;NUDT15_del;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
PRIMAQUINE;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;TT;CYP2C19_CT + TT;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC10;C;ABCC10_CT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:BLOOD_CONCENTRATION/DOSAGE_RATIO;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION/DOSE_RATIO;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
EFAVIRENZ, ISONIAZID;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE, OTHER:PREGNANCY;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME, OTHER:DYSLIPIDAEMIA,OTHER:DIABETES_MELLITUS, OTHER:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY_OR_HEPATOTOXICITY;PEOPLE;OTHER:NEUROLOGICAL_PROBLEMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:DIABETES_MELLITUS,OTHER:ACUTE_CORONARY_SYNDROME, OTHER:DYSLIPIDAEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;A;CYP3A4_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBOPLATIN, PACLITAXEL;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;A;CYP2C19_AA;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
NAN;IFNL4;TT/TT;IFNL4_TT/TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SPONTANEOUS_HCV_CLEARANCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC22A1;del;SLC22A1_del/del;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;GENE_NOT_SPECIFIED;AA + AG;AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:6-MMPN_LEVELS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NAN;SOD1;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;SOD1_GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;OTHER;DECREASED;LIKELIHOOD;OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BONE_MARROW_TOXICITY;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERALL_ADRS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
NAN;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;OTHER:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;OTHER:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER:DISCONTINUATION, OTHER:TREATMENT_MODIFICATION;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER:DISCONTINUATION, OTHER:TREATMENT_MODIFICATION;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HEMATOLOGICAL_INDICES;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;SIDE_EFFECT:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVELS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, PEMETREXED;MTHFR;GG + GT;MTHFR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;TT;CYP2C19_TT;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUFENTANIL;ADRB1;GG;ADRB1_CC;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;SIDE_EFFECT:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC10;G;ABCC10_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MORTALITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:CHRONIC_MYELOMONOCYTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IMATINIB;NR1I2;TT;NR1I2_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:CHRONIC_MYELOMONOCYTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;HTR1A;C;HTR1A_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;G;FASTKD3, MTRR_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TEGAFUR/GIMERACIL/OTERACIL;CYP2A6;*4 + *7 + *9 + *10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL, ROSUVASTATIN;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:P2Y12_REACTION_UNIT(PRU)_VALUES;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;A;CYP3A4_AA + AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
AZATHIOPRINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-C;*07:18;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;CC;ABCB1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DQB1;*06:09;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RISK;SIDE_EFFECT:THROMBOEMBOLISM;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ENDOMETRIAL_HYPERPLASIA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CLOPIDOGREL_RESISTANCE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;A;MTHFD1_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;T;CYP3A4_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;CD274;AG + GG;CD274_AG + GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;CD274;CC + CG;CD274_CC + CG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN;CD274;GT + TT;CD274_GT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE, MORPHINE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PRURITUS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN;NCF4;AA + AG;NCF4_AG + GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATION;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATION;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;CT + TT;CBR1_CT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DRB1;*04:04;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;CG + GG;CBR1_CG + GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY_BY_P2Y12_REACTION_UNITS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;CES1_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE, QUETIAPINE, RISPERIDONE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DIZZINESS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOEMBOLISM;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, PLATINUM;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PERCENTAGE_OF_DAYS_ABSTINENT_AND_LOWER_NUMBER_OF_DRINKS_PER_DRINKING_DAY;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;CBR3;AA + AG;CBR3_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;ABCC2;AA + AG;ABCC2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;T;SLC19A1_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:WORSE_PROGNOSES;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*11;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
GEMCITABINE, PLATINUM_COMPOUNDS;RRM1;C;RRM1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_PROBABILITY;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC;SLC19A1_TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;HTR2A;CC + TT;HTR2A_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TREMOR, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE;HLA-B;*15:18;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ASTHENIA, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, PACLITAXEL;TYMS;TTAAAGTTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;PTPN2;C;PTPN2_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:LUPUS_ERYTHEMATOSUS,OTHER:AUTOIMMUNE_DISEASES;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;A;SHMT1_AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034);PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA;MTHFD1_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;CT + TT;CYP2D6_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AA;GSTP1_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;TPMT;C;TPMT_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GI_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;T;SLCO1B1_T;TOXICITY;INCREASED;RISK;DISEASE:MUCOSITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;ERAP1, ERAP2;G;ERAP1, ERAP2_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;PTPN22;A;PTPN22_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;G;TYMS_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TYMS;C;ENOSF1, TYMS_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;G;ENOSF1, TYMS_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NME1, NME1-NME2;TT;NME1, NME1-NME2_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
RIVAROXABAN;SUSD3;TT;SUSD3_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
NAN;CYP3A5, ZSCAN25;CC;CYP3A5_CC;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;G;SLCO1B1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GI_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-A;*02:07;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;FCER1G;AA;FCER1G_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LAPATINIB;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;MS4A2;AG + GG;MS4A2_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANCE_OF_POSITIVE_RESPONSE_TO_PACLITAXEL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;FECH;CC;FECH_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;FCER1G;AG + GG;FCER1G_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, RADIOTHERAPY;EPHX1;CT + TT;EPHX1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, RADIOTHERAPY;ERCC2;GG + GT;ERCC2_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS, OTHER:LUNG_NEOPLASMS,OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, RADIOTHERAPY;ERCC2;CT + TT;ERCC2_CT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS, OTHER:LUNG_NEOPLASMS,OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE, PLATINUM_COMPOUNDS;CDA;C;CDA_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:NAUSEA;PEOPLE;DISEASE:MESOTHELIOMA;CAUTION_SIDE_EFFECT
NAN;CYP2A6;*4/*4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;CYP3A5;AA;CYP3A5_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;SLC28A3;AA;SLC28A3_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:GASTRIC_PH;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;DOSAGE, OTHER;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;TTAAAGTTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THROMBOCYTOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;C;SLCO1B1_TT;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPARAGINASE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:CHRONIC_KIDNEY_FAILURE;PEOPLE;DISEASE:GLOMERULONEPHRITIS, IGA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUCCINYLCHOLINE, VOLATILE_ANESTHETICS;RYR1;G;RYR1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;EGFR;GG;EGFR_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE, PLATINUM_COMPOUNDS;RRM1;A;RRM1_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NAUSEA;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE, PLATINUM_COMPOUNDS;RRM1;C;RRM1_C;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NAUSEA;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VERAPAMIL;ADRB1;AA + AG;ADRB1_AG + GG;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
HEROIN;DRD2;G;DRD2_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
REPAGLINIDE;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:REPAGLINIDE_AUC;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAEMATOPOIETIC_TOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A7;C;CYP3A7_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;A;CYP2C19_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*3/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;G;CYP3A4_AA + AG;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ISONIAZID, RIFAMPIN;NAT2;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;SOD2;GG;SOD2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CYP1A2;AC + CC;CYP1A2_AA;OTHER;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;OTHER:INCREASED_COFFEE_INTAKE;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;HLA-B;*39:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
TRASTUZUMAB;ERBB2;AG + GG;ERBB2_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;CYP2C9_CT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BETA_BLOCKING_AGENTS;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;ADRA2C_GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
PACLITAXEL;FZD3;A;FZD3_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;TYMS;TTA/TTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SERTRALINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB1;*04:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DIRECT_ACTING_ANTIVIRALS;IFNL3, IFNL4;TT;IFNL3_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEPATOCELLULAR_CARCINOMA;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLYBURIDE;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;DISEASE:HYPOGLYCEMIA;PEOPLE;DISEASE:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*5/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, BETA_BLOCKING_AGENTS, CLOPIDOGREL, HMG_COA_REDUCTASE_INHIBITORS;NOS3;T;NOS3_GG + GT;OTHER;INCREASED;RISK;OTHER:IN-STENT_RESTENOSIS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;UGT1A1;AA;UGT1A1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTHRACYCLINES_AND_RELATED_SUBSTANCES, TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C9;AC + CC;CYP2C9_AC + CC;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;C;CYP3A4_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;UGT1A1;AA;UGT1A1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;OTHER:EPILEPSY, OTHER:MOOD_DISORDER,OTHER:NEUROPATHIC_PAIN;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_CONTROL_RATE_AND_LOWER_OVERALL_SURVIVAL_RATE;PEOPLE;OTHER:METASTATIC_BREAST_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CLOPIDOGREL_ACTIVE_METABOLITE_LEVEL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ACHIEVING_TARGET_CONCENTRATIONS;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:POST-TREATMENT_ADP-STIMULATED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP3A5;C;CYP3A5_CC;TOXICITY;DECREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HOT_FLASHES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;HLA-DQB1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DPB1;*10:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DRB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HLA-DPB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*6/*6;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:GOUTY_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;CPT1A, IGHMBP2;T;CPT1A, IGHMBP2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_BLOOD_LEVELS;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;C;CYP3A4_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:CREATININE_CLEARANCE;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AGE-RELATED_DECLINE_IN_FLECAINIDE_CLEARANCE_PATIENTS_TREATED_WITH_ORAL_FLECAINIDE_FOR_SUPRAVENTRICULAR_TACHYARRHYTHMIAS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRANILAST;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:MYOCARDIAL_ISCHEMIA;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ORAL_CLEARANCE_(CL/F)_OF_FLECAINIDE_IN_PATIENTS_WITH_SUPRAVENTRICULAR_TACHYARRHYTHMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTITHYROID_PREPARATIONS;HLA-DRB1;*08:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;HLA-DQA1;*01:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;HLA-DQB1;*06:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;AT;DPYD_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;ABCB1;CC;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:3_YEAR_EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP1A2;A;CYP1A2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;T;OPRM1_T;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;C/T + T/T;CYP3A4_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:ACUTE_CELLULAR_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RHODAMINE_123;ABCB1;GG;ABCB1_A;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EFFLUX_OF_RHODAMINE_FROM_CD56+_NATURAL_KILLER_CELLS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;AC;PEAR1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:STROKE;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*68:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PAIN;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TETANUS_ANTITOXIN;HLA-A;*02:06;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*24:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*24:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-B;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VANCOMYCIN;HLA-A;*32:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*14:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:13;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;TPMT;*3A + *3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLINDAMYCIN;HLA-B;*15:27;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*38:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-B;*39:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*40:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:S-MIRTAZAPINE_PLASMA_LEVELS_IN_NON-SMOKERS_AT_DAY_14_OF_TREATMENT;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
CLINDAMYCIN;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ISONIAZID;HLA-B;*52:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*4 + *5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATIONS_OF_S(+)-MIRTAZAPINE, _MIRTAZAPINE_S(+)/R(-)_RATIOS_AND_S(+)-N-DESMETHYLMIRTAZAPINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;A;OPRM1_A;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;*1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-C;*07:27;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-C;*12:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;HLA-DPB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-C;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2J2;AA + AC;CYP2J2_AA + AC;TOXICITY;INCREASED;RISK;DISEASE:NAUSEA, DISEASE:VOMITING;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DQB1;*03:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-DQB1;*03:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DQB1;*05:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUPIRTINE;HLA-DQB1;*05:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATITIS;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
HYDRALAZINE;HLA-DRB1;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LUPUS_ERYTHEMATOSUS_DUE_TO_HYDRALAZINE;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-DRB1;*04:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASPARAGINASE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;AA;SOCS3_AG;TOXICITY;DECREASED;RISK;DISEASE:THROMBOCYTOPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LDLR;G;LDLR_G;EFFICACY;INCREASED;RISK;DISEASE:CORONARY_DISEASE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DRB1;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUPIRTINE;HLA-DRB1;*16:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
THALIDOMIDE;GSTT1;AA;GSTT1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
MINOCYCLINE;HLA-B;*35:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROTHROMBIN_TIME_(PT)_AT_INDUCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:KIDNEY_DISORDER;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CALCINEURIN_INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:KIDNEY_DISORDER;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;*2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HIGH_RISK_PATIENTS_(ACUTE_MYOCARIDAL_INFARCTION, DIABETES_E.G.);CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PACLITAXEL, PLATINUM_COMPOUNDS;NAT2;AA;NAT2_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:INTAKE;WOMEN;DISEASE:PREGNANCY;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GNB3;CT + TT;GNB3_CC;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;HMGCR;AA;HMGCR_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:HMGCRV_1_EXPRESSION_AND_AN_INCREASE_IN_THE_EXPRESSION_OF_THE_FULL-LENGTH_TRANSCRIPT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATAZANAVIR, RITONAVIR;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PRIMARY_GRAFT_FAILURE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;CHILDREN;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;T/del + TT;ADORA2A_T/del + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:BRONCHOPULMONARY_DYSPLASIA;INFANTS;OTHER:APNEA_OF_PREMATURITY, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;DHFR;del/del;DHFR_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SERUM_AND_RED_BLOOD_CELL_FOLATE_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;UGT1A1;AA;UGT1A1_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;SEVERITY;EFFICACY:DEPRESSION;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;SEVERITY;EFFICACY:ANXIETY_DISORDERS;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METABOLISM;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
COCAINE, ETHANOL, OPIOIDS;OPRM1;A;OPRM1_A;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS,OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
COCAINE, ETHANOL, OPIOIDS;OPRM1;G;OPRM1_G;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INTERFERON_BETA-1A, INTERFERON_BETA-1B;HLA-DQA1;G;HLA-DQA1_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTI-IFN-BETA_ANTIBODIES;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS,OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLCO1B1;*37/*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;EGFR;A;EGFR_AA + AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:CYTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATAZANAVIR, RITONAVIR;UGT1A1;*28/*28 + *1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
INTERFERON_BETA-1A, INTERFERON_BETA-1B;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTI-IFN-BETA_ANTIBODIES;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGASPARGASE;HLA-DRB1;*16:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;RISK;EFFICACY:CNS_RELAPSE, EFFICACY:HEMATOLOGIC_RELAPSE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;G;RRM1_GG;TOXICITY;DECREASED;RISK;DISEASE:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;PD;DECREASED;LIKELIHOOD;OTHER:TIME_TO_THERAPEUTIC_INR;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;T;OPRM1_T;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DQB1;*02:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR, MSH3;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;DHFR_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;ENOSF1, TYMS;TTA/TTA + TTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED;LIKELIHOOD;OTHER:COVID-19;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE, TACROLIMUS;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_EMERGENT_MANIA;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
NAN;ACE;del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, BETA_BLOCKING_AGENTS, CLOPIDOGREL, HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;A;A;OTHER;INCREASED;RISK;OTHER:IN-STENT_RESTENOSIS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_EMERGENT_MANIA;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANAKINRA, CANAKINUMAB, RILONACEPT, TOCILIZUMAB;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;OTHER:JUVENILE_RHEUMATOID_ARTHRITIS, OTHER:ADULT-ONSET_STILL_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;GG;IFNL4_TT/TT;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:_APPARENT_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUCLOXACILLIN;HLA-B;*57:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3B + *3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
PREDNISONE, TACROLIMUS;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;RISK;OTHER:REMAINING_ON_STEROIDS_AT_1_YEAR_AFTER_TRANSPLANTATION;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ORAL_CLEARANCE_(CL)_OF_ATAZANAVIR;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;EGFR;T;EGFR_GT + TT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:CYTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC_AGENTS;TYMS;TTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*74:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:07;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LOW_LEUKOCYTE_COUNTS;PEOPLE;DISEASE:RHEUMATIC_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TREATMENT_DURATION;PEOPLE;DISEASE:RHEUMATIC_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ATORVASTATIN, PRAVASTATIN;APOE;CC + CT;APOE_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_C-REACTIVE_PROTEIN_(CRP);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTM1;null/null;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:THROMBOTIC_DISEASE, EFFICACY:SUDDEN_CARDIAC_DEATH, EFFICACY:MYOCARDIAL_INFARCTION;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA;OPRM1_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:METABOLISM_OF_TRAMADOL_AND_DECREASED_RESPONSE_TO_TRAMADOL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*12:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*04:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:INTRAGASTRIC_PH;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*46:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-DRB1;*09:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DQA1;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
TICAGRELOR;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION_INHIBITION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-DRB1;*08:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-C;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*04:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*11;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;AA;ABCB1_A;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_BLOOD_CONCENTRATION;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_DOSE_ADJUST
NAN;TMPRSS2;CC;TMPRSS2_CC;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAPATINIB;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR/RITONAVIR;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;ABCB1_C;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_BLOOD_CONCENTRATION;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_SERUM_CONCENTRATIONS_OF_SERTRALINE_AND_N-DESMETHYL_SERTRALINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;G;CYP3A4_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:FLUVOXAMINE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_TIME-PLASMA_CONCENTRATION_CURVE_(AUC(0-24));POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;DECREASED;RISK;DISEASE:CORONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*55:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:INHIBITION_OF_METABOLISM;PEOPLE;DISEASE:BACK_PAIN;CAUTION_DOSE_ADJUST
LAMOTRIGINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;T;CYP3A4_CT + TT;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;RPL13, SNORD68, SPG7;G;RPL13, SNORD68, SPG7_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;CHST3;A;CHST3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:DEPRESSION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;A;CYP3A4_A;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ETHANOL, OPIOIDS;OPRM1;T;OPRM1_T;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;NAT2;G;NAT2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
DOCETAXEL, THALIDOMIDE;CYP4B1;T;CYP4B1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*07:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-C;*07:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;GSTM1;null/null;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:ACQUIRED_IMMUNODEFICIENCY_SYNDROME;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FATIGUE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;GGGAGCTGG/del + del/del;DHFR_GGGAGCTGG/del + del/del;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;CC;OPRM1_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE, R-5-HYDROXYOMEPRAZOLE_AND_S-5-HYDROXYOMEPRAZOLE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:LEUKOCYTES_AND_NEUTROPHILS;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
ALPRAZOLAM;CYP3A4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
DOCETAXEL;VEGFA;del/del;VEGFA_del/del;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ADVERSE_EFFECT_BURDEN;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:ADENOCARCINOMA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;MEN;OTHER:ALCOHOLIC_PSYCHOSIS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;HLA-DPB1;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN;DPYD;Reference;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;DAOA;T;DAOA_T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;CHILDREN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE, OMEPRAZOLE_SULFONE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:HIGHER_STABLE_DOSE_LEVELS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;OPRM1;C;OPRM1_G;TOXICITY;DECREASED;RISK;OTHER:METHAMPHETAMINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*02:06;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-B;*44:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE, OMEPRAZOLE_SULFONE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;HLA-C;*14:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;A;CYP3A4_AA;OTHER;DECREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CLOPI-H4_CONCENTRATIONS_AFTER_300_OR_900_MG_CLOPIDOGREL_LOADING_DOSE;MEN;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;APOE;CT + TT;APOE_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATENOLOL, HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VERAPAMIL;GRK5;AT + TT;GRK5_AT + TT;OTHER;DECREASED;RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES;PEOPLE;OTHER:HYPERTENSION_AND_CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:LEPROSY;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;CC;BDNF, BDNF-AS_CC;TOXICITY;DECREASED;SEVERITY;OTHER:METHAMPHETAMINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;ABCB1_A;EFFICACY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:DELAYED_GRAFT_FUNCTION;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTICHOLINERGIC_AGENTS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_ANTICHOLINERGIC_ACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:FORMATION_OF_METABOLITES;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HUMAN_LIVER_MICROSOMES;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
NAN;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;OTHER:ASTHMA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;OTHER:ASTHMA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;DAOA;A;DAOA_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:NEUROBLASTOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:NEUROBLASTOMA;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-DQB3;C;HLA-DQB3_C;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;MTHFR;GG;MTHFR_GG;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN;UGT1A1;*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;GGAGTC;NUDT15_del;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:AUTOIMMUNE_DISEASES, OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;MTHFR;CC;MTHFR_CC;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NAN;G6PD;T;G6PD, IKBKG_TT;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROTECTION_AGAINST_SEVERE_MALARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;T;PERP_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*3A + *3B + *3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC1;GG;ERCC1_AA;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR/RITONAVIR;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:JAUNDICE;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, RADIOTHERAPY;GSTM1;null/null;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;OTHER:DEATH, OTHER:RECURRENCE;WOMEN;DISEASE:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA_BLOCKING_AGENTS, CALCIUM_CHANNEL_BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:USE;PEOPLE;OTHER:CHRONIC_MIGRAINE;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA_BLOCKING_AGENTS, CALCIUM_CHANNEL_BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:USE;PEOPLE;DISEASE:MIGRAINE_WITH_AURA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:C/D_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAZOPANIB;UGT1A1;*28 + *37 + *6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;A;CYP3A4_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CC;VKORC1_CT + TT;OTHER;INCREASED;LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PPP2R5D;C;PPP2R5D_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;PEOPLE;DISEASE:CEREBROVASCULAR_DISORDERS;CAUTION_SIDE_EFFECT
ATAZANAVIR/RITONAVIR, LAMIVUDINE, ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE, OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CCNK;G;CCNK_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;SCN1A_CC;EFFICACY;INCREASED;RISK;EFFICACY:DISCONTINUATION;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;CHRNB2;GG;CHRNB2_A;NAN;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;PLIN1;CT + TT;PLIN1_CT + TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;ABCC1;GG + GT;ABCC1_GG + GT;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;DISEASE:PAIN;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;LRP5;T;LRP5_T;NAN;INCREASED;RISK;OTHER:OSTEOPOROTIC_FRACTURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;PIK3R2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_OF_CITALOPRAM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DRUGS_USED_IN_NICOTINE_DEPENDENCE;COMT;AA;COMT_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;ANKK1;AA + AG;DRD2_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;OTHER:FEMALE_GENDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALGANCICLOVIR;ABCC4;AC;ABCC4_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;NFATC1;CC;NFATC1_CC;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP2C8;A;CYP2C8_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;AA;PEAR1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DELAYED_GRAFT_FUNCTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:21;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;G;COMT_AA;TOXICITY, OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_PSYCHOTIC_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;SIDE_EFFECT:EPILEPSY;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:BOSENTAN_METABOLISM_IN_VITRO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:BOSENTAN_METABOLISM_IN_VITRO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN;TNF;GG;TNF_AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*44:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;G/TT + GG;IFNL4_TT/TT;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE_IN_JAPANESE_PATIENTS_WITH_WITH_CHRONIC_GENOTYPE_1_HCV_INFECTION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR), PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*02:07;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;OTHER:RECURRENCE;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_BASED_ON_HAM-D_SCORE_PERCENTAGE_REDUCTION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR__BUT_NOT_MINOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;T;SLCO1B1_T;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR__BUT_NOT_MINOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CODEINE, TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:PAIN;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOSENTAN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;OTHER:TUBULAR_VACUOLAR_DEGENERATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_LEVELS;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;DISEASE:INTERSTITIAL_FIBROSIS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:C/D_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY_AFTER_9MONTH_OF_TREATMENT;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;PK:ACUTE_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:DELAYED_GRAFT_FUNCTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:BLOOD_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;BDKRB2_(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA, SIDE_EFFECT:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CODEINE, TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNE1;T;KCNE1_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;del/del;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACEI-RELATED_COUGH;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;del/del;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;RGS2;TC/del + del/del;RGS2_TC/del + del/del;OTHER;INCREASED;RISK;DISEASE:HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*14:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;T;CBR3_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;RISK;DISEASE:STOMATITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*30:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*13:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:27;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:19;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*48:04;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
RALOXIFENE;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_MINERAL_DENSITY;WOMEN;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DQB1;*03:02;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;DECREASED;SEVERITY;DISEASE:ASPIRIN-INDUCED_ASTHMA;PEOPLE;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*27:09;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCB1;AG;ABCB1_A;OTHER;INCREASED;RISK;OTHER:DISEASE_RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*58:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;CC;IFNL3_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;TT;PEAR1_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;HLA-C;*02:10;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;ABCC1;AA + AG;ABCC1_AA + AG;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;MIR27A;CT;MIR27A_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BUPROPION;CYP2B6;TT;CYP2B6_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;OTHER:FEMALE_GENDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53AIP1;T;TP53AIP1_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, SULFASALAZINE;CYP2D6;*3 + *4;GENOTYPE_NOT_SPECIFIED;DOSAGE, TOXICITY;INCREASED;LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS;CHILDREN;SIDE_EFFECT:RUSSITIS;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;TT;PEAR1_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_IMPROVE_(BASED_ON_MEAN_REDUCTIONS_FROM_BASELINE_IN_HRSD);PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ABCB1;AG;ABCB1_A;OTHER;INCREASED;RISK;OTHER:DISEASE_RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GNL3;T;GNL3_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SIGNIFICANTLY_HIGHER_TRAMADOL_CONSUMPTION_IN_CHINESE_GASTRIC_CANCER_PATIENTS_RECOVERING_FROM_GASTRECTOMY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;CC;PEAR1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFIRI;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:CARCINOMA, SQUAMOUS_CELL;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;ABCB1;CC;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_REMISSION;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:ABORTION, SPONTANEOUS;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TOP2A;A;TOP2A_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*13:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION_AFTER_SECOND_TREATMENT_SWITCH;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVED_SECOND_TREATMENT_SWITCH_RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;T;PERP_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-REMISSION;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;OAS1;AG;OAS1_AG;TOXICITY;DECREASED;RISK;DISEASE:ANEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;VDR;A;VDR_G;NAN;INCREASED;RISK;DISEASE:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;CC;ABCB1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;A;UGT1A1_AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;T;CBR3_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;GALR1;CC + CT;GALR1_CT + TT;EFFICACY;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*46:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;AG;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;NFATC1;GG;NFATC1_GG;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA_AND_VOMITING;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
RISPERIDONE;LEP;A;LEP_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BUPROPION;GALR1;CC + CT;GALR1_CT + TT;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;CTLA4;AG;CTLA4_G;TOXICITY;DECREASED;RISK;DISEASE:ANEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NOS1;G;NOS1_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;DHFR;GG;DHFR_GG;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETRAVIRINE;CYP2C19;AA + AG;CYP2C19_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ETRAVIRINE_CLEARANCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CISPLATIN;ERCC1;A;ERCC1_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;T;ABCG2_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDL-C)_LEVEL, IN_A_GENE-DOSE-DEPENDENT_MANNER,;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;TT;MTHFR_TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_BASED_ON_CHANGE_OF_HAM-D_SCORE_AFTER_ANTIDEPRESSANT_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PEMETREXED;GGH;A;GGH_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;GAT/del;SLC22A1_del/del;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TROUGH_METFORMIN_STEADY-STATE_CONCENTRATION;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:NEUROPATHIC_PAIN;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENAZEPAM;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;AG + GG;CDA_G;TOXICITY;INCREASED;RISK;DISEASE:DEHYDRATION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;G;PIK3R2_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;AG + GG;CDA_G;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP3A4;*22;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HOT_FLASHES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*74:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS;PEOPLE;DISEASE:PERIPHERAL_VASCULAR_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;SLC22A1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HEADACHE, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:SEDATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;DISEASE:SKIN_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;OPRM1_AA;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ALCOHOL_RESPONSE, CONSUMPTION, AND_PREFERENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:VENLAFAXINE_LEVELS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;T;HMMR_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
EXEMESTANE;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;C;PERP_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;FOXO1;T;FOXO1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;AA;PEAR1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;PEAR1;AA;PEAR1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:VENLAFAXINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:VENLAFAXINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION_INHIBITION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;ABCB1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CMAX_AND_AUC_OF_THIOL_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALL_AND_MINOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;PIK3R2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;G;ABCB1_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
FLUTICASONE_PROPIONATE;CD14, TMCO6;AA;CD14, TMCO6_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PC20;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;IRS1;A;IRS1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;T;INSR_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;GG;ATIC_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53;T;TP53_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;AA;ERCC1_AC + CC;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALBOCICLIB;ABCG2;CT;ABCG2_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EXEMESTANE;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_MUSCULOSKELETAL_ADVERSE_EVENTS_(MSAES)_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
PRIMAQUINE;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DECREASED_HEMOCRIT_LEVELS;PEOPLE;DISEASE:MALARIA_VIVAX;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;PIK3R2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DAOA;C;DAOA_C;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;G;UGT1A1_G;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:VASCULITIS, DISEASE:WEGENER_GRANULOMATOSIS;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DESIPRAMINE/2-HYDROXY-DESIPRAMINE_RATIO;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:THE_INTRINSIC_METABOLIC_ACTIVITY_(V(MAX)/K(M));CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:THE_MEAN_MAXIMAL_ELIMINATION_RATES_(V(MAX));CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATAZANAVIR, RITONAVIR;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PALBOCICLIB;SULT2A1;CC;SULT2A1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION, SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;A;HMMR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PRIMAQUINE;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SULFANILAMIDE;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CHLORAMPHENICOL;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:BILIARY_TRACT_NEOPLASM, OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CODEINE, MORPHINE, TRAMADOL;UGT2B7;A;UGT2B7_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PAIN;CHILDREN;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOCETAXEL;ALDH2;AA + AG;ALDH2_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;C;HMMR_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*8;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:IN_VITRO_INTRINSIC_CLEARANCE_OF_S-WARFARIN_WITH_THE_CDNA-EXPRESSED_R150H_PROTEIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;CBR3;G;CBR3_A;TOXICITY;INCREASED;RISK;DISEASE:HEART_FAILURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;G;ERCC2_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;CAT;CC;CAT_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIAC_DAMAGE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EXEMESTANE;UGT2B17;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:FATIGUE;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BLEEDING_TIME;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VALPROIC_ACID;XBP1;G;XBP1_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROPHYLACTIC_TREATMENT_RESPONSE;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;ACE;del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP1B1;GG;CYP1B1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;CYP1B1;CC;CYP1B1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*8;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC4;T;ABCC4_T;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:ADR;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;ABCC4_T;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;ABCC4_T;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_POTASSIUM_EXCRETION;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F5;T;F5_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ENALAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_MINERAL_DENSITY_RESPONSE;WOMEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_SERUM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
FLUCLOXACILLIN;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ANK3;T;ANK3_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;DISEASE:RESPIRATORY_TRACT_INFECTIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;T;CCHCR1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
RITONAVIR;APOC3;G;APOC3_CG + GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TRIGLYCERIDE_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METFORMIN;BDNF;C;BDNF, BDNF-AS_CC;EFFICACY;INCREASED;LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*1/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EFAVIRENZ_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
LUMIRACOXIB;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_(_R_, S_)-METHADONE_PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, METHOTREXATE;TPMT;*12;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;IMPDH1;CT + TT;IMPDH1_CT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;ABCB1;AA;ABCB1_C;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SENSITIVITY_IN_VITRO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LUMIRACOXIB;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;RISK;OTHER:OVERANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;PON1_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;RISK;OTHER:OVERANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PROLONGED_QTC;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:(S)-METHADONE_PLASMA_LEVELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEDATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;A;ABCB1_A;OTHER;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;T;HLA-C_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;IL1B;A;IL1B_A;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:PEPTIC_ULCER_DISEASE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;CC + CT;SLC22A16_CC + CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;EPHX1;G;EPHX1_G;TOXICITY;INCREASED;RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON;PEOPLE;OTHER:FIRST_TRIMESTER_PREGNANCY;CAUTION_SIDE_EFFECT
PHENYTOIN;EPHX1;T;EPHX1_CC;TOXICITY;INCREASED;RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON;PEOPLE;OTHER:FIRST_TRIMESTER_PREGNANCY;CAUTION_SIDE_EFFECT
NEVIRAPINE;TCF19;T;TCF19_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;NRG3;G;NRG3_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;EPHX1;CC;EPHX1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BEING_OVERANTICOAGULATED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:STEROL/BILE_ACID_METABOLITES;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EFAVIRENZ_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSIVENESS;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TT;ADORA2A_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:ANXIETY_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PACLITAXEL, PLATINUM_COMPOUNDS;NAT2;AG + GG;NAT2_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
NEMONAPRIDE;ANKK1;A;DRD2_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PROLACTIN_CONCENTRATIONS;WOMEN;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREAS_UNDER_THE_SERUM_CONCENTRATION-TIME_CURVE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;AA;GGH_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
RISPERIDONE;DRD2;C;DRD2_CT;TOXICITY;INCREASED;RISK;DISEASE:HYPERPROLACTINEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH, SIDE_EFFECT:MYOCARDIAL_INFARCTION, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
RISPERIDONE;ANKK1;AA + AG;DRD2_G;TOXICITY;INCREASED;RISK;DISEASE:HYPERPROLACTINEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;IMPDH2;G;IMPDH2_AG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:INOSINE_MONOPHOSPHATE_DEHYDROGENASE_ACTIVITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;XDH;CC + CT;XDH_CC + CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TREATMENT_INTERRUPTION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:_ADP-INDUCED_ON_TREATMENT_PLATELET_AGGREGATION_(OTPR);PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;SLCO1B3;G;SLCO1B3_GG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-NORMALIZED__CMAX_AND_DOSE-NORMALIZED__AUC0TO12_H;PEOPLE;OTHER:KIDNEY_TRANSPLANTS;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDINAVIR;UGT1A1;*6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANASTROZOLE;ABCB1;AA;ABCB1_A;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;GG;MTHFR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HAVING_INR_ABOVE_TARGET_RANGE_IN_WEEK_1;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AC;ITPA_AC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:FEBRILE_NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_SIDE_EFFECT
FLECAINIDE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SYSTEMIC_EXPOSURE_(AUC)_AND_LOWER_ORAL_CLEARANCE_OF_FLECAINIDE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;ALDH2;GG;ALDH2_AA + AG;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DIDANOSINE;XDH;AA;XDH_AA;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SZRD1;T;SZRD1_T;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:IC50;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DIDANOSINE;NT5C2;CC + CT;NT5C2_CC + CT;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIDANOSINE;XDH;AA;XDH_AA;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DAUNORUBICIN;GENE_NOT_SPECIFIED;GG;GG;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:IC50;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
AZACITIDINE;TYMS;del/del;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;MAN1B1;T;MAN1B1_T;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:IC50;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_OXYMORPHONE/OXYCODONE_RATIOS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIDANOSINE;NT5C2;CG + GG;NT5C2_CG + GG;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;HLA-DQA1;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*22;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*14:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*56:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;AT + TT;CYP2A6_AT + TT;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HYPOTENSIVE_DISORDER;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:STEADY-STATE_PLASMA_CONCENTRATIONS_OF_DESIPRAMINE/DAILY_DOSE_OF_DESIPRAMINE/BODY_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;(CA)16/(CA)16;EGFR_(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FATIGUE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;NAT1;*11B/*4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;GSTM3;CCT/CCT;GSTM3_CCT/CCT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_CURVE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_CURVE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;XDH;CC + CT;XDH_CC + CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANASTROZOLE;CYP19A1;AA;CYP19A1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;*4/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;CC;SLCO1B1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;*4/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*18/*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EFAVIRENZ_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO2;C;NQO2_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:WORSE_PROGNOSIS_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)_IN_PATIENTS_WHO_WERE_ER-VE/PR-VE_NEGATIVE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:M-III:PIOGLITAZONE_AUC0-48_RATIO_AND_M-III:M-IV_AUC0-48_RATIO_IN_HEALTHY_AFRICAN-AMERICAN_VOLUNTEERS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DICLOFENAC;UGT2B7;T;UGT2B7_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:HEMORRHAGE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RISK;OTHER:NON-FATAL_MYOCARDIAL_INFARCTION,STROKE, REVASCULARIZATION_OR_DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C8;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:R-IBUPROFEN_METABOLISM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;GSTM3_TC/TC + TC/TCCTC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HIGHER_COMPOSITE_HAR_OUTCOME_(CARDIAC_DEATH, NON_FATAL_MYOCARDIAL_INFARCTION_AND_STENT_THROMBOSIS)_UP_TO_12_MONTHS'_FOLLOW_UP;PEOPLE;OTHER:DRUG-ELUTING_STENTS;CAUTION_DOSE_ADJUST
NAN;IRS1;C;IRS1_C;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:LYMPH_NODE_INVOLVEMENT;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
ESTRADIOL;GENE_NOT_SPECIFIED;A;A;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_LEVEL;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;EGFR_(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEDIAN_SURVIVAL_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;EGFR_(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_(RR);POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-DRB1;*08:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOMYOPATHIES;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;EGFR_(CA)16/(CA)16 + (CA)16/(CA)17;NAN;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
DICLOFENAC;ABCC2;T;ABCC2_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIARRHYTHMICS, CLASS_I_AND_III;GENE_NOT_SPECIFIED;GG;GT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUCCESSFUL_RHYTHM_CONTROL;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBIMAZOLE, METHIMAZOLE;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;EGFR_(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;EGFR_(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BETTER_CLINICAL_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIFAMPIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HAM-D_SCORE_CHANGES_IN_FLUVOXAMINE-TREATED_PATIENTS_COMPARED_TO_PAROXETINE-TREATED_PATIENTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WAKEFULNESS_ACTIVITY_LEVEL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;IGFBP3;T;IGFBP3_TT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:TUMOR_SIZE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;GSTM3_TC/TC + TC/TCCTC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;GSTM3_TC/TC + TC/TCCTC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;GSTM3;TC/TC + TC/TCCTC;GSTM3_TC/TC + TC/TCCTC;OTHER;INCREASED;LIKELIHOOD;OTHER:METASTATIC_NEOPLASM;CHILDREN;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO;CHILDREN;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;CC;ITPA_AC;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN;PEOPLE;DISEASE:HEPATITIS;CAUTION_DOSE_ADJUST
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH1A1;CTGGTGAGGAGAGAACC/del;ALDH1A1_CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;HLA-B;*27:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_PLATELET_REACTIVITY;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
NAN;IFNL3;TT;IFNL3_GG;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:BASELINE_VIRAL_LOAD;PEOPLE;DISEASE:HEPATITIS;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
HEPARIN;HLA-DRB3;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEPARIN-INDUCED_THROMBOCYTOPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;TT/TT;IFNL4_TT/TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:NON-REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:RACEMIC, S-IBUPROFEN_AND_R-IBUPROFEN_METABOLISM, WITH_INCREASE_OF_AUC(0-INFINITY)_AND_REDUCTION_OF_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_4BETA-OHC/CHOL_RATIO;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PIROXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*4 + *10 + *9;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_AND_URINARY_RATIO_OF_METABOLITES_TRANS-3'-HYDROXYCOTININE_TO_COTININE_(3HC/COT);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMIRACOXIB;HLA-DQA1;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:INOS_EXPRESSION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A6;A;UGT1A6_AG + GG;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C8;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:R-IBUPROFEN_METABOLISM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;EGFR;CC;EGFR_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOPROFEN, TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
PIROXICAM;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIROXICAM;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PIROXICAM;CYP2C9;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GEFITINIB;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;G;IFNL4_TT/TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM;CYP2D6;A;CYP2D6_GG;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;MEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_SIDE_EFFECT
NAN;CYP2D6;*2xN;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;DISEASE:SUICIDE;PEOPLE;OTHER:GENE_DUPLICATION/MULTIDUPLICATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;SEVERITY;DISEASE:DEPRESSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A9;C;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METOPROLOL;ADRB2;CG;ADRB2_GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TRIGLYCERIDES;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
TAMOXIFEN;IGF1R;GG;IGF1R_GG;EFFICACY;INCREASED;RISK;DISEASE:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, RALTITREXED;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2D6;*1xN;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;DISEASE:SUICIDE;PEOPLE;OTHER:GENE_DUPLICATION/MULTIDUPLICATION;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*48:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;C;CYP2C8_C;TOXICITY;INCREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, RALTITREXED;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PAZOPANIB;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:OVARIAN_NEOPLASMS,DISEASE:SARCOMA, DISEASE:SOFT_TISSUE_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, RALTITREXED;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASTHENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TTTTTTT/TTTTTTT;ADORA2A_TTTTTTT/TTTTTTT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANXIETY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*14:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*09:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ZONISAMIDE;HLA-A;*02:07;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENOBARBITAL;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION_AND_HIGHER_MEAN_METABOLIC_RATIO;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;SEVERITY;OTHER:PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;*35:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TIME_TO_ACHIEVE_THERAPEUTIC_WINDOW;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DEATH;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AG + GG;ABCC2_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVEL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB2;CC;ADRB2_GG;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TOTAL_CHOLESTEROL;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;GG + GT;ABCC4_GG + GT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVEL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;NUDT15;del;NUDT15_del;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:S-CIT_SERUM_CONCENTRATIONS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_WHEN_MEASURED_BY_THE_GERIATRIC_DEPRESSION_SCALE_AT_DAY_7_AND_DAY_28;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LOWER_FINAL_DAILY_DOSE, DECREASED_DOSING_COMPLIANCE_AND_LOWER_PLASMA_LEVELS_AT_DAY_28;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
LISINOPRIL;MMP3;del/del;MMP3_AA;EFFICACY;DECREASED;RISK;SIDE_EFFECT:STROKE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;RISK;DISEASE:INFECTIOUS_DISEASE;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:POSITIVE_CORRELATION_OF_PAROXETINE_CONCENTRATION_WITH_IMPROVEMENT_IN_HAMD_SCORES_AT_WEEK_2;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ACENOCOUMAROL, WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;*4/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_SIDE_EFFECT
DIRECT_ACTING_ANTIVIRALS, SOFOSBUVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DEMETHYLATION_CLEARANCE_OF_DESMETHYLCITALOPRAM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LONG_QT_SYNDROME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_T;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL;UGT1A6;*2a;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;TYMS;TTA/TTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL;UGT1A1;*60;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;TTA/TTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;PEOPLE;DISEASE:TRANSIENT_ISCHEMIC_ATTACK, DISEASE:STROKE;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR_INHIBITORS;HLA-A;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;SLCO1B3;A;SLCO1B3_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID;GABRA1;GG;GABRA1_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DRUG-RESISTANT_PHENOTYPE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*2 + *3 + *4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;MEN;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE;HLA-A;*30:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;GENE_NOT_SPECIFIED;A;A;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DRB1;*15:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:09;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP1A2;AA;CYP1A2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION_INHIBITION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*05:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID;GABRA1;G;GABRA1_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DRUG-RESISTANT_PHENOTYPE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;GENOTYPE_NOT_SPECIFIED;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:GREATER_HEART_RATE_(HR)_REDUCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUCILLAMINE;HLA-DRB1;*08:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PROTEINURIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
BUCILLAMINE;HLA-DQB1;*04:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PROTEINURIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT;CYP2B6_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE;PEOPLE;DISEASE:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:HIGH_PLATELET_REACTIVITY_(HPR);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;*05:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DQB1;*06:09;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*13:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;*05:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DPB1;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB5;*02:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C19;*17/*17 + *1/*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:INFLAMMATION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:JAUNDICE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;GENOTYPE_NOT_SPECIFIED;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:A_CORRELATION_OF_BRAIN_SERT_OCCUPANCY_WAS_ASSOCIATED_WITH_LARGER_PROPORTIONAL_HDRS17_DECREASES;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DRB5;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATITIS;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATITIS;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-DRB1;*13:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EFFICACY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EFFICACY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;*41;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_NORTRIPTYLINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
TICLOPIDINE;HLA-C;*14:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT;CYP2B6_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;LEPR;GG;LEPR_GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
TICLOPIDINE;HLA-DQB1;*06:04;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
BUSULFAN, CYTARABINE, ETOPOSIDE;ABCC3;G;ABCC3_G;EFFICACY, TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:DISEASE-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;HLA-B;*44:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE, ETHANOL, NICOTINE;OPRM1;TT;OPRM1_TT;TOXICITY;INCREASED;RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;A;COMT_AA;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:METHYLATION_AT_SITES_1_AND_2_IN_THE_COMT_PROMOTER;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*09:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;*05:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;CYP2E1;*1A/*5B;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DQB1;*03:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*13:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPIRIN;HLA-DQB1;*06:09;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUTICASONE_PROPIONATE;CD14, TMCO6;AA + AG;CD14, TMCO6_AA + AG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FEV1/FVC_RATIO;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;non-null/non-null;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:HODGKIN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ, NEVIRAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;T;ADH1B_TT;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_HYDRAZINE_CONCENTRATIONS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;T;DPYD_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_HYDRAZINE_CONCENTRATIONS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-DQB1;*05:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;C;CYP3A4_TT;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*27;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*59:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:SIGNIFICANTLY_HIGHER_(S)-FLUOXETINE_AND_LOWER_AND_(S)-NORFLUOXETINE_CONCENTRATIONS;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
NAN;TRPA1;CT + TT;TRPA1_TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:PAIN;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ALDH2;A;ALDH2_AA + AG;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:INSULIN_RESISTANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE_AND_THE_ACTIVE_MOIETY_IN_PATIENTS_WITH_TWO_FUNCTIONAL_CYP2D6_ALLELES;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATIONS_OF_10-OH-NORTRIPTYLINE_AND_HIGHER_NORTRIPTYLINE/10-OH-NORTRIPTYLINE_RATIO;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
RITODRINE;CACNA1C;AA + AG;CACNA1C_AA + AG;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;DISEASE:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION, END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME;PEOPLE;OTHER:CHRONIC_HEART_FAILURE;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOE;TT;APOE_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOE;CC;APOE_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, QUINAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_D-DIMER_LEVELS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TIMOLOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:GASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RABEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:GASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;AREG;A;AREG_A;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, EPIRUBICIN, FLUOROURACIL;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, QUINAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_IL-6_LEVELS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, QUINAPRIL;ACE;del/del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_CRP_LEVELS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:AVERAGE_CUMULATIVE_NEUROTOXICITY_GRADE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CYP2E1;T;CYP2E1, DUX1_CT + TT;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;OTHER:BLOOD_COAGULATION_DISORDERS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:ATRIAL_FLUTTER,DISEASE:VENOUS_THROMBOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TOLTERODINE_EXPOSURE_AND_INCREASED_ACTIVE_METABOLITE_(5-HM)_CONCENTRATIONS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;*03:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;CHILDREN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ANASTROZOLE;CYP19A1;GG;CYP19A1_GG;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE_INHIBITORS, PLAIN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;A;INSR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;ATIC;AA;ATIC_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
LEVETIRACETAM;HLA-A;*11:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;PIK3R2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;UGT1A6_GG;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;UGT1A6_AG + GG;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;PIK3R2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MED12L, P2RY12;T/del;MED12L, P2RY12_T/del;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-A;*24:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EXEMESTANE;GENE_NOT_SPECIFIED;TT;TT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;A;PERP_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:INFLAMMATION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;INSIG2;CC;INSIG2_CC;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;HLA-A;*33:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID;ABCB1;T;ABCB1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DRUG-RESISTANT_PHENOTYPE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTRITIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;A;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_METOPROLOL_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;C;ACE2_C;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""BETA_BLOCKING_AGENTS"", ""CALCIUM_CHANNEL_BLOCKERS"", ""DIGOXIN"", ""DIURETICS""";ACE;del;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MORTALITY;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR, TEZACAFTOR;CFTR;del/del;CFTR_del/del;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIOS_OF_DESIPAMINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAMAQUINE;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:HEMOLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:G6PD_DEFICIENT_MICE;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY, OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:HEMOLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:G6PD_DEFICIENT_MICE;CAUTION_DOSE_ADJUST
ITRACONAZOLE, KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;DECREASED;SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HUMAN_LIVER_MICROSOMES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;A;CETP_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROTECTION_AGAINST_MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TIME_BELOW_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OSIMERTINIB;CYP2A6;CC;CYP2A6_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
PAZOPANIB, PEMETREXED;VEGFA;CC + CT;VEGFA_CC + CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PENICILLIN_G, PENICILLIN_V;HLA-B;*55:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;GHSR;AG;GHSR_AG;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:WEIGHT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;OPRM1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*46/*46;GENOTYPE_NOT_SPECIFIED;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:CIGARETTES_PER_DAY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AA + AG;OPRM1_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:STEADY_STATE_CONCENTRATION_PER_DOSAGE;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01/*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:GOUTY_ARTHRITIS;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, PHENYTOIN, VALPROIC_ACID;SCN2A;A;SCN2A_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR7;T;HTR7_T;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*18;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ELEVATED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DOCETAXEL, TEGAFUR;CYP2A6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EFFICACY;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;T;ERCC2_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*40:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;SLC6A3;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;SLC6A3_CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS_IN_TAIWANESE_PATIENTS_RECEIVING_CLOPIDOGREL_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-DRB1;*16:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_SERUM_CONCENTRATIONS_(CMIN);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIPHENYLHYDANTOIN-INDUCED_SKIN_RASH;POPULATION_AFFECTED_NOT_SPECIFIED;SIDE_EFFECT:NEUROLOGICAL_PATIENTS;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DURATION_OF_INHIBITION_OF_PROSTANOIDS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:THE_MAXIMAL_ELIMINATION_RATE_(VMAX);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;CYP2E1;*1/*5B;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ELIMINATION_RATE;PEOPLE;DISEASE:ALCOHOLIC_LIVER_DISEASES;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_METHYLMERCAPTOPURINE_NUCLEOTIDES_LEVELS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3 + *1/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;CYP2A7;C;CYP2A7_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*18;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:HYDROXYBUPROPION_CONCENTRATIONS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS, CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CUTANEOUS_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2C19;*2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*11A;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;NAT1;*10/*4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CLERANCE_OF_PACLITAXEL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:HYDROXYBUPROPION_CONCENTRATIONS_AND_HYDROXYBUPROPION/BUPROPION_RATIO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IRINOTECAN, RALTITREXED;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;DECREASED;RISK;DISEASE:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TEMSIROLIMUS;NR1I2;AG + GG;NR1I2_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C/C;CYP3A4_CT + TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;NAT1;*11B/*3;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*10;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CALCINEURIN_INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALLOGRAFT_DYSFUNCTION_IN_KIDNEY_TRANSPLANT_RECIPIENTS_TREATED_WITH_CALCINEURIN_INHIBITORS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
DAUNORUBICIN;NRP2;C;NRP2_C;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:IC50;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;GSTM3_CCT/CCT;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;GSTM3_CCT/CCT;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:ANEMIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;GSTM3_CCT/CCT;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;del/del;CYP2D6_A/DELA;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;SLC6A4_(CCCACCCGA)12/(CCCACCCGA)12;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LACK_OF_REMISSION_AND_LACK_OF_RESPONSE;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;SLC6A4_(CCCACCCGA)12/(CCCACCCGA)12;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION_AFTER_THE_SECOND_SWITCH_IN_TREATMENT;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
VALPROIC_ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;C;UGT1A6_AC + CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ELEVATED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ISONIAZID, PYRIDOXAL_PHOSPHATE;CYP2E1;*1A/*1A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATENOLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AMITRIPTYLINE/(E)-10-_OH-AT_RATIO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:NORTRIPTYLINE/(E)-10-OH-NT_RATIO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
BENZENE;NQO1;AA;NQO1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR, EFAVIRENZ;TPH2;TT;TPH2_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;DHFR_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED;RISK;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*1;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION_OF_EFAVIRENZ;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTITHYROID_PREPARATIONS;HLA-B;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TEGAFUR;CYP2A6;*1;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_FLUOROURACIL;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LIVER_INJURY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ATORVASTATIN_LACTONIZATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;UGT1A3;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TOTAL_AND_THE_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_MAXIMUM_PERCENT_DECREASES_FROM_BASELINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2C9;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HOSPITAL_STAY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;COMT;A;COMT_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;CYP2C8;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_ABSOLUTE_DIFFERENCE_IN_HBA1C;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1/*2xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:RELATIVE_BIOAVAILABILITY_OF_PRAVASTATIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:PEPTIC_ULCER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAFFEINE;ADORA2A;TT;ADORA2A_TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANXIETY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;EFFICACY;INCREASED;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SERUM_CREATINE_KINASE_LEVELS_(INCREASED_RISK_OF_MYALGIA_AND_GREATER_DEGREE_OF_MUSCLE_DAMAGE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCC10;CC;ABCC10_CT;EFFICACY, METABOLISM/PK;INCREASED;LIKELIHOOD;PK:LOWER_NEVIRAPINE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_STEVENS-JOHNSON_SYNDROME_(SJS)_AND_TOXIC_EPIDERMAL_NECROLYSIS_(TEN);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;GTAAGTTG;SLC22A1_GTAAGTTG;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;CYP2E1;*1A/*1A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY_SYNDROME;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:ENHANCED_RESPONSE_TO_CLOPIDOGREL_(AS_MEASURED_BY_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PHENYTOIN_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NAT1;*10/*11B;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;HLA-DQB1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;NAT1;*11A/*4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_THIOGUANINE_NUCLEOTIDES_METABOLITES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*1/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*1/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;DOSAGE, TOXICITY;INCREASED;RISK;OTHER:COMPLICATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, TOXICITY;INCREASED;RISK;DISEASE:BRADYCARDIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15/*15;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_AFTER_ADJUSTMENT_FOR_VKORC1*1173;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*3/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HALOPERIDOL;COMT;AG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCLE_EFFECTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2D6;*4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_INR_VALUES_IN_PATIENTS_WITH_HEART_VALVE_REPLACEMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2B6;*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CMAX_AND_AUC_OF_VENLAFAXINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_INR_VALUE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CMAX_AND_AUC_OF_VENLAFAXINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACHIEVING_A_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACHIEVING_A_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*4/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FREQUENCY_OF_REMITTERS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:INTRAGASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:INTRAGASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TRAMADOL_METABOLISM_AND_RESPONSE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAL-STIMULATED_PLASMA_GASTRIN_CONCENTRATIONS;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*4/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*6/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FREQUENCY_OF_REMITTERS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*6;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*4;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:MEAN_PLASMA_CONCENTRATION_OF_OXYMORPHONE_AND_LOWER_MEAN_OXYMORPHONE/OXYCODONE_RATIO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*1 + *1/*41;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIOS_OF_DESIPAMINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*2/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;GENOTYPE_NOT_SPECIFIED;DOSAGE, EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*10 + *1/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATION_AT_AN_ADMINISTERED_DOSE_OF_30MG/DAY;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:SHORTER_CONTININ_HALF-LIFE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ORAL_CLEARANCE_OF_CITALOPRAM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*10/*10 + *1/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:_PLASMA_PAROXETINE_CONCENTRATIONS_AT_ADMINISTERED_DOSE_OF_10MG/DAY;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*36;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CODEINE_METABOLISM_AND_MORPHINE_AND_GLUCURONIDES_FORMATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVEL_OF_MORPHINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;UGT1A1;T;UGT1A1_T;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLURBIPROFEN;CYP2C9;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC, HIGHER_HALF-LIFE_AND_LOWER_FLURBIPROFEN_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
PYRIMIDINE_ANALOGUES;MIR27A;CC + CT;MIR27A_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_RATIO_CITALOPRAM_(CIT)/N-DESMETHYLCIT_(DCIT);PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_TO_TIMOLOL_(HIGHER_AREA-UNDER-CURVE, LONGER_ELIMINATION_HALF-LIVES_);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;C;PON1_T;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TENOXICAM;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_AND_HALF-LIFE_TIME_(T1/2);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INOS_EXPRESSION_AND_FEWER_ADVERSE_EVENTS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;A;P2RY12_AG + GG;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DPB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFONAMIDES, UREA_DERIVATIVES;TCF7L2;CC;TCF7L2_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(REDUCTIONS_IN_HAEMOGLOBIN_A1C_(HBA1C)_AND_FASTING_PLASMA_GLUCOSE_(FPG)_LEVELS);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LUMACAFTOR;CFTR;del/del;CFTR_del/del;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANGE_IN_SWEAT_CHLORIDE;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;CYP1A2_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ABORTION, SPONTANEOUS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:LEPROSY;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ACENOCOUMAROL_DOSE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*10 + *10/*10;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVELS_OF_MORPHINE, M3G_AND_M6G_LEVELS_BUT_NOT_THOSE_OF_CODEINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*1/*1 + *1/*4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:OROCECCAL_TRANSIT_TIME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;CYP1B1;CC + CG;CYP1B1_CC;NAN;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
TETRABENAZINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LESS_ROBUST_TREATMENT_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEMENTIA;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_CIT/DCIT_VALUES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PTGS1;T;PTGS1_T;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:CLOMIPRAMINE-INDUCED_PROLACTIN_RELEASE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_OF_CITALOPRAM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PRESENTATION_IN_THE_NON-REPONDER_GROUP;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENOBARBITAL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_DRUG_REACTIONS;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIZZINESS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PRU;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*07:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRICHLOROETHYLENE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;*3A/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_EVENT_OCCURRENCE;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*08:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, OXALIPLATIN, TEGAFUR/GIMERACIL/OTERACIL;UGT1A7;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2C9;CC;CYP2C9_AC + CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;CYP2C8;CC;CYP2C8_T;TOXICITY;DECREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB3;*02:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;C;TPMT_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;UGT2B7;G;UGT2B7_AA;TOXICITY;INCREASED;RISK;DISEASE:ANEMIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-C;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB1;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS, PYRIMIDINE_ANALOGUES;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
CILOSTAZOL, CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DOLASETRON;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;NFATC2;AA;NFATC2_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP2C8;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABACAVIR;HLA-B;*57:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
IFOSFAMIDE;ALDH1A1;AA;ALDH1A1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTT1;null/null;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACHIEVING_SVR_IN_OLDER_PATIENTS_WITH_GENOTYPE_1B_CHRONIC_HEPATITIS_C;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;del;NUDT15_del;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:AUTOIMMUNE_DISEASES, OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;ADAMTS1;CC;ADAMTS1_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:THE_MOST_BENEFIT_FROM_STATIN_TREATMENT_IN_REDUCING_THE_RISK_OF_MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CYP2B6;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*1/*1;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYROID_PREPARATIONS;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;HLA-DRB1;*08:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:VIRUS_DISEASES;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:INFECTIOUS_DISEASE;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
GEFITINIB;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RISK;EFFICACY:ALLOGRAFT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
LAMOTRIGINE;SCN1A;C;SCN1A_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TONIC_BLOCK_OF_NA(V)_1.1_CHANNELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:FORMATION_OF_METABOLITES;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HUMAN_KIDNEY_MICROSOMES;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEMETREXED;TYMS;TTAAAGTTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;TYMS;del;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
NAN;SLCO1B1;C;SLCO1B1_TT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:ERYTHROMYCIN_TRANSPORT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BETA-LACTAM_ANTIBACTERIALS, PENICILLINS;HLA-DRB1;*10:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL, PROTON_PUMP_INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;ADRB2;GG;ADRB2_GG;TOXICITY;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ZOLEDRONATE;GENE_NOT_SPECIFIED;CC;CC;TOXICITY;INCREASED;RISK;DISEASE:OSTEONECROSIS;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:DRUG-DRUG_PHARMACOKINETIC_INTERACTION;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;T;HMGCR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:DRUG-DRUG_PHARMACOKINETIC_INTERACTION;CAUTION_SIDE_EFFECT
TACROLIMUS, VORICONAZOLE;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:DRUG-DRUG_PHARMACOKINETIC_INTERACTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;LIG3;T;LIG3_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;OTHER:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;A;CYP1A2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;T;HMGCR_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
VANCOMYCIN;HLA-A;*32:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ATORVASTATIN;PCSK9;T;PCSK9_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
"""BETA-LACTAM_ANTIBACTERIALS, PENICILLINS"", ""OTHER_BETA-LACTAM_ANTIBACTERIALS""";HLA-A;*02:07;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA-LACTAM_ANTIBACTERIALS, PENICILLINS"", ""OTHER_BETA-LACTAM_ANTIBACTERIALS""";HLA-A;*01:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""BETA-LACTAM_ANTIBACTERIALS, PENICILLINS"", ""OTHER_BETA-LACTAM_ANTIBACTERIALS""";HLA-C;*06:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""BETA-LACTAM_ANTIBACTERIALS, PENICILLINS"", ""OTHER_BETA-LACTAM_ANTIBACTERIALS""";HLA-DRB1;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""BETA-LACTAM_ANTIBACTERIALS, PENICILLINS"", ""OTHER_BETA-LACTAM_ANTIBACTERIALS""";HLA-DQB1;*03:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;T;APOE_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
ENALAPRIL;GENE_NOT_SPECIFIED;TT;ABO_GG;TOXICITY;INCREASED;RISK;DISEASE:COUGH;WOMEN;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
RIBAVIRIN, SOFOSBUVIR;ITPA;AC;ITPA_AC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;GENE_NOT_SPECIFIED;TT;ABO_GG;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;T;APOE_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
NAN;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_TO_DRUG;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, DOCETAXEL, FLUOROURACIL;TYMS;TTA/TTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPONATREMIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:DRUG_HYPERSENSITIVITY, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:ERYTHEMA_MULTIFORME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:DISCONTINUATION, OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYS;(T)7/(T)8;DPYS_(T)7/(T)8;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_TO_DRUG;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2A6;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OSIMERTINIB;ABCG2;TT;ABCG2_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
L-ASPARAGINE, PREDNISONE, VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;ASNS_(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PRAVASTATIN;NPC1L1;CC;NPC1L1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_LDL-C;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;NPC1L1;CC;NPC1L1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_LDL-C;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP3A4;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-B;C;HLA-B_C;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;HLA-A;*34:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;HLA-DRB1;*16:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;GG;HMGCR_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_LEVEL_IN_BASAL_STATE_AND_POSSIBLY_IN_RESPONSE_TO_ATORVASTATIN.;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY, SIDE_EFFECT:TREMOR, SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:CROHN_DISEASE,DISEASE:AUTOIMMUNE_HEPATITIS;CAUTION_SIDE_EFFECT
BETA_BLOCKING_AGENTS, METOPROLOL;ADRB1;AG + GG;ADRB1_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;TYMS;del/del;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;ALOX5;T;ALOX5_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETOPOSIDE;GENE_NOT_SPECIFIED;GG;GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SENSITIVITY_TO_ETOPOSIDE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
"""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;CC;ITPA_AC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;CC;ITPA_AC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
ASPARAGINASE;F5;CT;F5_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DABIGATRAN;CES1;GG + GT;CES1_G;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
DESIPRAMINE;MC1R;G;MC1R_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;A;ABCB1_A;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:LEVEL_OF_APOLIPOPROTEIN_A1;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;VKORC1_AA + AG;DOSAGE, EFFICACY, TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DOSE_REQUIREMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DESIPRAMINE;MC1R;A;MC1R_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;LTA, TNF;A;TNF_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SERIOUS_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPARAGINASE;IL16;GG + GT;IL16_GG + GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOTIC_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;TT;PACSIN2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC29A1;CT + TT;SLC29A1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;SPG7;A;SPG7_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;CTH;CC;CTH_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, THALIDOMIDE;ABCC6;C;ABCC6_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;ATP7A;G;ATP7A_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;GNMT;CT + TT;GNMT_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CC;CYP4F2_TT;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CT;CYP4F2_TT;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;CES1_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENT;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CC;CYP4F2_TT;DOSAGE, EFFICACY, TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DOSAGE_REQUIREMENT;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;AA + AG;SLCO1B1_AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;CHRM3;AA + AG;CHRM3_GG;NAN;INCREASED;RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*16;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:A_MILD_INCREASE_OF_LIVER_ENZYMES;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SALBUTAMOL, SALMETEROL;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RISK;EFFICACY:ASTHMA_EXACERBATIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;del/del;UGT1A9_T/del + del/del;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CISPLATIN;SLC16A5;T;SLC16A5_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;MEN;DISEASE:TESTICULAR_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_REACTIONS;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC2;CC;ABCC2_C;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ENALAPRIL, IMIDAPRIL, LISINOPRIL;BDKRB2;CT + TT;BDKRB2_T;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;CT + TT;ABCG2_CC;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOZAPINE, RISPERIDONE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SREBF1;AA + AG;SREBF1_AA + AG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:TOTAL_CHOLESTEROL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;PK:OXYCODONE_CONSUMPTION_UP_TO_THE_12(TH)_HOUR_IN_POSTOPERATIVE_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN;GSTP1;G;GSTP1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;BDKRB2;T;BDKRB2_T;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCG2;TT;ABCG2_T;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:GASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
IRBESARTAN;AGTR1;AC + CC;AGTR1_AA + AC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BLOOD_PRESSURE_RESPONSE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;PDE3A_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ADRA2A;G;ADRA2A_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BISPECTRAL_INDEX_AND_RAMSAY_SEDATION_SCORES, INDICATING_A_LONGER_PERIOD_FOR_FALLING_ASLEEP;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP2C8;G;CYP2C8_CG + GG;TOXICITY;DECREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;MUC16;T;MUC16_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;TT;ABCG2_T;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:ACQUIRED_IMMUNODEFICIENCY_SYNDROME;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;UGT1A1_AA;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GG;ABCG2_T;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;*6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SORAFENIB;TNF;GG;TNF_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;PDE3A_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;RISK;DISEASE:PAIN;PEOPLE;OTHER:EXTRACORPOREAL_SHOCK_WAVE_LITHOTRIPSY_(ESWL);CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""INTERFERON_ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;CC;ITPA_AC;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HEMOGLOBIN_LEVELS;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;OPRM1_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SALMETEROL;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RISK;OTHER:ASTHMA_EXACERBATIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;DNAAF9, ITPA;C;ITPA_AC + CC;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MIR6076;GG + GT;MIR6076_GG + GT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:GASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;LRMDA;C;LRMDA_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:RECURRENCE-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;CRYBG2;T;CRYBG2_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;G;NAT2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;CLCC1;T;CLCC1_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;CT + TT;CDA_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
BOCEPREVIR, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;SLC31A1;AC;SLC31A1_AC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;POM121L2;T;POM121L2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
"""ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS"", ""DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_AND_TUBERCULOSIS_CO-INFECTION;CAUTION_SIDE_EFFECT
DIPYRONE;NAT2;*16 + *6 + *7 + *14;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7 + *14;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AG + GG;ABCC2_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IRINOTECAN;NR3C1;A;NR3C1_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;VKORC1;T;VKORC1_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;SLC31A1;AA;SLC31A1_AA;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ZNF165;C;ZNF165_C;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;TPMT;CT;TPMT_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CATARACT;PEOPLE;OTHER:CARDIO-METABOLIC_CONDITIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;AA;RRM1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE, RISPERIDONE;DRD2;C;DRD2_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_UNTIL_RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;SLC31A1;AA;SLC31A1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT + TT;CYP2C19_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;GG + GT;ABCC4_GG + GT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PSYCHOMOTOR_AGITATION, SIDE_EFFECT:HYPERKINESIS, SIDE_EFFECT:IMPULSE_CONTROL_DISORDER;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALIPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;CT + TT;CYP2C19_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MAGNITUDE_OF_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*6 + *7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6 + *7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOTOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:HEPATITIS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;HLA-DRB1;*04:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;SLC31A1;AC;SLC31A1_AC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;AC + CC;CDA_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*7 + *6/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOTOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*16 + *6 + *7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OLANZAPINE, RISPERIDONE;DRD2;del;DRD2_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_RESPOND;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;CYP2A7P1, CYP2B6;GG;CYP2B6_GT;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;HLA-B;*35:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;SLC31A1;AC;SLC31A1_AC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;LIKELIHOOD;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN, SOFOSBUVIR;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
PROTON_PUMP_INHIBITORS;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS;TYMS;AG + GG;TYMS_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE;CYP2B6;AG + GG;CYP2B6_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:RHABDOMYOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOAFFECTIVE_DISORDER, OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:GASTRIC_PH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:HOT_FLASHES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;AKR1C3;G;AKR1C3_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADIPOQ;CG + GG;ADIPOQ_CG + GG;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
MYCOPHENOLIC_ACID, TACROLIMUS;IMPDH1;T;IMPDH1_CT;EFFICACY;DECREASED;LIKELIHOOD;OTHER:SUBCLINICAL_ACUTE_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;AA;CDA_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRY_MOUTH, SIDE_EFFECT:ERECTILE_DYSFUNCTION, SIDE_EFFECT:HYPERHIDROSIS, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:URINARY_RETENTION;PEOPLE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2D6;*2xN;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEMCITABINE;DCK;TT;DCK_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;RBX1;A;RBX1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;T;NAT2_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;SLC31A1;AG + GG;SLC31A1_AG + GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;BDNF-AS;CC + CT;BDNF-AS_CC + CT;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN, PLATINUM_COMPOUNDS;NAT2;AA;NAT2_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;SLC31A1;CC + CT;SLC31A1_CC + CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HEMATOLOGIC_DISORDER, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;SLC31A1;AC;SLC31A1_AC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
COCAINE;SYT1;G;SYT1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:AUTOIMMUNE_HEPATITIS;CAUTION_SIDE_EFFECT
VALGANCICLOVIR;ABCB1;CT;ABCB1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:FLUOXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TETRABENAZINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:LONGER_TITRATION_TO_ACHIEVE_OPTIMAL_BENEFIT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;UGT1A9;T;UGT1A9_T/del + del/del;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP2C9;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""FOLIC_ACID"", ""VITAMIN_B-COMPLEX, PLAIN""";MTRR;AA + AG;FASTKD3, MTRR_AG + GG;EFFICACY;DECREASED;SEVERITY;DISEASE:PAIN;WOMEN;DISEASE:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;HTR3B;TT;HTR3B_C;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;DPYD_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ENALAPRIL;PCGF3;A;PCGF3_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PAROXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TRAMADOL;COMT;AA + AG;COMT_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
ANTICHOLINERGIC_AGENTS;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_ANTICHOLINERGIC_ACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;ABCG2;CC + CT;ABCG2_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLATE_MOFETIL;UGT1A9;T;UGT1A9_T/del + del/del;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID-7-O-GLUCURONIDE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;ABCC2;AG;ABCC2_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_THE_ACYL_GLUCURONIDE_OF_MYCOPHENOLIC_ACID;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;CT;DPYD_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;GG;OPRM1_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATENOLOL;PAH;AA;PAH_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;PON1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD2;CC + CT;DRD2_C;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;OPRM1_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;VEGFA_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD2;CT + TT;DRD2_CT + TT;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AA + AG;COMT_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;ABCC2;TT;ABCC2_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;AG + GG;TYMS_AG + GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;ABCC3;T;ABCC3_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A9;AA;UGT1A9_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;AA;KDR_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;LIKELIHOOD;OTHER:DRUG_DOSAGE_ALTERED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TRAMADOL;COMT;GG;COMT_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
"""FOLIC_ACID"", ""VITAMIN_B-COMPLEX, PLAIN""";MTHFR;AG + GG;MTHFR_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE;WOMEN;DISEASE:MIGRAINE_WITH_AURA;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ANTIDEPRESSANT_SERUM_LEVELS;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
SORAFENIB;SLC15A2;CC;SLC15A2_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CCND1;AA;CCND1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME-TO-TUMOR_RECURRENCE;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CAPECITABINE;UMPS;CC + CT;UMPS_CC + CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;GENE_NOT_SPECIFIED;TT;TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE;TYMS;CT + TT;TYMS_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;SLC22A7;AG + GG;SLC22A7_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ABCC3;G;ABCC3_G;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_PLASMA_LEVELS;PEOPLE;DISEASE:DEMENTIA;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;RISK;OTHER:MAJOR_ADVERSE_CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;T;SLC19A1_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABT-751;UGT1A4;AC;UGT1A4_AC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_PREDOSE_CONCENTRATION_(CTROUGH);PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CAPECITABINE;UMPS;CC + CG;UMPS_CC + CG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ABT-751;UGT1A8;CC + CT;UGT1A8_CC + CT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATION_METABOLIC_RATIOS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC)_OF_DESIPRAMINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC_AGENTS;DPYD;AA + AG;DPYD_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;CC + CT;TPMT_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;SERPINA3;AC + CC;SERPINA3_AC + CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_PEAK_PLASMA_CONCENTRATION_OF_H4;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
VALPROIC_ACID;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PTGS1;AG + GG;PTGS1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:ST-SEGMENT_ELEVATION_MYOCARDIAL_INFARCTION_(STEMI);CAUTION_SIDE_EFFECT
METFORMIN;SLC47A2;AA;SLC47A2_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TAMOXIFEN;NCOA1;CT;NCOA1_CT;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:CHANGE_IN_LUMBAR_BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;GENE_NOT_SPECIFIED;A;A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:POOR_RESPONSE_AT_8_WEEK_OF_TREATMENT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
CITALOPRAM;GENE_NOT_SPECIFIED;A;A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:POOR_RESPONSE_AT_6_WEEK_OF_TREATMENT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
MIDAZOLAM;POR;CT;POR_CT + TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MIDAZOLAM_METABOLIC_RATIOS_BY_45%;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
LENVATINIB;ABCG2;GG;ABCG2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRY_MOUTH, SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;G;CHRNA3, CHRNA5_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVEL;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:TOBACCO_USERS;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_PLASMA_LEVELS;PEOPLE;DISEASE:DEMENTIA;CAUTION_DOSE_ADJUST
TRAZODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AG;DPYD_AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:STOMATITIS;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:ST-SEGMENT_ELEVATION_MYOCARDIAL_INFARCTION_(STEMI);CAUTION_SIDE_EFFECT
LENVATINIB;CYP3A4;C;CYP3A4_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
LENVATINIB;CYP3A5;C;CYP3A5_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TT;ENOSF1, TYMS_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRK1;C;OPRK1_CC + CT;TOXICITY;DECREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;CSNK1E;T;CSNK1E_T;TOXICITY;DECREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;AG;DPYD_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA5;G;CHRNA3, CHRNA5_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;GAL;A;GAL_A;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRD1;A;OPRD1_A;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;SLC22A7;TT;SLC22A7_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;OPRD1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHADONE;CRHBP;G;CRHBP_G;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:RECURRENCE;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;FAAH;A;FAAH_AA;OTHER;INCREASED;LIKELIHOOD;OTHER:DEPENDENCE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CHRNA3;G;CHRNA3_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;OPRD1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NALOXONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PEAK_CORTISOL_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;CT + TT;ENOSF1, TYMS_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEIOMYOMA, SIDE_EFFECT:LIVER_DISORDER, SIDE_EFFECT:OVARIAN_CYSTS;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;HTR3B;C;HTR3B_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OSIMERTINIB;ABCG2;GG;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2C;C;HTR2C_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:PAIN;MEN;DISEASE:NEUROPATHIC_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_PAIN_AUC;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;GNMT;CT + TT;GNMT_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OXYCODONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;CHRNA3_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:METABOLIC_RATIO_DEM/DOR;PEOPLE;DISEASE:ANXIETY_DISORDERS;CAUTION_DOSE_ADJUST
IRINOTECAN, PLATINUM_COMPOUNDS;NAT2;AA;NAT2_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;C;OPRM1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_AUC, PLASMA_HALF-LIFE_AND_STEADY-STATE_PLASMA_CONCENTRATIONS_OF_PAROXETINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO;CHILDREN;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
ALKYLATING_AGENTS, CISPLATIN;ESR1;A;ESR1_A;TOXICITY;INCREASED;RISK;DISEASE:OLIGOSPERMIA;PEOPLE;OTHER:CHILDHOOD_CANCER;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;OPRM1_T;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION_IF_TOLERANT_TO_CITALOPRAM_TREATMENT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PARKINSONIAN_DISORDER, SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OSIMERTINIB;STAT3;GG;STAT3_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAIL_DISORDER;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;AA;CYP2D6_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_AND_REMISSION_RATE;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
3, 4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERTENSION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;SLCO1B1;GG + GT;SLCO1B1_GG + GT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, EPIRUBICIN;GENE_NOT_SPECIFIED;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;GENE_NOT_SPECIFIED;T;T;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:COFFEE_CONSUMPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE;GCLC;AA;GCLC_A;TOXICITY;DECREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:6-TG_LEVELS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH, SIDE_EFFECT:MYOCARDIAL_INFARCTION, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;CYP1A1;T;CYP1A1_T;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:COFFEE_CONSUMPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE;GCLC;A;GCLC_A;TOXICITY;DECREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CES1;GT + TT;CES1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:LOW_BACK_PAIN, DISEASE:OSTEOARTHRITIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;ABCC2;AG + GG;ABCC2_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;TT;KDR_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG;CYP3A4_AA + AG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:CREATININE_CLEARANCE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;ABCC2;TT;ABCC2_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CC;PON1_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(PR)_AT_1_MONTH_AND_AT_6_MONTHS_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);PEOPLE;DISEASE:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOAFFECTIVE_DISORDER, OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ISONIAZID;ASTN2;C;ASTN2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ALECTINIB;PPARA;AA + AG;PPARA_AA + AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
VALPROIC_ACID;SCN1A;TT;SCN1A_CT;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;CYP2D6;*1/*4 + *4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;ABCB1_C;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
ETHANOL;CRHBP;TT;CRHBP_TT;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;TT;NR1I2_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;del;DRD2_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEXUAL_DYSFUNCTION;MEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OXALIPLATIN;HLA-DRB1;*12:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TEGAFUR/GIMERACIL/OTERACIL;CYP2A6;*4 + *7 + *9 + *10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFACLOR;HLA-DRB1;*14:54;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-A;*11:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*56:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;*1/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HEART_RATE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHAMPHETAMINE;DAOA;C;DAOA_C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CEFACLOR;HLA-DRB1;*04:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANAPHYLAXIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CEFACLOR;HLA-DRB1;*04:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*20;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*37;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:ANGINA_PECTORIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*5;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;GG;KDR_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*15;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*14;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;RISK;DISEASE:HYPOKALEMIA;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RISPERIDONE;ADRB2;G;ADRB2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEXUAL_ADVERSE_EVENTS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BECLOMETHASONE, BUDESONIDE, FLUTICASONE, FLUTICASONE_PROPIONATE, MOMETASONE;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STATUS_ASTHMATICUS;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*1x2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYTARABINE;GLI1;AA;GLI1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ARHGAP9, GLI1;GT + TT;ARHGAP9, GLI1_GT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;ABCB1;A;ABCB1_A;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;TT;KDR_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;ABCB1_C;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;A;ABCB1_A;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
CLOPIDOGREL, RESPIRATORY_SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ELDERLY_ADULT, OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CELSR2, PSRC1;T;CELSR2, PSRC1_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
COCAINE, ETHANOL, OPIOIDS;OPRM1;A;OPRM1_A;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR, INDINAVIR;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ATAZANAVIR, RITONAVIR;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR/RITONAVIR;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;G;SLCO1B1_AA;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
BETA_BLOCKING_AGENTS;GRK5;AA;GRK5_AT + TT;EFFICACY;DECREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;SCN1A;AA;SCN1A_AA;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE/WEIGHT_ADJUSTED_AUC_FOR_MIRTAZAPINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TROGLITAZONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BETA_CELL_FUNCTION;PEOPLE;OTHER:HIGH_RISK_FOR_TYPE_2_DIABETES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC2;CC + CT;ERCC2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_LEVEL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;PICK1;T;PICK1_T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IMATINIB;ABCG2;T;ABCG2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
CAFFEINE;DRD2;GG;DRD2_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
OPIOIDS;GENE_NOT_SPECIFIED;AG + GG;AG + GG;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE, ETHANOL, OPIOIDS;OPRM1;G;OPRM1_G;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;GENE_NOT_SPECIFIED;C;C;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:INSULIN_SECRETION_AT_BASELINE;PEOPLE;OTHER:HIGH_RISK_OF_TYPE_2_DIABETES;CAUTION_DOSE_ADJUST
CISPLATIN;COMT;T;COMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4 + *6;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
OPIOIDS;TACR3;AG + GG;TACR3_AG + GG;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;C;COMT_C;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;ABCC2;GG;ABCC2_GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CITALOPRAM_AUC_AND_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;SLC22A2;CT + TT;SLC22A2_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;T;ABCC2_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;PICK1;T;PICK1_T;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:RECURRENCE;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CYP2D6;AA;CYP2D6_GG;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI;ABCC2;AA;ABCC2_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
OPIOIDS;DRD3;CC + CT;DRD3_CT + TT;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;GENE_NOT_SPECIFIED;CC + CT;CC + CT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:FASTING_GLUCOSE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD3;AA + AG;DRD3_AG + GG;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;DISEASE:BREAST_TENDERNESS, DISEASE:VAGINAL_DRYNESS, DISEASE:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;EXOC4;TT;EXOC4_TT;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;NAT2_A;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:HEPATITIS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:BIPOLAR_DISORDER,OTHER:PERSONALITY_DISORDER, OTHER:PSYCHOTIC_DISORDER, OTHER:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;T;CHRNB2_C;OTHER;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
DIRECT_ACTING_ANTIVIRALS;IFNL4;GG;IFNL4_TT/TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;APLF_CCGG/CCGG + CCGG/del;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;GG;IFNL3_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LACK_OF_TREATMENT_RESPONSE;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
ATAZANAVIR/RITONAVIR;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC2;GG;ERCC2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;ABCG2;GG;ABCG2_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;NAT2_AA;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:HEPATITIS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;A;CHRNB2_A;OTHER;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
CODEINE, HYDROCODONE, OXYCODONE;CYP2D6;*3/*3 + *4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOCEPREVIR, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC1;AA + AG;ERCC1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP2C8;GG;CYP2C8_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_SIDE_EFFECT
OPIUM_ALKALOIDS_AND_DERIVATIVES;CHRNA5;GG;CHRNA5_GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:TOBACCO_USE_DISORDER;PEOPLE;DISEASE:PAIN;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;ABO;GT + TT;ABO_GG;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
GLICLAZIDE;KCNJ11;CT + TT;KCNJ11_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1 + *17;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF804A;CC;ZNF804A_CC;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4/*4;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIUM_ALKALOIDS_AND_DERIVATIVES;CHRNA3;AA;CHRNA3_A;TOXICITY;INCREASED;SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS;PEOPLE;DISEASE:PAIN;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP3A5;TT;CYP3A5_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;IL16;GT + TT;IL16_GT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
INDOMETHACIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;INFANTS;OTHER:PATENT_DUCTUS_ARTERIOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA3;AA + AG;CHRNA3_A;OTHER;INCREASED;LIKELIHOOD;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-B;*15:10;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:STROKE, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:DEATH;PEOPLE;OTHER:TRANSIENT_ISCHEMIC_ATTACK, OTHER:STROKE;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;A;TBXA2R_GG;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
OPIOIDS;CNR1;TT;CNR1_TT;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;NQO1;AA;NQO1_A;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SIGNIFICANTLY_SHORTER_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C9;*2 + *3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METFORMIN;SLC29A4;G;SLC29A4_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NQO1;A;NQO1_A;TOXICITY;INCREASED;RISK;DISEASE:LEUKEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;ACE_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;CNR1;CC;CNR1_CC;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;CC + CG;CYP2B6_CC + CG;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:EVENT-FREE_SURVIVAL, DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH, SIDE_EFFECT:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:ANGINA_PECTORIS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;CHST3;C;CHST3_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
"""FOLIC_ACID"", ""VITAMIN_B-COMPLEX, PLAIN""";MTHFR;AG + GG;MTHFR_AA;EFFICACY;DECREASED;SEVERITY;DISEASE:PAIN;WOMEN;DISEASE:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*51:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;SLC10A2;A;SLC10A2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
AXITINIB, SORAFENIB;HIF1A;CT;HIF1A_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;TYMS;TTAAAGTTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;EFFICACY;INCREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CC + CT;SLC19A1_TT;EFFICACY;INCREASED;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;AA;KDR_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;DBH;AA + AG;DBH_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A;GG;ADORA2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*5/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_AGGREGATION_WITH_ADP;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;CT + TT;CYP2D6_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS, SIDE_EFFECT:TREMOR, SIDE_EFFECT:MUSCLE_RIGIDITY;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
NAN;CYP2B6;TT;CYP2B6_T;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:RS1800497_GG_GENOTYPES;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2B6;CT;CYP2B6_T;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:RS1800497_GG_GENOTYPES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSYCHOMOTOR_AGITATION, SIDE_EFFECT:INSOMNIA;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;G;UGT1A1_GG;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CYP24A1;C;CYP24A1_C;OTHER;DECREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIUM_ALKALOIDS_AND_DERIVATIVES;CHRNA5;A;CHRNA3, CHRNA5_A;TOXICITY;INCREASED;SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS;PEOPLE;DISEASE:PAIN;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_OUTCOME;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ORTHOPEDIC_PATIENTS;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;ABCC3_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
CITALOPRAM;PAPLN;T;PAPLN_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFONAMIDES, UREA_DERIVATIVES;KCNJ11;CT + TT;KCNJ11_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C_AFTER_6-MONTH_TREATMENT;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;*1/*1xN;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;TT;SLC22A1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN;ERCC2;GG + GT;ERCC2_TT;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
VERAPAMIL;KCNIP1, KCNMB1;CT + TT;KCNIP1, KCNMB1_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:EARLIER_ACHIEVEMENT_OF_BLOOD_PRESSURE_CONTROL;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
OPIOIDS;DRD3;AG + GG;DRD3_AG + GG;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;IFNL4_TT/TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;CYP2C9;AC;CYP2C9_AC + CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD3;AG + GG;DRD3_AA + AG;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF568;G;ZNF568_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*53:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PENICILLIN_G;HLA-DPB1;*05:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*38:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;CC;ABCB1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS, SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;OTHER:CEREBROVASCULAR_DISORDERS, OTHER:CAROTID_STENOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;AMHR2;G;AMHR2_G;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METFORMIN_SECRETORY_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;SLCO1B3;GG;SLCO1B3_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE), EFFICACY:DEATH, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, SIDE_EFFECT:UNSTABLE_ANGINA;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;PON1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:THROMBOTIC_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *4;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*8;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATEZOLIZUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;HLA-A;*26:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS, SIDE_EFFECT:HYPOTHYROIDISM;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:UROLOGIC_NEOPLASMS,OTHER:MELANOMA, OTHER:BREAST_NEOPLASMS, OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;RRM1;GG;RRM1_GG;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:HEMATOLOGIC_DISORDER;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;A;SLC22A1_GG;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
OPIOIDS;GABRB3;AA;GABRB3_AA;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*4;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_NORTRIPTYLINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*10;GENOTYPE_NOT_SPECIFIED;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_NORTRIPTYLINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
BECLOMETHASONE_DIPROPIONATE, FLUTICASONE_PROPIONATE;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STATUS_ASTHMATICUS, EFFICACY:EMERGENCIES;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;SLCO1B3;AA;SLCO1B3_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;TT;IFNL3_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID, RIFAMPIN;HLA-DPB1;*05:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;HLA-A;*11:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHANOL;DRD2;GG;DRD2_GG;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SALBUTAMOL;THRB;A;THRB_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(BDR);CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TACR1;AA;TACR1_AA;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:THROMBOTIC_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;APOB;AA + AG;APOB_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:DEATH, EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, TAMOXIFEN;CYP2D6;*10/*10;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;CC;OPRM1_T;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FIRST-GENERATION_CEPHALOSPORINS, FOURTH-GENERATION_CEPHALOSPORINS, OTHER_CEPHALOSPORINS, THIRD-GENERATION_CEPHALOSPORINS;HLA-B;*55:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-B;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""METFORMIN"", ""SULFONAMIDES, UREA_DERIVATIVES""";SLC22A1;GAT/del;SLC22A1_del/del;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEPATOTOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
FIRST-GENERATION_CEPHALOSPORINS, FOURTH-GENERATION_CEPHALOSPORINS, OTHER_CEPHALOSPORINS, THIRD-GENERATION_CEPHALOSPORINS;HLA-C;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FIRST-GENERATION_CEPHALOSPORINS, FOURTH-GENERATION_CEPHALOSPORINS, OTHER_CEPHALOSPORINS, THIRD-GENERATION_CEPHALOSPORINS;HLA-DQB1;*06:09;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DQA1;*05;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A13;CT;CYP2A13_CT;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:CYSTITIS;CHILDREN;OTHER:RHABDOMYOSARCOMA;CAUTION_SIDE_EFFECT
NAN;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTT1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DIPEPTIDYL_PEPTIDASE_4_(DPP-4)_INHIBITORS;HLA-DQB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;UGT1A1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SACITUZUMAB_GOVITECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:FEBRILE_NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *1/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;TT;KDR_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28 + *6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
MIRABEGRON;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:HEADACHE, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:DRUG_TOXICITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MIRABEGRON;SLCO1B1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:HEADACHE, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:DRUG_TOXICITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;GG;MTR_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE, PURINE_ANALOGUES;TPMT;*1/*3A + *3A/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN;GSTT1;non-null;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEARING_LOSS;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;NAT2;*4;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_REACTIONS;CHILDREN;DISEASE:PNEUMONIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;GENOTYPE_NOT_SPECIFIED;DOSAGE;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2 + *3 + *8;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;RISK;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK, EFFICACY:DEATH, EFFICACY:STROKE, EFFICACY:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG + GG;CYP3A4_AA + AG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE_DERIVATIVES;RYR3;TT;RYR3_TT;EFFICACY;INCREASED;RISK;EFFICACY:HEART_FAILURE, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:ANGINA_PECTORIS;PEOPLE;OTHER:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
NAN;CYP4A11;AG + GG;CYP4A11_AG + GG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:HDL-C_CONCENTRATION;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEMETREXED;SLC19A1;TT;SLC19A1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*6 + *28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN;DPYD;c.1627A>G (*5);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_OF_THE_S-ETIOMER_OF_CITALOPRAM_(NO_EFFECT_ON_R-CT);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEMETREXED;SLC19A1;AA + AG;SLC19A1_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEADACHE, SIDE_EFFECT:MUSCLE_SPASM, SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:DIZZINESS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CETUXIMAB;FCGR2A;GG;FCGR2A_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, AMPICILLIN, BACAMPICILLIN;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DRD3;CC + CT;DRD3_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COGNITIVE_DISORDER;MEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;OTHER;DECREASED;RISK;DISEASE:LUNG_NEOPLASMS;MEN;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ACTN1;T;ACTN1_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;UPB1;GG;UPB1_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PEMETREXED;MTHFR;AA + AG;MTHFR_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, FOLFIRI, FOLFIRINOX, FOLFOX;DPYD;c.2194G>A (*6);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:STOMATITIS, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;PAPPA;A;PAPPA_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;UPB1;GG;UPB1_GG;TOXICITY;DECREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;AA + AG;DPYD_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEMETREXED;SLC19A1;GG + GT;SLC19A1_GG + GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;CHILDREN;OTHER:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;ANKK1, DRD2;AA + AG;DRD2_G;TOXICITY;DECREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, ANTIDEPRESSANTS, CLOMIPRAMINE, DESIPRAMINE, FLUOXETINE, IMIPRAMINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
SIROLIMUS;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TOTAL_CHOLESTEROL;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*1;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
VINCRISTINE;NRG3;T;NRG3_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
VINCRISTINE;LRRTM3;G;LRRTM3_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
VINCRISTINE;ARHGAP5;G;ARHGAP5_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;TPMT;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;CC;CYP2A6_C;TOXICITY;DECREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;METTL8;G;METTL8_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DEATH, EFFICACY:STROKE, EFFICACY:HEART_FAILURE, EFFICACY:MYOCARDIAL_INFARCTION;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;CT;UGT1A1_CT;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;UGT1A1;G;UGT1A1_G;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NALOXONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CORTISOL_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CERS6;T;CERS6_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;TLR4;C;TLR4_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NFIB;G;NFIB_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIARRHYTHMICS, CLASS_I_AND_III;GENE_NOT_SPECIFIED;GT + TT;GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MCM3AP;T;MCM3AP_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;SPDYA;T;SPDYA_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;PDE4D;C;PDE4D_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;FBN2;T;FBN2_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;VTI1A;T;VTI1A_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ZFAND3;C;ZFAND3_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;HLA-DRB1;*11:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANAPHYLAXIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;EFFICACY:PERIPHERAL_VASCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL, PREDNISONE, TACROLIMUS;CYP3A5;*1/*1 + *1/*3;GENOTYPE_NOT_SPECIFIED;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:VIRUS_DISEASES;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIROLIMUS;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACETAMINOPHEN/CODEINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:CONSTIPATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASBURICASE;G6PD;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;OTHER:HYPERURICEMIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SIROLIMUS;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TRIGLYCERIDES;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ATRIAL_FIBRILLATION;PEOPLE;OTHER:CORONARY_DISEASE, OTHER:SURGERY;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ADALIMUMAB, AMIODARONE, BEVACIZUMAB, BICALUTAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, ERLOTINIB, EVEROLIMUS, FLUOROURACIL, GEFITINIB, GEMCITABINE, IRINOTECAN, LEUCOVORIN, METHOTREXATE, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB, SITAGLIPTIN, TEGAFUR/GIMERACIL/OTERACIL, TRASTUZUMAB;HLA-DRB1;*04:05;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMSULOSIN;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANASTROZOLE, EXEMESTANE, LETROZOLE;CCDC148;CT + TT;CCDC148_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:ERYTHEMA_MULTIFORME;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
PEMETREXED;DHFR;AA + AG;DHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C8;*1/*1;GENOTYPE_NOT_SPECIFIED;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;GG;PTGS2_GG;EFFICACY;DECREASED;RISK;DISEASE:PROSTATIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:PRECURSOR_T-CELL_LYMPHOBLASTIC_LEUKEMIA-LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;G;CYP2A6_G;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DBH;C;DBH_C;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7;GENOTYPE_NOT_SPECIFIED;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
FLURBIPROFEN, IRINOTECAN;UGT1A1;*1/*36;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID, RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;A;UGT1A1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CASP9;T;CASP9_T;EFFICACY;INCREASED;SEVERITY;EFFICACY:LEUKOCYTOSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AA + AG;DPYD_AG + GG;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;A;UGT1A1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;SLC19A1;CC;SLC19A1_TT;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;ATIC;CC;ATIC_CC;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;NFATC2;TT;NFATC2_TT;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;ABCC2;AA;ABCC2_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CETUXIMAB;FCGR3A;CC;FCGR3A_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIBODY-DEPENDENT_CELLULAR_CYTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;ABCC1;AA;ABCC1_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*24:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*15:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR, EFAVIRENZ;TPH2;GG;TPH2_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*01:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*52:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;*03:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR, EFAVIRENZ;TPH2;GG;TPH2_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;*13:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;TT;ENOSF1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*40:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*31:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;OPRM1;GG + GT;OPRM1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLATE_MOFETIL;IMPDH1;T;IMPDH1_T;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GI_INTOLERANCE;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ERLOTINIB, GEFITINIB;USP36;CC;USP36_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;HLA-B;*51:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CACNB2;CT;CACNB2_CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CACNA2D2;AA;CACNA2D2_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;UGT2B10;AA;UGT2B10_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2B;AA + CC;ADRA2B_AA + CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;CES1;T;CES1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
PURINE_ANALOGUES;NUDT15;*1/*3;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;THSD7A;G;THSD7A_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;GENE_NOT_SPECIFIED;C;C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY, EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:POSTOPERATIVE_NAUSEA_AND_VOMITING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ERAP2;TT;ERAP2_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;UGT1A8;CC;UGT1A8_CC;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DRB1;*13:01;GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:ADENOCARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA,OTHER:CARCINOMA_ SQUAMOUS_CELL, OTHER:NEUROENDOCRINE_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DPB1;*02:02;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:ADENOCARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA,OTHER:CARCINOMA_ SQUAMOUS_CELL, OTHER:NEUROENDOCRINE_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;SLC22A1;del/del;SLC22A1_del/del;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;GSTM1;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;CASP9;C;CASP9_C;EFFICACY;INCREASED;SEVERITY;EFFICACY:LEUKOCYTOSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CASP8;G;CASP8_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEPR;AG + GG;LEPR_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;TOXICITY;INCREASED;RISK;DISEASE:SEIZURES;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CISPLATIN, PACLITAXEL;GGT1;CC;GGT1_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;T;TPMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;UGT1A1;A;UGT1A1_AA;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEPR, LEPROT;AA;LEPR_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
DOLUTEGRAVIR;NR1I2;CT + TT;NR1I2_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;T;TPMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;GG;LEPR_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;AC + CC;LEPR_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;DRD2;AA + AG;DRD2_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
NAN;UGT1A1;A;UGT1A1_A;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;C;TPMT_C;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;ASPH;T;ASPH_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PACLITAXEL;SLCO1B3;AA;SLCO1B3_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;AA + AG;PEAR1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:STROKE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;MTHFR_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;AC;ITPA_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_DISTURBANCES_IN_HCV-HIV_COINFECTED_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;CETP;A;CETP_A;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HDL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRIMIDINE_ANALOGUES;MTHFR;AA + AC;MTHFR_AA;NAN;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
METHOTREXATE;ITPA;A;ITPA_AC;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
GEFITINIB;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;CTLA4;A;CTLA4_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;GENE_NOT_SPECIFIED;T;AHR_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:HABITUAL_CONSUMPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LIRAGLUTIDE;GLP1R;AA + AG;GLP1R_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:WEIGHT_LOSS;PEOPLE;OTHER:DIABETES_MELLITUS_T2, OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ESR1;CC;ESR1_C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;ABCG8;CG;ABCG8_CG;OTHER;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM;ERCC5;GG;ERCC5_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;ERCC5;GG;ERCC5_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2C;T;HTR2C_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;FGD4;A;FGD4_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A1;T;CYP1A1_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:HABITUAL_CONSUMPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM;SLC6A4;C;SLC6A4_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEMENTIA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;SOCS3;AG;SOCS3_AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA_IN_HCV-HIV_COINFECTED_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;POR;TT;POR_CT + TT;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_OF_MIDAZOLAM;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ENALAPRIL;PNPT1;G;PNPT1_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ITPA;A;ITPA_AC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TO_METHOTREXATE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
NICOTINE;HTR3B;CT + TT;HTR3B_CT + TT;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;SLC6A12;A;SLC6A12_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
GEFITINIB;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;GG;CYP4F2_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;SLC6A12;G;SLC6A12_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;WIF1;GG + GT;WIF1_GG + GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCB1;G;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;CBR3;AG;CBR3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;WNT5B;AG + GG;WNT5B_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;AXIN2;AA + AC;AXIN2_AA + AC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;PACSIN2;T;PACSIN2_CT + TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GI_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLCO1B1;T;SLCO1B1_T;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GI_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;ITPA;CC;ITPA_AC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;CXXC4;AA + AG;CXXC4_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;PNPT1;C;PNPT1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;T;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC2;GG;ERCC2_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PNEUMONITIS;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;ERCC2;CT + TT;ERCC2_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PNEUMONITIS;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
DOXORUBICIN;NCF4;AA + AG;NCF4_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMPHETAMINE;DRD2;AA;DRD2_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:STOP_REACTION_TIME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG-RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG-RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR2A;GG;HTR2A_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATIONS_DUE_TO_ADVERSE_EVENTS_AND_GREATER_SEVERITY_OF_SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CD80;AA;CD80_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;UGT1A9;A;UGT1A9_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;GENE_NOT_SPECIFIED;TT;TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;AXIN2;CC + CG;AXIN2_CC + CG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;UGT1A9;T;UGT1A9_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;GG;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, MYCOPHENOLATE_MOFETIL;UGT1A8;CC;UGT1A8_CC;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;IL10;AA;IL10_AG + GG;METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ACHIEVING_TARGET_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ARID5B;CC + CT;ARID5B_CC + CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CYP2B6;AA;CYP2B6_AA;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLLITROPIN_BETA, THYROTROPIN_ALFA, UROFOLLITROPIN;FSHR;T;FSHR_T;EFFICACY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY, OTHER;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
NAN;UGT2B10;CC;UGT2B10_CC;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F5;T;F5_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;CT + TT;CYP2C19_TT;EFFICACY, OTHER;DECREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F2;A;F2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;TYMP;AA + AG;TYMP_AA + AG;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_MK-4_CONCENTRATION;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CG;DPYD_C;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;VDR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_MINERAL_DENSITY;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;PPARA;TT;PPARA_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_FASTING_LDL-C;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;PPARA;CC + CT;PPARA_CC + CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_FASTING_IL-2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_SENSITIVITY_INDEX_(INR/CPSS);CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;VDR;CC;VDR_TT;NAN;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_MINERAL_DENSITY;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;DISEASE:DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENOFIBRATE;PPARA;TT;PPARA_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_FASTING_LDL-C;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;VDR;CC;VDR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:URINARY_DPD/CR_LEVELS;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
EXEMESTANE;CYP19A1;TT;CYP19A1_TT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;PPARA;GG;PPARA_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;SLC5A7;AG + GG;SLC5A7_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;ADH1B;T;ADH1B_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERURICEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VINCRISTINE;NKAIN3;A;NKAIN3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ATENOLOL;PROX1;C;PROX1_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GLUCOSE_ELEVATION;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEPSIS, SIDE_EFFECT:SEIZURES, SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCG2;GT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCC1;T;ABCC1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:SIGNIFICANTLY_HIGHER_ON-TREATMENT_PLATELET_REACTIVITY_WITH_A_MAINTECE_DOSE_OF_75_MG_DAILY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;COMT_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;CG + GG;IL6_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;CYP3A4;AG;CYP3A4_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_INTERRUPTION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;CEP72_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;GG;CYP2D6_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HEART_RATE;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CONJUGATED_ESTROGENS, MEDROXYPROGESTERONE;VDR;TT;VDR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SPINE_BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;CACNB2;GG;CACNB2_GG;EFFICACY, TOXICITY;INCREASED;RISK;EFFICACY:ADVERSE_OUTCOME;PEOPLE;OTHER:HYPERTENSION_AND_CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;CC;SLC47A1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TO_METFORMIN;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;CYP3A5_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;CC;SLC47A1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TO_METFORMIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAZODONE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PROLONGED_QTC_INTERVAL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INTERFERONS, RIBAVIRIN;BCL2;T;BCL2_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FREQUENCY_(ABOUT_DOUBLE)_IN_NON-RESPONDER_PATIENTS_COMPARED_WITH_RESPONDER_PATIENTS_(HCV_GENOTYPE_4);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN;KRAS;T;KRAS_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MSH6;GG;MSH6_GG;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC3;CC;XRCC3_CC;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NR1I2;GG;NR1I2_GG;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:FATTY_LIVER_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;CCND1;AA;CCND1_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
VERAPAMIL;CACNB2;AT + TT;CACNB2_AT + TT;EFFICACY, TOXICITY;INCREASED;RISK;EFFICACY:ADVERSE_OUTCOME;PEOPLE;OTHER:HYPERTENSION_AND_CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC1;C;ABCC1_CC + CG;TOXICITY;DECREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;GENE_NOT_SPECIFIED;AA;AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:BETTER_SURVIVAL_OUTCOME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;AA;ABCC2_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;IGFBP3;TT;IGFBP3_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:BETTER_SURVIVAL_OUTCOME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;TT;ABCC2_CT + TT;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;TT;ABCC2_C;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
COCAINE;DRD2;C;DRD2_C;TOXICITY;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;DRD2_A;TOXICITY;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;DRD2_A;TOXICITY;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;SLCO1B1;A;SLCO1B1_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;SLCO1B1;TT;SLCO1B1_TT;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;CC;COMT_CC + CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;WOMEN;OTHER:PAIN;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;SLCO1B1;C;SLCO1B1_TT;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN/TRAMADOL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CONSTIPATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;VDR;AA + AG;VDR_AA + AG;NAN;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;CT;COMT_CC + CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CAPECITABINE;ABCB1;AA;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;OPRM1_AA;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;CC;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ERECTILE_DYSFUNCTION, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:SEDATION, SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCB1;GG;ABCB1_A;TOXICITY;DECREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;A;CYP2C9_A;DOSAGE, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_VARIABILITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUNITINIB;NR1I2;TT;NR1I2_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AMPHETAMINE;OPRM1;TT;OPRM1_T;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:STIMULATION_AND_EUPHORIA_SCORES_AFTER_AMPHETAMINE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;DISEASE:MUSCULAR_DISEASES;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;CT;ABCG2_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;LRP5;T;LRP5_T;NAN;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN;NHLH1;CT + TT;NHLH1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA, OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GENE_NOT_SPECIFIED;A;A;NAN;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:LUMBAR_SPINE_BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;GENE_NOT_SPECIFIED;A;A;NAN;INCREASED;RISK;DISEASE:OSTEOPOROSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;LRP5;T;LRP5_T;NAN;INCREASED;RISK;DISEASE:OSTEOPOROSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BORTEZOMIB;CBS;TT;CBS_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:PAIN, SIDE_EFFECT:NEUROPATHIC_PAIN;PEOPLE;OTHER:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
NAN;UGT2B15;AA;UGT2B15_AA;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE;OPRM1;CC;OPRM1_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:EUPHORIC_AND_ENERGETIC_AFTER_AMPHETAMINE_(10_MG);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;HNF4A;CC;HNF4A_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;SEMA6A;A;SEMA6A_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA, OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY, OTHER;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
WARFARIN;HNF4A;GG;HNF4A_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;ITGB3;CC + CT;ITGB3_TT;EFFICACY, OTHER;DECREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;HNF4A;TT;HNF4A_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ONDANSETRON;SLC6A4;AA;SLC6A4_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TREATMENT_RESPONSE_AMONG_PATIENTS_CARRYING_THE_SLC6A4_PROMOTER_LENGTH_POLYMORPHISM_LONG/LONG_GENOTYPE;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GENE_NOT_SPECIFIED;G;G;OTHER;INCREASED;LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2A;GG;HTR2A_GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;G;OPRM1_G;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;GENE_NOT_SPECIFIED;TT;TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;NEDD4L;AA;NEDD4L_AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADRB1;GG;ADRB1_AG + GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA + AG;MTHFR_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;CT + TT;HTR2C_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BLEOMYCIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE, VINDESINE;ABCB1;CT;ABCB1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;C;CYP2B6_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;CC;CYP3A5_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XPC;GG + GT;XPC_G;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_SIDE_EFFECT
METHADONE;OPRM1;G;OPRM1_AA;OTHER;DECREASED;LIKELIHOOD;DISEASE:RECURRENCE;PEOPLE;DISEASE:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2C9;C;CYP2C9_AC + CC;NAN;DECREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2C9;C;CYP2C9_AC + CC;NAN;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUFENTANIL;CYP3A4;TT;CYP3A4_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;ADRA2A;A;ADRA2A_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADRA2A;G;ADRA2A_G;OTHER;DECREASED;LIKELIHOOD;DISEASE:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
MURAGLITAZAR;REN;TT;REN_TT;TOXICITY;DECREASED;RISK;DISEASE:EDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROQUINE, PRIMAQUINE;SLCO2B1;GG;SLCO2B1_GG;EFFICACY;INCREASED;SEVERITY;EFFICACY:PARASITEMIA;PEOPLE;DISEASE:MALARIA;CAUTION_SIDE_EFFECT
ASPIRIN;IL4;TT;IL4_TT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CNR1;CC;CNR1_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;AC + CC;CYP2C9_AC + CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC16A7;A;SLC16A7_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_METHOTREXATE;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METFORMIN;AMHR2;G;AMHR2_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC_ACID_DERIVATIVES, PYRAZOLONES;PLA2G4A;G;PLA2G4A_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CNR1;CC;CNR1_CC;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SHORTER_TIME_TO_FIRST_THERAPEUTIC_INR_AND_TIME_TO_FIRST_INR>4;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;C;DPYD_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYCSP5;A;CYCSP5_AA + AC;TOXICITY, OTHER;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:ACQUIRED_IMMUNODEFICIENCY_SYNDROME;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC_ACID_DERIVATIVES, PYRAZOLONES;PLCG1;G;PLCG1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC_ACID_DERIVATIVES, PYRAZOLONES;TNFRSF11A;C;TNFRSF11A_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA, SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIHYPERTENSIVES;NOS3;G;NOS3_GG + GT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;NOS3;C;NOS3_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;ADRA2A;A;ADRA2A_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CISPLATIN;SLC22A1;CG + GG;SLC22A1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GENE_NOT_SPECIFIED;G;G;TOXICITY;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;T;ABCC5_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;A;ABCC5_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG1;T;ABCG1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CC;PON1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;PPARD;AG + GG;PPARD_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;CYP3A5_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;A;CYP2C19_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROPERTION_OF_THE_FIRST_6_MONTHS'_TREATMENT_TIME_SPENT_WITHIN_THE_TARGET_INR_RANGE_(PTIR);CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:MYELOSUPPRESSION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;G;DPYD_AG;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;CC + CT;CYP3A5_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN/TRAMADOL;MIR107;AA + AG;MIR107_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GSK3B;AA;GSK3B_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE;NQO1;AA;NQO1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN/TRAMADOL;MIR23B;GG;MIR23B_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
ACETAMINOPHEN/TRAMADOL;MIR23B;CG + GG;MIR23B_CG + GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NEUROPATHIC_PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CYP1A2;AA + AG;CYP1A2_GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD3;AA + AG;DRD3_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;DRD3;AG + GG;DRD3_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;FAAH;A;FAAH_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:METHAMPHETAMINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A4;CC + CT;CYP3A4_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;UGT1A6;AC + CC;UGT1A6_AC + CC;EFFICACY;INCREASED;RISK;DISEASE:COLONIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN/TRAMADOL;OPRM1;CT + TT;OPRM1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CONSTIPATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;AA + AG;CYP3A5_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
REGORAFENIB;KDR;A;KDR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;TT;NR1I2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;TT;NR1I2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;AA + TT;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAXANES;NR1I3;CC;NR1I3_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A1;G;UGT1A_CG + GG;OTHER;INCREASED;RISK;SIDE_EFFECT:NEPHROLITHIASIS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;AC + CT;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_CC;TOXICITY;INCREASED;RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCB1;TT;ABCB1_C;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;AA;UGT2B7_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A1;T;UGT1A_CT + TT;OTHER;INCREASED;RISK;SIDE_EFFECT:NEPHROLITHIASIS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;TT;UGT2B7_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A1;G;UGT1A_CG + GG;OTHER;INCREASED;RISK;SIDE_EFFECT:NEPHROLITHIASIS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;AA;UGT2B7_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;UGT2B7;TT;UGT2B7_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY;INCREASED;RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER;MEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GRM3;TT;GRM3_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;PON1_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NON-RESPONSIVENESS;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
RISPERIDONE;BDNF;TT;BDNF, BDNF-AS_CC;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;FCER2;G;FCER2_G;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHMA-RELATED_ER_VISIT_OR_HOSPITALIZATION;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, RADIOTHERAPY;CXCL8;AA;CXCL8_A;EFFICACY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL, RADIOTHERAPY;KDR;AA;KDR_A;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:RECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IL6;CC;IL6_CC;TOXICITY;DECREASED;RISK;DISEASE:DEPRESSION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP7A1;TT;CYP7A1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_PERCENTAGE_REDUCTION_OF_TRIGLYCERIDES_LEVEL;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANGRELOR;P2RY12;G;P2RY12_G;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:5%_LOWER_ADP-INDUCED_PEAK_PLATELET_AGGREGATION_IN-VITRO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;APOC1, APOE;A;APOC1, APOE_A;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
SUNITINIB;FGFR2;AA;FGFR2_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE/TRIMETHOPRIM;NAT2;A;NAT2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_REACTIONS;CHILDREN;DISEASE:PNEUMONIA;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;CC + CT;FLT4_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;OPRM1;AG + GG;OPRM1_AA;TOXICITY;DECREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NR1I3;AA + AG;NR1I3_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;FADS1, FEN1, MIR611, TMEM258;T;FADS1, FEN1, MIR611, TMEM258_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
NAN;GENE_NOT_SPECIFIED;C;C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
NAN;LDLR;T;LDLR_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
NAN;PNMT;T;PNMT_T;OTHER;DECREASED;RISK;OTHER:SICKLE_CELL_PAIN_CRISIS;PEOPLE;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY;GSTP1;GG;GSTP1_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE, LENALIDOMIDE;ABCB1;CT;ABCB1_CT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;DDRGK1, ITPA;AC;ITPA_AC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;PNMT;GG;PNMT_GG;OTHER;DECREASED;RISK;OTHER:SICKLE_CELL_PAIN_CRISIS;PEOPLE;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;SLCO1B3;GT + TT;SLCO1B3_GG;EFFICACY;INCREASED;RISK;OTHER:CHRONIC_LUNG_ALLOGRAFT_DYSFUNCTION;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NAN;PNMT;AA + AG;PNMT_AA + AG;OTHER;DECREASED;RISK;OTHER:SICKLE_CELL_PAIN_CRISIS;WOMEN;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, BISOPROLOL;ACY3;C;ACY3_C;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE, EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;MEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;KIRREL2, NPHS1;T;KIRREL2, NPHS1_T;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ADORA1;TT;ADORA1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;FPGS;TT;FPGS_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NR1I3;AA;NR1I3_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT4;AA + AC;FLT4_AC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ALPRAZOLAM;CYP3A4;AG;CYP3A4_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
MYCOPHENOLIC_ACID;SLCO1B3;AG + GG;SLCO1B3_AA;EFFICACY;INCREASED;RISK;OTHER:TRANSPLANT_REJECTION;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MYCOPHENOLIC_ACID;SLCO1B3;AG + GG;SLCO1B3_AA;EFFICACY;DECREASED;LIKELIHOOD;OTHER:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AG + GG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP1A1;T;CYP1A1_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:25%_HIGHER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
MYCOPHENOLIC_ACID;SLCO1B3;GT + TT;SLCO1B3_GG;EFFICACY;INCREASED;RISK;OTHER:TRANSPLANT_REJECTION;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN;MGAT4A;G;MGAT4A_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ADGRV1;C;ADGRV1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CAPECITABINE, OXALIPLATIN;MGAT4A;G;MGAT4A_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;FMO3;AA;FMO3_A;EFFICACY;DECREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;EFFICACY:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID;SLCO1B3;GT + TT;SLCO1B3_GG;EFFICACY;DECREASED;LIKELIHOOD;OTHER:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;UGT1A1_AG;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;G;PEAR1_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;PEAR1;C;PEAR1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION, NICOTINE;APOE;CC + CT;APOE_C;OTHER;INCREASED;LIKELIHOOD;DISEASE:RECURRENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PEAR1;TT;PEAR1_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LOW_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ALENDRONATE, IBANDRONATE, RISEDRONATE, ZOLEDRONATE;SIRT1;A;SIRT1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;LEPR;AG + GG;LEPR_AG + GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;GSTM5;C;GSTM5_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ATORVASTATIN, BEZAFIBRATE;APOE;AT + TT;APOE_AT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LIPID-LOWERING_EFFECT;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;SLC6A5;AA;SLC6A5_AA;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MOTOR_SIDE_EFFECTS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OLANZAPINE;AHR;T;AHR_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:29%_LOWER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA + AG;P2RY12_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;T;PEAR1_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP4F2;T;CYP4F2_AA;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EPISTAXIS, SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE, SIDE_EFFECT:HEMATOMA, SIDE_EFFECT:HEMATURIA, SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;del;CYP2D6_A/DELA;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:IMPAIRED_METABOLIC_ACTIVITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ASPIRIN, TICAGRELOR;CYP4F2;T;CYP4F2_AA;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EPISTAXIS, SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE, SIDE_EFFECT:HEMATOMA, SIDE_EFFECT:HEMATURIA, SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AA + AC;MED12L, P2RY12_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN;CASP3;C;CASP3_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;XPNPEP2;A;XPNPEP2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;SLCO1B1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;GG + GT;CES1_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;C;CCHCR1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN;CYP3A4;A;CYP3A4_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GLI1;CC;GLI1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;ANKK1, DRD2;AA + AG;DRD2_G;TOXICITY;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VALPROIC_ACID;UGT1A6;AG + GG;UGT1A6_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREMOR;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;T;CYP1A2_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;ACKR1;CC;ACKR1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ESCITALOPRAM;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;T;PEAR1_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP1A2;C;CYP1A2_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NAUSEA/VOMITING;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;T;CYP1A2_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NAUSEA/VOMITING;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;C;CYP1A2_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NAUSEA/VOMITING;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;AA + AC;CYCSP5_AA + AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;AA + AC;CYP1A2_AA;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:CIGARETTE_SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRK1;CC + CT;OPRK1_CC + CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ALCOHOL_ABUSE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO1;A;NQO1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:WORSE_OUTCOME_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL);PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
HEROIN;GRM3;T;GRM3_T;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
THIAZOLIDINEDIONES;AQP2;T;AQP2_T;TOXICITY;INCREASED;RISK;DISEASE:EDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA3;G;CHRNA3, CHRNA5_GG;TOXICITY, OTHER;DECREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN;ABCC5;G;ABCC5_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOXORUBICIN;FASLG;T;FASLG_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOXORUBICIN;MSH2;C;MSH2_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;SLC1A1;C;SLC1A1_C;EFFICACY;INCREASED;SEVERITY;EFFICACY:PHARMACOLOGICAL_RESISTANCE;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
COCAINE;CHRNA5;G;CHRNA5_G;OTHER;INCREASED;LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;XPNPEP2;A;XPNPEP2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;GENE_NOT_SPECIFIED;AG + GG;AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;AA + AG;PSORS1C1, PSORS1C2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FEXOFENADINE;SLCO2B1;T;SLCO2B1_T;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC_AGENTS;SLC28A3;AA;SLC28A3_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION_(P<0.001);PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;TRAT1;C;TRAT1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2A6;AC + CC;CYP2A6_AC + CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION_(P=0.028);PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;CC;CYP3A4_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;CT;CYP3A4_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ADH1B;A;ADH1B_A;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC_AGENTS;DCTD;AA;CTPS1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;UGT2B7;CC + CT;UGT2B7_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC2;G;ERCC2_TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;TRAC;A;TRAC_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;G;CCHCR1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NAN;FGFBP1;CC;FGFBP1_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH, DISEASE:GASTROINTESTINAL_HEMORRHAGE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
NAN;FGFBP1;TT;FGFBP1_TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:BONE_MINERAL_DENSITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;GG;SLCO1B1_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_LDL;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GENE_NOT_SPECIFIED;G;G;OTHER;INCREASED;RISK;DISEASE:VENTRICULAR_FIBRILLATION;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
NEVIRAPINE;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NICOTINE;FMO1;C;FMO1_C;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;POLR3G;T;POLR3G_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NICOTINE;FMO1;T;FMO1_CT + TT;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPARAGINASE;GRIA1;T;GRIA1_T;TOXICITY;INCREASED;RISK;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP17A1;AG + GG;CYP17A1_AG + GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;C;CYP2C9_AC + CC;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH, DISEASE:GASTROINTESTINAL_HEMORRHAGE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL;ERCC1;AA + AC;ERCC1_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYP2C19;AA + AG;CYP2C19_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;TNFRSF11B;CC;TNFRSF11B_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;SOX10;CG;SOX10_CG;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;TNFRSF11B;CC;TNFRSF11B_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, SIDE_EFFECT:PAIN;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;TNFSF11;CC;TNFSF11_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;CTPS1;A;CTPS1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;CYP2C19_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;CTPS1;A;CTPS1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE;CES2;CG + GG;CES2_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ANASTROZOLE, LETROZOLE;TNFSF11;CC;TNFSF11_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, SIDE_EFFECT:PAIN;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;SOD2;AG + GG;SOD2_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""ANALGESICS_AND_ANESTHETICS"", ""ANTIBIOTICS"", ""ANTIEPILEPTICS"", ""ANTIFUNGALS_FOR_SYSTEMIC_USE"", ""ANTIINFLAMMATORY_AND_ANTIRHEUMATIC_PRODUCTS, NON-STEROIDS"", ""ANTIMYCOBACTERIALS"", ""ANTITHYROID_PREPARATIONS""";SOD2;AG + GG;SOD2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;CYP2C19_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;PPARG;G;PPARG_CG;OTHER;INCREASED;LIKELIHOOD;OTHER:SHORT_AND_LONG-TERM_WEIGHT_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOTANE;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:BEING_A_PREDICTOR_OF_MITOTANE_PLASMA_CONCENTRATIONS_OF_AT_LEAST_14_G/ML_AFTER_3_MONTHS_OF_TREATMENT;PEOPLE;DISEASE:ADRENOCORTICAL_CARCINOMA;CAUTION_DOSE_ADJUST
BORTEZOMIB, MELPHALAN, PREDNISONE;CTLA4;GG;CTLA4_GG;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:EARLIER_ONSET_OF_BORTEZOMIB-INDUCED_PERIPHERAL_NEUROPATHY;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PBMC-ASSOCIATED_DRUG_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;CRHR1;TT;CRHR1_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:BASELINE_CORTISOL_LEVELS;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:INTRACELLULAR_PBMC_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
VALPROIC_ACID;SOD2;AG + GG;SOD2_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ALOPECIA;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;AA;ABCB1_A;OTHER;INCREASED;LIKELIHOOD;OTHER:HELICOBACTER_PYLORI_INFECTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;LEPR;AG + GG;LEPR_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ALOPECIA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ADP-STIMULATED_PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;AG + GG;CDA_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;ABCB1;CC + CT;ABCB1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL, TICAGRELOR;CYP4F2;TT;CYP4F2_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:RECURRENCE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;CYP2B6_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MINIMUM_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;CC;UGT1A3_CC;EFFICACY;DECREASED;RISK;EFFICACY:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;GG;ERCC2_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;TT;UGT1A1_CT;EFFICACY;DECREASED;RISK;DISEASE:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;AA + AG;SLC47A2_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:RENAL_AND_SECRETORY_CLEARANCE_OF_METFORMIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA;SLC47A2_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TO_METFORMIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CES1;GG + GT;CES1_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ORAL_CLEARANCE_OF_ATORVASTATIN;PEOPLE;DISEASE:OBESITY;CAUTION_DOSE_ADJUST
CAPECITABINE;CES1;GG + GT;CES1_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DEFERASIROX;CYP1A2;AA;CYP1A2_AA;EFFICACY;DECREASED;RISK;EFFICACY:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS;CYP3A5;T;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;GG;ERCC2_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;CYP1A1;CC;CYP1A1_A;EFFICACY;DECREASED;RISK;EFFICACY:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;GRM3;C;GRM3_C;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;CC + CT;ABCB1_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ACCUMULATION_OF_DRUG_IN_PBMCS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ETHANOL;CHRNA4;G;CHRNA4_G;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F2;AG;F2_A;TOXICITY;INCREASED;RISK;DISEASE:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;ENPP2;AA;ENPP2_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F5;CT;F5_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;XRCC1;CT + TT;XRCC1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ADORA1;GG + GT;ADORA1_GG + GT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG + GT;MTHFR_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SKIN_DISORDER;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AG + GG;FASTKD3, MTRR_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PROPRANOLOL;CYP2D6;AA;CYP2D6_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_PLASMA_CONCENTRATION_OF_PROPRANOLOL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;G;HLA-DQB1_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;CC;ERCC2_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CT + TT;APOE_C;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_DISEASE, OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;C;DPYD_C;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;PPARG;G;PPARG_CG;OTHER;INCREASED;LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CC + CT;APOE_C;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HYPERTRIGLYCERIDEMIA;PEOPLE;OTHER:CORONARY_DISEASE, OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
CLOZAPINE;HLA-DQB1;G;HLA-DQB1_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SIMVASTATIN;APOE;C;APOE_C;EFFICACY;INCREASED;RISK;OTHER:MORTALITY_AFTER_MYOCARDIAL_INFARCTION, HOWEVER_THIS_CAN_BE_ELIMINATED;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE;HTR2C;G;HTR2C_C;OTHER;INCREASED;LIKELIHOOD;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, ILOPERIDONE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;HTR2C;C;HTR2C_T;OTHER;INCREASED;RISK;DISEASE:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;SOD2;TT;SOD2_TT;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;ENPP2;A;ENPP2_A;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;BCL2;TT;BCL2_TT;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;OPRM1;TT;OPRM1_TT;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;GENE_NOT_SPECIFIED;AG;AG;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
TOLCAPONE;GENE_NOT_SPECIFIED;GG;COMT_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REACTION_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ABSTINENT_SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLASETRON, GRANISETRON;NOS1AP;GT + TT;NOS1AP_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:QTC_PROLONGATION;PEOPLE;OTHER:SURGERY_AS_PART_OF_ANESTHETIC_MANAGEMENT;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;A;ABCB1_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;ELAVL2;A;ELAVL2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MID-DOSE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CC + CT;DPYD_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;SLCO1B3_G;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
TOLCAPONE;COMT;AG;COMT_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REACTION_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:ABSTINENT_SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
HEROIN;SOD2;AC + CC;SOD2_AC + CC;TOXICITY;DECREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;SLCO1B3_G;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;A;SLCO1B3_AA;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
IRINOTECAN;TOP1;GG;TOP1_GG;TOXICITY;DECREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOB;G;APOB_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;GG;EGFR_GT + TT;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCG2;CC;ABCG2_CT + TT;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_AUC;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;APOB;G;APOB_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_PAIN;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_PAIN;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;ABCB1;G;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, FLUVASTATIN, HMG_COA_REDUCTASE_INHIBITORS, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;C;SLCO1B1_TT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;B4GALT2;CT + TT;B4GALT2_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;CYB5A;AA + AG;CYB5A_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS;WOMEN;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F5;CT;F5_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:STROKE;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CT;CYP2B6_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CETUXIMAB, PANITUMUMAB;KRAS;C;KRAS_AC + CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:NONRESPONSE_TO_ANTI-EGFR-BASED_TREATMENT;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_DOSE_ADJUST
EDOXABAN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;GG;ABCB1_A;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN;BLMH;CC;BLMH_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;MEN;DISEASE:TESTICULAR_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTP1;AA + AG;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_HEARING_IMPAIRMENT;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;FKBP5;A;FKBP5_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TH;AA + AG;TH_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DISULFIRAM;DBH;CC;DBH_T;EFFICACY;DECREASED;SEVERITY;EFFICACY:COCAINE_DEPENDENCE;PEOPLE;OTHER:COCAINE_DEPENDENCE, OTHER:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AA;COMT_AA;TOXICITY;DECREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VEGFA;CC + CG;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR;IFNL3, IFNL4;CT + TT;IFNL3_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TH;CT + TT;TH_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;ABCB1;A;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_DRUG_LEVELS;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;A;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_DRUG_LEVELS;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;CBR3;GG;CBR3_A;TOXICITY;INCREASED;RISK;DISEASE:CARDIOMYOPATHIES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;PRKCB;T;PRKCB_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:DEXMEDETOMIDINE_ED50_VALUES_FOR_DRUG-INDUCED_DORSAL_HAND_VEIN_(DHV)_CONSTRICTION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;T;CYP2C19_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;CC;ABCB1_CT + TT;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;CYP2C19;T;CYP2C19_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:_RATE_OF_HIGH_ON-TREATMENT_PLATELET_REACTIVITY_(HTPR)_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;LPA;G;LPA_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CORONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PRASUGREL;CYP2C19;T;CYP2C19_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_COMPLICATIONS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;A;DRD1_A;EFFICACY, TOXICITY, OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
PRASUGREL;CYP2C19;T;CYP2C19_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:_RATE_OF_HYPER-RESPONSE_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;del;DRD2_GG;TOXICITY;INCREASED;RISK;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MITOTANE;CYP2B6;GT + TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MITOTANE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:ADRENOCORTICAL_CARCINOMA;CAUTION_DOSE_ADJUST
NICOTINE;DRD1;T;DRD1_CC;EFFICACY, TOXICITY, OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLC30A8;AG;SLC30A8_AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EFFICACY;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A7;AA;UGT1A7_AA;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
BEVACIZUMAB;EDN1;TT;EDN1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;G6PD, IKBKG;A;G6PD, IKBKG_A;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:PROTECTION_FROM_PLASMODIUM_VIVAX_MALARIA_INFECTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;IMPDH1;T;IMPDH1_CT + TT;EFFICACY;DECREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A3;CC;UGT1A3_CC;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
GEFITINIB;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;IMPDH1;T;IMPDH1_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ATAZANAVIR, RITONAVIR;UGT1A7;GG;UGT1A9_G;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC2, KLC3;GG + GT;ERCC2_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT, OLANZAPINE;HTR3C;CC;HTR3C_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NAUSEA, EFFICACY:VOMITING;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A7;GG;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_G;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
BEVACIZUMAB;VEGFA;TT;VEGFA_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT, OLANZAPINE;MTHFR;TT;MTHFR_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:NAUSEA, EFFICACY:VOMITING;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT, OLANZAPINE;HTR3B;GG;HTR3B_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:NAUSEA, EFFICACY:VOMITING;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAFENOQUINE;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA_VIVAX;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;CC;GGH_CC;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:BONE_MARROW_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TIMOLOL;ADRB1;AA;ADRB1_AG + GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SYSTOLIC_(SAP)_AND_DIASTOLIC_(DAP)_ARTERIAL_PRESSURE_RESPONSES_TO_TIMOLOL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN;LRP2;G;LRP2_G;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DISULFIRAM;DBH;CT + TT;DBH_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
FENTANYL, PROPOFOL, REMIFENTANIL, SEVOFLURANE;ADRB2;AA;ADRB2_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;T;ABCG2_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;SLC30A8;C;SLC30A8_C;OTHER;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;SLCO2A1;T;SLCO2A1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPONATREMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ROSUVASTATIN;FMO3;A;FMO3_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;C;GGCX_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AG + GG;GSTP1_GG;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:MEDULLOBLASTOMA;CAUTION_SIDE_EFFECT
WARFARIN;GGCX;G;GGCX_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;COMT;A;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY, OTHER:FETAL_ALCOHOL_SYNDROME;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;SCN2A;A;SCN2A_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;G;GGCX_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;NQO1;AA + AG;NQO1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;G6PD;T;G6PD, IKBKG_TT;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROTECTION_AGAINST_SEVERE_(P=0.006)_AND_MILD_MALARIA_(P=0.027);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTITHYROID_PREPARATIONS, METHIMAZOLE, PROPYLTHIOURACIL;KLRC4;C;KLRC4_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC1;AA;ERCC1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;GENE_NOT_SPECIFIED;CC + CT;CC + CT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH;PEOPLE;OTHER:HOMOZYGOUS_GG_GENOTYPE_FOR_RS4343;CAUTION_DOSE_ADJUST
ACE_INHIBITORS, PLAIN;GENE_NOT_SPECIFIED;AA + AT;AA + AT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH;PEOPLE;OTHER:HOMOZYGOUS_GG_GENOTYPE_FOR_RS4343;CAUTION_DOSE_ADJUST
NAN;G6PD;T;G6PD, IKBKG_TT;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROTECTION_AGAINST_DEVELOPING_SEVERE_MALARIA;PEOPLE;DISEASE:MALARIA;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AG;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:ALOPECIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;BDKRB2;AG;BDKRB2_AG;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;F5;C;F5_CT + TT;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;TRIM5;C;TRIM5_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;MTHFR;G;MTHFR_TT;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;MTHFR;G;MTHFR_AA;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SERPINE1;A;SERPINE1_A;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;PPARG;TT;PPARG_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_HYPERSENSITIVITY;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;ZNF100;C;ZNF100_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_INR_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PTGIR;AG + GG;PTGIR_AG + GG;OTHER;DECREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NUMBER_OF_EXAMINATIONS_ABOVE_THE_THERAPEUTIC_RANGE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TBXA2R;GG;TBXA2R_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;PTGER3;A;PTGER3_A;OTHER;INCREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR>=2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;PTGER2;GG;PTGER2_GG;OTHER;INCREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;PTGER2;G;PTGER2_G;OTHER;DECREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, PACLITAXEL;CYP3A4;CC;CYP3A4_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:STABLE_WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AG + GG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:_VASP_INDEX;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PPARG;TT;PPARG_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DECLINE_IN_FEV_1_AFTER_ASPIRIN_PROVOCATION;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG + GG;CYP2C19_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:UNDERGOING_SCHEDULED_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;NECAB1;G;NECAB1_G;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG + GG;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:UNDERGOING_SCHEDULED_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ATHEROTHROMBOTIC_EVENTS_DURING_THE_6-YEAR_FOLLOW_UP_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;CYP2C9_CT;EFFICACY, TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;EFR3A;G;EFR3A_G;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DOCETAXEL, PACLITAXEL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A1;GG;SLC28A1_GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;EFFICACY, TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;CC + CT;CDA_CT + TT;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ELIMINATION_CLEARANCE_OF_DFDU_AND_FORMATION_CLEARANCE_OF_DFDCTP;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PACLITAXEL;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;LPA_AG + GG;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;LPA_AG + GG;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;LPA_AG + GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;AA;NAT2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;LPA_AG + GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;ABCB1;CC;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CMPK1;CC;CMPK1_CC;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:FORMATION_CLEARANCE_OF_DFDCTP;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;WDR24;G;WDR24_G;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;CC;CDA_CC;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:ELIMINATION_CLEARANCE_OF_DFDU;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBOPLATIN, PACLITAXEL;MAD1L1;CT + TT;MAD1L1_CT + TT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:BIOCHEMICAL_RESPONSE, OPTIMAL_CYTOREDUCTION, AND_SENSITIVITY_TO_THE_INDUCTION_CHEMOTHERAPY_TREATMENT;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_DOSE_ADJUST
VARENICLINE;ICAM5;T;ICAM5_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SLEEP_DISORDERS;PEOPLE;OTHER:TOBACCO_USE_DISORDER, OTHER:SMOKING_CESSATION;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;AG;ABCC1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PSORIASIS;CAUTION_SIDE_EFFECT
MITOXANTRONE;ABCB1;AA;ABCB1_A;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SENSITIVITY_IN_VITRO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, METHOTREXATE;FOLH1;A;FOLH1_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;CC;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;TT;NAT2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;CYP2B6_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME/EPIDERMAL_NECROLYSIS, TOXIC;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NAN;PPARA;AA + AG;PPARA_AA + AG;OTHER;DECREASED;RISK;OTHER:ALL-CAUSE_MORTALITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS, SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS, ISONIAZID;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ABNORMAL_LIVER-FUNCTION_TESTS_(ALFTS);PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;C;ATIC_C;EFFICACY;DECREASED;RISK;EFFICACY:DISEASE_ACTIVITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS, ISONIAZID;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ANTITUBERCULOSIS_DRUG-INDUCED_HEPATOTOXICITY_(ATDIH);PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS;APOC3;CG + GG;APOC3_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUTICASONE_PROPIONATE;CYP3A4;AA + AG;CYP3A4_AA + AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVED_ASTHMA_CONTROL_(AS_MEASURED_BY_DECREASE_IN_AVERAGE_ASTHMA_CONTROL_SCORE);CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ALLOPURINOL;CCHCR1;A;CCHCR1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LETROZOLE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;AGTR1;C;AGTR1_AA + AC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MITOXANTRONE;SLCO1B1;CT + TT;SLCO1B1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_BLOOD_CONCENTRATION_NORMALIZED_FOR_THE_DAILY_DOSE_(C)_PER_KILOGRAM_BODY_WEIGHT_(D)_(C/D, NG/ML/MG/KG/DAY)_RATIO_DURING_THE_FIRST_MONTH_AFTER_TRANSPLANTATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;A;CYCSP5_AA + AC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;FOXP3;GT;FOXP3_GT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PSORIASIS;CAUTION_SIDE_EFFECT
NAN;CHAT;G;CHAT_G;OTHER;INCREASED;RISK;DISEASE:SCHIZOPHRENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS;SIK3;AA + AG;SIK3_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
OXALIPLATIN;XRCC1;TT;XRCC1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:RENAL_FUNCTION_(LOWER_CREATININE_CLEARANCE)_AT_3_MONTHS_OF_FOLLOW-UP;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AA;SLC22A1_C;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CL_RENAL_REFERENCE_AND_LOWER_AND_CL_SEC_REFERENCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ALLOPURINOL;PSORS1C2;T;PSORS1C2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;CT + TT;ABCG2_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:PSORIASIS;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1, PSORS1C2;A;PSORS1C1, PSORS1C2_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
EXEMESTANE, LETROZOLE;GENE_NOT_SPECIFIED;G;G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS;APOA5;CG + GG;APOA5_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
VALPROIC_ACID;POLG;C;POLG_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;ADH1C;CT;ADH1C_CT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:COMPLETE_RESPONSE;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EXEMESTANE, LETROZOLE;CCDC148;T;CCDC148_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
OXALIPLATIN;GSTP1;GG;GSTP1_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DRD2;G;DRD2_G;NAN;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A4;AA + AG;CYP3A4_AA + AG;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;DRD2;G;DRD2_GG;NAN;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VALPROIC_ACID;POLG;A;POLG_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EDOXABAN;SLCO1B1;GG;SLCO1B1_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EDOXABAN;ABCB1;CC;ABCB1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;TT;ADD1_GT + TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_CALCIUM_RETENTION;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
EDOXABAN;SLCO1B1;AA + AC;SLCO1B1_AA + AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LEVODOPA;DRD3;TT;DRD3_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
LEVODOPA;DRD2;GG;DRD2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;SIDE_EFFECT:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
BUSULFAN, CYCLOPHOSPHAMIDE;CTH;TT;CTH_TT;TOXICITY;INCREASED;RISK;DISEASE:HEPATIC_VENO-OCCLUSIVE_DISEASE;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FUROSEMIDE, SPIRONOLACTONE;CYP11B2;AA + AG;CYP11B2_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DIURETIC_UNRESPONSIVENESS;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EDOXABAN;SLCO1B1;CC + CT;SLCO1B1_CC + CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AC;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE, SPIRONOLACTONE;ACE;CG + GG;ACE_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DIURETIC_UNRESPONSIVENESS;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;NOS3;CC;NOS3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTI-INFLAMMATORY_EFFECTS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;NOS3;CC;NOS3_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:WHOLE_BLOOD_NITRITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAROXETINE;CYP1A2;A;CYP1A2_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE, SPIRONOLACTONE;ADD1;GT + TT;ADD1_GT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DIURETIC_UNRESPONSIVENESS;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;T;CYP1A2_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCB1;AA;ABCB1_C;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, DOXORUBICIN;ERCC1;AA;ERCC1_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ARRB2;C;ARRB2_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GT;ABCG2_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;T;CYP1A2_CT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;SCARB1;GG;SCARB1_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS, RADIOTHERAPY;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATITIS;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN;CYBA;AA + AG;CYBA_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;AA;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C19;AA;CYP2C19_AA;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;AA;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;GG;SLCO1B1_AA + AG;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS, RADIOTHERAPY;GENE_NOT_SPECIFIED;AG + GG;AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AA;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_SIMVASTATIN_ACID;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;SLC18A2;TT;SLC18A2_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS, RADIOTHERAPY;GENE_NOT_SPECIFIED;CC;CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;GRIK3;CT;GRIK3_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS, RADIOTHERAPY;GENE_NOT_SPECIFIED;AA + AG;AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;TT;CYP1A2_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
METHOTREXATE;SHMT1;AG + GG;SHMT1_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ABDOMINAL_PAIN;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;A;CYP1A2_AA;TOXICITY;INCREASED;RISK;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;AG + GG;HTR2A_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS, RADIOTHERAPY;GENE_NOT_SPECIFIED;CC;CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATITIS;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;AA + AG;DRD2_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS, RADIOTHERAPY;MEG3;CC;MEG3_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:_SERUM_R_-WARFARIN_CONCENTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;UGT1A9;C;UGT1A9_C;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DIMINISHED_ESTIMATED_GLOMERULAR_FILTRATION_RATE_(EGFR)_DURING_THE_FIRST_YEAR_AFTER_ENGRAFTMENT;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;AT + TT;ABCC2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;SLC6A9;T;SLC6A9_T;TOXICITY, OTHER;INCREASED;RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;UGT1A9;C;UGT1A9_C;TOXICITY;INCREASED;RISK;DISEASE:PROTEINURIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;KCNH2_GG;OTHER;INCREASED;LIKELIHOOD;DISEASE:ATRIAL_FIBRILLATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ARRB2;A;ARRB2_GG;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;CHILDREN;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;P2RY1;CT;P2RY1_CT;EFFICACY;INCREASED;RISK;EFFICACY:_ASPIRIN-RESISTANT_PHENOTYPE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;CRHR1;AA;CRHR1_AA;OTHER;INCREASED;RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;ARRB2;A;ARRB2_A;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;A;CYP2C9_A;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEDIAN_WEEKLY_WARFARIN_DOSE_REQUIREMENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY;CHILDREN;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;MTHFR;GG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARVEDILOL;ADRB2;C;ADRB2_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_RESTING_BLOOD_PRESSURE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CC + CT;PON1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;CHILDREN;OTHER:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;NTRK2;G;NTRK2_G;TOXICITY;INCREASED;RISK;DISEASE:SUICIDE;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;UGT1A1_AG;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BEVACIZUMAB;GENE_NOT_SPECIFIED;CT + TT;CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;AA;TBXA2R_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;ARRB2;T;ARRB2_TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;GP1BA;CC;GP1BA_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;PMCH;G;PMCH_G;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA;UGT1A1_AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA;VKORC1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;TGFB1;AA + AG;TGFB1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_CHRONIC_URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;F7;AA;F7_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SEN_SITIVITY_TO_WARFARIN_DURING_INDUCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F7;AA;F7_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL, VINORELBINE;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE_TO_CHEMOTHERAPY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;KRTAP10-4, TSPEAR;A;KRTAP10-4, TSPEAR_A;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA + AG;MTHFD1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT + TT;MTHFR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ATORVASTATIN;NOS3;CC;NOS3_CC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:ERYTHROCYTE_PLASMA_MEMBRANE_FLUIDITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;CYP2C9_A;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:S-WARFARIN_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;ECHS1;T;ECHS1_T;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIGB;G;PIGB_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;CT + TT;SLCO1B1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;AGAP3;A;AGAP3_A;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;AA + AG;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A2;CC;SLC28A2_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;TLR4;AA + AG;TLR4_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHMA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TIMOLOL;GENE_NOT_SPECIFIED;AA + AG;CYP2D6_GG;TOXICITY;INCREASED;RISK;DISEASE:BRADYCARDIA;PEOPLE;DISEASE:OPEN-ANGLE_GLAUCOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A2;CC;SLC28A2_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;ABCG2;TT;ABCG2_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;ZDHHC3;A;ZDHHC3_A;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;CT + TT;CYP2D6_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:VENLAFAXINE_CONCENTRATION_PER_UNIT_DOSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
NAN;ADORA2A;AC + CC;ADORA2A_AC + CC;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADORA2A;CT;ADORA2A_CT;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IFITM3;GG;IFITM3_GG;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:PRECURSOR_T-CELL_LYMPHOBLASTIC_LEUKEMIA-LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;CC;CYP1A2_AA;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;PEOPLE;OTHER:COFFEE_CONSUMPTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;CC;CYP1A2_CT + TT;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;PEOPLE;OTHER:COFFEE_CONSUMPTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA;VKORC1_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_AUC_(AREA_UNDER_CURVE)_PROTHROMBIN_TIME;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;CC;ITPA_AC;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNJ11;TT;KCNJ11_T;NAN;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS, TYPE_2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;SLCO1B1;A;SLCO1B1_A;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;A;SLCO1B1_A;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;DNAAF9;AA;ITPA_AC + CC;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;SERPINE1;AA + AG;SERPINE1_AA + AG;TOXICITY;INCREASED;RISK;DISEASE:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;AA + AC;CDA_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;GG;CHRNB2_A;EFFICACY, TOXICITY, OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ABSTINENCE;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_D_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;SLC28A3;A;SLC28A3_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;A;CYP1A2_GG;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;AG + GG;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
EVEROLIMUS;MTOR;C;MTOR_C;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:KIDNEY_NEOPLASMS,OTHER:NEUROENDOCRINE_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN, METHOTREXATE;ERCC2;GG + GT;ERCC2_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRM2;T;CHRM2_T;TOXICITY, OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;EGFR;GT + TT;EGFR_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VDR;C;VDR_TT;NAN;INCREASED;RISK;DISEASE:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;del;CYP1A2_T;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, PANITUMUMAB;AREG;AA + AG;AREG_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, IRINOTECAN;VEGFA;GG;VEGFA_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CT + TT;PON1_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SMALL-DENSE_LDL_LEVELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PROTON_PUMP_INHIBITORS;TRPM6;T;TRPM6_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;FKBP5;CC + CT;FKBP5_T;EFFICACY;INCREASED;LIKELIHOOD;EFFECT_SUBCAT_NOT_SPECIFIED;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C, MIR1264, MIR1912;GG;HTR2C, MIR1264, MIR1912_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;GGH_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
HALOTHANE, SUCCINYLCHOLINE;RYR1;T;RYR1_T;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;AREG;AA;AREG_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCB1;AA;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_SIMVASTATIN_ACID;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PROTON_PUMP_INHIBITORS;TRPM6;C;TRPM6_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;AG + GG;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC1;AA + AC;ERCC1_AC + CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;CC;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;ABCB1_C;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_SIMVASTATIN_ACID;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;RYR1_T;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;CYP2B6_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASUNAPREVIR, DACLATASVIR, DIRECT_ACTING_ANTIVIRALS, LEDIPASVIR/SOFOSBUVIR, OMBITASVIR/PARITAPREVIR/RITONAVIR;IFNL3, IFNL4;GG + GT;IFNL3_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;RYR1_A;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;RYR1_T;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;RYR1_A;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;CYP2B6_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CC + CT;DPYD_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;RYR1_A;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;C;DPYD_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD3;CT + TT;DRD3_CT + TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INTOLERABILITY;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;AA + AG;ACYP2_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CT + TT;PON1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_(COMPOSITE_OF_CARDIAC_DEATH, MI, STENT_THROMBOSIS)_IN_KOREAN_PATIENTS_AFTER_PCI;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN;XPC;GG + GT;XPC_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;GG;OPRM1_AG;TOXICITY;INCREASED;SEVERITY;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BLUNTING_OF_ALCOHOL_CRAVING;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_RATE_OF_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;FTO;CC;FTO_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA-LACTAM_ANTIBACTERIALS, PENICILLINS;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG1;GG;ABCG1_GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
XELOX;ABCA2;AA;ABCA2_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC5;CC;ABCC5_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;TACR1;AG + GG;TACR1_AG + GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD2;CT + TT;DRD2_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;CC + CT;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;AG;SLCO1B1_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;AA;ABCB1_A;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;CC + TT;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PACLITAXEL;SLCO1B3;AA;SLCO1B3_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;FPGS;CC + CT;FPGS_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ALOPECIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
NAN;HIF1A;AG;HIF1A_AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;FTO;GG;FTO_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COUMARIN, NICOTINE;CYP2A6;C;CYP2A6_C;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUNITINIB;ABCG2;TT;ABCG2_T;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;PEMT;T;PEMT_T;NAN;INCREASED;RISK;DISEASE:FATTY_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIBIOTICS;LGALS3;AT + TT;LGALS3_AT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;ABCG2_T;TOXICITY;INCREASED;RISK;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;GENE_NOT_SPECIFIED;CG + GG;CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;ABCG2_T;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;ABCG2_T;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;T;DHFR_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;AG;ABCG2_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NICOTINE;HINT1;CC;HINT1_CC;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;MEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;INCREASED;RISK;EFFICACY:METASTATIC_NEOPLASM;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NAN;VDR;CC;VDR_TT;OTHER;DECREASED;LIKELIHOOD;OTHER:PRE-ECLAMPSIA;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;ALAS1;AA + AG;ALAS1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC6A4;AA;SLC6A4_AA;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;GSTP1;AA;GSTP1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;A;ALDH1A1_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;A;ALDH1A1_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;SLCO1B3;GG;SLCO1B3_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;AA + AG;IFNL3, IFNL4_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL, NALTREXONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:INTOXICATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;TT;NAT2_T;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERALGESIA;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;AA;NAT2_AA;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CC;SLC19A1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;DHFR;CC;DHFR_CC;TOXICITY;INCREASED;RISK;EFFICACY:METASTATIC_NEOPLASM;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;HS6ST3;A;HS6ST3_A;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;ABCB1;A;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_DRUG_LEVELS;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
"""3, 4-METHYLENEDIOXYMETHAMPHETAMINE"", ""COCAINE"", ""ETHANOL"", ""OPIOIDS""";OPRM1;AG;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TRASTUZUMAB;FCGR3A;CC;FCGR3A_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC_ACID, TACROLIMUS;ABCC2;C;ABCC2_CT + TT;EFFICACY;INCREASED;LIKELIHOOD;"""EFFICACY:PRIMARY_GRAFT_FAILURE"", ""EFFICACY:KIDNEY_TUBULAR_NECROSIS, ACUTE""";PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;TT;CYP2B6_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;OTHER:POSTOPERATIVE_PAIN, OTHER:SCOLIOSIS;CAUTION_SIDE_EFFECT
TRASTUZUMAB;FCGR2A;AA;FCGR2A_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CC + CT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;BCHE;C;BCHE_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUCCINYLCHOLINE;BCHE;T;BCHE_TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THROMBOCYTOPENIA;WOMEN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C18;A;CYP2C18_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HNMT;GG;HNMT_GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:SEDATION;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;DPYD_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;AG + GG;CYP2B6_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;OTHER:POSTOPERATIVE_PAIN, OTHER:SCOLIOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;NOC3L;A;NOC3L_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;LPP;A;LPP_A;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;T;NAT2_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;TOXICITY, OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C8;A;CYP2C8_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AC;ABCB1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;A;CHRNA3, CHRNA5_GG;TOXICITY, OTHER;DECREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;LPP;A;LPP_A;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;UGT1A6;T;UGT1A6_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:SARCOMA,OTHER:NEUROBLASTOMA, OTHER:OSTEOSARCOMA, OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RIFAMPIN;RIPOR2;C;RIPOR2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;RARG;A;RARG_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:SARCOMA,OTHER:NEUROBLASTOMA, OTHER:OSTEOSARCOMA, OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
NAN;EGFR;AA;EGFR_AA;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;GAL;C;GAL_CC;OTHER;INCREASED;SEVERITY;DISEASE:ANXIETY_DISORDERS;WOMEN;DISEASE:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;ZNRD1-AS1_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;EYS;G;EYS_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;A;AGBL4_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;CYP2C9_CT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS, OTHER_COMBINATIONS;EYS;A;EYS_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;SLC30A9;A;SLC30A9_A;TOXICITY, OTHER;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM, NORTRIPTYLINE;BDNF;C;BDNF_C;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;KCNMA1;G;KCNMA1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS, OTHER_COMBINATIONS;EYS;A;EYS_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;TSC1;C;TSC1_C;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;G;AGBL4_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;THRA;G;THRA_G;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
RIFAMPIN;CUX2;G;CUX2_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;SLC28A3;A;SLC28A3_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:SARCOMA,OTHER:NEUROBLASTOMA, OTHER:OSTEOSARCOMA, OTHER:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;GATM;A;GATM_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;SLCO1B1_CC + CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;CHIA;A;CHIA_A;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;GENE_NOT_SPECIFIED;C;C;TOXICITY, OTHER;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;T;CYP2C9_CT;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;CYP2C9_AC + CC;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
HEROIN;GRM3;A;GRM3_A;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;ZBTB22;C;ZBTB22_C;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, SIROLIMUS, TACROLIMUS;TCF7L2;T;TCF7L2_T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;CYP2C9_AC + CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;HLA-DPB1_C;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB2;C;HLA-DPB2_C;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;G;HLA-DPB1_G;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;HLA-DPB1_C;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RIFAMPIN;RIPOR2;A;RIPOR2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
PREDNISOLONE;GATA3;AA;GATA3_A;PD;INCREASED;RISK;SIDE_EFFECT:SEPSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;A;AGBL4_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;DPP6;C;DPP6_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;EPHX1;CT;EPHX1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY_GRADES_1-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;NAT2;CT;NAT2_C;TOXICITY;INCREASED;RISK;DISEASE:ANEMIA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;MUTYH;CT;MUTYH_CT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ALK;G;ALK_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;MED19, TMX2;A;MED19, TMX2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;CC;ATIC_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ENZYMES;A2M;TT;A2M_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGIC_TRANSFORMATION;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;GT + TT;ATIC_GT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;NCF4;AA;NCF4_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENZYMES;F12;GG;F12_GG;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;A;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;CG + GG;ATIC_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;ADH1C;A;ADH1C_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;ATIC_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;RAD52;AG;RAD52_AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SLC39A8;A;SLC39A8_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;LIG3;CC;LIG3_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ABIRATERONE, PREDNISOLONE;TSPYL1;AA;TSPYL1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AA + AG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;XRCC1;AA + AG;XRCC1_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;MEN;OTHER:CARCINOMA, SQUAMOUS_CELL;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDINAVIR;UGT1A1;AG;UGT1A1_AA;TOXICITY;INCREASED;RISK;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;T;ADH1B_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;AA;FPGS_AA;EFFICACY, TOXICITY, OTHER;DECREASED;LIKELIHOOD;OTHER:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FPGS;TT;FPGS_TT;EFFICACY, TOXICITY, OTHER;DECREASED;LIKELIHOOD;OTHER:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;AC + CC;DPYD_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;FPGS;TT;FPGS_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;THSD7B;A;THSD7B_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;TT;ABCB1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;A;A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;GENE_NOT_SPECIFIED;A;A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;TT;ABCB1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;CADM2;A;CADM2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;ADH1B;T;ADH1B_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, VINCRISTINE;METTL3;AA + AG;METTL3_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEVER, SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:MEDULLOBLASTOMA, OTHER:GLIOBLASTOMA,OTHER:ASTROCYTOMA, OTHER:BRAIN_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;OTHER:HEROIN_DEPENDENCE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;T;CYP2A6_T;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;PDE4B;A;PDE4B_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;GCKR;T;GCKR_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;AA + AT;CHRNA5_A;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SPATA9;A;SPATA9_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;BIRC5;GG;BIRC5_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEIN_KINASE_INHIBITORS;STAT6;TT;STAT6_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;ANKK1, DRD2;AA + AG;DRD2_G;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;C1QTNF6;C;C1QTNF6_C;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;AA + AT;CHRNA5_A;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;CC;VEGFA_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;GG;VEGFA_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;GG;VEGFA_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;A;GATA3_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RELAPSE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;A;GATA3_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MINIMAL_RESIDUAL_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;AA;VEGFA_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP4F2;CT;CYP4F2_TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_AGGREGATION_WITH_EPINEPHRINE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT + TT;DPYD_AT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;COL26A1;T;COL26A1_T;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HEARING_AND_VISION-RELATED_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GENERAL_SIDE-EFFECT_BURDEN;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1, PSORS1C2;A;PSORS1C1, PSORS1C2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;ACE;CC + CT;ACE_CC + CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA;MED12L, P2RY12_AC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:STRONGER_AGGREAGTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;SLC22A17;T;SLC22A17_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT + TT;DPYD_AT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;T;ACE2_T;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA;MED12L, P2RY12_AC;EFFICACY;INCREASED;RISK;EFFICACY:CLOPIDOGREL_RESISTANCE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;F2R;T;F2R_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:TRANSIENT_ISCHEMIC_ATTACK, OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;AA;MED12L, P2RY12_AC;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;P2RY1;CT;P2RY1_CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NET_DECREASE_IN_AA-INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_TREATMENT;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;AC;ITPA_AC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:6-MMPN_LEVELS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NAN;FGFR2;G;FGFR2_G;TOXICITY, OTHER;INCREASED;RISK;DISEASE:BREAST_NEOPLASMS;WOMEN;DISEASE:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
ANASTROZOLE;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;CT + TT;CYP2C9_CT;TOXICITY;INCREASED;RISK;DISEASE:GASTROINTESTINAL_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:TRANSIENT_ISCHEMIC_ATTACK, OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;SLC10A2;A;SLC10A2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
NAN;AGT;AG;AGT_GG;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;GENE_NOT_SPECIFIED;C;C;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;COMT;CC + CG;COMT_CG + GG;OTHER;INCREASED;SEVERITY;OTHER:PAIN;CHILDREN;OTHER:DENTAL_CARIES, OTHER:TOOTH_DISORDER,OTHER:TOOTHACHE;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;UGT2B7;G;UGT2B7_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;UGT2B7;C;UGT2B7_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY, TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CEFACLOR;LIMD1;C;LIMD1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CEFACLOR;LIMD1;G;LIMD1_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLCO1B1;CC;SLCO1B1_TT;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_PLASMA_AUC;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE_DERIVATIVES;ADRA1A;AG + GG;ADRA1A_AG + GG;EFFICACY;DECREASED;RISK;EFFICACY:KIDNEY_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;XRCC5;AG;XRCC5_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;ERCC1;AC + CC;ERCC1_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE;GCG;C;GCG_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CLOZAPINE, OLANZAPINE;GLP1R;T;GLP1R_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AA + AG;OPRM1_AA;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SMOKING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AG + GG;OPRM1_AA;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SMOKING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TOLCAPONE;COMT;AA;COMT_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:ALCOHOL_ABUSE;PEOPLE;OTHER:ALCOHOL-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
NICOTINE;UGT2B10;AG + GG;UGT2B10_AG + GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATION_OF_NICOTINE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NICOTINE;UGT2B10;T;UGT2B10_T;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:NICOTINE_GLUCURONIDATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOZAPINE, OLANZAPINE;GCG;CC;GCG_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE_DERIVATIVES;CYP3A5;TT;CYP3A5_CC;EFFICACY;INCREASED;RISK;EFFICACY:KIDNEY_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;HTR1A;A;HTR1A_A;TOXICITY, OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:PSYCHOTIC_DISORDER;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;TT;GALNT14_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;AA;ACE_AT + TT;EFFICACY;DECREASED;SEVERITY;DISEASE:KIDNEY_FAILURE;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;LEPR;G;LEPR_AG + GG;OTHER;INCREASED;LIKELIHOOD;DISEASE:OBESITY;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;HAS3;A;HAS3_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
STAVUDINE;SAMHD1;A;SAMHD1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;ADRB1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(HEART-RATE_LOWERING);PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;TGFB1;AG + GG;TGFB1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;RARG;A;RARG_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
CYTARABINE, DAUNORUBICIN, MITOXANTRONE;DCK;CT;DCK_CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;NIPAL2;A;NIPAL2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OXALIPLATIN, PACLITAXEL;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
AMLODIPINE, CHLORTHALIDONE, LISINOPRIL;ACE;AA + AT;ACE_AT + TT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:FASTING_GLUCOSE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
SORAFENIB;KDR;T;KDR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;TGFBR2;GG;TGFBR2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;T;KDR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;CT;FLT4_CT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCED_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
SUNITINIB;CYP3A5;TT;CYP3A5_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_REDUCTIONS_DUE_TO_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
RITODRINE;PDE4B;AA;PDE4B_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;ABCC1;CC;ABCC1_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;AC;FLT4_AC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA_BLOCKING_AGENTS;ADRB2;AG + GG;ADRB2_AA;EFFICACY;INCREASED;RISK;EFFICACY:HEART_TRANSPLANTATION, EFFICACY:DEATH;PEOPLE;OTHER:HEART_FAILURE;CAUTION_SIDE_EFFECT
SALBUTAMOL;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;COL22A1;T;COL22A1_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CDH15;C;CDH15_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS, EFFICACY:DISEASE_PROGRESSION;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;DDX12P;C;DDX12P_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;ABCC2;CC;ABCC2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SALBUTAMOL;CLOCK;A;CLOCK_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;T;T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;GENE_NOT_SPECIFIED;C;C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ACE2;A;ACE2_A;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;MEN;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTP1;AG + GG;GSTP1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CDH13;AA + AG;CDH13_AA + AG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS, EFFICACY:DISEASE_PROGRESSION;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;CYCSP5;A;CYCSP5_AA + AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SALBUTAMOL;GENE_NOT_SPECIFIED;A;A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;SLCO1B1;CT + TT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE;GABRA2;G;GABRA2_G;TOXICITY;INCREASED;SEVERITY;OTHER:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;C;OPRM1_C;TOXICITY;DECREASED;SEVERITY;OTHER:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;SLCO1B1;AG + GG;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SORAFENIB;SLCO1B1;AG + GG;SLCO1B1_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;AGT;A;AGT_GG;OTHER;DECREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANGRELOR;P2RY12;TT;P2RY12_TT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:20%_AND_17%_LESS_INHIBITION_OF_PLATELET_AGGREGATION_WITH_CRANGRELOR_(0.05_AND_0.25_MICROM)_IN-VITRO;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SORAFENIB;NOS3;TT;NOS3_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;TANC1;C;TANC1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
SORAFENIB;NOS3;GG;NOS3_GG + GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;NOS3;GG;NOS3_GG + GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;GLCCI1;GG;GLCCI1_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:POOR_RESPONSE;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;A;ABCG2_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TUMOR_RESPONSE_RATE;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;NOS3;TT;NOS3_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;T;NUDT15_CT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INTERVAL_OF_THERAPY_TO_LEUKOPENIA_ONSET;PEOPLE;DISEASE:LEUKOPENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CTLA4;AG + GG;CTLA4_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FBXL19;GG;FBXL19_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;IL23R;AG;IL23R_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;TT;NUDT15_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;MTHFR_AA;METABOLISM/PK;INCREASED;RISK;PK:PROLONGED_HIGH_CONCENTRATIONS;CHILDREN;DISEASE:LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;ABCB1;CC;ABCB1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
COLISTIMETHATE;SLC15A2;T;SLC15A2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:BACTERIAL_INFECTIONS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;GT + TT;MTHFR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;GGCX;CT + TT;GGCX_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CETUXIMAB;FCGR3A;A;FCGR3A_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CT;CYP2C9_CT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CETUXIMAB;CCND1;G;CCND1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;F7;GT + TT;F7_GT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;IL10;AA;IL10_AG + GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR1B;AC + CC;HTR1B_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS;PEOPLE;DISEASE:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
CETUXIMAB;CCND1;AA;CCND1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;MDGA2;A;MDGA2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXSUAL_DYSFUNCTION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
"""ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOC1, APOE, TOMM40;CC + CT;APOE_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:NON-HDL_CHOLESTEROL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CT + TT;HTR2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS;PEOPLE;DISEASE:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
TACROLIMUS;IL10;TT;IL10_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GENE_NOT_SPECIFIED;G;G;NAN;INCREASED;RISK;DISEASE:CROHN_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LEVODOPA;HOMER1;AG + GG;HOMER1_AG + GG;TOXICITY;DECREASED;RISK;DISEASE:DYSKINESIAS;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;SOD2;AG + GG;SOD2_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LEVODOPA;HOMER1;AG + GG;HOMER1_AG + GG;TOXICITY;DECREASED;RISK;DISEASE:HALLUCINATIONS;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GENE_NOT_SPECIFIED;T;T;NAN;INCREASED;RISK;DISEASE:ATRIAL_FIBRILLATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ESTRADIOL;NFE2L2;T;NFE2L2_T;TOXICITY;INCREASED;RISK;DISEASE:VENOUS_THROMBOEMBOLISM;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;YEATS4;CC;YEATS4_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;F2;CT + TT;F2_TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;HLA-DRA;A;HLA-DRA_A;NAN;INCREASED;RISK;DISEASE:MULTIPLE_SCLEROSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;CEP72_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
NAN;NOD2;G;NOD2_G;NAN;INCREASED;RISK;DISEASE:CROHN_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, PACLITAXEL;TP53;CG + GG;TP53_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ONE_YEAR_PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AC;ITPA_AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FLU-LIKE_SYMPTOMS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1;CT;CES1_CT;PD;INCREASED;LIKELIHOOD;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TCF7L2;T;TCF7L2_T;NAN;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;IL6;AG + GG;IL6_AG + GG;OTHER;INCREASED;SEVERITY;OTHER:PAIN;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;TCF7L2;C;TCF7L2_C;NAN;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;TCF7L2;T;TCF7L2_T;NAN;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;T;ADH1B_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AG;VKORC1_AA + AG;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;CDKN2B-AS1;G;CDKN2B-AS1_G;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MORPHINE;COMT;AA;COMT_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN_DURING_PAINFUL_PROCEDURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;RABGAP1L;G;RABGAP1L_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA;COMT_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_MEAN_NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CDKN2B-AS1;G;CDKN2B-AS1_G;OTHER;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;CC;CYP2D6_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;PEOPLE;OTHER:DEATH;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;CYP2D6_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2B6;CC;CYP2B6_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;PEOPLE;OTHER:DEATH;CAUTION_SIDE_EFFECT
NAN;ACE2;CC;ACE2_C;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;ACE2;C;ACE2_C;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2D6;AA;CYP2D6_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION, SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;AA;CYP2D6_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:PANCREATITIS, SIDE_EFFECT:VOMITING;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;CYP2D6_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION, SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ5;AA + AG;COQ5_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC;ITPA_AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ZOLEDRONATE;FDPS;TT;FDPS_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ3;TT;COQ3_TT;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP2B6;GG;CYP2B6_GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ2;CG + GG;COQ2_G;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;CT + TT;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;T;CYP2B6_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;CLMN;A;CLMN_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANGE_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;AG;CYP2B6_AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NINTEDANIB;DSP;TT;DSP_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;CT;CYP2B6_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_PROGRESSION;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN;MTHFR;GG;MTHFR_AA;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F2;CT + TT;F2_TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C19;CC;CYP2C19_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;CAUTION_DOSE_ADJUST
CAPECITABINE;MTHFR;TT;MTHFR_TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F7;GG;F7_GG;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;TAP1;CT;TAP1_CT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE, QUETIAPINE, RISPERIDONE;ANKK1;AA;DRD2_G;TOXICITY;INCREASED;RISK;DISEASE:HEADACHE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;SLC12A8;AA;SLC12A8_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TANC1;A;TANC1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;G;TANC1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BUSULFAN;CYP2C9;CT + TT;CYP2C9_CT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;C;SLC22A16_CC + CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TANC1;T;TANC1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;A;ABCG2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GRADE_3-4_NONHEMATOLOGICAL_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;T;TANC1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;T;TANC1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCB1;CC;ABCB1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
RADIOTHERAPY;TANC1;G;TANC1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;T;CYP2B6_GT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;T;CYP2B6_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;XPC;AA + AG;XPC_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:HEMATOLOGIC_DISORDER, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SECUKINUMAB;ERAP2;GG;ERAP2_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;G;SLC22A16_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;G;SLC22A16_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;G;SLC22A16_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;LTC4S;C;LTC4S_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, ROSUVASTATIN;COQ2;G;COQ2_G;TOXICITY;INCREASED;RISK;DISEASE:MUSCULAR_DISEASES;PEOPLE;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;SEMA5A;A;SEMA5A_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA + AG;MTHFD1_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;VKORC1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ, NELFINAVIR;ABCB1;AA;ABCB1_A;EFFICACY, OTHER;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RISE_IN_CD4-CELL_COUNT;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:FAVORABLE_VIROLOGIC_RESPONSES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;EDIL3;T;EDIL3_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCC2;A;ABCC2_A;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;AG + GG;ABCB1_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;XDH;AA + AG;XDH_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS,OTHER:NEUROMYELITIS_OPTICA;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS,OTHER:NEUROMYELITIS_OPTICA;CAUTION_SIDE_EFFECT
NAN;ATP8B3;G;ATP8B3_G;TOXICITY;DECREASED;LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;AA;ABCB1_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;T;NAT2_T;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;NAT2_AA;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES, DOXORUBICIN, EPIRUBICIN;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_PROGRESSION;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;APOC3;T;APOC3_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NAN;AGTR1;CC;AGTR1_AA + AC;OTHER;INCREASED;RISK;DISEASE:ISCHEMIA;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
IMATINIB;ARID5B;TT;ARID5B_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;T;NAT2_T;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;C;NAT2_C;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
FEXOFENADINE;ABCB1;AA;ABCB1_A;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CMIN_VALUES;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;CYP2B6_CT + TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CMIN_VALUES;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
IMATINIB;ATIC;G;ATIC_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;CYP3A4;CC + CT;CYP3A4_TT;OTHER;DECREASED;RISK;OTHER:DOSE_DECREASE_OR_DRUG_SWITCHING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEXOFENADINE;ABCB1;AA;ABCB1_C;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RITODRINE;KCNMB2;GG;KCNMB2_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CMIN_VALUES;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCC1;T;ABCC1_T;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;A;ABCC2_A;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CAPECITABINE, FOLFOX, TEGAFUR;SMAD7;CC;SMAD7_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;NCF4;AA;NCF4_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
NAN;ATP8B3;A;ATP8B3_A;TOXICITY;DECREASED;LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;A;ABCB1_A;EFFICACY;DECREASED;RISK;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;T;ACE2_T;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYBA;A;CYBA_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;A;ABCB1_A;EFFICACY;DECREASED;RISK;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;RAC2;T;RAC2_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;C;ABCB1_C;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
NAN;ABO;T;ABO_T;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ACE_ACTIVITY;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATORVASTATIN, SIMVASTATIN;PON1;AA + AG;PON1_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
ATORVASTATIN, SIMVASTATIN;PON1;CC + CT;PON1_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
ATORVASTATIN;PON1;GG;PON1_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:OXIDATIVE_STRESS;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
CLOZAPINE;TACR1;C;TACR1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUCONAZOLE, TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;PK:TIME_TO_REACH_STABLE_DOSE_OF_TACROLIMUS;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUCONAZOLE, TACROLIMUS;CYP3A5;CC;CYP3A5_CC;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE_OF_TACROLIMUS;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;PK:TIME_TO_REACH_STABLE_DOSE;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
TAMOXIFEN;SLCO1A2;AG + GG;SLCO1A2_AG + GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DIZZINESS;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ERBB4;C;ERBB4_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP2C19;AA + AG;CYP2C19_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS"", ""BETA_BLOCKING_AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB2;GG;ADRB2_AA;OTHER;INCREASED;RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;AA + AC;ITPA_AC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;AT;ASNS_AT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CUSHING_SYNDROME;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS"", ""BETA_BLOCKING_AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";NOS3;TT;NOS3_GG + GT;OTHER;INCREASED;RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_SIDE_EFFECT
EFAVIRENZ, LOPINAVIR, NUCLEOSIDE_AND_NUCLEOTIDE_REVERSE_TRANSCRIPTASE_INHIBITORS, RITONAVIR;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP2C19;CT + TT;CYP2C19_TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS"", ""BETA_BLOCKING_AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB1;GG;ADRB1_CC;OTHER;DECREASED;RISK;OTHER:EMERGENCIES;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ABCB1;CT;ABCB1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A4;GG + GT;UGT1A4_GG + GT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:AUTONOMIC_NERVOUS_SYSTEM_DISORDER;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A4;CC + CT;CYP3A4_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRY_MOUTH;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;T;ABCB1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT1A4;GG + GT;UGT1A4_GG + GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATED_METABOLITES_OF_OLANZAPINE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;COL1A1;AA + AC;COL1A1_AA;NAN;INCREASED;RISK;DISEASE:FRACTURES, BONE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AG;ABCB1_A;TOXICITY;INCREASED;SEVERITY;DISEASE:GINGIVAL_HYPERPLASIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;EFFICACY;INCREASED;RISK;EFFICACY:ACUTE_REJECTION;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA + AG;P2RY12_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;T;ABCB1_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NOD2;CC;NOD2_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HOSPITAL_STAY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;EFFICACY;INCREASED;RISK;OTHER:ACUTE_REJECTION;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;EFFICACY;INCREASED;RISK;OTHER:ACUTE_REJECTION;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CYP3A4;CT;CYP3A4_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;VKORC1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;FTO;CC;FTO_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSELTAMIVIR;CES1;CT + TT;CES1_CT + TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:SIGNIFICANTLY_LARGER_MEAN_AUC_OF_OSELTAMIVIR, LOWER_CMAX_OF_OSELTAMIVIR_CARBOXYLATE, AND_A_SMALLER_OSELTAMIVIR_CARBOXYLATE-TO-OSELTAMIVIR_AUC_RATIO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;FTO;CT;FTO_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PBMC_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CABAZITAXEL;CYP2C8;T;CYP2C8_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;GNB3_CC;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;VKORC1_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;GNB3_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SLEEP_INITIATION_AND_MAINTECE_DISORDERS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AC + CC;VKORC1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;GNB3_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENTS_IN_NEUROVEGETATIVE_SYMPTOMS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;SLC19A1;C;SLC19A1_TT;OTHER;INCREASED;LIKELIHOOD;OTHER:DOWN_SYNDROME;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;ABCB1_A;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DUODENAL_ABSORPTION_OF_DIGOXIN_AFTER_DIRECT_DELIVERY_TO_THE_SURFACE_OF_THE_DUODENUM_BY_ENDOSCOPE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;HTR2A;AA;HTR2A_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;OTHER:PSYCHIATRIC_DISORDERS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;T;DPYD_CT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;A;DPYD_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;A;ABCB1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:POSITIVE_RELATIONSHIP_BETWEEN_OLANZAPINE_PLASMA_LEVELS_AND_POSITIVE_SYMPTOM_REDUCTION_COMPARED_TO_SUBJECTS_WITH_THE_GG_GENOTYPE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;AA;CYP1A2_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;PEOPLE;OTHER:PSYCHIATRIC_DISORDERS;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;A;DRD2_AG + GG;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROLACTIN;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;CBR1;GG;CBR1_GG;TOXICITY;INCREASED;RISK;DISEASE:CARDIOMYOPATHIES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;G;DRD2_G;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROLACTIN;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CEPHALEXIN;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;T;DRD2_T;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROLACTIN;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;A;DRD2_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROLACTIN;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;A;MTHFD1_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;PPARA;AA;PPARA_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;A;MTHFR_AA;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CODEINE;WBP2NL;G;WBP2NL_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;OPRM1;T;OPRM1_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A2;CC;SLC22A2_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A2;CC;SLC22A2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
SIMVASTATIN;PPARA;GG;PPARA_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ANKK1;GG;DRD2_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;COMT_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RELAPSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2A;CT + TT;HTR2A_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION, SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:DELIBERATE_SELF-HARM;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
NICOTINE;ANKK1;AA + AG;DRD2_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMIODARONE, ANTIBIOTICS, ANTIPSYCHOTICS, DIURETICS, QUINIDINE, SOTALOL;KCNE1;T;KCNE1_T;TOXICITY;INCREASED;RISK;DISEASE:TORSADES_DE_POINTES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;GG;OPRM1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG;OPRM1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;ANKK1;GG;DRD2_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;G;DRD2_G;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROLACTIN;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PYRIMIDINE_ANALOGUES;DPYD;CT + TT;DPYD_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GG;ABCG2_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PERCENTAGE_CHANGE_IN_LDL-CHOLESTEROL_LEVELS;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;AA;CYP2C19_AA;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:LOG_METABOLIC_RATIO_OF_AMITRIPTYLINE/NORTRIPTYLINE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_DEATH, MYOCARDIAL_INFARCTION, OR_STROKE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_DEATH, MYOCARDIAL_INFARCTION, OR_STROKE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;TT;ABCG2_T;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_DEATH, MYOCARDIAL_INFARCTION, OR_STROKE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS;PEOPLE;DISEASE:PERIPHERAL_VASCULAR_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOCETAXEL, FLUOROURACIL;CCL2;GG;CCL2_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
NAN;SERPINE1;T;SERPINE1_T;OTHER;INCREASED;LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SERPINE1;G;SERPINE1_G;OTHER;INCREASED;LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;MTHFR_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CLINICAL_RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;A;CDA_A;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;GGH_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;IL1B;GG;IL1B_GG;EFFICACY;INCREASED;LIKELIHOOD;PK:RESISTANCE;PEOPLE;DISEASE:OSTEITIS_DEFORMANS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLODRONATE;VDR;C;VDR_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANCE;PEOPLE;DISEASE:OSTEITIS_DEFORMANS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLODRONATE;VDR;A;VDR_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANCE;PEOPLE;DISEASE:OSTEITIS_DEFORMANS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;NT5C3A;GG;NT5C3A_GG;EFFICACY;INCREASED;RISK;EFFICACY:INDUCTION_FAILURE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;APOA5;AG + GG;APOA5_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_LDLC;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, SERTRALINE;HTR2A;T;HTR2A_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CISPLATIN, DOCETAXEL, FLUOROURACIL;IL6;CC;IL6_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;AA;HTR2A_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BUPRENORPHINE/NALOXONE;OPRM1;AG + GG;OPRM1_AG + GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A;T;ADORA2A_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A;T;ADORA2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A;T;ADORA2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:BLOOD_PRESSURE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ADORA2A;T;ADORA2A_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CISPLATIN, DOCETAXEL, FLUOROURACIL;TNF;CC + CT;TNF_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PEAR1;AA + AG;PEAR1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOCETAXEL, FLUOROURACIL;ABCC2;CT + TT;ABCC2_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;NELL1;C;NELL1_C;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PLASMA_TRIGLYCERIDES;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
BUPRENORPHINE/NALOXONE;OPRD1;TT;OPRD1_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANXIETY_DISORDERS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DAOA;A;DAOA_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BRIEF_PSYCHIATRIC_RATING_SCALE_SCORES;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE/NALOXONE;OPRD1;A;OPRD1_A;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:CRAVING;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2C;C;HTR2C_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;T;CYP3A5_CC;TOXICITY;INCREASED;RISK;OTHER:TACROLIMUS_NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;EFFICACY, TOXICITY;INCREASED;RISK;OTHER:SUBCLINICAL_ALLOGRAFT_NEPHROPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYBA;AA + AG;CYBA_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_DNA_DAMAGE;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;CT;CYP2B6_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;OTHER:FEMALE_GENDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ABCB1;AG + GG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD3;CC;DRD3_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:GREATER_POSITIVE_SYMPTOM_IMPROVEMENT_AND_POSITIVE_SYMPTOM_REMISSION;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_SIDE_EFFECT
OLANZAPINE;RGS4;CT;RGS4_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;TUBB1;G;TUBB1_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;RGS4;TT;RGS4_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE, PERPHENAZINE;RGS4;CC;RGS4_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:POSITIVE_RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;CYP2C8;C;CYP2C8_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;LEP;GG;LEP_GG;TOXICITY;INCREASED;RISK;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HEROIN;GRM3;T;GRM3_T;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE;G;ACE_AA + AG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ACE_ACTIVITY;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;HTR1A;GG;HTR1A_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TREATMENT_RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;CC + CT;ABCB1_TT;TOXICITY;DECREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES, TAXANES;ABCB1;AA;ABCB1_A;EFFICACY, METABOLISM/PK;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_RESPONSE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE, SERTRALINE;HTR1A;CC;HTR1A_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KCNJ6;TT;KCNJ6_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FREQUENCY_OF_RESCUE_ANALGESIC_ADMINISTRATION;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;CT;CYP2B6_CC;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP3A5;CC + CT;CYP3A5_CC;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;C9orf72;T;C9orf72_T;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DTNBP1;C;DTNBP1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSYCHOTIC_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MOB3B;T;MOB3B_T;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;PICK1;T;PICK1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:RELAPSE_OF_PSYCHOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CT + TT;CYP2B6_CT + TT;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;GBP6;A;GBP6_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OVERALL_GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;C9orf72;C;C9orf72_C;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CSRP3;T;CSRP3_T;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MOB3B;A;MOB3B_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;MTHFR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;MTHFR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_BASE_ON_DISEASE_ACTIVITY_SCORE_IN_44_JOINTS_IMPROVEMENT_AT_6_MONTHS_OF_TREATMENT;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:_DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN, LESS_PATIENT-ASSESSED_DIFFICULTY_WITH_PHYSICAL_TASKS, AND_FEWER_SWOLLEN_JOINTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;GT + TT;EGFR_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIANDROGENS;AKR1C3;CC;AKR1C3_CC;EFFICACY;INCREASED;RISK;EFFICACY:PROSTATE_CANCER-SPECIFIC_MORTALITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:MAINTECE_DOSE_OF_WARFARIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;AG;ERCC1_AA;TOXICITY;INCREASED;RISK;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;TP53;GG;TP53_GG;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;TT;CYP2C8_TT;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;GG;ABCC1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MAFB;T;MAFB_T;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;HTR2C_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:DEPRESSIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MAFB;C;MAFB_C;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;HTR2C_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CST5;T;CST5_T;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;HTR2C_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTP1;AA;GSTP1_GG;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CLCN6, MTHFR;A;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;PON1;A;PON1_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;PON1;A;PON1_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;MOB3B;A;MOB3B_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
BUPRENORPHINE;CYP3A4;CC + CT;CYP3A4_TT;EFFICACY;INCREASED;RISK;OTHER:SUBSTANCE_WITHDRAWAL_SYNDROME;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AG;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE_OF_INR_(TTR);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;GENE_NOT_SPECIFIED;CT;CT;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOCETAXEL;RXRA;AG;RXRA_AG;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;TPMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;RXRA_AG;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;GT;RXRA_GT;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;GG;RXRA_GG;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;DRD2;GG;DRD2_GG;NAN;INCREASED;LIKELIHOOD;DISEASE:SCHIZOPHRENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;SCN1A;CT;SCN1A_CT;OTHER;INCREASED;LIKELIHOOD;DISEASE:EPILEPSY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GENE_NOT_SPECIFIED;G;G;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE.;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOCETAXEL;HNF4A;TT;HNF4A_TT;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;GG;HTR2A_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP3A4;GG;CYP3A4_AA + AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;AG;HTR2A_AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;HNF4A;CT;HNF4A_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;HNF4A;CT;HNF4A_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:A_MORE_RAPID_ATTAINMENT_OF_TARGET_INR_AND_HIGHER_FREQUENCY_OF_DOSE_ADJUSTMENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOCETAXEL;NR1I2;TT;NR1I2_TT;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NRXN1;C;NRXN1_C;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA_BLOCKING_AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;AG + GG;NEDD4L_AG;EFFICACY;DECREASED;RISK;OTHER:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPERIDINE;SERINC5;C;SERINC5_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;AA;GSTA1_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;NR1I2;AA;NR1I2_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;CHRNA5_C;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
NICOTINE;COMT;AA;COMT_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;DISEASE:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PENICILLIN_G, PENICILLIN_V;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;COMT;AG;COMT_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RELAPSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOCETAXEL;NR1I2;CC + TT;NR1I2_C;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NRXN1;C;NRXN1_C;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;NR1I3;TT;NR1I3_TT;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;SEPTIN3, WBP2NL;A;SEPTIN3, WBP2NL_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPERIDINE;FIP1L1;G;FIP1L1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AG;NR1I3_AG;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NRXN1;C;NRXN1_C;OTHER;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;T;COMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;CC;NR1I3_CC;TOXICITY;DECREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;CT;ERCC2_CT + TT;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;AC;ERCC1_AC + CC;TOXICITY;INCREASED;RISK;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;XRCC1;CC;XRCC1_CC;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
MEPERIDINE;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;RXRA_AG;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;XPC;G;XPC_G;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;GG;NR1I3_GG;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AA;NR1I3_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2, KLC3;G;ERCC2_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;ACSS2;T;ACSS2_T;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AG;DPYD_AG;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;C;CYP2D6_C;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;G;ERCC1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CC;APOE_C;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;T;CYP2D6_T;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;T;NAT2_C;OTHER;INCREASED;SEVERITY;DISEASE:INSULIN_RESISTANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;G;CYP2D6_G;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;G;CYP2C19_G;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;G;CYP2D6_G;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;A;NAT2_G;OTHER;INCREASED;SEVERITY;DISEASE:INSULIN_RESISTANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEFITINIB;ABCG2;GT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;G;CYP2D6_G;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;MIR23A, MIR24-2, MIR27A;C;MIR27A_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;PTPN22;A;PTPN22_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SLEEP_APNEA_SYNDROMES;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE;CNR1;GT + TT;CNR1_GT + TT;OTHER;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;PTGS2;G;PTGS2_CC;NAN;INCREASED;RISK;DISEASE:STROKE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATENOLOL, BETA_BLOCKING_AGENTS, CARVEDILOL, METOPROLOL;PPARA;GG;PPARA_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:CARDIAC_REHOSPITALIZATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;RARG;AG;RARG_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ASPIRIN;TMEM196;T;TMEM196_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;HIF1A;AG;HIF1A_AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CLOCK;AA + AG;CLOCK_AA + AG;OTHER;INCREASED;LIKELIHOOD;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;ITPA;CC;ITPA_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
COCAINE;CNR1;GT + TT;CNR1_GT + TT;OTHER;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RITUXIMAB;FCGR3A;C;FCGR3A_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:COMPLETE_RESPONSE_RATE;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;IMPDH1;CT;IMPDH1_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RITUXIMAB;FCGR3A;AA;FCGR3A_AC + CC;NAN;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:LEVELS_OF_IGG;PEOPLE;OTHER:NON-HODGKIN'S_LYMPHOMA_AND_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
COCAINE;CNR1;C;CNR1_C;OTHER;DECREASED;RISK;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALENDRONATE, RALOXIFENE;VDR;CC;VDR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_BONE_MINERAL_DENSITY;PEOPLE;DISEASE:OSTEOPOROSIS, POSTMENOPAUSAL;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, DEXAMETHASONE, METHOTREXATE;PYGL;CC + CT;PYGL_CC + CT;DOSAGE;INCREASED;RISK;EFFICACY:RELAPSE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
INTERFERONS;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;CXCL8;AA;CXCL8_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;T;EGFR_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB, GEFITINIB;EGFR;T;EGFR_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERONS;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(SVR)_TO_INTERFERON_MONOTHERAPY_IN_HCV_GENOTYPE_1_PATIENTS;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, IRINOTECAN, OXALIPLATIN;DPYD;AG;DPYD_AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;GENE_NOT_SPECIFIED;G;G;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG;ABCB1_A;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AC + CT;ABCB1_C;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC1;AA;ABCC1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;OPRM1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;DPYD_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EPIDERMAL_GROWTH_FACTOR_RECEPTOR_(EGFR)_TYROSINE_KINASE_INHIBITORS;CTBP2;A;CTBP2_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PCI-SCHEDULED_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(SVR)_IN_HCV_GENOTYPE_1_PATIENTS;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;AG;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;AA + AG;HTR2A_GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLC22A5;C;SLC22A5_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:PRIMARY_CLINICAL_ENDPOINT_OF_DEATH_DUE_TO_CARDIOVASCULAR_CAUSES, NON-FATAL_MI_OR_STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLC22A5;C;SLC22A5_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;PTGS2;CG + GG;PTGS2_CC;NAN;DECREASED;RISK;DISEASE:STROKE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL_GROWTH_FACTOR_RECEPTOR_(EGFR)_TYROSINE_KINASE_INHIBITORS;CTBP2;G;CTBP2_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;CC;HTR2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BETA_BLOCKING_AGENTS;ADRB2;GG;ADRB2_AA;EFFICACY;DECREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME, OTHER:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYS;G;DPYS_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;IL4R;C;IL4R_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEGA-3_POLYUNSATURATED_FATTY_ACIDS;PTGS2;CG + GG;PTGS2_CC;OTHER;INCREASED;RISK;DISEASE:COLONIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;PTGS2;CG + GG;PTGS2_CC;OTHER;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYS;G;DPYS_AG + GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CLCN6, MTHFR;AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:PRIMARY_CENTRAL_NERVOUS_SYSTEM_LYMPHOMA;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;SLC22A5;C;SLC22A5_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;IL4R;G;IL4R_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;BDNF;TT;BDNF_TT;TOXICITY;DECREASED;AGE_AT_ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMINOGLYCOSIDE_ANTIBACTERIALS;MT-RNR1;T;MT-RNR1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC4;CC + CT;ABCC4_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:INTRACELLULAR_TENOFOVIR_DIPHOSPHATE_(TFV-DP)_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
AZITHROMYCIN, ERYTHROMYCIN;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:BACTERIAL_INFECTIONS, OTHER:INFLUENZA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;DTNBP1;T;DTNBP1_T;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP1B1;CC + CG;CYP1B1_CC;OTHER;INCREASED;RISK;DISEASE:BREAST_NEOPLASMS;WOMEN;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
THIOTEPA;GSTP1;T;GSTP1_CT + TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:NON-INDUCIBLE_THIOTEPA_CLEARANCE_AND_DECREASED_TEPA_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;TT;ABCC4_TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:TENOFOVIR_RENAL_CLEARANCE, AND_LOWER_AUC;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;A;DPYD_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;G6PD;T;G6PD_T;OTHER;INCREASED;LIKELIHOOD;OTHER:DIABETES_MELLITUS, TYPE_2;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;KL;G;KL_G;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON_BETA-1A, INTERFERON_BETA-1B;IRF6;G;IRF6_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;NR1I2;C;NR1I2_C;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;A;ABCC2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BONE_MARROW_DISORDER;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
FLUOROURACIL;WNT5B;CC;WNT5B_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR);PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ME3;A;ME3_A;EFFICACY;INCREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;GG;OPRD1_GG;TOXICITY;DECREASED;AGE_AT_ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NR1I2;G;NR1I2_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;LHX2;A;LHX2_A;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;C;DPYD_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;LHFPL3;G;LHFPL3_G;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CORTICOSTEROIDS, CYCLOPHOSPHAMIDE, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE;IL10;CC;IL10_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;GSK3B_A;METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:BONE_MARROW_DISORDER, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;BDNF;TT;BDNF, BDNF-AS_CC;TOXICITY;DECREASED;AGE_AT_ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;T;SLC22A1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;TRDN;T;TRDN_T;EFFICACY;INCREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;CHRNA5_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;AA;OPRD1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GIPR;AA + AT;GIPR_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;CHRNA5_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;C;CYCSP5_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;G;DPYD_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;SLC22A17;T;SLC22A17_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;CYCSP5;C;CYCSP5_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;CHRNA5_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMANTADINE, ANTICHOLINERGICS, DOPAMINE_AGONISTS, LEVODOPA, SELEGILINE;SLC22A1;C;SLC22A1_C;DOSAGE, EFFICACY, TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:PARKINSON_DISEASE;CAUTION_DOSE_ADJUST
MELPHALAN;POLR1G;A;POLR1G_A;EFFICACY, TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_AND_TIME-TO-TREAT_FAILURE;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;ACOT7;G;ACOT7_G;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
MORPHINE;TLR2;CC + CT;TLR2_CC + CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:COGNITIVE_DISORDER, SIDE_EFFECT:CONSTIPATION, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;SLC22A7;G;SLC22A7_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SCAP;CC + CT;SCAP_CC + CT;EFFICACY;DECREASED;SEVERITY;EFFICACY:HYPERLIPIDEMIAS;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C3;A;PSORS1C3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;APOBEC3B;A;APOBEC3B_A;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C3;A;PSORS1C3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;COMT;AA + AG;COMT_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE, PACLITAXEL;CDA;CC;CDA_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
MONTELUKAST;ABCC1;CT;ABCC1_CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANGES_IN_FEV1;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIAMCINOLONE;HCG22;T;HCG22_T;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:OCULAR_HYPERTENSION;PEOPLE;DISEASE:RETINAL_DISEASES;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CREB1, METTL21A;GG;CREB1, METTL21A_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL6;CC;IL6_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;G;POU5F1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;G;POU5F1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EPIDERMAL_GROWTH_FACTOR_RECEPTOR_(EGFR)_TYROSINE_KINASE_INHIBITORS;HLA-DRB5;A;HLA-DRB5_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;CREB1, METTL21A;A;CREB1, METTL21A_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL_GROWTH_FACTOR_RECEPTOR_(EGFR)_TYROSINE_KINASE_INHIBITORS;HLA-DRB5;T;HLA-DRB5_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOE;T;APOE_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;C;POU5F1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TRIAMCINOLONE;HCG22;G;HCG22_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:OCULAR_HYPERTENSION;PEOPLE;DISEASE:RETINAL_DISEASES;CAUTION_SIDE_EFFECT
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C1;A;PSORS1C1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;IL6R;AC + CC;IL6R_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;C;POU5F1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;BDNF;TT;BDNF, BDNF-AS_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C1;A;PSORS1C1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;IL2;AC + CC;IL2_AC + CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL_GROWTH_FACTOR_RECEPTOR_(EGFR)_TYROSINE_KINASE_INHIBITORS;HLA-DRB5;C;HLA-DRB5_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;B4GALT2;CT + TT;B4GALT2_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC28A2;AA;SLC28A2_AT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CHLORTHALIDONE;NPPA;G;NPPA_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC28A2;AT;SLC28A2_AT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SOD2;G;SOD2_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;C;CYP3A4_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PRIMARY_OVARIAN_FAILURE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;CC;SLC22A16_CC + CT;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOXORUBICINOL_AUC;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC29A1;CC;SLC29A1_CG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS, SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;CYP2B6_GG;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:ORAL_MUCOSITIS;PEOPLE;OTHER:RECIPIENTS_OF_HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;CYP2B6_CT + TT;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGIC_CYSTITIS;PEOPLE;OTHER:RECIPIENTS_OF_HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
EPIDERMAL_GROWTH_FACTOR_RECEPTOR_(EGFR)_TYROSINE_KINASE_INHIBITORS;KIR3DL2;G;KIR3DL2_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRA;T;HLA-DRA_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;CYP2B6_GT;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:VENOOCCLUSIVE_DISEASE_OF_THE_LIVER;PEOPLE;OTHER:HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;C;CYP2D6_T;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;GG;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SLEEP_DISORDERS;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;MTHFR;A;MTHFR_AA;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:RECIPIENTS_OF_HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN, GEMCITABINE;GSTP1;AG + GG;GSTP1_GG;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:GALLBLADDER_NEOPLASMS;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;T;CYP2D6_T;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;ABCC4;CC;ABCC4_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;CBR3_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TUMOR_RESPONSE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR3;G;CBR3_G;TOXICITY, METABOLISM/PK;DECREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;A;CBR3_A;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOXORUBICINOL_AUC;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
ANTIHYPERTENSIVES;ATP2B1;AA + AG;ATP2B1_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;A;CYP2D6_A;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PRURITUS;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC28A3;CC + CT;SLC28A3_CC + CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HEROIN;GRM3;A;GRM3_A;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;T;VKORC1_T;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:ATRIAL_FLUTTER,DISEASE:VENOUS_THROMBOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CORTICOSTEROIDS;CRHR1;AA;CRHR1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PERCENT_CHANGE_IN_FEV;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CLCN6, MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;FKBP5;AA + AG;FKBP5_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:GLUCOCORTICOID_RESPONSIVENESS;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE, FLUTICASONE_PROPIONATE;CRHR1;AA;CRHR1_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;G;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:LOW_BACK_PAIN;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;CRHR1;TT;CRHR1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PERCENT_CHANGE_IN_FEV;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC1;AA + AT;ABCC1_AT + TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE, FLUTICASONE_PROPIONATE;CRHR1;TT;CRHR1_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;SLC22A6;CC + CT;SLC22A6_CC + CT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;GENE_NOT_SPECIFIED;AA + AG;AA + AG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;GENE_NOT_SPECIFIED;A;A;EFFICACY, TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;SLC22A6;CT + TT;SLC22A6_CT + TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;GG;OPRM1_AA;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NAUSEA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;HMGCS2;G;HMGCS2_G;EFFICACY, TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
METHOTREXATE;CLCN6, MTHFR;AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;DAO;TT;DAO_TT;EFFICACY;INCREASED;SEVERITY;EFFICACY:SUBSTANCE_WITHDRAWAL_SYNDROME;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC5;CC;ABCC5_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;KCNIP1, KCNMB1;CT + TT;KCNIP1, KCNMB1_CT + TT;OTHER;DECREASED;RISK;DISEASE:HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL1B;GG;IL1B_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;UGT1A1_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AT;ABCB1_C;TOXICITY;INCREASED;RISK;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DABIGATRAN;ABCB1;CC + CT;ABCB1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:STROKE;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC1;AA + AG;ABCC1_AA + AG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL23R;TT;IL23R_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;UGT1A1_AG;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC5;CC;ABCC5_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
INFLIXIMAB;SLCO1C1;GG;SLCO1C1_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;CHRNA3, CHRNA5_GG;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_FUNCTION_(LVEF);PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;IL7;A;IL7_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC1;CT + TT;ABCC1_CT + TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCB1;AC + CC;ABCB1_AC + CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;C;CHRNA3_C;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC5;GG;ABCC5_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB4;G;CHRNB4_G;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC1;AG + GG;ABCC1_AG + GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;ADRB1_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SIGNIFICANTLY_GREATER_IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION_(LVEF);PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;AA;UGT1A1_AA;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:CEREBRAL_PALSY, SIDE_EFFECT:HEARING_LOSS;CHILDREN;OTHER:NEONATAL_HYPERBILIRUBINEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;NT5C2;CT;NT5C2_CT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
INFLIXIMAB;ADAM17;TT;ADAM17_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;MED12L, P2RY12;AG;MED12L, P2RY12_AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;AGO2;AA + AC;ago-02_AA + AC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
STAVUDINE;TNF;C;TNF_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROPATHY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MED12L, P2RY12;AG;P2RY12_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;MED12L, P2RY12;AC;MED12L, P2RY12_AC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC5;AA;ABCC5_AA + AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;CHRNA5_G;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMINOGLYCOSIDE_ANTIBACTERIALS;MT-RNR1;C;MT-RNR1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC5;GG;ABCC5_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;CHRNA5_A;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL1A;A;IL1A_A;OTHER;INCREASED;SEVERITY;DISEASE:PAIN;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_SIDE_EFFECT
FLUTICASONE/SALMETEROL;CRHR1;CC;CRHR1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_CHANGE_IN_FEV;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;COMT;G;COMT_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC5;AA;ABCC5_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A;CYP27B1, METTL1;GT + TT;CYP27B1, METTL1_GT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPRANOLOL;COMT;G;COMT_CG + GG;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;APOBEC3B;T;APOBEC3B_T;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;IFNL3;TT;IFNL3_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;KCNN1;C;KCNN1_C;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A;VDR;AA;VDR_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ANKRD30B;A;ANKRD30B_A;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CRP;CT + TT;CRP_CT + TT;EFFICACY, OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPRANOLOL;COMT;G;COMT_AG + GG;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AND_IMMUNOMODULATING_AGENTS;ABCC1;CC + CG;ABCC1_CC + CG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;TT;HTR2A_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;GRM3;T;GRM3_T;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ROSUVASTATIN;GENE_NOT_SPECIFIED;CC + CT;CC + CT;EFFICACY, OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;OPRD1;AT + TT;OPRD1_AT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;HNF1A;AC + CC;HNF1A_AC + CC;EFFICACY, OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING_AND_GREATER_INCREASE_IN_LVEF_(LEFT_VENTRICULAR_EJECTION_FRACTION);PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;COMT;C;COMT_CC + CT;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
BUCINDOLOL;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROMYCIN;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:BACTERIAL_INFECTIONS, OTHER:INFLUENZA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;AA + AG;PEAR1_AA + AG;TOXICITY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;KCNIP1, KCNMB1;CT + TT;KCNIP1, KCNMB1_CT + TT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:BLOOD_PRESSURE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;A;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, ISOFLURANE;RYR1;AC;RYR1_AC;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RISPERIDONE;NR1I2;GG;NR1I2_GG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:9-HYDROXY-RISPERIDONE_LEVELS;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;GG;SLCO1B1_AA + AG;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:REPAGLINIDE_PLASMA_CONCENTRATION_(AUC)_AND_CMAX;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HALOTHANE;RYR1;CT;RYR1_CT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RISPERIDONE;NR1I2;GG;NR1I2_GG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ACTIVE_MOIETY_LEVELS;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;G;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;CYP2D6;AA + AG;CYP2D6_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DALCETRAPIB;ADCY9;AA;ADCY9_AA;EFFICACY;DECREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR_INHIBITORS;PIK3CA;C;PIK3CA_C;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR_INHIBITORS;PIK3CA;T;PIK3CA_T;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MISOPROSTOL;SLCO1B1;GG;SLCO1B1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEVER;WOMEN;DISEASE:POST-PARTUM_HEMORRHAGE;CAUTION_SIDE_EFFECT
MISOPROSTOL;ABCC4;AA;ABCC4_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEVER;WOMEN;DISEASE:POST-PARTUM_HEMORRHAGE, DISEASE:THERAPEUTIC_ABORTION;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;A;PEAR1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:COLLAGEN_INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_OR_DUAL_ANTIPLATELET_THERAPY_(DAPT)_ADMINISTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;TT;CYP2E1, DUX1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;RAF1;AG;RAF1_AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;TOXICITY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PEAR1;AA + AG;PEAR1_AA + AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OLANZAPINE;GSTP1;AG + GG;GSTP1_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;AA + AG;PEAR1_AA + AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;ALOX15;C;ALOX15_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
METHADONE;CCL11;A;CCL11_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INSOMNIA;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;PIK3CA;C;PIK3CA_C;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HAMD_SCORES;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;MTHFR;G;MTHFR_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, PREDNISOLONE, VINCRISTINE;PNPLA3;CG + GG;PNPLA3_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;PTGS1;C;PTGS1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;CT;NAT2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;PNPLA3;G;PNPLA3_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LEUCOVORIN, TEGAFUR;UMPS;CC;UMPS_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;T;EGFR_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_NEGATIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;AA + AG;MAP3K1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;CT + TT;CYP2C9_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;CYP4X1;AA;CYP4X1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;TPMT;C;TPMT_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;AA + AG;CYP2C19_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;PTGS1;A;PTGS1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CG + GG;SLC22A1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;DISEASE:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GABRG3;A;GABRG3_A;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
GEMCITABINE;GENE_NOT_SPECIFIED;CT + TT;CT + TT;TOXICITY;DECREASED;RISK;DISEASE:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LONGER_MEDIAN_PROGRESSION-FREE_SURVIVAL_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;CC + CT;MAP3K1_CC + CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;A;RRM1_A;DOSAGE;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;GENE_NOT_SPECIFIED;AG + GG;AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;ACSS2;AT;ACSS2_AT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;ABCC1_GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ONSET_OF_TOXICITY;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION, NICOTINE;EPB41;AA;EPB41_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ABSTINENCE;MEN;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;METTL14;G;METTL14_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL17F;CC;IL17F_CC;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;NOS3;GG;NOS3_GG + GT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL17A;AA;GG;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;KCNIP4;A;KCNIP4_A;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;ATIC;C;ATIC_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;A;PDYN_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;UGT1A1_AA;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:BILIARY_TRACT_NEOPLASM, DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;KCNIP4;C;KCNIP4_C;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI, FOLFOX, XELOX;MTHFR;GG;MTHFR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;ALG10;AA + AG;ALG10_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;UGT1A1;T;UGT1A1_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RITONAVIR;APOC3;C;APOC3_CC + CT;OTHER;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEMETREXED;GGH;CT + TT;GGH_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;UGT1A4;GG;UGT1A4_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:GLUCURONIDATION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:HUMAN_LIVER_MICROSOMES;CAUTION_DOSE_ADJUST
HALOPERIDOL;CYP2D6;CT;CYP2D6_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_WITHDRAWAL_DELIRIUM;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE_INHIBITORS, PLAIN;KCNIP4;A;KCNIP4_A;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;VEGFA;CC;VEGFA_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING;WOMEN;OTHER:SMOKERS_WHO_ARE_PREGNANT;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;TRAF3IP2;C;TRAF3IP2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
GEMCITABINE;ALOX5AP;AG + GG;ALOX5AP_AG + GG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CMAX_AND_A_LOWER_MEAN_AUC;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;IL7;AA + AG;IL7_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEMTUZUMAB_OZOGAMICIN;CD33;CC + CG;CD33_CC + CG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DEATH;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;BRAF;T;BRAF_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;CLCN6, MTHFR;AG + GG;MTHFR_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OPIOIDS;TH;G;TH_G;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEMTUZUMAB_OZOGAMICIN;CD33;GG;CD33_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;CYP2E1, DUX1;AT;CYP2E1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CISPLATIN;SLC22A2;A;SLC22A2_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS, FLUOROURACIL, LEUCOVORIN;SPARC;AG + GG;SPARC_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_TUMOR_RECURRENCE;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DBH;G;DBH_G;TOXICITY;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HSPG2;C;HSPG2_C;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;DPYD;AG + GG;DPYD_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;HSPG2;T;HSPG2_T;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
QUETIAPINE;RIMS1;CC + CT;RIMS1_CC + CT;EFFICACY, TOXICITY;DECREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;TAS2R16;C;TAS2R16_C;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;METTL3;G;METTL3_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;C1orf167, CLCN6, MTHFR;GG + GT;MTHFR_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F5;T;F5_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;CT + TT;KDR_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;SCN1A;CC;SCN1A_CC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;CYP2B6_GT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;CT + TT;OPRM1_T;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD2;A;DRD2_A;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;NR1I2_T;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;KRAS;T;KRAS_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;CG + GG;VEGFA_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTR;GG;MTR_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
SORAFENIB;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;AA + AG;VEGFA_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:MUSCULAR_DISEASES, SIDE_EFFECT:RHABDOMYOLYSIS, SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE, HEROIN;OPRM1;T;OPRM1_T;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE, DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;CT + TT;KDR_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;KRAS;A;KRAS_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;CYP2C9;T;CYP2C9_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;MTR;GG;MTR_AA + AG;OTHER;INCREASED;LIKELIHOOD;DISEASE:RHEUMATOID_ARTHRITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;GG;MTR_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METHOTREXATE-INDUCED_NODULOSIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRD1;AG + GG;OPRD1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC0-12;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F2;A;F2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;EFFICACY;INCREASED;RISK;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL;SCN1A;TT;SCN1A_CC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR);POPULATION_AFFECTED_NOT_SPECIFIED;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
ATAZANAVIR;UGT1A1;T;UGT1A1_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;SLCO1B1_CC + CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;TOXICITY;INCREASED;RISK;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CT + TT;CYP2B6_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_T;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DPD_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ALLOPURINOL;PSORS1C1;AG + GG;PSORS1C1_AG + GG;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;MTHFR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:EVENT-FREE_SURVIVAL, DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;CT + TT;PDYN_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CYP2A6;GG;CYP2A6_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;AA;OPRM1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PAIN;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;CC;PDYN_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
RISPERIDONE;LEP;GG;LEP_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
PERINDOPRIL;AGTR1;TT;AGTR1_TT;EFFICACY;DECREASED;RISK;EFFICACY:CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)_AND_CHANGES_IN_VIRAL_LOAD_AFTER_4_WEEKS_OF_TREATMENT;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;AC + CC;CDA_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;GG;CDA_G;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CYTOTOXICITY;PEOPLE;DISEASE:MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;CYP2D6_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;MEN;DISEASE:ALCOHOLIC_PSYCHOSIS, DISEASE:ALCOHOL_ABUSE,DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;TT;CDA_TT;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CYTOTOXICITY;PEOPLE;DISEASE:MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;CYCSP5;AA + AC;CYCSP5_AA + AC;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;RBMS3;A;RBMS3_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OSTEONECROSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;NEDD4L;AG;NEDD4L_AG;OTHER;INCREASED;RISK;DISEASE:CARDIOVASCULAR_DISEASE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AC;DPYD_AC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DPD_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;INSIG2;C;INSIG2_C;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;CC;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CTLA4;A;CTLA4_A;OTHER;DECREASED;RISK;DISEASE:RHEUMATOID_ARTHRITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;CC + CT;GCKR_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;DPYD_CT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DPD_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC4;G;ABCC4_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:KIDNEY_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;C;IGF2BP2_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;CC;CDA_AA;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CYTOTOXICITY;PEOPLE;DISEASE:MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;VKORC1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;NOTCH4;AA + AG;NOTCH4_AA + AG;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;KCNQ1;CC + GG;KCNQ1_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NQO1;AA;NQO1_A;OTHER;DECREASED;LIKELIHOOD;OTHER:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIRAL_RESPONSE_(RVR)_TO_PEG-IFN/RIBAVIRIN_THERAPY_AT_4_WEEKS_IN_HCV_GENOTYPE_3_PATIENTS;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;G;IGF2BP2_G;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:CHEMOREFRACTORY_ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB, GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;CYP2B6_GT;EFFICACY;INCREASED;RISK;EFFICACY:IMMUNOLOGICAL_FAILURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NQO1;AA;NQO1_A;TOXICITY;DECREASED;LIKELIHOOD;OTHER:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;AG + GG;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;GT;CYP2B6_GT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SLEEP_DISORDERS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;CACNA1C;AA;CACNA1C_GG;EFFICACY;DECREASED;RISK;OTHER:PRIMARY_OUTCOME;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEDIAN_SURVIVAL_TIME_(MST);POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, IRINOTECAN;UGT1A1;AA + AG;UGT1A1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:THROMBOCYTOPENIA;WOMEN;DISEASE:FEMALE_REPRODUCTIVE_SYSTEM_NEOPLASM;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_LEVEL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;UGT1A1;AA + AG;UGT1A1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;WOMEN;DISEASE:FEMALE_REPRODUCTIVE_SYSTEM_NEOPLASM;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2A6;AC + CC;CYP2A6_C;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;DRD2;AA + AG;DRD2_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DEATH;PEOPLE;DISEASE:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
VERAPAMIL;CACNA1C;GG;CACNA1C_GG;EFFICACY;INCREASED;RISK;EFFICACY:PRIMARY_OUTCOME;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;CC + CT;GCKR_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG_IN_USERS_WITH_A_STARTING_DOSE_OF_MORE_THAN_20_MG;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN, GEMCITABINE;GENE_NOT_SPECIFIED;AG;AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;UGT1A1;AA + AG;UGT1A1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;WOMEN;DISEASE:FEMALE_REPRODUCTIVE_SYSTEM_NEOPLASM;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;TT;NUDT15_CT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ALOPECIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS;ABCB1;AG;ABCB1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEDIAN_SURVIAL_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;EFFICACY:NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, GEMCITABINE;NRAS;CT;NRAS_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;EFFICACY:NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, GEMCITABINE;GPX5;AG + GG;GPX5_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ACTG1;A;ACTG1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;VKORC1;T;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;GG;CYP2B6_GT;TOXICITY;INCREASED;SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, TAXANES;ATP7B;AA;ATP7B_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;CAPG;T;CAPG_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;COL1A1;AA + AC;COL1A1_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;AKR1C3;GG;AKR1C3_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:ABSOLUTE_LEUCOCYTE_AND_NEUTROPHIL_COUNTS_ON_DAY_15;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;AA;CYP2B6_GG;TOXICITY;INCREASED;SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2C9;CC;CYP2C9_CT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DYSPEPSIA;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;SLCO1B3;GG;SLCO1B3_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
REMIFENTANIL;OPRM1;GG;OPRM1_AA;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;WOMEN;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AA + AC;ITPA_AC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, TAXANES;GSR;CC;GSR_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;APOE;C;APOE_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;T;SLC6A4_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, TAXANES;VEGFA;TT;VEGFA_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;CYP2C9;C;CYP2C9_AC + CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;COMT;AA + AG;COMT_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALOXONE;OPRM1;G;OPRM1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CORTISOL_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SLC6A4;C;SLC6A4_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS, RIBAVIRIN;VDR;AG + GG;VDR_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CRYOGLOBULINEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EGFR_INHIBITORS;PIK3CA;C;PIK3CA_T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;EGFR;AA + AG;EGFR_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EGFR_INHIBITORS;PIK3CA;T;PIK3CA_T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;CES1;CC;CES1P1_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NEOPLASMS, OTHER:PANCREATIC_NEOPLASMS,OTHER:COLORECTAL_NEOPLASMS, OTHER:OVARIAN_NEOPLASMS, OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;GG;ATIC_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;A;SLC6A4_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS, SALMETEROL;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RISK;EFFICACY:EXACERBATIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;IL1B;AA + AG;IL1B_AA + AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BETA_BLOCKING_AGENTS;CYP2D6;GG;CYP2D6_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;GG;DPYD_AG + GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DPD_ACTIVITY;HEALTHY;OTHER:WITHOUT_THE_RS115232898_A>G_VARIANT_(DPYD_Y186C);CAUTION_DOSE_ADJUST
EGFR_INHIBITORS;PIK3CA;C;PIK3CA_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;IL1B;AG;IL1B_GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;SLC28A3;A;SLC28A3_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH;PEOPLE;DISEASE:HEART_TRANSPLANTATION, DISEASE:KIDNEY_TRANSPLANTATION,DISEASE:LIVER_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;PIK3CA;T;PIK3CA_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ADRB2;AA;ADRB2_AA;EFFICACY;INCREASED;RISK;EFFICACY:UNCONTROLLED_ASTHMA;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
IRINOTECAN;CES1;AA + AG;CES1_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NEOPLASMS, OTHER:PANCREATIC_NEOPLASMS,OTHER:COLORECTAL_NEOPLASMS, OTHER:OVARIAN_NEOPLASMS, OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE, LETROZOLE;CYP19A1;AA;CYP19A1_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;IL1B;AA;IL1B_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;BDNF, BDNF-AS_CC;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADGRL3;CG + GG;ADGRL3_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;SLC28A3;A;SLC28A3_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT;NUDT15_CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;CYP2C9_CT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBOPLATIN, TAXANES;ATP7B;TT;ATP7B_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AG;UGT1A1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;SUGCT;T;SUGCT_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;FMO3;AG + GG;FMO3_GG;OTHER;DECREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;KNG1;C;KNG1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AA;DPYD_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS, OTHER:PANCREATIC_NEOPLASMS,OTHER:COLORECTAL_NEOPLASMS, OTHER:OVARIAN_NEOPLASMS, OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN;LPA;CT;LPA_CT;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BOCEPREVIR, PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;T;CYP2C19_T;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;DPYD_CT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DPD_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;ABCC11;GG + GT;ABCC11_GG + GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
EGFR_INHIBITORS;PIK3CA;C;PIK3CA_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;DPYD_CT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DPD_ACTIVITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;ABO;del;ABO_del;TOXICITY;DECREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A3;AG;SLC6A3_AG;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;ABO;C;ABO_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;TT;SLCO1B1_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;PROCR;G;PROCR_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HORMONAL_CONTRACEPTIVES_FOR_SYSTEMIC_USE;F11;T;F11_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AG + GG;SLCO1B1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INFECTIOUS_DISEASE, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;NR1I2;CC;NR1I2_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;CAUTION_SIDE_EFFECT
NAN;MAOA;TT;MAOA_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MAOB;CC;MAOB_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:INFECTIOUS_DISEASE, SIDE_EFFECT:NEPHROTOXICITY, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;A;CBR3_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;GG;UGT1A1_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;GG;EGF_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_PATHOLOGIC_RESPONSE;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB, ERLOTINIB, GEFITINIB;UHRF1;TT;UHRF1_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HAVCR2;AA + AC;HAVCR2_AA + AC;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HAVCR2;AC + CC;HAVCR2_AC + CC;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB, ERLOTINIB, GEFITINIB;DVL2;AA;DVL2_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER_ACETATE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;OR10AE3P, PSMB3P;A;OR10AE3P, PSMB3P_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;BDNF;TT;BDNF, BDNF-AS_CC;OTHER;INCREASED;RISK;OTHER:ADDICTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;T;BDNF, BDNF-AS_CC;OTHER;INCREASED;RISK;OTHER:ADDICTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;ABCB1;C;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;CBR3;A;CBR3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;T;OPRM1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
ASPIRIN, TICAGRELOR;CYP4F2;AA;CYP4F2_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;T;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
AFATINIB, ERLOTINIB, GEFITINIB;NUP62;CC;NUP62_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;GENE_NOT_SPECIFIED;GG;GG;OTHER;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;GG;OPRM1_AA;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;CYP2C9_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;CYP2C9_AC + CC;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C18;AG + GG;CYP2C18_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F5;G;F5_G;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;PROS1;AA;PROS1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRM3;GG;CHRM3_GG;TOXICITY;INCREASED;RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, GEMCITABINE;CDA;AA;CDA_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;G;DPYD_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTP1;GG;GSTP1_GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:MICRONUCLEATED_BINUCLEATED_CELLS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;MTHFR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;MTHFR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;FCGR2A;AG;FCGR2A_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SCN5A;GT + TT;SCN5A_GG;OTHER;INCREASED;LIKELIHOOD;DISEASE:CARDIAC_RHYTHM_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, TAXANES;VEGFA;GG;VEGFA_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
EXEMESTANE, LETROZOLE;ESR1;CT + TT;ESR1_TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;AG + GG;FASTKD3, MTRR_AG + GG;METABOLISM/PK;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CARBOPLATIN, TAXANES;SCN10A;TT;SCN10A_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, TAXANES;VEGFA;CC;VEGFA_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
LETROZOLE;ESR1;TT;ESR1_TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CC;CYP2C9_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AA + AG;ABCC2_GG;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
EXEMESTANE, LETROZOLE;ESR1;TT;ESR1_TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;ESR1;TT;ESR1_TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, ETOPOSIDE;NQO1;AA;NQO1_A;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN;SLC22A2;AC;SLC22A2_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
LETROZOLE;ESR2;CC;ESR2_CC;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;ESR1;AA;ESR1_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;CYP19A1;AA;CYP19A1_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
BISPHOSPHONATES;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;OTHER:OSTEOPOROSIS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;PTGS1;TT;PTGS1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;DPYD;AT;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;TNF;A;TNF_AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;CC;KDR_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;COMT;AG + GG;COMT_AA;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:LENGTH_OF_HOSPITAL_STAY;INFANTS;DISEASE:NEONATAL_ABSTINENCE_SYNDROME;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;PRRC2A;G;PRRC2A_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;PRRC2A;T;PRRC2A_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHADONE, MORPHINE;COMT;AG + GG;COMT_AA;OTHER;DECREASED;LIKELIHOOD;OTHER:TREATMENT;INFANTS;OTHER:NEONATAL_ABSTINENCE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;FLT1;TT;FLT1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;AA;KDR_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, GEMCITABINE;MSH5;T;MSH5_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;AA + AG;ALDH1A1_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;ATP2B1;T;ATP2B1_T;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;DOCK8;A;DOCK8_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
NAN;EPO;A;EPO_A;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ENDOGENOUS_LEVELS_OF_EPO;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;DMPK;G;DMPK_G;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
ASPIRIN;EYA1;T;EYA1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PEPTIC_ULCER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;CYP2C8;A;CYP2C8_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;CYP2C8;A;CYP2C8_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZITHROMYCIN, CHLORPROMAZINE, CILOSTAZOL, CIPROFLOXACIN, CITALOPRAM, CLARITHROMYCIN, DOFETILIDE, DONEPEZIL, DRONEDARONE, ERYTHROMYCIN, ESCITALOPRAM, FLECAINIDE, FLUCONAZOLE, HALOPERIDOL, HYDROXYCHLOROQUINE, LEVOFLOXACIN, METHADONE, MOXIFLOXACIN, ONDANSETRON, OXALIPLATIN, PAPAVERINE, PENTAMIDINE, PROCAINAMIDE, PROPOFOL, QUINIDINE, SOTALOL;KCNE1;T;KCNE1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;C6orf15;A;C6orf15_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;CDSN;T;CDSN_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ETOPOSIDE, PLATINUM_COMPOUNDS;DYNC2H1;AG + GG;DYNC2H1_AG + GG;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:BRONCHIOLOALVEOLAR_CARCINOMA_AND_ADENOCARCINOMA_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE, MORPHINE;OPRM1;AG + GG;OPRM1_AA;OTHER;DECREASED;LIKELIHOOD;OTHER:TREATMENT;INFANTS;DISEASE:NEONATAL_ABSTINENCE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;NQO1;AA + AG;NQO1_A;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE, PLATINUM_COMPOUNDS;YAP1;GT + TT;YAP1_GT + TT;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ2;A;COQ2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN_INTOLERANCE, DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ2;G;COQ2_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN_INTOLERANCE, DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;HLA-C;C;HLA-C_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:BRONCHIOLOALVEOLAR_CARCINOMA_AND_ADENOCARCINOMA_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;HCP5;G;HCP5_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CTNNB1;AA;CTNNB1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, ERLOTINIB, PACLITAXEL;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;SERPINC1;C;SERPINC1_C;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBRUTINIB;KCNQ1;AA;KCNQ1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE, SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA_OTHER:WALDENSTROM_MACROGLOBULINEMIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC;SLC19A1_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;SCN5A;GG;SCN5A_GG;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUDDEN_INFANT_DEATH;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;CTNNB1;AA;CTNNB1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
BETA_BLOCKING_AGENTS;ADRB1;AG + GG;ADRB1_AG + GG;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;ATAT1;C;ATAT1_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;GG;VEGFA_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;GG;VEGFA_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABO;GG;ABO_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ACE_ACTIVITY;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;PPP1R18;T;PPP1R18_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;OPRM1;AG + GG;OPRM1_AA;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:LENGTH_OF_HOSPITAL_STAY;INFANTS;DISEASE:NEONATAL_ABSTINENCE_SYNDROME;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;KCNQ1;GG;KCNQ1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE, SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA_OTHER:WALDENSTROM_MACROGLOBULINEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;MUCL3;A;MUCL3_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OLANZAPINE;GIPR;AA;GIPR_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PLASMA_INSULIN_LEVELS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SORAFENIB;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;CC;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CTLA4;A;CTLA4_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;CC;VEGFA_CC + CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;CC;VEGFA_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG;OPRM1_AG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;VEGFA_CC + CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;ABCC4;AA + AC;ABCC4_AC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PHYSICAL_AND_LIFE_WELL-BEING_QUALITY_OF_LIFE_(QOL)_SCALES;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PEOPLE_WITH_EGFR_MUTATION_POSITIVE_ADVANCED_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB, GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB, GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;DOSAGE, EFFICACY, TOXICITY;INCREASED;RISK;EFFICACY:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PAZOPANIB;HFE;TT;HFE_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;GENE_NOT_SPECIFIED;GG;GG;OTHER;INCREASED;RISK;DISEASE:HEART_FAILURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER_ACETATE;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
GLATIRAMER_ACETATE;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GAD2;AG + GG;GAD2_AG + GG;OTHER;INCREASED;LIKELIHOOD;DISEASE:METHAMPHETAMINE_DEPENDENCE, DISEASE:PSYCHOTIC_DISORDER, DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE, GLYBURIDE;ABCC8, KCNJ11;CC;ABCC8, KCNJ11_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA + AC;IFNL3_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;CT + TT;ABCB1_CT + TT;EFFICACY;INCREASED;RISK;EFFICACY:RENAL_TRANSPLANT_FAILURE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;CC;IFNL3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:TROUGH_LEVELS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB, ERLOTINIB, GEFITINIB;ARF1;GT + TT;ARF1_GT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;CYP2E1;CT + TT;CYP2E1, DUX1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OSELTAMIVIR;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEPRESSION, SIDE_EFFECT:GASTRITIS, SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;OTHER:ACUTE_RESPIRATORY_DISEASES, OTHER:SUSPECTED_INFLUENZA_A/H1N1_INFECTION;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;AA + AT;ABCC3_AA + AT;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PLASMA_LEVELS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;AA + AT;ABCC3_AA + AT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COCAINE;OPRD1;T;OPRD1_T;TOXICITY;DECREASED;RISK;OTHER:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERIVASTATIN;RYR2;AA;RYR2_A;TOXICITY;DECREASED;RISK;DISEASE:RHABDOMYOLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCC2;A;ABCC2_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROBABILITY_OF_ANTIEPILEPTIC_DRUG_RESPONSE;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC3;AA + AT;ABCC3_AA + AT;EFFICACY;INCREASED;RISK;EFFICACY:RELAPSE_IN_THE_CENTRAL_NERVOUS_SYSTEM;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CYP1A2;T;CYP1A2_T;OTHER;INCREASED;LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYMOCYTE_GLOBULIN;FCGR3A;AC + CC;FCGR3A_AC + CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SENSITIVE_TO_ANTILYMPHOCYTE_SERUM;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;LINC00251;G;LINC00251_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PEGASPARGASE;ARHGAP28;T;ARHGAP28_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;DOK5;A;DOK5_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCG2;CT + TT;ABCG2_CT + TT;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH;CHILDREN;OTHER:CENTRAL_NERVOUS_SYSTEM_CANCER;CAUTION_SIDE_EFFECT
THEOPHYLLINE;CYP1A2;T/del + TT;CYP1A2_T;EFFICACY;INCREASED;SEVERITY;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;CAUTION_SIDE_EFFECT
THEOPHYLLINE;CYP1A2;T;CYP1A2_T;EFFICACY, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_DRUG_LEVELS;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP1A2;C;CYP1A2_AA;OTHER;INCREASED;LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;ATP7B;CC;ATP7B_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;T;NR1H3_T;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;A;NR1H3_A;EFFICACY;DECREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;T;DDC_T;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATENOLOL, VERAPAMIL;NR1H3;G;NR1H3_G;EFFICACY;DECREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;C;DDC_C;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SEVOFLURANE;KCNK2;CC + CG;KCNK2_CC + CG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SEDATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;T;DDC_T;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CHOP, RITUXIMAB;SLC35F4;CC;SLC35F4_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEASE_INHIBITORS;APOC3;CC + CT;APOC3_CC + CT;EFFICACY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNB1, ZBTB4;C;CHRNB1, ZBTB4_C;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PROTEASE_INHIBITORS;APOC3;CT + TT;APOC3_CT + TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNB2;A;CHRNB2_A;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;BMP7;T;BMP7_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
VARENICLINE;CHRNB2;T;CHRNB2_T;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
VARENICLINE;CHRNB2;C;CHRNB2_C;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH;CHILDREN;OTHER:CENTRAL_NERVOUS_SYSTEM_CANCER;CAUTION_SIDE_EFFECT
AZATHIOPRINE;DDRGK1, ITPA;A;ITPA_AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA;FAAH_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;CHILDREN;DISEASE:KYPHOSIS, DISEASE:SCOLIOSIS;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;OXNAD1;TT;OXNAD1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;FAAH;TT;FAAH_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;DISEASE:KYPHOSIS, DISEASE:SCOLIOSIS;CAUTION_SIDE_EFFECT
PROTEASE_INHIBITORS;APOC3;CG + GG;APOC3_CG + GG;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AC;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;SLCO1B3_G;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
APIXABAN;ABCB1;CT + TT;ABCB1_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCC2;G;ABCC2_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;DTNBP1_T;NAN;DECREASED;RISK;DISEASE:BIPOLAR_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CT;ITGB3_TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SENSITIVITY_TO_ASPIRIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CHOP, RITUXIMAB;CIDEA;TT;CIDEA_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;C/del + del/del;CDA_C/del + CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;CC;BDNF, BDNF-AS_CC;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;NOS1;GG;NOS1_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;BDNF;CC;BDNF, BDNF-AS_CC;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:PSYCHOTIC_DISORDER;MEN;DISEASE:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;AC + CC;CDA_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GENE_NOT_SPECIFIED;GG + GT;GG + GT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;DTNBP1_T;NAN;DECREASED;SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;DTNBP1;C;DTNBP1_C;NAN;DECREASED;SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AG + GG;CDA_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;OPRD1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;CT + TT;CDA_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG_TOXICITY;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;A;OPRD1_A;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;AA + AG;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:THROMBOEMBOLISM;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRD1;C;OPRD1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;NRXN1;C;NRXN1_C;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SMOKING_QUANTITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_DOSE_ADJUST
HEROIN;OPRD1;C;OPRD1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;NRXN1;C;NRXN1_C;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SMOKING_QUANTITY, HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_DOSE_ADJUST
NICOTINE;NRXN1;A;NRXN1_A;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SMOKING_QUANTITY, HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_DOSE_ADJUST
SUNITINIB;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;COMT;AA;COMT_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;DTNBP1_T;NAN;DECREASED;SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;FUT2;A;FUT2_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;FTO;A;FTO_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM;RICTOR;GG;RICTOR_GG;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;NR3C1;G;NR3C1_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;PK:ANTIDEPRESSANT_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERIVASTATIN;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;RISK;DISEASE:RHABDOMYOLYSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAROXETINE;HTR3B;AA;HTR3B_C;TOXICITY;INCREASED;RISK;DISEASE:NAUSEA;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;A;A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;TNIP3;CC;TNIP3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;APEX1;GG;APEX1_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;MEN;OTHER:CARCINOMA, SQUAMOUS_CELL;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;IL10;AG + GG;IL10_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;A;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;MUTYH;CG + GG;MUTYH_CG + GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;MEN;OTHER:CARCINOMA, SQUAMOUS_CELL;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;SLC4A8;C;SLC4A8_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;ITGB3;CC + CT;ITGB3_TT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SHORTER_BLEEDING_TIME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;NR3C1;G;NR3C1_G;NAN;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIDEPRESSANT_RESPONSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ESCITALOPRAM;HTR2A;C;HTR2A_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIDEPRESSANT_RESPONSE;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ARID4A;T;ARID4A_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;AG;OPRM1_AA;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;TNRC6A;A;TNRC6A_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;NOS1AP;T;NOS1AP_GG;TOXICITY;INCREASED;RISK;OTHER:HYPOGLYCEMIA;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
KETOROLAC;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SLOWER_ANALGESIC_ONSET_IN_EUROPEAN_AMERICANS_UNDERGOING_ORAL_SURGERY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;DOSAGE;DECREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ABCC1;CC + CG;ABCC1_CC + CG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
FLUVASTATIN;SREBF1;CC;SREBF1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:APOLIPOPROTEIN_A1_AND_C3;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, PEMETREXED;SLC19A1;G;SLC19A1_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, RADIOTHERAPY;TP53;CG;TP53_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;OTHER:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SLC30A8;C;SLC30A8_C;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:BASELINE_PROINSULIN_LEVELS_AFTER_ADJUSTING_FOR_INSULIN_LEVELS;PEOPLE;OTHER:SUSPECTED_INCREASED_RISK_OF_DIABETES;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;DOSAGE;DECREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;AGT;GG;AGT_GG;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;MMP1, MMP10;AG + GG;MMP1, MMP10_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
LEVONORGESTREL;ADAMTS10;CG;ADAMTS10_CG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;MMP1, MMP10;CT + TT;MMP1, MMP10_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;HTR2A_GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEART_PALPITATIONS;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;PTGS1;TT;PTGS1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;KL;CG + GG;KL_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;CRP;CT + TT;CRP_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;AG;CHRNA4_G;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_INITIATION;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;CDKN2B-AS1;AA + AG;CDKN2B-AS1_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;GG;CHRNA4_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;AGT;GG;AGT_GG;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;CC;CHRNA4_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COXIBS;PTGS2;CG + GG;PTGS2_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
COXIBS;PTGS2;AG + GG;PTGS2_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
SEVOFLURANE;FASTKD3, MTRR;CC + CT;FASTKD3, MTRR_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;A;OPRM1_A;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;OPRM1_T;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;G;OPRM1_G;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ADK;TT;ADK_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;OPRM1_T;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;A;ACYP2_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;DISEASE:BRAIN_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;SLC29A1;CG + GG;SLC29A1_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;IMPDH2;AG + GG;IMPDH2_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;OPRM1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AZATHIOPRINE;IMPDH1;CT + TT;IMPDH1_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;A;SLC1A1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OBSESSIVE_COMPULSIVE_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;A;OPRM1_A;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;G;SLC1A1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OBSESSIVE_COMPULSIVE_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;C;SLC1A1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OBSESSIVE_COMPULSIVE_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HEROIN;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;GENE_NOT_SPECIFIED;G;G;NAN;INCREASED;RISK;OTHER:CURRENT_SMOKING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;USH2A;C;USH2A_C;NAN;INCREASED;RISK;OTHER:CURRENT_SMOKING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;AK4;C;AK4_C;NAN;INCREASED;RISK;OTHER:CURRENT_SMOKING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;ITGA2;AA + AG;ITGA2_AA + AG;EFFICACY;INCREASED;RISK;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
NAN;ITGB1;AA;ITGB1_AA;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;OPRM1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;DPYD_CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LETROZOLE;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM, VINORELBINE;STMN1;AA;STMN1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR;DPYD;TT;DPYD_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ITGB1;GG;ITGB1_GG;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;OPRM1_C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BEVACIZUMAB, PEMETREXED;GGH;G;GGH_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TPH2;TT;TPH2_TT;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:AGGRESSION, SIDE_EFFECT:DEPRESSION;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;ITGA2;CT + TT;ITGA2_CT + TT;EFFICACY;INCREASED;RISK;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
HEROIN;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP1A2;AC + CC;CYP1A2_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:QT_INTERVAL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;SLC22A2;AA + AC;SLC22A2_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;SLC22A2;AA + AC;SLC22A2_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS, ANTIPSYCHOTICS, BENZODIAZEPINE_DERIVATIVES, OPIOIDS, SYMPATHOMIMETICS;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:CARDIAC_ARREST, OTHER:RESPIRATORY_INSUFFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:OVERDOSE;CAUTION_SIDE_EFFECT
BEVACIZUMAB, PEMETREXED;GGH;CT;GGH_CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;NOS1AP;GG;NOS1AP_GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SHORTENED_QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;CC;ABCB1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;ITGA2;CT + TT;ITGA2_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION_AFTER_STIMULI_WITH_ADENOSINE_DIPHOSPHATE, COLLAGEN, AND_EPINEPHRINE;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;GG;OPRM1_AA;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_FENTANYL_DOSE_REQUIREMENT_TO_ACHIEVE_ADEQUATE_PAIN_RELIEF_IN_CHINESE_WOMEN_UNDERGOING_GYNECOLOGIC_SURGERY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CANNABINOIDS, COCAINE, ETHANOL, NICOTINE, OPIOIDS;OPRM1;G;OPRM1_AA;TOXICITY;DECREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;MIR27A;CT;MIR27A_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;GG;FLT1_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;NFE2L2;GG + GT;NFE2L2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;FLT1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;AG + GG;OPRM1_AA;DOSAGE, EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_RESPONSIVENESS_TO_OPIOIDS_AND_REQUIRED_LESS_ANALGESIC_DRUGS_IN_LABORING_WOMEN;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUVOXAMINE;HTR2A;CC + CT;HTR2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;OPRM1_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LESS_PAIN_CONTROL_IN_JAPANESE_PATIENTS_UNDERGOING_PAINFUL_OROFACIAL_COSMETIC_SURGERY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;FMO3;GG;FMO3_GG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_N-OXIDE_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;T;CYP2D6_TT;EFFICACY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL_AND_GREATER_REDUCTIONS_IN_HEART_RATE, DIASTOLIC_BLOOD_PRESSURE, AND_MEAN_ARTERIAL_PRESSURE_IN_PMS_THAN_IN_NON-PMS.;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT1;AA;FLT1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;CCN4;AA + AC;CCN4_AA + AC;EFFICACY;DECREASED;RISK;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CC + CT;ITGB3_TT;EFFICACY;INCREASED;RISK;EFFICACY:THE_LACK_OF_ASPIRIN_EFFECT;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;AA;FLT1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;FMO1;AA + AC;FMO1_AA + AC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;ERCC1;CC;ERCC1_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;CC;DRD2_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PSYCHOMOTOR_AGITATION;PEOPLE;OTHER:PSYCHOTIC_DISORDER, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS, TAXANES;GSTP1;AA;GSTP1_GG;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM, TAXANES;ABCB1;CC;ABCB1_C;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;FLT1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;FMO1;CT + TT;FMO1_CT + TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;C;SLC12A3_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE, CANNABINOIDS, COCAINE, OPIOIDS;KAT2B;C;KAT2B_C;TOXICITY;DECREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA5;TT;EPHA5_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;ABCG2;TT;ABCG2_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;NAT2;C;NAT2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;OPRM1_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:PAIN, OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ARRB2;AA;ARRB2_AA;EFFICACY;INCREASED;RISK;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;G;SCNN1G_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;CCN4;GG + GT;CCN4_GG + GT;EFFICACY;DECREASED;RISK;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;TT;HTR2A_CC;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHADONE;ARRB2;CC;ARRB2_TT;EFFICACY;INCREASED;RISK;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
METHADONE;MYOCD;AA + AG;MYOCD_AA + AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:INCREASED_RISK_OF_BEING_NONRESPONDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;ARRB2;GG;ARRB2_GG;EFFICACY;INCREASED;RISK;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;A;SCNN1G_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;CC;CYP1A2_AA;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;A;CYP2D6_GG;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;HTR2C_C;TOXICITY;DECREASED;RISK;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;CETP;AG;CETP_A;EFFICACY;DECREASED;SEVERITY;EFFICACY:CORONARY_ARTERY_DISEASE;MEN;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BENEFIT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;TT;ITGB3_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:ASPIRIN-DEPRESSED_THROMBIN_GENERATION_AND_PROLONGED_BLEEDING_TIME_AFTER_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN;F13A1;AA + AC;F13A1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_FXIII_ACTIVATION_BY_ASPIRIN;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;ADRB1;CC + CG;ADRB1_CC;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;C;ITPA_AC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;NCF4;GG;NCF4_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;CFTR_A;EFFICACY;DECREASED;SEVERITY;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;ABCG2;CC;ABCG2_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;CETP;GG;CETP_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_LUMINAL_DIAMETER;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE, DIURETICS, SOTALOL;NOS1AP;T;NOS1AP_T;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GENE_NOT_SPECIFIED;CT + TT;CT + TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
AMIODARONE;NOS1AP;T;NOS1AP_T;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;VKORC1_T;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LOWER_LEVELS_OF_TRANSTHYRETIN_PRECUROR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMIODARONE;NOS1AP;T;NOS1AP_T;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN;HNMT;G;HNMT_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ACETYLSALICYLIC_ACID-INTOLERANT_CHRONIC_URTICARIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMIODARONE;NOS1AP;T;NOS1AP_T;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN;LTC4S;AC + CC;LTC4S_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SENSITIVITY_TO_ASPIRIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;SMYD3;T;SMYD3_T;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;TT;NAT2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOTOXICTY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;CC;NAT2_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEPATOTOXICTY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_REMISSION;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LEVONORGESTREL;TP53;CG;TP53_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;GP6;AG;GP6_AG;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2;CT + TT;ERCC2_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;ABCB1;GG;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:3-YEAR_EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2, KLC3;GG;ERCC2_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, PHENPROCOUMON, WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPIRIN;ITGB3;CT;ITGB3_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BLOOD_LOSS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;C;KDR_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
CAPECITABINE, EPIRUBICIN, PLATINUM;GSTP1;GG;GSTP1_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;PON1_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ITGB3;CC + CT;ITGB3_TT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SHORTER_BLEEDING_TIME;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BETA_BLOCKING_AGENTS;GRK5;AA;GRK5_AT + TT;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:HEART_FAILURE;CAUTION_SIDE_EFFECT
FENTANYL, HYDROMORPHONE, OXYCODONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;PON1_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;CXCR4;AA + AG;CXCR4_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA_BLOCKING_AGENTS;ADRB1;CC;ADRB1_CC;OTHER;DECREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;PPCDC;G;PPCDC_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:AMENORRHEA;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT4;GG;FLT4_C;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;ABCB5;CT;ABCB5_CT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;GENE_NOT_SPECIFIED;G;G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:AMENORRHEA;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCG2;T;ABCG2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;CNIH3;A;CNIH3_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;ITPA;AC + CC;ITPA_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;CT + TT;VEGFA_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP1A2;CC;CYP1A2_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;MTHFR_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;SLC22A2;A;SLC22A2_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;C;ABCB1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS""";F5;CT + TT;F5_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;NFE2L2;T;NFE2L2_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB2;CC;ADRB2_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:IMPROVED_LEFT_VENTRICULAR_EJECTION_FRACTION;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;FOXP3;GT + TT;FOXP3_GT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + CT;CYP3A4_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;RAVER2;A;RAVER2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;CYP2C9_AC + CC;EFFICACY;INCREASED;RISK;SIDE_EFFECT:ATAXIA, SIDE_EFFECT:DIPLOPIA, SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DYSARTHRIA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;CYP2C9_CT;EFFICACY;INCREASED;RISK;SIDE_EFFECT:ATAXIA, SIDE_EFFECT:DIPLOPIA, SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DYSARTHRIA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;PPARD;T;PPARD_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CT + TT;CYP2B6_CT + TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;SULT1A1, SULT1A2;CC + CT;SULT1A1, SULT1A2_CC + CT;OTHER;INCREASED;LIKELIHOOD;DISEASE:HOT_FLASHES;PEOPLE;OTHER:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;MCOLN1;A;MCOLN1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:OVERDOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CERIVASTATIN, HMG_COA_REDUCTASE_INHIBITORS, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;AKT1;CC;AKT1_CC;OTHER;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;PEOPLE;DISEASE:MARIJUANA_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BEVACIZUMAB;KCNAB1;G;KCNAB1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;VKORC1_AA + AG;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;AA + AG;GSTP1_GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CEP68;AA;CEP68_AA + AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:DECLINE_OF_FORCED_EXPIRATORY_VOLUME_IN_1S_(FEV(1))_BY_ASPIRIN_PROVOCATION;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
OPIOIDS;MCOLN1;T;MCOLN1_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:OVERDOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;MDM2;GT + TT;MDM2_GT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AG + GG;FLT3_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN;ITGB3;CT;ITGB3_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_INHIBITION_BY_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SLC2A9;AG;SLC2A9_AG;OTHER;DECREASED;LIKELIHOOD;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;CYP2B6_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN;TLR3;CT + TT;TLR3_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-EXACERBATED_RESPIRATORY_DISEASE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC + CT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
OPIOIDS;MCOLN1;G;MCOLN1_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:OVERDOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + CT;CYP3A4_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;AA + AG;DRD2_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:CRAVING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;DRD2;GG;DRD2_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:CRAVING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CC;VKORC1_CC;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IL6;CC;IL6_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCG2;GT + TT;ABCG2_T;OTHER;INCREASED;LIKELIHOOD;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;CYP2C9;AG;CYP2C9_AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELBIVUDINE;TK2;CC + CT;TK2_CC + CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;FLT1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;SLC22A12;CT;SLC22A12_CT;OTHER;INCREASED;LIKELIHOOD;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CYP1A1;C;CYP1A1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;T;DRD2_T;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
PRAVASTATIN;ADAMTS1;GG;ADAMTS1_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:FATAL_CORONARY_DISEASE_OR_NONFATAL_MYOCARDIAL_INFARCTION;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2C;G;HTR2C_GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;CYP1A2_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:NEURAL_TUBE_DEFECTS;WOMEN;OTHER:WHO_ARE_PREGNANT;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;G;HTR2C_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;CEP72_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PIOGLITAZONE;LPL;CG + GG;LPL_CG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_AFTER_10_WEEKS_OF_PIOGLITAZONE_TREATMENT;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;EPHA5;CT + TT;EPHA5_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;SCN1A;T;SCN1A_CC;OTHER;INCREASED;RISK;DISEASE:SEIZURES, FEBRILE;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
NAN;UGT1A1;AA + AG;UGT1A1_AA;OTHER;INCREASED;SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA, OTHER:HYPERBILIRUBINEMIA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG + GG;ABCB1_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NOS1AP;GG;NOS1AP_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:QTC_PROLONGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;TT;PACSIN2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;GENE_NOT_SPECIFIED;A;CHRNA3_A;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
NAN;CYP2R1;A;CYP2R1_A;OTHER;INCREASED;LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SOCIAL_AND_CLINICAL_NEEDS;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;A;NAT2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;CYP2R1;A;CYP2R1_AA + AG;OTHER;DECREASED;LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;NAT2;T;NAT2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAROXETINE;HTR1A;GG;HTR1A_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_AT_4_WEEKS_AFTER_THE_INITIATION_OF_TREATMENT;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;E2F7;CC;E2F7_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:LUMBAR_BONE_LOSS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ALENDRONATE;DKK1;AA;DKK1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_DENSITY;WOMEN;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CES1;G;CES1_G;EFFICACY;DECREASED;RISK;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK, EFFICACY:STROKE;PEOPLE;OTHER:CEREBROVASCULAR_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;GG;DRD2_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;CC;KDR_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;CYP2C9_C;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;CC;VEGFA_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;ANKK1;GG;DRD2_G;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_CURVE_FROM_BASELINE_TO_THE_LAST_MEASURED_CONCENTRATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EXEMESTANE;ESR1;CC;ESR1_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;CYP2C9_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OLANZAPINE;ANKK1;GG;DRD2_G;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PEAK_PLASMA_CONCENTRATION_OF_INCREASED_PROLACTIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;G;VEGFA_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;C;FLT4_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GSTP1;AA;GSTP1_GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SYNCOPE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;TT;NR1I2_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;HAS3;AA;HAS3_AA;TOXICITY;INCREASED;RISK;DISEASE:CARDIOMYOPATHIES;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SUNITINIB;FLT3;AG + GG;FLT3_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ORTHOSTATIC_HYPOTENSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;VKORC1_A;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MORPHINE, OXYCODONE;OPRM1;GG;OPRM1_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE, OXYCODONE;COMT;GG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HNF4A;GG;HNF4A_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;PK:CONCENTRATION-TO-DOSE_RATIOS;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;VKORC1_G;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;MTHFR;GG;MTHFR_AA;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;VEGFA;CC + CT;VEGFA_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, MYCOPHENOLATE_MOFETIL;IMPDH2;AG + GG;IMPDH2_AG;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLATE_MOFETIL;TNF;AA + AG;TNF_AG;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLATE_MOFETIL;IL10;TT;IL10_TT;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AT;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK, EFFICACY:STROKE;PEOPLE;OTHER:CEREBROVASCULAR_DISORDERS;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;G;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;SEVERITY;OTHER:SMOKING;PEOPLE;OTHER:SCHIZOPHRENIA_WHO_ARE_SMOKERS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;SEVERITY;OTHER:SMOKING;PEOPLE;OTHER:SMOKING;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:SCHIZOPHRENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;N6AMT1;GG;N6AMT1_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
NICOTINE;GALR1;CT + TT;GALR1_CT + TT;OTHER;INCREASED;SEVERITY;OTHER:CRAVING;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;A;DPYD_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;T;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:ERYTHROMYCIN_METABOLISM;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PAZOPANIB, SIMVASTATIN;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GENTAMICIN;MT-RNR1;G;MT-RNR1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;INFANTS;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;LEP;A;LEP_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;ABCB1_A;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;GT;NUDT15_GT;DOSAGE;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ETHANOL;HTR3B;C;HTR3B_C;OTHER;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A, SPECC1L;G;ADORA2A, SPECC1L_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CALCIUM_CHANNEL_BLOCKERS, NITRENDIPINE;KCNH2;AA + AG;KCNH2_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;KDR;CC;KDR_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ANGINA_PECTORIS;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;MTHFR_TT;EFFICACY;INCREASED;RISK;DISEASE:GRAFT_VS_HOST_DISEASE;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;EFFICACY;DECREASED;RISK;DISEASE:GRAFT_VS_HOST_DISEASE;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GALR1;CT + TT;GALR1_CT + TT;OTHER;INCREASED;SEVERITY;OTHER:CRAVING;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;CLCN6, MTHFR;GG;MTHFR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AG;UGT1A1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;MTHFR;G;MTHFR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN, CYCLOPHOSPHAMIDE, METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;ABCB1_A;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;MTHFR_TT;EFFICACY;DECREASED;RISK;EFFICACY:RELAPSE;PEOPLE;OTHER:ALLOGENEIC_HEMATOPOIETIC_CELL_TRANSPLANTATION_FOR_CHRONIC_MYELOGENOUS_LEUKEMIA.;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;KDR;TT;KDR_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGINA_PECTORIS, SIDE_EFFECT:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;MTHFR_TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ORAL_MUCOSITIS;PEOPLE;OTHER:HEMATOPOIETIC-CELL-TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;ABCB1_C;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
PACLITAXEL;ARHGEF10;C;ARHGEF10_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;FKBP5;CC + CT;FKBP5_T;NAN;INCREASED;RISK;OTHER:POST-TRAUMATIC_STRESS_DISORDER_(PTSD);PEOPLE;OTHER:HISTORY_OF_CHILD_ABUSE;CAUTION_SIDE_EFFECT
NAN;FKBP5;AA + AC;FKBP5_AA + AC;OTHER;INCREASED;RISK;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;PEOPLE;OTHER:HISTORY_OF_CHILD_ABUSE;CAUTION_SIDE_EFFECT
PACLITAXEL;ARHGEF10;C;ARHGEF10_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TBX21;A;TBX21_A;NAN;INCREASED;RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;PSMB4;T;PSMB4_T;OTHER;INCREASED;RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;A;SLC22A1_A;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:BIOAVAILABILITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;C;SLC22A1_T;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:BIOAVAILABILITY_(AUC, CL_&_AUC/CL_RATIO);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;CHRNA5_C;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
METHOTREXATE;PTPN22;AA;PTPN22_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;CHRNA3;G;CHRNA3_A;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;TNFAIP3;A;TNFAIP3_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;CHRNA3, CHRNA5;G;CHRNA3, CHRNA5_GG;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;ABCG2_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;A;CHRNA3, CHRNA5_A;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;AA;ABCB1_A;METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;WOMEN;DISEASE:BIPOLAR_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER,DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;CHRNA5_C;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC_ACID;CYP1A1;A;CYP1A1_A;EFFICACY, METABOLISM/PK;INCREASED;RISK;DISEASE:SEIZURES;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
NAN;SLCO1B3;C;SLCO1B3_C;OTHER;INCREASED;SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA, OTHER:HYPERBILIRUBINEMIA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SERTRALINE;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:GENERAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;TT;CYP2D6_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;TT;CYP2D6_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;TT;CYP2D6_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RELAPSE_FREE_TIME;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;KIF6;AG + GG;KIF6_AG + GG;OTHER;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;A;ITPA_AC;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;GATM;AA + AG;GATM_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;T;CYP2D6_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;SLCO1B1_CC + CT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;C;ITPA_AA;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA;UGT1A1_AA;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, OXALIPLATIN;GSTP1;AA;GSTP1_GG;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PRAVASTATIN;IL1B;GG;IL1B_GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:CORONARY_FLOW_RESERVE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;KCNH2_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;CC;HTR2A_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNH2;CT + TT;KCNH2_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM;GRIK4;C;GRIK4_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;KCNH2;GT + TT;KCNH2_GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;NR1I2;C;NR1I2_T;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:BIOAVAILABILITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;CT + TT;NAT2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;AA + AG;NAT2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;GSTP1;G;GSTP1_GG;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;NAT2;AA + AG;NAT2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;KCNH2;G;KCNH2_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, PREDNISOLONE, VINCRISTINE;PNPLA3;CG + GG;PNPLA3_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;KCNH2_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXALIPLATIN;GSTP1;GG;GSTP1_GG;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;KCNQ1;G;KCNQ1_G;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;KCNH2;T;KCNH2_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;IL1B;GG;IL1B_GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:ADENOSINE-STIMULATED_MYOCARDIAL_FLOW;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;VEGFA;CG + GG;VEGFA_CC;OTHER;INCREASED;RISK;OTHER:PREMATURE_BIRTH;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;KCNH2;GG;KCNH2_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;KCNQ1;G;KCNQ1_G;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:QT_INTERVAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXALIPLATIN;GSTP1;AA;GSTP1_GG;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;TT;SLCO1B1_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NR1I2;T;NR1I2_T;DOSAGE, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:BIOAVAILABILITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
RIFAMPIN;NR1I2;TT;NR1I2_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:ERYTHROMYCIN_BREATH_TEST;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;CCN4;CC + CT;CCN4_CC + CT;EFFICACY;DECREASED;RISK;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;HTR2A_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;CC + TT;CYP3A4_TT;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;A;HTR2A_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;CYP3A5_CC;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NR1I2;C;NR1I2_CC;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:BIOAVAILABILTY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;MYOM2;CC + CT;MYOM2_CC + CT;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;G;HTR2A_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;A;HTR2A_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;COMT;AA + AG;COMT_AA;DOSAGE;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:PREGNANCY;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GRIK4;CC;GRIK4_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG + GG;OPRM1_AA;DOSAGE;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:PREGNANCY;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GRIK4;GG;GRIK4_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KIF6;AG + GG;KIF6_AG + GG;OTHER;INCREASED;RISK;DISEASE:CORONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;G;SLCO1B1_AA + AG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_AUC;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;AG;SLCO1B1_AG;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC0-12;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;CCN4;CC + CT;CCN4_CC + CT;EFFICACY;DECREASED;RISK;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TP53;GG;TP53_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;ITPA;AC + CC;ITPA_AC + CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3, CHRNA5;GG;CHRNA3, CHRNA5_GG;TOXICITY;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;AA;CHRNA4_G;TOXICITY;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;CC;CHRNA4_CC;TOXICITY;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;COMT, TXNRD2;T;COMT, TXNRD2_T;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;TLR4;AG + GG;TLR4_G;EFFICACY;DECREASED;RISK;EFFICACY:CARDIOVASCULAR_EVENTS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMINOGLYCOSIDE_ANTIBACTERIALS;MT-RNR1;G;MT-RNR1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;VDR;TT;VDR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FLUOROURACIL;IGFBP3;CC;IGFBP3_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:BETTER_SURVIVAL_OUTCOME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;GSTP1;AA;GSTP1_GG;EFFICACY;INCREASED;RISK;EFFICACY:DYING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;ERCC2, KLC3;GG;ERCC2_TT;EFFICACY;INCREASED;RISK;EFFICACY:DYING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PHENPROCOUMON;EPHX1;CC;EPHX1_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;ERCC1;AA;ERCC1_AA;EFFICACY;INCREASED;RISK;EFFICACY:DYING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;ABCB1_C;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;GSTP1;AA;GSTP1_GG;EFFICACY;INCREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;NR1I2;TT;NR1I2_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS, DISEASE:PERITONEUM_CANCER,DISEASE:NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS, DISEASE:UTERINE_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES, DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;AA;EGF_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;NR1I2;CC;NR1I2_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS, DISEASE:PERITONEUM_CANCER,DISEASE:NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS, DISEASE:UTERINE_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA + AG;UGT1A1_AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;SLCO1B3;GT + TT;SLCO1B3_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS, DISEASE:PERITONEUM_CANCER,DISEASE:NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS, DISEASE:UTERINE_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;G;CHRNA4_G;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;LRP2;T;LRP2_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;AA;EGF_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;C/del + CC;CDA_C/del + CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;POR;GG;POR_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;POR;TT;POR_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLCO1B3;GG;SLCO1B3_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;EFFICACY:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC + CT;SLC19A1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;T;CDA_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1P1;AC + CC;CES1P1_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;G;ATIC_G;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LEUCOVORIN, TEGAFUR;FASTKD3, MTRR;GG;FASTKD3, MTRR_AG + GG;TOXICITY;INCREASED;SEVERITY;DISEASE:STOMATITIS;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
LEUCOVORIN, TEGAFUR;UMPS;CC;UMPS_CC;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
LEUCOVORIN, TEGAFUR;UMPS;CC;UMPS_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANY_GRADE_3_ADVERSE_EVENT;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;F13A1;AA + AC;F13A1_AA;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PAZOPANIB;CXCL8;TT;CXCL8_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;G;CHRNA4_A;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANGIOTENSIN_II_ANTAGONISTS;CYP2D6;CT;CYP2D6_CT;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE, EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CT + TT;SLC19A1_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;AA + AG;CHRNA3_A;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:LUNG_FUNCTION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, FLUOROURACIL;MTHFR;A;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;TT;IFNL3_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HSPA1A;T;HSPA1A_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;F13A1;AA + AC;F13A1_AA;EFFICACY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HSPA1A;G;HSPA1A_G;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;F13A1;AA;F13A1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:FIBRIN_CLOT_FORMATION_TIME;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, FLUOROURACIL;TP53;G;TP53_GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HSPA1L;G;HSPA1L_G;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;P2RY12_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION, SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCC1;AT + TT;ABCC1_AT + TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HYPERTENSION;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;MLN;A;MLN_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;CYP2B6_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;AG + GG;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;ABCC1;AT + TT;ABCC1_AT + TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TT;ADORA2A_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;CC;ADORA2A_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_SIDE_EFFECT
CAFFEINE;GENE_NOT_SPECIFIED;CC;CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_SIDE_EFFECT
NAN;MT-RNR1;G;MT-RNR1_G;OTHER;INCREASED;LIKELIHOOD;OTHER:HEARING_LOSS, SENSORINEURAL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;CC;ADORA2A_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:BEING_SENSITIVE_TO_CAFFEINE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;CC;ADORA2A_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSOMNIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL, HEROIN, METHAMPHETAMINE;ANKS1B;T;ANKS1B_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE, SIDE_EFFECT:HEROIN_DEPENDENCE, SIDE_EFFECT:METHAMPHETAMINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;MICA;C;MICA_C;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ASPIRIN""";GENE_NOT_SPECIFIED;TT;TT;OTHER;DECREASED;RISK;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;TT;ADORA2A_TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:HABITUAL_CONSUMPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;BAG6, PRRC2A;C;BAG6, PRRC2A_C;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ASPIRIN""";GENE_NOT_SPECIFIED;AA;AA;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRNA5;T;CHRNA5_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;VKORC1_AA + AG;DOSAGE;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:WARFARIN_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
RIBAVIRIN;ITPA;AA;ITPA_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
SIMVASTATIN;LEPR;GG;LEPR_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PERCENTAGE_CHANGE_IN_HDL-C_LEVELS;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;SOST;CC;SOST_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_DENSITY;WOMEN;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, DAUNORUBICIN;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
CYTARABINE, DAUNORUBICIN;CDA;CC;CDA_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:COLITIS;CHILDREN;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, DAUNORUBICIN;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
ALENDRONATE;SOST;GG;SOST_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BONE_DENSITY;WOMEN;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MED12L, P2RY12;T;MED12L, P2RY12_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;AA + AC;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MED12L;G;MED12L_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB, GEFITINIB;EGFR;T;EGFR_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;ABCB1;GG;ABCB1_A;OTHER;DECREASED;LIKELIHOOD;OTHER:ADVERSE_EVENTS;CHILDREN;OTHER:TONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;KCNJ11;CT + TT;KCNJ11_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIABETES_MELLITUS, TYPE_2;PEOPLE;DISEASE:HEART_TRANSPLANTATION, DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;ETV6;GG;ETV6_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ERLOTINIB, GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TAPBP;CC + CG;TAPBP_CC + CG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;ABCC2;AG + GG;ABCC2_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2A;CT + TT;HTR2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COMPOSITE_OUTCOME_OF_NON-FATAL_MI, ALL_CAUSE_DEATH_AND_STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;C;KCNJ1_C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VALPROIC_ACID;LEPR;AA + AG;LEPR_AG + GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CFHR4;G;CFHR4_G;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;A;KCNJ1_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;A;ABCB1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;ANKK1;AG + GG;DRD2_G;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;A;KCNJ1_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;G;P2RY12_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CABAZITAXEL;CYP3A5;T;CYP3A5_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;PRKCQ;CT + TT;PRKCQ_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;KCNJ1;A;KCNJ1_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;GG;GSTP1_GG;EFFICACY;DECREASED;RISK;EFFICACY:CHEMORESISTANCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;DRD2;AA + AC;DRD2_A;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:HEART_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA4;A;CHRNA4_A;OTHER;INCREASED;LIKELIHOOD;OTHER:NICOTINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;UGT1A_CG + GG;TOXICITY;DECREASED;RISK;DISEASE:LIVER_FAILURE, ACUTE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;ABCB1_A;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;UGT1A_CG + GG;TOXICITY;DECREASED;RISK;DISEASE:LIVER_FAILURE, ACUTE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;T;EGFR_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_(RR);POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;KCNJ1;AG;KCNJ1_AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SERUM_POTASSIUM;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ETHANOL;CACNA1C;TT;CACNA1C_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;TOXICITY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;EPHA7;A;EPHA7_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;UGT1A;CT + TT;UGT1A_CT + TT;TOXICITY;DECREASED;RISK;DISEASE:LIVER_FAILURE, ACUTE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;XPNPEP2;T;XPNPEP2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;TNF;AA + AG;TNF_AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;ADGRL3;AG;ADGRL3_AG;TOXICITY;INCREASED;RISK;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
NICOTINE;ADGRL3;AT;ADGRL3_AT;TOXICITY;INCREASED;RISK;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;CC;EGFR_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_(RR);POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;CC;EGFR_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;MAP2K4;CT;MAP2K4_CT;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A9;T;UGT1A9_T;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;POPULATION_AFFECTED_NOT_SPECIFIED;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;GT + TT;EGFR_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_(RR);PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;XPNPEP2;A;XPNPEP2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;CEP72_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)_(MORE_THAN_ONE_YEAR)_WHEN_RECEIVING_A_LOADING_DOSE_OF_300_MG;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC10;CT;ABCC10_CT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ARNT;CG + GG;ARNT_CG + GG;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;GG;CYP2E1_CC + CG;TOXICITY;INCREASED;SEVERITY;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TOXIC_LIVER_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;DEPTOR;AA + AG;DEPTOR_AG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:HDL_CHOLESTEROL;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;SYNE3;CC;SYNE3_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;DEPTOR_AG;OTHER;DECREASED;LIKELIHOOD;OTHER:BRAIN_ISCHEMIA, OTHER:MYOCARDIAL_INFARCTION, OTHER:PERIPHERAL_VASCULAR_DISEASES;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS"", ""DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS""";CYP2B6;TT;CYP2B6_GT;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_AND_TUBERCULOSIS_CO-INFECTION;CAUTION_SIDE_EFFECT
NAN;DEPTOR;AG;DEPTOR_AG;OTHER;DECREASED;LIKELIHOOD;OTHER:DIABETIC_RETINOPATHY, OTHER:CHRONIC_KIDNEY_FAILURE;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;STK39;GG + GT;STK39_GG + GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_AMBULATORY_BLOOD_PRESSURE;MEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;AHR;AA + AG;AHR_AA + AG;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR6;CC + CT;HTR6_CC + CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;DCBLD1;AG;DCBLD1_AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;GENE_NOT_SPECIFIED;AG + GG;AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TYMS;A;TYMS_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
NAN;TNF;C;TNF_C;EFFICACY;INCREASED;SEVERITY;EFFICACY:LEUKOCYTOSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;GENE_NOT_SPECIFIED;TT;TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2A;CC;HTR2A_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC_AGENTS, CORTICOSTEROIDS;ITPA;AA + AC;ITPA_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;GENE_NOT_SPECIFIED;TT;TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;BDNF;CT + TT;BDNF, BDNF-AS_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, CORTICOSTEROIDS;ADORA2A;CC;ADORA2A_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LEUCOVORIN, METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DISTRIBUTION_VOLUME;PEOPLE;DISEASE:LYMPHOMA;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;GENE_NOT_SPECIFIED;TT;TT;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_RELAPSE;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;OPRM1;G;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;SYNE3;CC;SYNE3_CC;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_RELAPSE;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_RELAPSE;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;AA;ABCC4_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RISPERIDONE;UGT1A1;AG;UGT1A1_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;HTR2C_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
CYCLOSPORINE;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;ABCB1;AA;ABCB1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;DBH;TT;DBH_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT;PEOPLE;OTHER:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DILTIAZEM;PLCD3;T;PLCD3_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, OXALIPLATIN;MTHFR;GG;MTHFR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;AC;ITPA_AC;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
"""BETA_BLOCKING_AGENTS"", ""THIAZIDES, PLAIN""";GENE_NOT_SPECIFIED;C;C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;COMT_AA;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:WITHDRAWAL;WOMEN;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MINIMUM_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;CC + CT;ABCB1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, CORTICOSTEROIDS;ABCC1;GG;ABCC1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LENALIDOMIDE;NCF4;AA + AG;NCF4_AG + GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;COMT_AA;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:BLOOD_PRESSURE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
LENALIDOMIDE;GSTP1;GG;GSTP1_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, IRINOTECAN;ABCC4;CT;ABCC4_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;ITGA2;CT + TT;ITGA2_CT + TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:COLLAGEN-INDUCED_PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_CORONARY_STENTING;CAUTION_DOSE_ADJUST
MYCOPHENOLATE_MOFETIL;SLCO1B3;TT;SLCO1B3_GG;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;ABCB1;GG;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLC29A3;CT + TT;SLC29A3_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;A;ITPA_AC;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;SLCO1B3;TT;SLCO1B3_GG;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;C;ITPA_AA;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;AC + CC;CYP1A2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ALBUMINURIA, SIDE_EFFECT:HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEMCITABINE;ABCG2;GT + TT;ABCG2_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;ERCC1;AA;ERCC1_AA;EFFICACY;INCREASED;RISK;DISEASE:DEATH;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;CT + TT;CDA_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;CT + TT;CYP2C9_CT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:MUSCULAR_DISEASES, SIDE_EFFECT:RHABDOMYOLYSIS, SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALLOPURINOL;CFLAR;A;CFLAR_A;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXYCODONE;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CES2;CG + GG;CES2_CG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_PROGRESSION;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC1;AA;ERCC1_AA;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE_OF_DISEASE;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;CT + TT;CYP2C9_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM_COMPOUNDS;HSPA5;TT;HSPA5_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;AGT;GG;AGT_GG;TOXICITY;INCREASED;RISK;DISEASE:PEPTIC_ULCER_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;A;NR1I2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
BUPROPION;SACM1L;C;SACM1L_C;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;GATM;AA;GATM_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;G;SACM1L_G;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID/PYRAZINAMIDE/RIFAMPIN;CYP3A4;AG;CYP3A4_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;AG;SLCO1B1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SACM1L;G;SACM1L_G;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C9;AC + CC;CYP2C9_AC + CC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;T;SACM1L_T;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;NR1I3;GG;NR1I3_GG;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;C;SACM1L_C;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SACM1L;G;SACM1L_G;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;AC + CC;CYP2C9_AC + CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;SACM1L;A;SACM1L_A;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;AG;SLCO1B1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;HSPA5;TT;HSPA5_TT;EFFICACY;INCREASED;LIKELIHOOD;OTHER:EARLY_RELAPSE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;AA;SLCO1B1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;DHFR;GG;DHFR_GT;TOXICITY;INCREASED;RISK;DISEASE:FATIGUE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;MTHFR_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
BUPROPION;SACM1L;T;SACM1L_T;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEMSIROLIMUS;NR1I2;T;NR1I2_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AA;FLT3_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;CT + TT;CES1_CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
GEMCITABINE;ABCG2;GT + TT;ABCG2_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;HSPA5;TT;HSPA5_TT;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;AA;SLCO1B1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRD1;A;OPRD1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:NALTREXONE-INDUCED_BLUNTING_OF_ALCOHOL_STIMULATION_AND_ALCOHOL_CRAVING;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A;AG + GG;UGT1A_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;RYR2;A;RYR2_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES, DISEASE:MYALGIA;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;GG;SPARC_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MET;AG + GG;MET_AG + GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:OVERALL_SURVIVAL;MEN;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ITPA;AC + CC;ITPA_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:CROHN_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;TT;SPARC_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MET;AG + GG;MET_AG + GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
"""ANTIVIRALS_FOR_TREATMENT_OF_HIV_INFECTIONS, COMBINATIONS"", ""DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS""";ABCB1;AA;ABCB1_A;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_AND_TUBERCULOSIS_CO-INFECTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EFAVIRENZ_EXPOSURE_(AUC)_DURING_THE_FIRST_24_WEEKS_OF_ANTIRETROVIRAL_THERAPY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;TOXICITY;INCREASED;RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;RYR1_A;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP3A4;C;CYP3A4_TT;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EFAVIRENZ_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP3A5;C;CYP3A5_CC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EFAVIRENZ_EXPOSURE;PEOPLE;PK:HIV;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;MME;CT + TT;MME_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;LILRB5;TT;LILRB5_TT;DOSAGE, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE;HTR2A;TT;HTR2A_CC;TOXICITY;INCREASED;LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER;MEN;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CABAZITAXEL;CYP3A5;CT;CYP3A5_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;CC;HTR2A_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:DEPRESSION;CAUTION_SIDE_EFFECT
CABAZITAXEL;TUBB1;AC;TUBB1_AC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;G;CYP2C19_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;CYP2C19_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;CYP2B6_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLASMA_LEVEL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;SLC2A9;T;SLC2A9_T;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:SERUM_URIC_ACID;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;IKZF3;CC;IKZF3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:NEUROBLASTOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AG;ABCB1_A;TOXICITY;DECREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;RYR1_A;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;RYR1_T;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DRD4;CC + CT;DRD4_CC + CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_PSYCHOSIS;PEOPLE;OTHER:METHAMPHETAMINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;GC;TT;GC_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
CETUXIMAB;GC;TT;GC_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;RYR1_T;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;TAPBP;AG + GG;TAPBP_AG + GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS""";F5;CT;F5_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
GEFITINIB;IKBKB;CC;IKBKB_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN"", ""SULFONAMIDES, UREA_DERIVATIVES""";SLC22A1;AA + AG;SLC22A1_GG;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;RYR1_T;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;T;SLC22A1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;A;SLC22A1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;AGT;GG;AGT_GG;EFFICACY;DECREASED;RISK;DISEASE:STROKE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;P2RY12;G;P2RY12_AG + GG;OTHER;INCREASED;RISK;DISEASE:PERIPHERAL_VASCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEFITINIB;RELA;CC;RELA_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;C;SLC22A1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;KCNQ5;C;KCNQ5_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;A;SLC22A1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;P2RY12;G;P2RY12_AG + GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GEFITINIB;IKBKE;AG + GG;IKBKE_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PHENYTOIN;NAT2;C;NAT2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PHENYTOIN;NAT2;A;NAT2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;T;CYP2D6_T;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;C;CYP2D6_TT;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;A;CYP2D6_GG;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;AG;HTR2A_AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVED_RESPONSE;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
GABAPENTIN, PREGABALIN;SLC7A5;AG;SLC7A5_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEUROPATHIC_PAIN;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCR2;TT;CXCR2_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR2A;AG;HTR2A_AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;T;CYP2C19_TT;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLCO1B1;AG + GG;SLCO1B1_AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR2A;GG;HTR2A_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;TT;GNB3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS;GRK5;AT + TT;GRK5_AT + TT;OTHER;DECREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;RISK;DISEASE:LUNG_NEOPLASMS;PEOPLE;OTHER:WHO_HAVE_EVER_BEEN_SMOKERS;CAUTION_SIDE_EFFECT
CITALOPRAM;GRIK2;CC;GRIK2_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;G;UGT1A9_G;TOXICITY;INCREASED;RISK;DISEASE:ANEMIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;CYP4F2_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;HYKK;C;HYKK_C;OTHER;INCREASED;RISK;DISEASE:LUNG_NEOPLASMS;PEOPLE;OTHER:WHO_HAVE_EVER_BEEN_SMOKERS;CAUTION_SIDE_EFFECT
ISONIAZID, PHENYTOIN;NAT2;T;NAT2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;TCF7L2;CC + CT;TCF7L2_CC + CT;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;AGT;GG;AGT_GG;EFFICACY;DECREASED;RISK;DISEASE:STROKE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;POLR2A;CC;POLR2A_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
VALPROIC_ACID;CYP2C9;AC;CYP2C9_AC + CC;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_PLASMA_DRUG_CONCENTRATIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CITALOPRAM;GRIA3;G;GRIA3_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A5;AA + AG;SLC22A5_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PHENYTOIN;NAT2;G;NAT2_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;CC + CG;COMT_CG + GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_VASCULAR_DISEASES;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:LUNG_NEOPLASMS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE, PROCARBAZINE;EPM2AIP1;AA + AG;EPM2AIP1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;PEOPLE;DISEASE:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
ISONIAZID, PHENYTOIN;NAT2;A;NAT2_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;CHRNA3_A;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:NUMBER_OF_CIGARETTES_SMOKED_PER_DAY;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
ISONIAZID, PHENYTOIN;NAT2;T;NAT2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;CT;ABCB1_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;AA + AC;ABCB1_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE, PROCARBAZINE;EPM2AIP1;AA + AG;EPM2AIP1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THERAPY-RELATED_ACUTE_MYELOID_LEUKEMIA_(T-AML);PEOPLE;DISEASE:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
IMATINIB;EGFR;CT + TT;EGFR_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AG;COMT_AA + AG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA;MEN;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CG + GG;SLC22A1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;AA;CYP2D6_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ERGOT_ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";HTR2A;A;HTR2A_A;OTHER;INCREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TBXA2R;AA;TBXA2R_AA;EFFICACY;INCREASED;RISK;OTHER:HIGH_ON-ASPIRIN_RESIDUAL_PLATELET_REACTIVITY;PEOPLE;OTHER:OFF-PUMP_CORONARY_ARTERY_BYPASS_GRAFTING;CAUTION_SIDE_EFFECT
"""ANALGESICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ERGOT_ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DBH;T;DBH_T;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;CT;DRD2_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;ABCB1_C;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
"""ANALGESICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ERGOT_ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";OPRM1;G;OPRM1_AA;OTHER;INCREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ERGOT_ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";BDNF;T;BDNF, BDNF-AS_CC;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;COMT;AA;COMT_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ERGOT_ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";COMT;AA;COMT_AA;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;AA;CYP2D6_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
TACROLIMUS;CAPN10;CT;CAPN10_CT;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C18;G;CYP2C18_G;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:OUTCOME_TIME_TO_STABLE_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IDARUBICIN;RAC2;AA;RAC2_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""ERGOT_ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DRD2;AA;DRD2_AG + GG;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;NCF4;AA;NCF4_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG;OPRM1_AG;OTHER;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, PROTEASE_INHIBITORS, RIBAVIRIN;ITPA;AA + AC;ITPA_AC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;GAL;CC;GAL_CC;OTHER;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;ABCB1;GG;ABCB1_A;OTHER;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRD1;A;OPRD1_A;OTHER;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AG + GG;CYBA_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;NOS3;GG;NOS3_GG + GT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AA + AG;CYBA_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;CETP;A;CETP_A;EFFICACY;INCREASED;RISK;DISEASE:DEATH;MEN;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, PROTEASE_INHIBITORS, RIBAVIRIN;SLC28A2;TT;SLC28A2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;PDE4D;TT;PDE4D_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BASELINE_MEAN_ARTERIAL_BLOOD_PRESSURE;PEOPLE;DISEASE:NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;T;ABCB1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;KCNE1;C;KCNE1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_INHIBITION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;KCNE1;TT;KCNE1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;OTHER:HIGH_PLATELET_REACTIVITY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE_UNDERGOING_STENT_IMPLANTATION;CAUTION_SIDE_EFFECT
DRUGS_USED_IN_NICOTINE_DEPENDENCE;CHRNA5;T;CHRNA5_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;CHRNA3;A;CHRNA3_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:AUTOIMMUNE_DISEASES, OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
DRUGS_USED_IN_NICOTINE_DEPENDENCE;CHRNA3;A;CHRNA3_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;G;ABCB1_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;DPYD_CC;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;DPYD_CC;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;C;ABCB1_C;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCC3;T;ABCC3_T;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NAN;FOXO3;TT;FOXO3_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;CHILDREN;OTHER:RHABDOMYOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;FOXO3;GG;FOXO3_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;CHILDREN;OTHER:RHABDOMYOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ARNT;T/del + del/del;ARNT_T/del + del/del;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ARRB2;GG;ARRB2_GG;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;A;ABCB1_C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;GHSR;AG;GHSR_AG;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:HEAVY_CONSUMPTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;G;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;C;ABCB1_C;EFFICACY;INCREASED;RISK;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;NEFM;G;NEFM_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TIME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;G;ABCB1_A;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;NEFM;G;NEFM_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_TIME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
NAN;ARNT;AA + AG;ARNT_AA + AG;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;IL23R;A;IL23R_A;TOXICITY;INCREASED;RISK;DISEASE:ADENOMA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CELECOXIB;ALOX12;A;ALOX12_A;TOXICITY;INCREASED;RISK;DISEASE:ADENOMA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CYP1A2;CT + TT;CYP1A2_CT + TT;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;GENE_NOT_SPECIFIED;CT + TT;CT + TT;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;PTGES;C;PTGES_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_TOXICITY_AND_SYMPTOMS;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CSK;CG + GG;CSK_CG + GG;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;PTGER4;T;PTGER4_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH3A1;CC + CG;ALDH3A1_CG + GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:CYSTITIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCC2;AA;ABCC2_AA;EFFICACY, METABOLISM/PK;INCREASED;RISK;EFFICACY:RECURRENCE_OF_BREAST_CANCER;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;CYP1A2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSOMNIA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FARGLITAZAR, INSULINS_AND_ANALOGUES;SCNN1B;A;SCNN1B_A;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:OEDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;SCNN1G;CC;SCNN1G_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
FARGLITAZAR, GLYBURIDE;SCNN1B;A;SCNN1B_A;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:OEDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;SCNN1G;TT;SCNN1G_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;IKBKE;CC;IKBKE_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;C;CHRNA5_C;OTHER;DECREASED;LIKELIHOOD;OTHER:ABSTINENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:ORAL_ULCER;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;ARRB2;CC;ARRB2_TT;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;CYP3A5_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B15;AA;UGT2B15_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AREA_UNDER_THE_VISUAL_ANALOG_SCALE-TIME_CURVE_DURING_THE_INDUCED_STATE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;G;ABCB1_G;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;TUBB2A;C;TUBB2A_C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NALOXONE, OXYCODONE;COMT;GG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ERYTHEMA;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CT;CYP3A4_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA5;A;CHRNA3, CHRNA5_A;OTHER;DECREASED;LIKELIHOOD;OTHER:ABSTINENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ARRB2;AA;ARRB2_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BISOPROLOL;CYP3A5;TT;CYP3A5_CC;EFFICACY;INCREASED;SEVERITY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE, EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NALOXONE, OXYCODONE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ERYTHEMA;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
PAZOPANIB;VEGFA;CC;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;WNK1;GG;WNK1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;T;CYP2C19_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;TT;CYP2B6_GT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SLC22A3;TT;SLC22A3_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NALOXONE, OXYCODONE;COMT;AA;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;GT;CYP2B6_GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:LUPUS_NEPHRITIS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN;UMPS;CC + CG;UMPS_CC;TOXICITY, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:DIARRHEA;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN;UMPS;CC;UMPS_CC;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_SIDE_EFFECT
BUPRENORPHINE, METHADONE;COMT;AG + GG;COMT_AA;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;SLC22A3;AA;SLC22A3_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, METHADONE;OPRM1;AG + GG;OPRM1_AA;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CC + CT;DPYD_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
GLUCARPIDASE;ABCC4;AG + GG;ABCC4_AG + GG;TOXICITY;INCREASED;RISK;OTHER:NEPHROTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADRB2;AA + AG;ADRB2_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;TT;CYP2B6_GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:LUPUS_NEPHRITIS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;GG;CHRNA3, CHRNA5_A;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:FUNCTIONAL_MRI_REACTIVITY_TO_SMOKING_IMAGES;WOMEN;OTHER:NICOTINE_DEPENDENCE;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;WNK1;CC;WNK1_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:URINARY_POTASSIUM_EXCRETION;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_DOSE_ADJUST
HEROIN;DRD2;A;DRD2_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SUFENTANIL;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;PEOPLE;OTHER:SURGERY, OTHER:FRACTURES*^BONE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;WNK1;CC + CT;WNK1_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;RAD52, WNK1;CC;RAD52, WNK1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MERCAPTOPURINE, PREDNISONE, VINCRISTINE;XRCC1;AA + AG;XRCC1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A2;T;SLC47A2_T;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METFORMIN_UPTAKE_IN_HEK-293_CELLS_AND_REDUCTION_IN_PROTEIN_EXPRESSION_LEVELS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
OXALIPLATIN;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;A;KDR_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION, SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;CBR3;GG;CBR3_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;EPHA7;C;EPHA7_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENOFIBRATE;FABP1;CC + CT;FABP1_CC + CT;TOXICITY;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;SNAP25;TT;SNAP25_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;TAB2;CT + TT;TAB2_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFIT1;TT;IFIT1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SVR_(SUSTAINED_VIROLOGICAL_RESPONSE);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;OASL;T;OASL_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RECURRENCE-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;TT;VEGFA_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;SLC6A3;TT;SLC6A3_TT;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_(RR);PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;A;ABCC2_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;DRD2;A;DRD2_A;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;A;ABCC2_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP1B1;C;CYP1B1_CC;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;A;KDR_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;EGFR_G;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_(RR);PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;NFKBIA;AA + AT;NFKBIA_AA + AT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SPIDR;G;SPIDR_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;NR1H2;CT + TT;NR1H2_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SLCO1B1;T;SLCO1B1_T;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CG + GG;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;EPHA6;G;EPHA6_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;GG;HTR2C_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;CC;HTR2C_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;GG;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;AA;ABCB1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;DRD2_A;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;CT + TT;KDR_CT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;A;DRD2_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;CC;DRD2_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;INSIG2;C;INSIG2_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GNB3;TT;GNB3_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;MC4R;AA;MC4R_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TIANEPTINE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;RISK;OTHER:SUICIDAL_IDEATION;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;BDNF, BDNF-AS;CC;BDNF, BDNF-AS_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;ADRA2A;G;ADRA2A_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;G;KDR_G;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;GG;CYP1A2_GG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:RATIO_OF_1,3_DMU/THEOPHYLLINE;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;del;DRD2_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIA;AG + GG;NFKBIA_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;NFKBIA;AG + GG;NFKBIA_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:CLOPIDOGREL_RESISTANCE;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_WHO_UNDERWENT_SUCCESSFUL_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIB;CC;NFKBIB_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;DRD3;CT + TT;DRD3_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HALLUCINATIONS;PEOPLE;OTHER:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIA;AG + GG;NFKBIA_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGB3;C;ITGB3_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LESS_DECREASE_IN_THE_PLATELET_REACTIVITY_AFTER_600_MG_OF_CLOPIDOGREL;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ITGB3;CT;ITGB3_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIPLATELET_EFFECT_TO_A_300_MG_CLOPIDOGREL_LOADING-DOSE_UP_TO_24_H_FOLLOWING_INTERVENTION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_CORONARY_STENT_IMPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;CYP2E1;A;CYP2E1_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;CYP2E1;T;CYP2E1_T;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
PERINDOPRIL;AGTR1;TT;AGTR1_TT;EFFICACY;DECREASED;RISK;EFFICACY:CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;SULT2B1;T;SULT2B1_T;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:FEVER;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;KCNH2;AA;KCNH2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;AA + AG;OPRM1_AA;OTHER;DECREASED;LIKELIHOOD;OTHER:ADDICTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;IKBKB;AA;IKBKB_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYTARABINE, FLUDARABINE, GEMTUZUMAB_OZOGAMICIN, IDARUBICIN;SLC22A12;TT;SLC22A12_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FEVER;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
GEFITINIB;IKBKE;CC + CT;IKBKE_CC + CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ASPIRIN;FSIP1;G;FSIP1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS1;G;PTGS1_AA + AG;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;XPO1;AA;XPO1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;CEP68;AA + AG;CEP68_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLATE_MOFETIL;ABCB1;A;ABCB1_C;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;CC;HTR2A_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;A/DELA;CYP2D6_A/DELA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:BIPOLAR_DISORDER,OTHER:PERSONALITY_DISORDER, OTHER:PSYCHOTIC_DISORDER, OTHER:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN, EPIRUBICIN;SLC28A3;AA + AG;SLC28A3_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;AA;NAT2_AA;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;AG;NAT2_A;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;KRAS;AC + CC;KRAS_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;TT;NAT2_T;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, FLUOROURACIL, METHOTREXATE;FGFR4;GG;FGFR4_A;EFFICACY;INCREASED;LIKELIHOOD;OTHER:DISEASE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR_NECROSIS_FACTOR_ALPHA_(TNF-ALPHA)_INHIBITORS;CERS6;A;CERS6_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1;CT;CES1_CT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:LEVELS_OF_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CES1;CT;CES1_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:_ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CES1;CT;CES1_CT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;PK:CMAX_OF_THE_ACTIVE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;PK:CMAX_OF_THE_ACTIVE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PEMETREXED;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VEMURAFENIB;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:MELANOMA;CAUTION_SIDE_EFFECT
VEMURAFENIB;CYP3A4;AA + AG;CYP3A4_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;"""SIDE_EFFECT:CARCINOMA, SQUAMOUS_CELL"", ""SIDE_EFFECT:HYPERBILIRUBINEMIA"", ""SIDE_EFFECT:NAUSEA""";PEOPLE;OTHER:MELANOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;AA;HTR2A_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;KLC1, XRCC3;GG;KLC1, XRCC3_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;CYP3A5_CC;DOSAGE, METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:RISK_OF_BEING_UNDERDOSED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
OPIOIDS;SLC18A2;A;SLC18A2_A;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;SLC18A2;G;SLC18A2_G;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;SLC18A2;C;SLC18A2_C;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;MISP;G;MISP_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION;PEOPLE;DISEASE:CEREBROVASCULAR_DISORDERS;CAUTION_DOSE_ADJUST
PACLITAXEL;EPHA5;TT;EPHA5_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;AA + AC;VEGFA_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;CC;VEGFA_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;NQO2;CC;NQO2_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA6;G;EPHA6_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;TOXICITY;INCREASED;RISK;DISEASE:HYPERLIPIDEMIAS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
WARFARIN;VEGFA;CC;VEGFA_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA8;G;EPHA8_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
URSODEOXYCHOLIC_ACID;MGAT5;TT;MGAT5_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:CHOLANGITIS;CAUTION_SIDE_EFFECT
GLUCOCORTICOIDS, METHOTREXATE, RADIOTHERAPY;CDH2;AT + TT;CDH2_AT + TT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;IMPDH2;AG;IMPDH2_AG;TOXICITY;DECREASED;RISK;DISEASE:LYMPHOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA5;TT;EPHA5_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION;PEOPLE;DISEASE:CEREBROVASCULAR_DISORDERS;CAUTION_DOSE_ADJUST
CYTARABINE, IDARUBICIN;NQO1;AA;NQO1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;VEGFA;AA;VEGFA_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCG1;AA;ABCG1_AA;TOXICITY;INCREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;AQP1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCB1;AG;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA6;AA;EPHA6_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;SULT1A1_CT + TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;SULT1A1_CT + TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:LUNG_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;SULT1A1_CT + TT;OTHER;INCREASED;LIKELIHOOD;OTHER:LYMPH_NODE_METASTASIS;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;TT;CYP2D6_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
CALCIUM;VDR;G;VDR_G;EFFICACY;INCREASED;RISK;DISEASE:FRACTURES, BONE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;SULT1A1;T;SULT1A1_CT + TT;OTHER;DECREASED;LIKELIHOOD;DISEASE:UROLOGIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AG;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SULT1A1;T;SULT1A1_CT + TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;T;ABCB1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;T;ABCB1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;IRS1;AG + GG;IRS1_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VAC14;T;VAC14_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A4;CT + TT;CYP3A4_CT + TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCED_GP_IIB/IIIA_ACTIVATION_AND_LOWER_PLATELET_ACTIVATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;C;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT_FACTOR_XA_INHIBITORS, DIRECT_THROMBIN_INHIBITORS;FGG;CC;FGG_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AG + GG;COMT_AG + GG;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUINDIONE;VKORC1;AA;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
OSIMERTINIB;EGFR;T;EGFR_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;C;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;VKORC1_AA + AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AG + GG;COMT_AA;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;TT;ADH1B_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:VMAX;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;C;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;VKORC1_AA + AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;CG + GG;COMT_CG + GG;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;VKORC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:AVERAGE_DAILY_DOSE_DURING_THE_FIRST_PERIOD_OF_STABILITY;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;CC + CT;COMT_CC + CT;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;G;ABCB1_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;NAT2_A;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;UGT1A;TT;UGT1A_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_SIDE_EFFECT:HYPERBILIRUBINEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT_FACTOR_XA_INHIBITORS, DIRECT_THROMBIN_INHIBITORS;F2;TT;F2_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BORTEZOMIB;PKNOX1;A;PKNOX1_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS;UGT1A;T;UGT1A_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;A;VEGFA_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;T;ABCB1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;FTO;G;FTO_G;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;C;VEGFA_CC + CT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ALFENTANIL, FENTANYL;OPRM1;AG + GG;OPRM1_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:TONSILLECTOMY;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;G;VEGFA_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;G;ABCB1_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ABCB1;G;ABCB1_G;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_FUNCTION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
ATENOLOL;ABCB1;G;ABCB1_G;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;DCAF4;CC;DCAF4_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CHANGE_IN_FORCED_EXPIRATORY_VOLUME_IN_1_S_(FEV1);PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NOS3;CC + CT;NOS3_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GRADE_3_HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATENOLOL;PRKCB;GT + TT;PRKCB_GT + TT;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_SIDE_EFFECT
ATENOLOL;FTO;AA;FTO_AA;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;ALDH1A1_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;P2RY12_AG + GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_FUNCTION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
ATENOLOL;GALNT2;T;GALNT2_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ATENOLOL;GALNT2;C;GALNT2_C;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ETHANOL;ANKK1, DRD2;A;DRD2_G;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;AC;CYP2C9_AC + CC;DOSAGE, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:IN_VIVO_METABOLISM_OF_(S)-WARFARIN_BUT_NOT_(R)-WARFARIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATENOLOL;PLA2G4A;C;PLA2G4A_C;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION_VALUES;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;PTGS2;G;PTGS2_G;OTHER;INCREASED;LIKELIHOOD;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;NOS2;CC;NOS2_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ENALAPRIL;SLCO1B1;AA;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;BACH1;GG;BACH1_GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;CT + TT;CYP2C19_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_AGGREGATION_VALUES;PEOPLE;EFFICACY:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID, RIFAMPIN;MAFK;AA + AG;MAFK_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;XPO1;AC + CC;XPO1_AC + CC;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CC;CYP2C19_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:GREATER_PLATELET_INHIBITION_2_H_AFTER_A_600-MG_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;T;NAT2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;G;AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;C;CYP2C9_AC + CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_INHIBITION_7H_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PLATELET_AGGREGATION_INHIBITION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;AA;ITPA_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;ESR1;A;ESR1_GG;OTHER;INCREASED;RISK;DISEASE:MUSCULOSKELETAL_PAIN;WOMEN;OTHER:WITH_EARLY_BREAST_CANCER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PLATELET_AGGREGATION_INHIBITION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE, LETROZOLE;ESR1;C;ESR1_C;OTHER;INCREASED;RISK;DISEASE:MUSCULOSKELETAL_PAIN;WOMEN;OTHER:WITH_EARLY_BREAST_CANCER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;P2RY12_AG + GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PLATELET_AGGREGATION_INHIBITION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP3A4;CC;CYP3A4_TT;OTHER;INCREASED;LIKELIHOOD;OTHER:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA + AG;OPRM1_AA;OTHER;DECREASED;LIKELIHOOD;OTHER:ADDICTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;C;DPYD_C;DOSAGE, TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
REPAGLINIDE;NEUROD1;CT + TT;NEUROD1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;PAX4;AA + AG;PAX4_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP3A4;CT;CYP3A4_TT;OTHER;INCREASED;RISK;DISEASE:ENDOMETRIAL_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VINCRISTINE;COCH;CG + GG;COCH_CG + GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, IRINOTECAN, LEUCOVORIN, TEGAFUR;EGFR;CC;EGFR_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP3A4;CT;CYP3A4_TT;OTHER;INCREASED;RISK;DISEASE:ENDOMETRIAL_NEOPLASMS;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
REPAGLINIDE;NEUROD1;CT + TT;NEUROD1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DIFFERENCE_IN_FASTING_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;VDR;G;VDR_G;OTHER;INCREASED;RISK;DISEASE:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;OPRL1;C;OPRL1_C;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH-ON_CLOPIDOGREL_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_ELECTIVE_CORONARY_STENT_PLACEMENT;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;A;P2RY12_A;EFFICACY;INCREASED;RISK;SIDE_EFFECT:NEUROLOGICAL_EVENTS;PEOPLE;DISEASE:PERIPHERAL_VASCULAR_DISEASES;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;COMT_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, PACLITAXEL;ABCB1;A;ABCB1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VDR;G;VDR_G;NAN;INCREASED;RISK;DISEASE:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;VDR;T;VDR_T;NAN;INCREASED;RISK;DISEASE:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;AQP1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIPLATELET_EFFECT;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCITRIOL;VDR;A;VDR_AA + AG;EFFICACY;INCREASED;RISK;DISEASE:FRACTURES, BONE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;AQP1_CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
PERINDOPRIL;BDKRB1;AA;BDKRB1_AA;EFFICACY;DECREASED;RISK;EFFICACY:CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AQP1;CC;AQP1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
ATENOLOL, VERAPAMIL;GRK4;TT;GRK4_TT;EFFICACY, TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES;PEOPLE;OTHER:HYPERTENSION_AND_CORONORY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA, DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;IMPDH1;CT + TT;IMPDH1_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANT;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;HLA-DOB;CT + TT;HLA-DOB_CT + TT;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;GENE_NOT_SPECIFIED;AA + AG;AA + AG;EFFICACY;DECREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;AA;CYP1A2_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;DROSHA;T;DROSHA_T;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OPIOIDS;DRD2;AG + GG;DRD2_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;TPMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;A;CYP2E1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CISPLATIN;GENE_NOT_SPECIFIED;AG + GG;AG + GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL, WARFARIN;CYP2C9;CC;CYP2C9_AC + CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;G;PTGS2_CC;OTHER;DECREASED;RISK;DISEASE:CORONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AQP1;AG;AQP1_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;CC;CYP2E1, DUX1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;G;PTGS2_CC;OTHER;INCREASED;RISK;DISEASE:CORONARY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFIRI;ABCC1;AA + AG;ABCC1_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRL1;G;OPRL1_G;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTIPLATELET_EFFECT;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CUX1;G;CUX1_G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
NAN;SULT1A1;CC + CT;SULT1A1_CT + TT;NAN;INCREASED;RISK;DISEASE:PROSTATIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;SULT1A1;CT + TT;SULT1A1_CT + TT;OTHER;INCREASED;RISK;DISEASE:BREAST_NEOPLASMS;WOMEN;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SULT1A1;CT + TT;SULT1A1_CT + TT;OTHER;DECREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;PEOPLE;OTHER:AT_LEAST_THREE_PREGNANCIES_AND_PREMENOPAUSAL;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;LEPR;AG + GG;LEPR_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;VKORC1;TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CUX1;A;CUX1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
BORTEZOMIB;PKNOX1;AA;PKNOX1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:PAIN, SIDE_EFFECT:NEUROPATHIC_PAIN;PEOPLE;OTHER:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;T;COMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;COMT;C;COMT_C;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;T;ENOSF1_T;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;C;ENOSF1_C;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:DRUG_TOXICITY;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC3;G;ABCC3_G;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;CES1;CC;CES1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROAMPHETAMINE, METHYLPHENIDATE;DRD1;CC;DRD1_CC;TOXICITY;INCREASED;SEVERITY;OTHER:SOCIAL_WITHDRAWAL;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;C;TPMT_C;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GRIN1;GG;GRIN1_GG;TOXICITY;INCREASED;RISK;DISEASE:PSYCHOTIC_DISORDER;MEN;DISEASE:METHAMPHETAMINE_DEPENDENCE;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A10, UGT1A8;AA;UGT1A10, UGT1A8_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;TPMT;T;TPMT_T;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;T;ENOSF1_T;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;C;ENOSF1_C;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;DPYD_T;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;TGFB1;AA;TGFB1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIALOADENITIS;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;CT + TT;CHRNA5_CT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;IFNL3_GG;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ATENOLOL;DPYS;AG + GG;DPYS_AG + GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
LENALIDOMIDE;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:MULTIPLE_MYELOMA, OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;IFNL3, IFNL4;CC;IFNL3_TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SPONTANEOUS_HCV_CLEARANCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
RISPERIDONE;LEP;G;LEP_AG + GG;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY, TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;ATG10;CC;ATG10_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FATIGUE;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;CEP72_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;EIF4E2, TIGD1;CC;EIF4E2, TIGD1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;ATM;AG;ATM_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:FATIGUE;PEOPLE;OTHER:THYROID_TUMOR;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GENE_NOT_SPECIFIED;CT + TT;CT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;GENE_NOT_SPECIFIED;CT + TT;CT + TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;AA + AT;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PIRFENIDONE;TOLLIP;CC + CT;TOLLIP_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:TIME_TO_THERAPEUTIC_INR;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;ABCB1_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;XBP1;GG;XBP1_GG;TOXICITY;INCREASED;RISK;DISEASE:NAUSEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CC;SLC22A1_CC;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;DSCAM;TT;DSCAM_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PACLITAXEL;ETS2;CT + TT;ETS2_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;ATG10;CC;ATG10_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:HEADACHE;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;TGFB1;AA;TGFB1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:HEADACHE;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;VKORC1_CT + TT;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;ATG10;TT;ATG10_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;A;NUDT15_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;CC;MC4R_CC + CT;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;A;MC4R_AA;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;AA;MC4R_AA;OTHER;INCREASED;LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA, SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, VERAPAMIL;PLEKHH2;G;PLEKHH2_G;TOXICITY;DECREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:PLATELET_AGGREGATION;PEOPLE;DISEASE:ANGINA_PECTORIS, DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
REGADENOSON;AMPD1;AA + AG;AMPD1_AG;EFFICACY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;CYP2B6_GT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SOMNOLENCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;DECREASED;SEVERITY;OTHER:SUBSTANCE-RELATED_DISORDERS;PEOPLE;OTHER:METHAMPHETAMINE_DEPENDENCE, OTHER:ALCOHOL_ABUSE,OTHER:EATING_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;CT;ERCC2_CT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
NICOTINE;DBH;CC;DBH_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:END_OF_TREATMENT_ABSTINENCE;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS_WITH_LOW_DEPENDENCY;LIKELIHOOD_THERAPEUTIC_FAILURE
REGADENOSON;AMPD1;AA + AG;AMPD1_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;CNR1;T;CNR1_T;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;CNR1;C;CNR1_C;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;T;ABCC4_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE;NFATC2;T;NFATC2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE;HLA-DRB1;T;HLA-DRB1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;AA;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IVACAFTOR;CFTR;A;CFTR_A;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
VANCOMYCIN;GENE_NOT_SPECIFIED;A;A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
LISINOPRIL;MMP3;AA;MMP3_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STROKE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;SERPINA5;C;SERPINA5_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SUBOPTIMAL_REPERFUSION_(POST-PCI_TIMI_FLOW_<3);PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;SERPINA5;T;SERPINA5_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;XYLT2;G;XYLT2_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;SERPINA5;G;SERPINA5_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ETHANOL;CAT;T;CAT_T;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;ETS2;A;ETS2_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;CC;VEGFA_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ANTI-VEGF_INJECTIONS;PEOPLE;DISEASE:CHOROIDAL_NEOVASCULARIZATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;ABCB1_A;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:RECURRENCE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA1;AA;GSTA1_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;AA;MC4R_AA;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ETHANOL;CAT;T;CAT_T;OTHER;INCREASED;SEVERITY;DISEASE:ALCOHOL_ABUSE;PEOPLE;DISEASE:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
NAN;ERCC1;AC;ERCC1_AC + CC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:DISEASE-FREE_SURVIVAL_AND_OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;GABRA2;GG;GABRA2_GG;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:HEART_RATE;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ESR1;AG + GG;ESR1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS""";F5;AG;F5_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA + AG;FAAH_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOZAPINE, OLANZAPINE;TBC1D1;CC;TBC1D1_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;DPYD_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;FAAH;CT + TT;FAAH_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;ABCB11;GG;ABCB11_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOCELLULAR_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOVENTILATION;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
NAN;DRD2;AA + AG;DRD2_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE, DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OPIOIDS;GNB3;CT + TT;GNB3_CC;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:INCREASED_PULSE_RATE;PEOPLE;SIDE_EFFECT:WITHDRAWAL_FROM_OPIOID_ADDICTION;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;FAAH;A;FAAH_AA;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;GT + TT;FAAH_GT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AC + CC;CYP1A2_AA;OTHER;DECREASED;RISK;DISEASE:BREAST_NEOPLASMS;PEOPLE;OTHER:BRCA1_MUTATIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;FAAH;AA + AC;FAAH_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;VDR;AA + AG;VDR_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB11;GG;ABCB11_GG;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AA;NR1I3_AA;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;EHMT2;G;EHMT2_G;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;TNF;AG;TNF_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:CONSTIPATION;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;HLA-G;G;HLA-G_G;OTHER;DECREASED;LIKELIHOOD;DISEASE:ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;RISK;DISEASE:DRY_MOUTH;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CYP2A6;C;CYP2A6_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SEDATION;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;GG;UGT1A6_GG;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_SIDE_EFFECT
DEFERIPRONE;UGT1A6;GG;UGT1A6_GG;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;GENE_NOT_SPECIFIED;del;del;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;HLA-B;C;HLA-B_C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;ATM;AA + AG;ATM_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
EFAVIRENZ;IL10;TT;IL10_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ETHANOL;ANKK1, DRD2;A;DRD2_G;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;NFKB1;AT;NFKB1_AT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;OPRM1_AA;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;DRD2;A;DRD2_G;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;TGFB1;TT;TGFB1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;TGFB1;GG;TGFB1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
ANTITHYROID_PREPARATIONS;FOXF2;del;FOXF2_del;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1P1;T;CES1P1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;GENE_NOT_SPECIFIED;GG;GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1P1;G;CES1P1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM;XRCC1;TT;XRCC1_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:WORSE_OVERALL_SURVIVAL_OUTCOME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
PLATINUM;ERCC1;AG + GG;ERCC1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CES1;G;CES1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM;ERCC1;AA + AC;ERCC1_AC + CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, ETHANOL;CYP1A2;GG;CYP1A2_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;PACSIN2;CT + TT;PACSIN2_CT + TT;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR4268;CC + CT;MIR4268_CC + CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CES1;G;CES1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CT + TT;IFNL3_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;AG;CYP2C19_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE, OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IODINE_(131I)_COMPOUNDS, RADIOTHERAPY;ATM;TT;ATM_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_TT;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC2;A;ABCC2_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC2;A;ABCC2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, IDARUBICIN;GENE_NOT_SPECIFIED;AA + AG;AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;ATF5;AA + AG;ATF5_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CC + CT;CYP2B6_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN;CYP2R1;AA + AG;CYP2R1_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR3117;AA + AG;MIR3117_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;T;CYP2B6_GT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TENOFOVIR_DISOPROXIL_FUMARATE;CYP24A1;TT;CYP24A1_TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;GG;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;WOMEN;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR_DISOPROXIL_FUMARATE;CYP27B1;GG;CYP27B1_GG;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DDC;C;DDC_C;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;RIPOR2;AA + AG;RIPOR2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;DDC;A;DDC_A;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;CYP2C19;CT + TT;CYP2C19_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2C19;CT + TT;CYP2C19_CT + TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CXCL5;GG;CXCL5_GG;OTHER;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;CYP2B6_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;G;CDA_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;T;CDA_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TENOFOVIR_DISOPROXIL_FUMARATE;ABCC2;TT;ABCC2_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;A;CDA_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC2;CC;ABCC2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD1;CC;DRD1_CC;TOXICITY;INCREASED;SEVERITY;OTHER:SOCIAL_WITHDRAWAL;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AA + AT;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:SUBCLINICAL_INTRA-STENT_THROMBUS;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_DRUG-ELUTING_STENT_(DES)_IMPLANTATION;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;G;CES1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;A;CDA_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TENOFOVIR_DISOPROXIL_FUMARATE;SLC28A2;CT + TT;SLC28A2_CT + TT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;HTR2A;CC;HTR2A_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;NSUN3;C;NSUN3_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;PHC1;C;PHC1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;VDR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SERUM_OSTEOCALCIN;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ITGB3;TT;ITGB3_TT;EFFICACY;INCREASED;RISK;EFFICACY:INADEQUATE_INHIBITION_OF_PLATELET_ACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;FAT1;T;FAT1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;XPC;GG + GT;XPC_G;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;TENM4;C;TENM4_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TICAGRELOR;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSPNEA;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;T;CYP4F2_TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:A_22%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_AFTER_ADJUSTMENT_FOR_CLINICAL_AND_GENETIC_COVARIATES_IN_HISPANIC-AMERICANS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DQB1;A;HLA-DQB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_INDUCED_LIVER_INJURY;PEOPLE;DISEASE:DRUG_TOXICITY;CAUTION_SIDE_EFFECT
CAPECITABINE;CD96;C;CD96_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, GOSERELIN;SLCO1B1;TT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AMENORRHEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;NQO1;A;NQO1_A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:A_34%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_WHILE_HOLDING_CLINICAL_AND_GENETIC_PREDICTORS_CONSTANT_IN_HISPANIC-AMERICANS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE;ZMIZ1;C;ZMIZ1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;VPS13D;G;VPS13D_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;RASSF1;CC;RASSF1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;CC;CYP1A2_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CCDC77;G;CCDC77_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;RGS2;C;RGS2_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS, SIDE_EFFECT:PARKINSONIAN_DISORDER;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;WBP2NL;AA;WBP2NL_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CAPECITABINE;ADGRG7;T;ADGRG7_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;AKT1;AA + AC;AKT1_AA + AC;EFFICACY;DECREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, MYCOPHENOLIC_ACID, PREDNISONE;NFATC1;CC;NFATC1_CC;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;PEAR1;T;PEAR1_T;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;GENE_NOT_SPECIFIED;AA + AC;AA + AC;EFFICACY;DECREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, RISPERIDONE;DRD2;CC;DRD2_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BODY_WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCC2;T;ABCC2_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NICOTINE;GRIN3A;C;GRIN3A_C;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP1A2;C;CYP1A2_AA;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;VKORC1_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR1B;CC;HTR1B_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGITATION;CHILDREN;DISEASE:ANXIETY_DISORDERS, DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
PRAVASTATIN;ABCA1;TT;ABCA1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:HDL-CHOLESTEROL;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PON1;T;PON1_T;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ABCG2;GG;ABCG2_T;EFFICACY;INCREASED;SEVERITY;EFFICACY:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC"", ""IBUPROFEN"", ""NAPROXEN"", ""PIROXICAM""";CYP2C9;C;CYP2C9_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;DPYD_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;GRIN3A;G;GRIN3A_G;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FATIGUE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY_AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC""";CYP2C9;C;CYP2C9_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SLEEP_DISORDERS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PRAVASTATIN;KIF6;AG + GG;KIF6_AG + GG;EFFICACY;DECREASED;RISK;DISEASE:CORONARY_DISEASE;PEOPLE;OTHER:PRIOR_VASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS""";F5;AG;F5_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE;SSU72;C;SSU72_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;F2R;T;F2R_T;EFFICACY;DECREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA_BLOCKING_AGENTS;GNB3;CT + TT;GNB3_CC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:HEART_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN;PIK3CA;CC;PIK3CA_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
BETA_BLOCKING_AGENTS;GNB3;CT + TT;GNB3_CC;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:HEART_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN;PTEN;AC + CC;PTEN_AC + CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MAN1A1;A;MAN1A1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;AKT1;C;AKT1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
COCAINE;BCHE;TT;BCHE_TT;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;DISEASE:COCAINE_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CC;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_PEAK_CONCENTRATION_IN_PLASMA_AND_AREA_UNDER_THE_PLASMA_CONCENTRATION;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;EGFR;AA;EGFR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL;ABCB1;GG;ABCB1_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SURVIVAL_RATE;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;P2RY12;AG + GG;P2RY12_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;STAT4;T;STAT4_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:DRUG-INDUCED_LIVER_INJURY;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL;ABCB1;AA + AG;ABCB1_A;EFFICACY;DECREASED;RISK;EFFICACY:LYMPH_NODE_METASTASES;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HEROIN;ALDH2;AA + AG;ALDH2_AA + AG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:HEROIN_DEPENDENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;CALCA_GG;DOSAGE;DECREASED;SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;WOMEN;OTHER:POSTOPERATIVE_PAIN, OTHER:CAESARIAN_SECTION;CAUTION_DOSE_ADJUST
"""METFORMIN"", ""SULFONAMIDES, UREA_DERIVATIVES""";KCNJ11;T;KCNJ11_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES, BETA_BLOCKING_AGENTS, DIURETICS;ADRB1;CC;ADRB1_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STROKE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GRIN3A;T;GRIN3A_T;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT + TT;DPYD_CT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1A2;T;SLCO1A2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:POOR-RESPONSE_TO_CLOPIDOGREL;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);CAUTION_SIDE_EFFECT
TRAMADOL;SLC22A1;del;SLC22A1_del;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;CYP2B6_GT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;FASTKD3, MTRR;AA + AG;FASTKD3, MTRR_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;P2RY12;AG + GG;P2RY12_AG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TRAMADOL;SLC22A1;A;SLC22A1_A;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;T;SLC22A1_T;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;KCNJ6;TT;KCNJ6_TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WITHDRAWAL_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1A2;CC;SLCO1A2_CC;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:IMATINIB_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
IMATINIB;SLCO1A2;CC;SLCO1A2_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:IMATINIB_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VINCRISTINE;ABCC2;T;ABCC2_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1A2;CC;SLCO1A2_CC;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:IMATINIB_CLEARANCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AC;DPYD_AC;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;NR1I2;CC;NR1I2_CC;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLIC_ACID, PREDNISONE;NFATC1;CC;NFATC1_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;FASTKD3, MTRR;AG + GG;FASTKD3, MTRR_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC;CYP2B6_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS""";F5;GT;F5_GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;G;IFNL3_GG;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ACE_INHIBITORS, PLAIN"", ""ANGIOTENSIN_II_ANTAGONISTS""";F5;AG;F5_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;TT;CYP1A2_TT;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CC;SCN1A_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:CORTICAL_SILENT_PERIOD_DURATION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHOTREXATE;MIR1206;GG;MIR1206_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;CC;CYP1A2_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;G;SLCO1B1_AA + AG;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FOLIC_ACID, METHOTREXATE;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENT;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;BRD10;AA + AG;BRD10_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;KDR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;T;IFNL3_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;PIK3R5;T;PIK3R5_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;GENE_NOT_SPECIFIED;AG;AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;AA;ABCC2_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;RISK;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;ABCC4;CT + TT;ABCC4_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CC + CT;ABCC2_CC;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TIME_TO_DISCONTINUATION_OR_DOSE_REDUCTION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CC;ABCC2_CC;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALOPECIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;GENE_NOT_SPECIFIED;CC;CC;EFFICACY;INCREASED;RISK;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
FOLIC_ACID, METHOTREXATE;TLR4;G;TLR4_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;T;ABCG2_T;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN;DPYD;AT;DPYD_A;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;C;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:BLOOD_PRESSURE_(BP)_REDUCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_G;DOSAGE;INCREASED;LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
NAN;HMGCR;AT + TT;HMGCR_AA;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SERUM_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
DOXORUBICIN;SLC28A3;AA + AG;SLC28A3_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS, OTHER:WILMS_TUMOR,OTHER:SARCOMA_ EWING'S, OTHER:HODGKIN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;T;CHRNA3_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB4;G;CHRNB4_G;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NDRG1;G;NDRG1_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB4;A;CHRNB4_A;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;ERCC2;AA + AG;ERCC2_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS, SIMVASTATIN;GENE_NOT_SPECIFIED;T;T;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;AA;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;SLCO1B1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS, SIMVASTATIN;GENE_NOT_SPECIFIED;C;C;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;CT;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;CT + TT;ABCC2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;UGT2A1;CC;UGT2A1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;ECT2L;A;ECT2L_A;EFFICACY;INCREASED;RISK;DISEASE:DEATH;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;AA;ATM_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A1;AA;SLC28A1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;AC + CC;CDA_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCB1;AA + AG;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:PROLONGED_QTC_INTERVAL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PITAVASTATIN;SLCO1B1;AG + GG;SLCO1B1_AA + AG;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PITAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
SORAFENIB;EGFR;C;EGFR_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC;SLCO1B1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:AUC_(P=0.002)_AND_CMAX_(P=0.003);HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GATM;A;GATM_A;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
EVEROLIMUS;ABCB1;A;ABCB1_C;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP1B1;CC;CYP1B1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
EVEROLIMUS;RPTOR;T;RPTOR_CT + TT;TOXICITY, OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;XPC;G;XPC_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;ABCB1;A;ABCB1_A;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;AA + AG;ATM_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;C;NUDT15_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
PLATELET_AGGREGATION_INHIBITORS_EXCL._HEPARIN;PEAR1;AA + AG;PEAR1_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:MYOCARDIAL_ISCHEMIA, EFFICACY:STROKE;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CC + CT;VEGFA_CC + CT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZACITIDINE;MTHFR;AA;MTHFR_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_A;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_TREATED_WITH_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);CAUTION_SIDE_EFFECT
PLATELET_AGGREGATION_INHIBITORS_EXCL._HEPARIN;PEAR1;AA;PEAR1_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:MYOCARDIAL_ISCHEMIA, EFFICACY:STROKE;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;AA;ERCC1_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;GG;SLC22A1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;GENE_NOT_SPECIFIED;CT + TT;CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IMATINIB;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;GRIA1;CC;GRIA1_CC;OTHER;DECREASED;RISK;SIDE_EFFECT:AROUSAL_DYSFUNCTION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;RPTOR;CT + TT;RPTOR_CT + TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CHST1;AA + AG;CHST1_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
IMATINIB;CYP2F1;AA;CYP2F1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;GENE_NOT_SPECIFIED;GT + TT;GT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CBR1;TT;CBR1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TP53;GG;TP53_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SORAFENIB;PRKCE;G;PRKCE_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;CC + CT;SLC22A16_CC + CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;IL10;C;IL10_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;XRCC1;CT + TT;XRCC1_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY_AGENTS, NON-STEROIDS;CTLA4;G;CTLA4_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADH7;CT + TT;ADH7_CT + TT;OTHER;INCREASED;SEVERITY;OTHER:PAIN;PEOPLE;OTHER:SICKLE_CELL_ANEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;ADAMTS18;A;ADAMTS18_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;XRCC1;CT + TT;XRCC1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;GSTP1;AA + AG;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;SLC31A1;GG + GT;SLC31A1_GG + GT;TOXICITY;INCREASED;SEVERITY;DISEASE:OTOTOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;CC;CYP2C19_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;TT;ABCC2_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ABCC9;AA;ABCC9_AA;EFFICACY;INCREASED;SEVERITY;EFFICACY:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCB1;GG;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;A;CEP72_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA,OTHER:BRAIN_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCG2;GT;ABCG2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;AC;ABCC4_AC;TOXICITY;INCREASED;SEVERITY;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;FTO;A;FTO_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ALDH3A1;CG + GG;ALDH3A1_CG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC_AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;AC;ABCC4_AC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;HMGCR;GT;HMGCR_GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_TREATED_WITH_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;GG;ABCC2_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;AA;SLC22A16_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
EVEROLIMUS;FGFR4;A;FGFR4_A;TOXICITY, OTHER;DECREASED;LIKELIHOOD;OTHER:DISCONTINUATION;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CEP72;TT;CEP72_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA,OTHER:BRAIN_NEOPLASMS, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA, OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;GENE_NOT_SPECIFIED;T;T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;AA + AG;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;SLC19A1;AG + GG;SLC19A1_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;FTO;C;FTO_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
AZACITIDINE;XRCC1;CC;XRCC1_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;NQO1;GG;NQO1_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;PIK3R1;G;PIK3R1_G;TOXICITY, OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESLORATADINE;HRH1;CC;HRH1_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:URTICARIA;CAUTION_SIDE_EFFECT
IMATINIB;ABCC2;GG;ABCC2_GG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, DOXORUBICIN, LEUCOVORIN, METHOTREXATE, PREDNISONE, VINCRISTINE;NOS3;TT;NOS3_GG + GT;TOXICITY;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:IQ;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB4;AA + AG;ABCB4_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;PIK3R1;G;PIK3R1_G;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;MIR2054;A;MIR2054_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES, DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS,DISEASE:SJOGREN'S_SYNDROME;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;CT + TT;DHFR_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAB2;TT;PRKAB2_TT;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;NECTIN4;AA;NECTIN4_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PRURITUS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;SPRY2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES, DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS,DISEASE:SJOGREN'S_SYNDROME;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;SPRY2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;AA;HMGCR_AA;EFFICACY;DECREASED;RISK;DISEASE:COLONIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A4;AA;CYP3A4_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;A;GGH_A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE;NCOA7;T;NCOA7_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC70;A;CCDC70_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;HMGCR;AT + TT;HMGCR_AA;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SERUM_LDL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;AG + GG;ERCC1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEPHROTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;TMEM131L;G;TMEM131L_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PRAVASTATIN;HMGCR;AT;HMGCR_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;TT;HMGCR_AA;EFFICACY;DECREASED;RISK;DISEASE:COLONIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;SIRPA;G;SIRPA_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAA2;AA;PRKAA2_AA;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A4;TT;CYP3A4_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;LMNTD1;T;LMNTD1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;MTHFR_AA;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC_AGENTS;RBFOX1;G;RBFOX1_G;EFFICACY;INCREASED;RISK;DISEASE:DEATH;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;AA;HMGCR_AA;EFFICACY;DECREASED;RISK;DISEASE:COLONIC_NEOPLASMS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;XRCC5;G;XRCC5_G;TOXICITY;DECREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, RISPERIDONE;LEP;AG + GG;LEP_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC1;A;ABCC1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;EPAS1;C;EPAS1_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM;XRCC5;A;XRCC5_A;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2A6;A;CYP2A6_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;T;ABCG2_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLIC_ACID;MTHFD1;AA;MTHFD1_AA;OTHER;DECREASED;LIKELIHOOD;OTHER:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;GG;DHFR_GT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;CT + TT;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9_CT + TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;T;AQP2_T;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
APIXABAN, RIVAROXABAN;ABCG2;AA + AC;ABCG2_AA + AC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B3;G;SLCO1B3_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TT;DHFR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;T;CYP2B6_GT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;AA + AC;AQP2_AA + AC;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B3;T;SLCO1B3_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;AA;DHFR_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN, RIVAROXABAN;ABCG2;CT + TT;ABCG2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;A;AQP2_A;TOXICITY;DECREASED;SEVERITY;DISEASE:DIARRHEA, DISEASE:NAUSEA, DISEASE:VOMITING;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;CC + CT;AQP2_CC + CT;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA, DISEASE:NAUSEA, DISEASE:VOMITING;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
MEPHENYTOIN, TOLBUTAMIDE;CYP2C19;C;CYP2C19_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:DRAMATIC_(APPROXIMATELY_90%_AND_70%)_REDUCTION_IN_THE_METABOLISM_OF_S-MEPHENYTOIN_AND_TOLBUTAMIDE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PLATINUM;CD74;A;CD74_A;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ASPIRIN;TBXAS1;AA;TBXAS1_AA;OTHER;DECREASED;RISK;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;CD74;C;CD74_C;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;CDA_AA;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:GRADE_III/IV_LIVER_TOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GENE_NOT_SPECIFIED;A;A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS, INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
WARFARIN;GENE_NOT_SPECIFIED;A;A;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS, INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;ALDH1A2;A;ALDH1A2_A;OTHER;INCREASED;LIKELIHOOD;OTHER:OSTEOARTHRITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE, TAMOXIFEN;GENE_NOT_SPECIFIED;G;G;EFFICACY;INCREASED;RISK;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;SLC2A1;CG + GG;SLC2A1_CG + GG;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;TT;DPYD_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;RISK;EFFICACY:INSUFFICIENT_ANTIPLATELET_RESPONSE_TO_CLOPIDOGREL;POPULATION_AFFECTED_NOT_SPECIFIED;OTHER:PATIENTS_UNDERGOING_ELECTIVE_CORONARY_STENT_IMPLANTATION;CAUTION_SIDE_EFFECT
DASATINIB;ABL1;CT;ABL1_CT;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:AUC_0-4_HOURS;PEOPLE;DISEASE:LEUKEMIA;CAUTION_DOSE_ADJUST
PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3;TT;IFNL3_GG;EFFICACY;DECREASED;SEVERITY;DISEASE:HEPATITIS_C_VIRUS_INFECTION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;AGT;T;AGT_T;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;AGTR1;A;AGTR1_AA + AC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ESR2;CC;ESR2_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:TRIGLYCERIDES_IN_POSTMENOPAUSAL_WOMAN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;NUDT15_CT;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;AA;ABCB1_A;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;ESR1;GG;ESR1_GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:IN_TOTAL_CHOLESTEROL_IN_POSTMENOPAUSAL_WOMAN_AND_INCREASE_IN_TRIGLYCERIDES_AND_DECREASE_IN_HIGH_DENSITY_LIPOPROTEIN_IN_PREMENOPAUSAL_WOMEN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TALINOLOL;ABCC2;A;ABCC2_GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:RESIDUAL_CLEARANCE_OF_INTRAVENOUS_TALINOLOL_AND_LOWER_BIOAVAILABLILTY_OF_ORALLY_ADMINISTERED_TALINOLOL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;CBR3_G;TOXICITY, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:DOXORUBICINOL_AUC;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;AA;ABCB1_C;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CYANOCOBALAMIN, FOLIC_ACID, PEMETREXED;MTHFR;GG + GT;MTHFR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;CT;G6PD, IKBKG_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MODERATE_ANEMIA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RALOXIFENE, TAMOXIFEN;ZNF423;A;ZNF423_A;EFFICACY;DECREASED;RISK;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + AG;ABCB1_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCC2;AA + AG;ABCC2_GG;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:NEUROLOGICAL_ADR;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;TT;G6PD, IKBKG_TT;OTHER;INCREASED;RISK;SIDE_EFFECT:MODERATE_ANEMIA;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFB;T;VEGFB_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;TT;CDA_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:5_YEAR_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;TT;CDA_TT;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;CEP72_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;ABCB1;AA + AG;ABCB1_A;EFFICACY;INCREASED;RISK;DISEASE:INFECTIOUS_DISEASE;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;GG;P2RY12_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACUTE_CORONARY_SYNDROME;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
VINCRISTINE;MIR6076;CC + CG;MIR6076_CC + CG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;WWOX;A;WWOX_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2C19;AA;CYP2C19_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;RARG;A;RARG_AA;TOXICITY;INCREASED;RISK;DISEASE:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;MIR4481;G;MIR4481_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;AG;CYP2C19_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;CC;DPYD_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT;SLC19A1_TT;EFFICACY;INCREASED;RISK;OTHER:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ACP1;TT;ACP1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;MAP2K6;C;MAP2K6_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT;MTHFR_TT;EFFICACY;DECREASED;RISK;OTHER:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;CDH13;C;CDH13_C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;CYP3A5_CC;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;OTHER:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2C19;AA;CYP2C19_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PAROXETINE;FKBP5;T;FKBP5_T;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;FKBP5;T;FKBP5_T;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
ILOPERIDONE;CYP2D6;GG;CYP2D6_GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:QTC_INTERVAL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
GEMCITABINE;SLC28A1;A;SLC28A1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, VENLAFAXINE;HTR1B;A;HTR1B_A;EFFICACY;DECREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1B;A;HTR1B_A;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;A;CDA_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABIDIOL;ABCC5;AA + AG;ABCC5_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;AG;ACYP2_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;ABCB1;A;ABCB1_C;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
MELPHALAN;SLC7A5;AA + AG;SLC7A5_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;MC4R;CC + CT;MC4R_CC + CT;OTHER;INCREASED;RISK;DISEASE:WEIGHT_GAIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM;SLC2A1;T;SLC2A1_T;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;RARG;AA;RARG_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS, OTHER:WILMS_TUMOR,OTHER:SARCOMA_ EWING'S, OTHER:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;GARS1_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
SORAFENIB;EGFR;A;EGFR_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;FGD4_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;SLC31A1;AA;SLC31A1_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MIR3117;AA + AG;MIR3117_AA + AG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, OXALIPLATIN;ERCC2, KLC3;GT;ERCC2_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;SLC2A1;CC;SLC2A1_CC;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;CC;ITPA_AC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
FLUOROURACIL, OXALIPLATIN;GSTP1;AG + GG;GSTP1_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADD1;GT + TT;ADD1_GT + TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;GT + TT;ERCC2_GT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A5;CC + CT;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;RAD52, WNK1;CC;RAD52, WNK1_CC;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;C;C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
SUNITINIB;IL13;TT;IL13_TT;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;G;G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;A;A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;G;G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
THIAZIDES, PLAIN;ADD1;GG;ADD1_GT + TT;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;TT;ERCC2_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;IL13;TT;IL13_TT;OTHER;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC + CT;SLCO1B1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;RHBDF2;AA + AG;RHBDF2_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE_INHIBITORS, PLAIN;SH2B1;T;SH2B1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RADIOTHERAPY;OSMR;T;OSMR_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;CC;BLMH_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PAIN;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;CDK1;G;CDK1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;CC;BLMH_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;CT;CYP2C9_CT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_CELECOXIB;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;REN;GG;REN_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_SBP;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;YEATS4;C;YEATS4_C;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;RBFOX3;C;RBFOX3_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;ADD1_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;PRKCE;G;PRKCE_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;MBOAT1;T;MBOAT1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RADIOTHERAPY;PRKCE;T;PRKCE_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROFECOXIB;PTGS1;T;PTGS1_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_COX-1_INHIBITION_AND_DEPRESSION_OF_THE_URINARY_THROMBOXANE_METABOLITE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;AA;ERCC1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:FEBRILE_NEUTROPENIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;RIGI;C;RIGI_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;TPMT_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DRUGS_FOR_TREATMENT_OF_TUBERCULOSIS;GENE_NOT_SPECIFIED;AA;AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;RBFOX3;G;RBFOX3_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;WNK1;TT;WNK1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_SBP;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;GENE_NOT_SPECIFIED;C;C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;PTGS1;T;PTGS1_T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_COX-1_INHIBITION;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;COL1A1;AA + AC;COL1A1_AA;NAN;INCREASED;RISK;DISEASE:FRACTURES, BONE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;T;ADD1_GT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ABSOLUTE_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE_INHIBITORS, PLAIN;GABRG2;G;GABRG2_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;COL1A1_AA;NAN;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:BONE_MINERAL_DENSITY_(BMD);POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
VINCRISTINE;BAHD1;AA + AC;BAHD1_AA + AC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;RBFOX3;G;RBFOX3_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;DPYD_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
METHYLPREDNISOLONE, PREDNISOLONE;ABCB1;AA;ABCB1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;GG;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE, TAMOXIFEN;ZNF613;C;ZNF613_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PIRFENIDONE;CYP1A2;AA;CYP1A2_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;GG + GT;ERCC2_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;OTOS;CC + CT;OTOS_CC + CT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE_INHIBITORS, PLAIN;RBFOX3;G;RBFOX3_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SELECTIVE_SEROTONIN_REUPTAKE_INHIBITORS;HTR2A;CC;HTR2A_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIMINISHED_ABILITY_TO_CONCENTRATE;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;CC;HTR2A_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;MTHFR;GG;MTHFR_TT;TOXICITY;DECREASED;RISK;DISEASE:MYELOSUPPRESSION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CXCL8;TT;CXCL8_T;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;PDGFRB;AA + AG;PDGFRB_AA + AG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;PNPLA3;GG;PNPLA3_GG;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;MEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;CC + CG;RGS5_CC + CG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;EPAS1;T;EPAS1_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;WT1;CC + CT;WT1_CC + CT;OTHER;INCREASED;LIKELIHOOD;DISEASE:EVENT-FREE_SURVIVAL;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;CYP3A5_CC;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;A;ITPA_AC;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CANNABINOIDS;FAAH;AA;FAAH_AA;TOXICITY;DECREASED;RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;GENE_NOT_SPECIFIED;C;C;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;A;GSTA1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
VINCRISTINE;MRPL47;CT + TT;MRPL47_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;SYNE2;A;SYNE2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;EPAS1;A;EPAS1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_DIASTOLIC_BLOOD_PRESSURE, SIDE_EFFECT:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;CC;DHFR_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:EVENT-FREE_SURVIVAL, OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;G;MTHFR_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_TRANSAMINASES;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTA1;C;GSTA1_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXICITY-RELATED_TREATMENT_FAILURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DOXORUBICIN;GALNT14;TT;GALNT14_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2D6;CC;CYP2D6_CC;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
DESFLURANE, PROPOFOL;ATP8B3;CT + TT;ATP8B3_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
LOSARTAN;CAMK1D;AG + GG;CAMK1D_AG + GG;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TT;DHFR_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LOSARTAN;CAMK1D;AG + GG;CAMK1D_AG + GG;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;C;GSTA1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;T;MTHFR_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;GT;DHFR_GT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;C;CYP2C9_AC + CC;EFFICACY;DECREASED;RISK;DISEASE:ADENOMA;PEOPLE;DISEASE:ADENOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;SLC19A1;CT + TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTIONS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;CYP3A4;CT;CYP3A4_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;ABCB1_A;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;CSPG4;AG;CSPG4_AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;SHMT1;AG;SHMT1_AG;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AG;FASTKD3, MTRR_AG + GG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:SPEED_OF_PLATELET_RECOVERY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;EPAS1;G;EPAS1_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;MTHFR_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:RED_BLOOD_CELL_TRANSFUSIONS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;T;CYP2B6_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
APIXABAN, RIVAROXABAN;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;ABCB1_C;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOCETAXEL;VEGFA;AA;VEGFA_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, GEMCITABINE;OR4D6;CC;OR4D6_CC;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;MAP2K6;G;MAP2K6_G;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;DDX53;T;DDX53_T;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA;MTHFD1_AA;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:RED_BLOOD_CELL_FOLATE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
METHOTREXATE;FASTKD3, MTRR;AA;FASTKD3, MTRR_AG + GG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;PK:RED_BLOOD_CELL_FOLATE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
IRINOTECAN;SEMA3C;T;SEMA3C_T;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;A;DRD2_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;COMT_AA;TOXICITY;DECREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SEMA3C;C;SEMA3C_C;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;ABCB1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;G;DRD2_G;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;ABCB1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE;MEN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;G;DRD2_G;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IRINOTECAN;GENE_NOT_SPECIFIED;G;G;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;ABCB1_C;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;AA;HTR2C_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;TT;CYP2E1_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;FCER2;G;FCER2_G;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:SEVERE_EXACERBATIONS_WITH_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;NOS3;TT;NOS3_GG + GT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;GG;HTR2C_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;IL12A;A;IL12A_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
IRINOTECAN;PLCB1;C;PLCB1_C;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NOS3;CC;NOS3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;CC;HTR2C_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, METHOTREXATE;NOS3;GG + GT;NOS3_GG + GT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;PDZRN3;C;PDZRN3_C;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;TT;UGT2B7_TT;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
DAPSONE;HLA-DRB1;A;HLA-DRB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
OLANZAPINE;PPARG;CG;PPARG_CG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;CC;UGT2B7_CC;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;BCL2L11;AA;BCL2L11_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;AA;UGT2B7_AA;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;UGT2B7;GG;UGT2B7_GG;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;AA + AG;GSTA1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ANEMIA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
OXALIPLATIN;PIN1;CC + CG;PIN1_CC + CG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;UGT2B7;CC;UGT2B7_CC;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;CT + TT;CYP2C9_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;TT;ABCG2_T;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;AG;AMPD1_AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;MEN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;UGT2B7_CC;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;G;ABCB1_GG;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;MEN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;GG;UGT2B7_GG;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;AA + AG;CYP2C19_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;CG;CYP2E1_CG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_EMESIS;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;G;ABCB1_GG;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;DPYD_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;GNB3;CC;GNB3_CC;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMLODIPINE;RYR3;TT;RYR3_TT;EFFICACY;INCREASED;RISK;DISEASE:HEART_FAILURE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;GG;GSTP1_GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;COL1A1;AA;COL1A1_AA;NAN;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:BONE_MINERAL_DENSITY_AT_FEMORAL_NECK_AND_LUMBAR_SPINE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;GG;UGT2B7_GG;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;COL1A1_AA;NAN;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:BMD_VALUES_AT_THE_LUMBAR_SPINE_AND_FEMORAL_NECK;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;AA;UGT2B7_AA;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;EIF3A;A;EIF3A_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;DPYD_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;AGTR1;AA + AC;AGTR1_AA + AC;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;ACE;GG;ACE_GG;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ATORVASTATIN, RIFAMPIN;SLCO1B1;TT;SLCO1B1_TT;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;PK:A_NEARLY_TRIPLED_INCREASED_PERCENTAGE_OF_ATORVASTATIN_AUC(0_-_48)_VALUES_AFTER_A_SINGLE_ORAL_DOSE_OF_RIFAMPICIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;MIR27A;C;MIR27A_C;TOXICITY;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ATORVASTATIN;FDPS;TT;FDPS_TT;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;OPRM1_AA;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:SUBJECTIVE_FEELINGS_OF_INTOXICATION, STIMULATION, SEDATION, AND_HAPPINESS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
NAN;ABCC2;C;ABCC2_C;METABOLISM/PK;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:ALLELIC_IMBALENCE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CISPLATIN;GSTM4;CC;GSTM4_CC;EFFICACY, TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IC-50;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;FDPS;AA;FDPS_AA;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
IRINOTECAN;C8orf34;C;C8orf34_C;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
DICLOXACILLIN, PROBENECID;ABCB1;GG;ABCB1_A;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE_OF_DICLOXACILLIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;HTR2C_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;OPRM1_AA;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE, DICLOXACILLIN;ABCB1;CC;ABCB1_C;OTHER, METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:CLEARANCE_OF_DICLOXACILLIN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;CT + TT;CYP2E1, DUX1_CT + TT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;CC;SLCO1B1_TT;NAN;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:CHOLESTEROL_SYNTHESIS_RATE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
PLATINUM_COMPOUNDS;MDM2;CC;MDM2_CC;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_DRUG_LEVELS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;GRIN2B;AA + AG;GRIN2B_AA + AG;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;G;CYP2C19_G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS_FOR_OBSTRUCTIVE_AIRWAY_DISEASES;ADRB2;GG;ADRB2_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:STATUS_ASTHMATICUS;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CCND1;AA;CCND1_AA;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCB1;A;ABCB1_A;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;MTHFR_AA;TOXICITY;DECREASED;SEVERITY;DISEASE:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SOD2;AA;SOD2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC19A1;CT + TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;ABCB1;AA;ABCB1_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
DOCETAXEL;ERCC2;TT;ERCC2_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CRTC2;AA;CRTC2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
DOCETAXEL;ERCC1;AA;ERCC1_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RATES_OF_TARGET_LESION_REVASCULARIZATION_AND_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;SP1_C;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METFORMIN_SECRETORY_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3, CHRNA5;A;CHRNA3, CHRNA5_A;TOXICITY;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METFORMIN;GENE_NOT_SPECIFIED;G;G;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TO_BE_CLASSIFIED_AS_CLOPIDOGREL_POOR_RESPONDERS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;GENE_NOT_SPECIFIED;G;G;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METFORMIN_SECRETORY_CLEARANCE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ATP10A;AA + AG;ATP10A_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;EIF3A;A;EIF3A_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;NCF4;AG + GG;NCF4_AG + GG;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;AC + CC;CYP2C9_AC + CC;EFFICACY;INCREASED;RISK;EFFICACY:CLOPIDOGREL_POOR_RESPONSE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;EIF3A;A;EIF3A_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;EIF3A;C;EIF3A_C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;AC + CC;CYP2C9_AC + CC;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;GSTP1;GG;GSTP1_GG;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;T;HTR2C_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;ABCB1;GG + GT;ABCB1_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;A;ABCB1_C;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_DRUG_LEVELS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
SEVOFLURANE;KCNK3;CT + TT;KCNK3_CT + TT;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;CC;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MYELOSUPPRESSION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOCETAXEL;CYP3A4;CC + CT;CYP3A4_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INFUSION_RELATED_REACTION;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;SP1;G;SP1_G;EFFICACY;DECREASED;SEVERITY;DISEASE:HYPERGLYCEMIA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;MTR;AA + AG;MTR_AA + AG;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;GABRA2;CC + CT;GABRA2_CC + CT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;TT;SLC19A1_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STAYING_IN_REMISSION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;VKORC1_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
PLATINUM_COMPOUNDS;EIF3A;T;EIF3A_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;CG + GG;CYP2C8_CG + GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;PPARA;T;PPARA_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;COL1A1;AA;COL1A1_AA;NAN;INCREASED;RISK;DISEASE:FRACTURES, BONE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;CYP4F2_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM_COMPOUNDS;SLC19A1;TT;SLC19A1_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;CYP2C8;CT + TT;CYP2C8_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LENALIDOMIDE;VEGFA;AA;VEGFA_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;SP1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;FASTKD3, MTRR;AG + GG;FASTKD3, MTRR_AG + GG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;G;CYP2C19_G;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
BUPROPION, NICOTINE;DRD1;A;DRD1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;HMGCR;TT;HMGCR_GT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NR3C1;C;NR3C1_C;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:SICKLE_CELL_PAIN_CRISIS;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_A;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
SEVOFLURANE;FASTKD3, MTRR;AA + AG;FASTKD3, MTRR_AA + AG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
PACLITAXEL;ERCC1;AA + AC;ERCC1_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;C;ABCC3_C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
NAN;P2RY12;G;P2RY12_AG + GG;NAN;INCREASED;RISK;SIDE_EFFECT:CORONARY_ARTERY_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
BUPROPION, NICOTINE;DRD1;T;DRD1_T;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;CYP2C19_TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB, SUNITINIB;CXCL8;T;CXCL8_T;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NR3C1;G;NR3C1_G;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:SICKLE_CELL_PAIN_CRISIS;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DOSE_ADJUST
MORPHINE;ABCC3;G;ABCC3_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;UGT2B7_CC;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
FENTANYL;MYD88;G;MYD88_G;TOXICITY;DECREASED;RISK;SIDE_EFFECT:COGNITIVE_DISORDER;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE, PREDNISONE;SLC19A1;TT;SLC19A1_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION, NICOTINE;DRD1;G;DRD1_G;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NR3C1;T;NR3C1_T;OTHER;INCREASED;EFFECT_NOT_SPECIFIED;DISEASE:SICKLE_CELL_PAIN_CRISIS;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DOSE_ADJUST
SPIRONOLACTONE;ACE;AA + AG;ACE_AA + AG;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION, END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME;PEOPLE;OTHER:CHRONIC_HEART_FAILURE;CAUTION_DOSE_ADJUST
SIMVASTATIN;HMGCR;AA;HMGCR_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ERCC1;CC;ERCC1_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SEVOFLURANE;CYP2E1;CC + CG;CYP2E1_CC + CG;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;GSTA1;AA + AG;GSTA1_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;CYP2E1, DUX1;CT + TT;CYP2E1, DUX1_CT + TT;OTHER;DECREASED;EFFECT_NOT_SPECIFIED;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
ANTIHYPERTENSIVES, DIURETICS;NOS3;CC;NOS3_CC;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;CYBA;AA;CYBA_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;PTGS2;CG + GG;PTGS2_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PAIN_RELIEF;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIFLOMOTECAN;ABCG2;T;ABCG2_T;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_CONCENTRATIONS_OF_DIFLOMOTECAN;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AA;ABCB1_C;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANCE;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CRTC2;AA;CRTC2_AA + AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
ROFECOXIB;PTGS2;CC;PTGS2_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PAIN_RELIEF;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;G;G;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GENE_NOT_SPECIFIED;C;C;TOXICITY;INCREASED;RISK;OTHER:NEOPLASMS;WOMEN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;T;T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PAZOPANIB, SUNITINIB;CXCL8;A;CXCL8_A;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;GG;GSTP1_GG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;GENE_NOT_SPECIFIED;T;T;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PHARMACODYNAMIC_RESPONSE;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;CCND1;AA;CCND1_AA;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;AC + CC;ERCC1_AC + CC;TOXICITY;DECREASED;RISK;SIDE_EFFECT:VOMITING;MEN;DISEASE:TESTICULAR_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PTGS1;AA + AG;PTGS1_AA + AG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:CEREBRAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;DPYD_A;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES_AND_RELATED_SUBSTANCES;ABCB1;CC;ABCB1_C;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CRTC2;AA + AG;CRTC2_AA + AG;TOXICITY;INCREASED;EFFECT_NOT_SPECIFIED;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:PLASMA_EXPOSURE_TO_THE_ACTIVE_METABOLITE_OF_CLOPIDOGREL;HEALTHY;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;TT;VKORC1_CT + TT;DOSAGE;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:ACENOCOUMAROL_DOSE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;T;DPYD_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;ABCC3_G;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ABCB1;AA;ABCB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;T;ABCC3_T;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;ABCB1_A;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;GENE_NOT_SPECIFIED;A;A;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;A;ABCB1_A;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS;PEOPLE;DISEASE:FRACTURES, BONE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;TT;CYP2C19_TT;METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_CIT/DCIT_VALUES;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
TRAMADOL;ABCB1;A;ABCB1_C;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS;PEOPLE;DISEASE:FRACTURES, BONE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, PEGINTERFERON_ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2B, RIBAVIRIN;ITPA;A;ITPA_AC;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;CYP2C19_AA;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;A;ABCC2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RISPERIDONE;UGT1A1;CT;UGT1A1_CT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
FLUOXETINE;CRHR1;CC;CRHR1_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RESPONSE;PEOPLE;OTHER:MAJOR_DEPRESSION_AND_HIGH_ANXIETY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;UGT1A1;AG;UGT1A1_AG;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
SARILUMAB;IL6R;CC;IL6R_CC;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;CT + TT;ERCC2_CT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;CT + TT;GSTP1_CT + TT;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;TT;IL6R_TT;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VITAMIN_K_ANTAGONISTS;CYP4F2;TT;CYP4F2_TT;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;GG;HTR2C_GG;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
WARFARIN;CRP;CT + TT;CRP_CT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;TCF7L2;A;TCF7L2_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIABETES;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;TCF7L2;T;TCF7L2_T;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ATORVASTATIN, CERIVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HMGCR;GT;HMGCR_GT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;TCF7L2;T;TCF7L2_T;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;CYP2C19_AA;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;AA;CYP2C19_AA;METABOLISM/PK;INCREASED;EFFECT_NOT_SPECIFIED;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
LENALIDOMIDE;ABCB1;CC;ABCB1_C;EFFICACY;DECREASED;EFFECT_NOT_SPECIFIED;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;CC;XRCC1_CC;OTHER;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:LATER_ONSET_OF_SENSORY_NEUROPATHY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_DOSE_ADJUST
DOCETAXEL, THALIDOMIDE;CHST3;A;CHST3_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;T/del + del/del;UGT1A9_T/del + del/del;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AA;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
SARILUMAB;IL6R;CC;IL6R_CC;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM, ETIDRONIC_ACID;VDR;TT;VDR_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:MEAN_SPINAL_BONE_MINERAL_DENSITY_CHANGES;PEOPLE;DISEASE:OSTEOPOROSIS, POSTMENOPAUSAL;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;AA;IL6R_AA;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRD1;CT;OPRD1_CT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;SOD2;AA + AG;SOD2_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;TT;IL6R_TT;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;ARRB2;TT;ARRB2_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISPHOSPHONATES;CYP2C8;TT;CYP2C8_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AG + GG;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AA + GG;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
NAN;IFNL3, IFNL4;CC;IFNL3_TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:JAUNDICE;WOMEN;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;CC;ABCC2_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AA + AG;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CRBN;CC;CRBN_CC;DOSAGE, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION, SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;CAUTION_DOSE_ADJUST
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AG;COMT_AA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;AA;ERCC1_AA;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;CC;XRCC1_CC;TOXICITY;DECREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NR1I2;T;NR1I2_T;OTHER, METABOLISM/PK;DECREASED;EFFECT_NOT_SPECIFIED;PK:CYP3A4_ACITVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
CARBAMAZEPINE, LAMOTRIGINE, OXCARBAZEPINE, PHENYTOIN, TOPIRAMATE;SCN2A;A;SCN2A_A;EFFICACY;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CAPECITABINE, OXALIPLATIN;PTGS2;AA;PTGS2_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;OTHER:PROGRESSION-FREE_SURVIVAL_AND_OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CETP;A;CETP_A;NAN;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;OTHER:VARIANCE_IN_LDL, HDL_AND_LDL/HDL;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;CETP;A;CETP_A;EFFICACY;DECREASED;RISK;EFFICACY:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;ADD1;GT + TT;ADD1_GT + TT;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;VKORC1_CT + TT;DOSAGE;EFFECT_DIRECTION_NOT_SPECIFIED;EFFECT_NOT_SPECIFIED;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_DOSE_ADJUST
ETHANOL;DRD2;A;DRD2_A;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;P2RY12_AG + GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PLATELET_ACTIVATION_RESPONSE_TO_ADP;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;CT + TT;ABCC2_CT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;ADD1_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;AA;MTHFR_AA;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BROMPERIDOL, NEMONAPRIDE;DRD2;GG;DRD2_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:IMPROVEMENT_IN_ANXIETY-DEPRESSION_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIAZIDES, PLAIN;SLC12A3;CC;SLC12A3_CC;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;ABCB1;GG;ABCB1_GG;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;IFNL3_TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC;ITPA_AC;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
VALPROIC_ACID;ABCB1;GG;ABCB1_GG;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:ALOPECIA, SIDE_EFFECT:HYPERSENSITIVITY;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, ROSUVASTATIN;CYP3A5;CC;CYP3A5_CC;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;DISEASE:DIABETES_MELLITUS, DISEASE:HYPERLIPIDEMIAS,DISEASE:HYPERTENSION, DISEASE:OBESITY;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;SLCO1B1_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
THIAZIDES, PLAIN;ADRB3;AA;ADRB3_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR2A;AA;FCGR2A_AA;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A9;T/del + del/del;UGT1A9_T/del + del/del;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPARAGINASE;CPA2;T;CPA2_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3;AA;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-DRB1;T;HLA-DRB1_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;POR;CT + TT;POR_CT + TT;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
WARFARIN;THBD;CC + CT;THBD_CC + CT;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;TT;IFNL3_GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;CES1;AC + CC;CES1_AC + CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:APPETITE_SUPPRESSION;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;BDKRB2;C;BDKRB2_C;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;BCL2L11;CC;BCL2L11_CC;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;MME;A;MME_A;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
IRINOTECAN;PIN1;CC + CG;PIN1_CC + CG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON_ALFA-2A, RIBAVIRIN;GENE_NOT_SPECIFIED;GG;GG;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;ADD1;GT;ADD1_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_MEAN_ARTERIAL_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;VKORC1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ASPIRIN;ACE;AT + TT;ACE_AT + TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;CYP2C8;A;CYP2C8_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;ADD1_GT + TT;EFFICACY;INCREASED;EFFECT_NOT_SPECIFIED;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;CYP2C8;T;CYP2C8_T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
ACE_INHIBITORS, PLAIN;PTGER3;C;PTGER3_C;TOXICITY;DECREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE_MOFETIL;HUS1;T;HUS1_T;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-DRB1;A;HLA-DRB1_A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;PPARA;AA + AG;PPARA_AA + AG;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MYCOPHENOLATE_MOFETIL;HUS1;A;HUS1_A;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADD1;GT + TT;ADD1_GT + TT;OTHER;INCREASED;LIKELIHOOD;DISEASE:HYPERTENSION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCB1;C;ABCB1_C;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SLCO1B1;A;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;ARG1;TT;ARG1_TT;OTHER;INCREASED;SEVERITY;OTHER:ASTHMA;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;TT;CYP3A4_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;ABCC1;CT;ABCC1_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LEVODOPA;COMT;AA;COMT_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSKINESIA, DRUG-INDUCED;PEOPLE;OTHER:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;SLC19A1_TT;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;ABCC2;A;ABCC2_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);GENOTYPE_NOT_SPECIFIED;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN, DOXORUBICIN;HFE;G;HFE_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;GPR35;T;GPR35_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;UGT1A6;T;UGT1A6_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;GSTA2;G;GSTA2_G;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;ETFB;A;ETFB_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;HNMT;A;HNMT_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;ABCC5;AA + AT;ABCC5_AA + AT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CEFAZOLIN, CEFDINIR, CEFTRIAXONE, CEFUROXIME, CEPHALEXIN;HLA-A;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2B6;GT;CYP2B6_GT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;WNT7B;A;WNT7B_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;POGK;A;POGK_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;FAM240C;A;FAM240C_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ZNF37A;A;ZNF37A_A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CODEINE, HYDROCODONE, TRAMADOL;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:EMERGENCIES, EFFICACY:PAIN;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
GANCICLOVIR, VALGANCICLOVIR;NUDT15;*2 + *3 + *4;GENOTYPE_NOT_SPECIFIED;NAN;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:LIVER_TRANSPLANTATION, OTHER:CYTOMEGALOVIRUS_INFECTION;CAUTION_DOSE_ADJUST
VALPROIC_ACID;ACOT1;T;ACOT1_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
TACROLIMUS;SLCO1B1;AA + AG;SLCO1B1_AA + AG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;MOCOS;GT;MOCOS_GT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
VALPROIC_ACID;GABPA;CC;GABPA_CC;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;NQO1;GG;NQO1_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC_ACID;PPARA;G;PPARA_G;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B3;AA;SLCO1B3_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B3;GG;SLCO1B3_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AA + AG;SLCO1B1_AA + AG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
APIXABAN;APOE;C;APOE_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
APIXABAN;APOE;C;APOE_C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;IFNL3;GG;IFNL3_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;IFNL3;GG;IFNL3_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
PD-1/PDL-1_(PROGRAMMED_CELL_DEATH_PROTEIN_1/DEATH_LIGAND_1)_INHIBITORS;IFNL3;TT;IFNL3_TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;TT;ABCB1_TT;EFFICACY;DECREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCC2;GG;ABCC2_GG;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;SLCO1B1;TT;SLCO1B1_TT;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C19;AA;CYP2C19_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT;NUDT15_CT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;RRM1;AG + GG;RRM1_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;GT + TT;TPMT_GT + TT;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN;TRPA1;TT;TRPA1_TT;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:CARCINOMA, OTHER:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX, XELOX;DPYD;AG + GG;DPYD_AG + GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;ALLELE_NOT_SPECIFIED;GENOTYPE_NOT_SPECIFIED;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_MODIFICATION;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;SLC29A1;AA;SLC29A1_AA;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION, OTHER:LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB, ERLOTINIB, GEFITINIB;AKT1;CC;AKT1_CC;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*44:03;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-B;*38:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE/TRIMETHOPRIM;HLA-C;*04:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
FOLFOX, XELOX;GSTP1;GG;GSTP1_GG;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX, XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;TYMS_TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX, XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TYMS_(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFOX, XELOX;GSTP1;GG;GSTP1_GG;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DQA1;*02:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PANCREATITIS;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DRB1;*07:01;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PANCREATITIS;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;ABCG2;T;ABCG2_T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TOXIC_LIVER_DISEASE;POPULATION_AFFECTED_NOT_SPECIFIED;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;TPMT;*3A + *3B + *3C;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;GENOTYPE_NOT_SPECIFIED;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;ENTITY_AFFECTED_NOT_SPECIFIED;CAUTION_SIDE_EFFECT
CODEINE, MORPHINE, OXYCODONE;OPRM1;AA;OPRM1_AA;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:URINARY_RETENTION, SIDE_EFFECT:CONSTIPATION, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING, SIDE_EFFECT:ABDOMINAL_PAIN, SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:WHEEZING, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
